<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

<meta charset="utf-8">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />



<title>Covid-19 trials</title>

<meta property="og:title" content="Covid-19 trials" />

<meta name='viewport' content='width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no' />

<link rel="icon" href="data:image/x-icon;" type="image/x-icon">


<script type="text/javascript">
window.FlexDashboardComponents = [];
</script>

<script src="site_libs/header-attrs-2.1/header-attrs.js"></script>
<script src="site_libs/jquery-1.12.4/jquery.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<script src="site_libs/stickytableheaders-0.1.19/jquery.stickytableheaders.min.js"></script>
<script src="site_libs/htmlwidgets-1.5.1/htmlwidgets.js"></script>
<link href="site_libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="site_libs/datatables-binding-0.13/datatables.js"></script>
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="site_libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<link href="site_libs/crosstalk-1.0.0/css/crosstalk.css" rel="stylesheet" />
<script src="site_libs/crosstalk-1.0.0/js/crosstalk.min.js"></script>
<script src="site_libs/jszip-1.10.20/jszip.min.js"></script>
<link href="site_libs/dt-ext-buttons-1.10.20/css/buttons.dataTables.min.css" rel="stylesheet" />
<script src="site_libs/dt-ext-buttons-1.10.20/js/dataTables.buttons.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.flash.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.html5.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.colVis.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.print.min.js"></script>
<style type="text/css">

/*
 Dashboard CSS from Keen IO Dashboards
 (https://github.com/keen/dashboards)
*/

body {
  background: #f2f2f2;
  padding: 60px 0 0 8px; /* padding-top overridden by theme */
}

body hr {
  border-color: #d7d7d7;
  margin: 10px 0;
}

.navbar-inverse .navbar-nav > li > a,
.navbar .navbar-brand {
  text-decoration: none;
}

.navbar-logo {
  margin-top: 1px;
}

.navbar-logo img {
  margin-right: 12px;
}

.navbar-author {
  margin-left: 10px;
  font-size: 15px;
}

.navbar .dropdown-menu .fa {
  min-width: 20px;
}

.navbar .dropdown-menu {
  min-width: 150px;
  max-height: 500px;
  overflow: auto;
}

.chart-wrapper,
.nav-tabs-custom,
.sbframe-commentary
{
  background: #fff;
  border: 1px solid #e2e2e2;
  border-radius: 3px;
  margin-bottom: 8px;
  margin-right: 8px;
}

.chart-title {
  border-bottom: 1px solid #d7d7d7;
  color: #666;
  font-size: 14px;
  font-weight: 300;
  padding: 7px 10px 4px;
}

.chart-wrapper .chart-title:empty {
  display: none;
}

.chart-wrapper .chart-stage {
  overflow: hidden;
  padding: 5px 10px;
  position: relative;
}

.chart-wrapper .chart-notes {
  background: #fbfbfb;
  border-top: 1px solid #e2e2e2;
  color: #808080;
  font-size: 12px;
  padding: 8px 10px 5px;
}

/*
 CSS for handling flexbox layout
*/

#dashboard-container {
  visibility: hidden;
}

.tab-content>.dashboard-page-wrapper.active {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.dashboard-page-wrapper {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.dashboard-row-orientation {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.dashboard-row {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: horizontal;
  -webkit-box-direction: normal;
  -webkit-flex-direction: row;
      -ms-flex-direction: row;
          flex-direction: row;
}

.dashboard-row-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
}

.dashboard-column-orientation {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: horizontal;
  -webkit-box-direction: normal;
  -webkit-flex-direction: row;
      -ms-flex-direction: row;
          flex-direction: row;
}

.dashboard-column {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.chart-wrapper-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.chart-stage-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  position: relative;
}

.chart-shim {
  position: absolute;
  left: 8px; top: 8px; right: 8px; bottom: 8px;
}

.no-padding .chart-shim {
  left: 0; top: 0; right: 0; bottom: 0;
}

.flowing-content-shim {
  overflow: auto;
  left: 0; top: 0; right: 0; bottom: 0;
  padding-left: 8px;
  padding-right: 8px;
}

.flowing-content-container {
  padding-top: 8px;
  padding-bottom: 8px;
}

.chart-stage .table-bordered {
  border: none;
}

.chart-stage .table-bordered > tbody > tr > th,
.chart-stage .table-bordered > tfoot > tr > th,
.chart-stage .table-bordered > tbody > tr > td,
.chart-stage .table-bordered > tfoot > tr > td {
  border: none;
}

.chart-stage .table-bordered > tbody > tr > td {
  border-top: 1px solid #dddddd;
}

.chart-stage .table-bordered > thead > tr > th {
  border: none;
  border-bottom: 2px solid #dddddd;
}

.bootstrap-table table>thead {
  background-color: #fff;
}

.bootstrap-table table.data,
.bootstrap-table table.shiny-table {
  width: inherit !important;
}

.bootstrap-table table.data>tbody>tr>th,
.bootstrap-table table.shiny-table>tbody>tr>th {
  border-top: none;
  border-bottom: 2px solid #dddddd;
  padding: 5px;
}

.bootstrap-table .data td[align=right] {
  font-family: inherit;
}

.chart-wrapper form {
  padding-left: 5px;
  padding-right: 5px;
}

.shiny-input-container label {
  font-weight: normal;
}

.chart-stage .html-widget {
  width: 100% !important;
  height: 100% !important;
}

.chart-stage .html-widget-static-bound {
  width: 100% !important;
  height: 100% !important;
}

.chart-stage .shiny-bound-output {
  width: 100% !important;
  height: 100% !important;
}

/* Omit display of empty paragraphs */

.chart-shim>p:empty {
  display: none;
}

.chart-stage>p:empty {
  display: none;
}

/* Omit display of special knitr options div*/

.chart-stage .knitr-options {
  display: none;
}

/* Automatically resizing images */

.image-container {
  position: absolute;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  margin: 0;
}

.image-container img {
  opacity: 0;
  overflow: hidden;
}

/* Value box */

.value-box {
  border-radius: 2px;
  position: relative;
  display: block;
  margin-right: 8px;
  margin-bottom: 8px;
  box-shadow: 0 1px 1px rgba(0, 0, 0, 0.1);
}

.value-box > .inner {
  padding: 10px;
  padding-left: 20px;
  padding-right: 20px;
}

.value-box .value {
  font-size: 38px;
  font-weight: bold;
  margin: 0 0 3px 0;
  white-space: nowrap;
  padding: 0;
}

.value-box .caption {
  font-size: 15px;
}
.value-box .caption > small {
  display: block;
  font-size: 13px;
  margin-top: 5px;
}

.value-box .icon i {
  position: absolute;
  top: 15px;
  right: 15px;
  font-size: 80px;
  color: rgba(0, 0, 0, 0.15);
}

.linked-value:hover {
  cursor: pointer;
}

.value-box.linked-value:hover {
  box-shadow: 0 2px 2px rgba(0, 0, 0, 0.3);
}

/* STORYBOARD */

.storyboard-nav button {
  background: transparent;
  border: 0;
  opacity: .3;
  outline: none;
  padding: 0;
}

.storyboard-nav button:hover,
.storyboard-nav button:hover {
  opacity: .5;
}

.storyboard-nav button:disabled,
.storyboard-nav button:disabled {
  opacity: .1;
}

.storyboard-nav .sbnext,
.storyboard-nav .sbprev {
  float: left;
  width: 2%;
  height: 120px;
  font-size: 50px;
}

.storyboard-nav .sbprev {
  text-align: left;
  width: 2%;
}

.storyboard-nav .sbnext {
  float: right;
  text-align: right;
  margin-right: 8px;
}

.storyboard-nav .sbframelist {
  margin: 0 auto;
  width: 94%;
  height: 120px;
  overflow: hidden;
  text-shadow: none;
  margin-bottom: 8px;
}

.storyboard-nav .sbframelist ul {
  list-style: none;
  margin: 0;
  padding: 0;
  height: 100%;
}

.storyboard-nav .sbframelist ul li {
  float: left;
  width: 270px;
  height: 100%;
  padding: 10px 10px 10px 10px;
  margin-right: 8px;
  background: #fff;
  border: 1px solid #e2e2e2;
  border-radius: 3px;
  color: #3a3c47;
  text-align: left;
  font-size: 14px;
  cursor: pointer;
}

.storyboard-nav .sbframelist ul li:last-child {
  margin-right: 0px;
}

.storyboard-nav .sbframelist ul li.active {
  color: #fff;
  background: #B8B8B8;
}

.sbframe-commentary {
  width: 300px;
  background: #fbfbfb;
  font-size: 14px;
}

.sbframe-commentary ul {
  padding-left: 22px;
}

.sbframe.active {
  display: flex;
}

.sbframe:not(.active) {
  display: none;
}

/* NAV TABS */

.nav-tabs-custom > .nav-tabs {
  margin: 0;
  border-bottom: 1px solid #d7d7d7;
  color: #666;
  font-size: 14px;
  font-weight: 300;
  border-top-right-radius: 3px;
  border-top-left-radius: 3px;
}
.nav-tabs-custom > .nav-tabs > li {
  border-top: 3px solid transparent;
  margin-bottom: -1px;
  margin-right: 5px;
}
.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:active {
  color: #666;
  font-weight: 300;
  font-size: 14px;
  border-radius: 0;
  padding: 3px 10px 5px;
  text-transform: none;
}

.nav-tabs-custom > .nav-tabs > li:not(.active) > a {
  border-bottom-color: transparent;
}

.nav-tabs-custom > .nav-tabs > li > a.text-muted {
  color: #999;
}
.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:hover {
  background: transparent;
  margin: 0;
}
.nav-tabs-custom > .nav-tabs > li > a:hover {
  color: #999;
}
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:hover,
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:focus,
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:active {
  border-color: transparent;
}
.nav-tabs-custom > .nav-tabs > li.active {
  border-top-color: #3c8dbc;
}
.nav-tabs-custom > .nav-tabs > li.active > a,
.nav-tabs-custom > .nav-tabs > li.active:hover > a {
  background-color: #fff;
  color: #666;
}
.nav-tabs-custom > .nav-tabs > li.active > a {
  border-top-color: transparent;
  border-left-color: #d7d7d7;
  border-right-color: #d7d7d7;
}
.nav-tabs-custom > .nav-tabs > li:first-of-type {
  margin-left: 0;
}
.nav-tabs-custom > .nav-tabs > li:first-of-type.active > a {
  border-left-color: transparent;
}
.nav-tabs-custom > .nav-tabs.pull-right {
  float: none !important;
}
.nav-tabs-custom > .nav-tabs.pull-right > li {
  float: right;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type {
  margin-right: 0;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type > a {
  border-left-width: 1px;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type.active > a {
  border-left-color: #d7d7d7;
  border-right-color: transparent;
}
.nav-tabs-custom > .nav-tabs > li.header {
  line-height: 35px;
  padding: 0 10px;
  font-size: 20px;
  color: #666;
}
.nav-tabs-custom > .nav-tabs > li.header > .fa,
.nav-tabs-custom > .nav-tabs > li.header > .glyphicon,
.nav-tabs-custom > .nav-tabs > li.header > .ion {
  margin-right: 5px;
}
.nav-tabs-custom > .tab-content {
  background: #fff;
  padding: 0;
  border-bottom-right-radius: 3px;
  border-bottom-left-radius: 3px;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.nav-tabs-custom > .tab-content > .chart-wrapper {
  background: #fff;
  border: none;
  margin: 0;
}


.nav-tabs-custom > .tab-content > .active {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.nav-tabs-custom .dropdown.open > a:active,
.nav-tabs-custom .dropdown.open > a:focus {
  background: transparent;
  color: #999;
}


@media (max-width: 767px) {
  .value-box {
    text-align: center;
    margin-right: 8px;
  }
  .value-box .icon {
    display: none;
  }
}

/* Fixed position sidebar */

.section.sidebar {
  position: fixed;
  top: 51px; /* overridden by theme */
  left: 0;
  bottom: 0;
  border-right: 1px solid #e2e2e2;
  background-color: white; /* overridden by theme */
  padding-left: 10px;
  padding-right: 10px;
  visibility: hidden;
  overflow: auto;
}

.section.sidebar form p:first-child {
  margin-top: 10px;
}

/* Embedded source code */

#flexdashboard-source-code {
  display: none;
}

.featherlight-content #flexdashboard-source-code {
  display: inline-block;
}

.featherlight-content {
  width: 80%;
  max-width: 800px;
  padding: 0 !important;
  border-bottom: none !important;
}

.featherlight:last-of-type {
  background: rgba(0, 0, 0, 0.7);
}

.featherlight-inner {
  width: 100%;
}

.featherlight-content pre {
  margin: 0;
  border: 0;
  background: #fff;
  font-size: 12px;
}

.unselectable {
  -ms-user-select: none;
  -webkit-user-select: none;
  -khtml-user-select: none;
  -moz-user-select: -moz-none;
  -o-user-select: none;
  user-select: none;
}

#flexdashboard-source-code code {
  -ms-user-select: text;
  -webkit-user-select: text;
  -khtml-user-select: text;
  -moz-user-select: text;
  -o-user-select: text;
  user-select: text;
}

/* DataTables Tweaks */

.dataTables_filter input[type="search"] {
  -webkit-appearance: searchfield;
  outline: none;
}

.dataTables_wrapper.no-footer
.dataTables_info {
  padding-top: 0;
}


table.dataTable thead th {
  border-bottom: 1px solid #d7d7d7;
}

.dataTables_wrapper.no-footer .dataTables_scrollBody {
  border-bottom: 1px solid #d7d7d7;
}

/* Mobile phone only CSS */

.desktop-layout div.section.mobile {
  display: none;
}

.mobile-layout div.section.no-mobile {
  display: none;
}

.mobile-figure {
  display: none;
}



body {
  padding-top: 60px;
}

.section.sidebar {
  top: 51px;
  background-color: rgba(39, 128, 227, 0.1);
}

.value-box {
  color: #f9f9f9;
}

.bg-primary {
  background-color: rgba(39, 128, 227, 0.7);
}

.storyboard-nav .sbframelist ul li.active {
  background-color: rgba(39, 128, 227, 0.7);
}

.nav-tabs-custom > .nav-tabs > li.active {
  border-top-color: rgba(39, 128, 227, 0.7);
}

.bg-info {
  background-color: rgba(153, 84, 187, 0.7);
}

.bg-warning {
  background-color: rgba(255, 117, 24, 0.7);
}

.bg-danger {
  background-color: rgba(255, 0, 57, 0.7);
}

.bg-success {
  background-color: rgba(63, 182, 24, 0.7);
}

.chart-title {
  font-weight: 500;
}

.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:active {
  font-weight: 500;
}

@media only screen and (min-width: 768px) {
html, body {
  height: 100%;
}

#dashboard-container {
  height: 100%;
}
}
</style>



</head>

<body>

<div class="navbar navbar-inverse navbar-fixed-top" role="navigation">
<div class="container-fluid">
<div class="navbar-header">

<button id="navbar-button" type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>

<span class="navbar-logo pull-left">
  
</span>
<span class="navbar-brand">
  Covid-19 trials
  <span class="navbar-author">
        </span>
</span>

</div>
<div id="navbar" class="navbar-collapse collapse">
<ul class="nav navbar-nav navbar-left">
</ul>
<ul class="nav navbar-nav navbar-right">
</ul>
</div><!--/.nav-collapse-->
</div><!--/.container-->
</div><!--/.navbar-->

<script type="text/javascript">


var FlexDashboard = (function () {

  // initialize options
  var _options = {};

  var FlexDashboard = function() {

    // default options
    _options = $.extend(_options, {
      theme: "cosmo",
      fillPage: false,
      orientation: 'columns',
      storyboard: false,
      defaultFigWidth: 576,
      defaultFigHeight: 461,
      defaultFigWidthMobile: 360,
      defaultFigHeightMobile: 461,
      isMobile: false,
      isPortrait: false
    });
  };

  function init(options) {

    // extend default options
    $.extend(true, _options, options);

    // add ids to sections that don't have them (pandoc won't assign ids
    // to e.g. sections with titles consisting of only chinese characters)
    var nextId = 1;
    $('.level1:not([id]),.level2:not([id]),.level3:not([id])').each(function() {
      $(this).attr('id', 'dashboard-' + nextId++);
    });

    // find navbar items
    var navbarItems = $('#flexdashboard-navbar');
    if (navbarItems.length)
      navbarItems = JSON.parse(navbarItems.html());
    addNavbarItems(navbarItems);

    // find the main dashboard container
    var dashboardContainer = $('#dashboard-container');

    // resolve mobile classes
    resolveMobileClasses(dashboardContainer);

    // one time global initialization for components
    componentsInit(dashboardContainer);

    // look for a global sidebar
    var globalSidebar = dashboardContainer.find(".section.level1.sidebar");
    if (globalSidebar.length > 0) {

      // global layout for fullscreen displays
      if (!isMobilePhone()) {

         // hoist it up to the top level
         globalSidebar.insertBefore(dashboardContainer);

         // lay it out (set width/positions)
         layoutSidebar(globalSidebar, dashboardContainer);

      // tuck sidebar into first page for mobile phones
      } else {

        // convert it into a level3 section
        globalSidebar.removeClass('sidebar');
        globalSidebar.removeClass('level1');
        globalSidebar.addClass('level3');
        var h1 = globalSidebar.children('h1');
        var h3 = $('<h3></h3>');
        h3.html(h1.html());
        h3.insertBefore(h1);
        h1.remove();

        // move it into the first page
        var page = dashboardContainer.find('.section.level1').first();
        if (page.length > 0)
          page.prepend(globalSidebar);
      }
    }

    // look for pages to layout
    var pages = $('div.section.level1');
    if (pages.length > 0) {

        // find the navbar and collapse on clicked
        var navbar = $('#navbar');
        navbar.on("click", "a[data-toggle!=dropdown]", null, function () {
           navbar.collapse('hide');
        });

        // envelop the dashboard container in a tab content div
        dashboardContainer.wrapInner('<div class="tab-content"></div>');

        pages.each(function(index) {

          // lay it out
          layoutDashboardPage($(this));

          // add it to the navbar
          addToNavbar($(this), index === 0);

        });

    } else {

      // remove the navbar and navbar button if we don't
      // have any navbuttons
      if (navbarItems.length === 0) {
        $('#navbar').remove();
        $('#navbar-button').remove();
      }

      // add the storyboard class if requested
      if (_options.storyboard)
        dashboardContainer.addClass('storyboard');

      // layout the entire page
      layoutDashboardPage(dashboardContainer);
    }

    // if we are in shiny we need to trigger a window resize event to
    // force correct layout of shiny-bound-output elements
    if (isShinyDoc())
      $(window).trigger('resize');

    // make main components visible
    $('.section.sidebar').css('visibility', 'visible');
    dashboardContainer.css('visibility', 'visible');

    // handle location hash
    handleLocationHash();

    // intialize prism highlighting
    initPrismHighlighting();

    // record mobile and orientation state then register a handler
    // to refresh if it changes
    _options.isMobile = isMobilePhone();
    _options.isPortrait = isPortrait();
    $(window).on('resize', function() {
      if (_options.isMobile !== isMobilePhone() ||
          _options.isPortrait !== isPortrait()) {
        window.location.reload();
      }
    });

    // trigger layoutcomplete event
    dashboardContainer.trigger('flexdashboard:layoutcomplete');
  }

  function resolveMobileClasses(dashboardContainer) {
     // add top level layout class
    dashboardContainer.addClass(isMobilePhone() ? 'mobile-layout' :
                                                  'desktop-layout');

    // look for .mobile sections and add .no-mobile to their peers
    var mobileSections = $('.section.mobile');
    mobileSections.each(function() {
       var id = $(this).attr('id');
       var nomobileId = id.replace(/-\d+$/, '');
       $('#' + nomobileId).addClass('no-mobile');
    });
  }

  function addNavbarItems(navbarItems) {

    var navbarLeft = $('ul.navbar-left');
    var navbarRight = $('ul.navbar-right');

    for (var i = 0; i<navbarItems.length; i++) {

      // get the item
      var item = navbarItems[i];

      // determine the container
      var container = null;
      if (item.align === "left")
        container = navbarLeft;
      else
        container = navbarRight;

      // navbar menu if we have multiple items
      if (item.items) {
        var menu = navbarMenu(null, item.icon, item.title, container);
        for (var j = 0; j<item.items.length; j++) {
          var subItem = item.items[j];
          var li = $('<li></li>');
          li.append(navbarLink(subItem.icon, subItem.title, subItem.href, subItem.target));
          menu.append(li);
        }
      } else {
        var li = $('<li></li>');
        li.append(navbarLink(item.icon, item.title, item.href, item.target));
        container.append(li);
      }
    }
  }

  // create or get a reference to an existing dropdown menu
  function navbarMenu(id, icon, title, container) {
    var existingMenu = [];
    if (id)
      existingMenu = container.children('#' + id);
    if (existingMenu.length > 0) {
      return existingMenu.children('ul');
    } else {
      var li = $('<li></li>');
      if (id)
        li.attr('id', id);
      li.addClass('dropdown');
      // auto add "Share" title on mobile if necessary
      if (!title && icon && (icon === "fa-share-alt") && isMobilePhone())
        title = "Share";
      if (title) {
        title = title + ' <span class="caret"></span>';
      }
      var a = navbarLink(icon, title, "#");
      a.addClass('dropdown-toggle');
      a.attr('data-toggle', 'dropdown');
      a.attr('role', 'button');
      a.attr('aria-expanded', 'false');
      li.append(a);
      var ul = $('<ul class="dropdown-menu"></ul>');
      ul.attr('role', 'menu');
      li.append(ul);
      container.append(li);
      return ul;
    }
  }

  function addToNavbar(page, active) {

    // capture the id and data-icon attribute (if any)
    var id = page.attr('id');
    var icon = page.attr('data-icon');
    var navmenu = page.attr('data-navmenu');

    // get hidden state (transfer this to navbar)
    var hidden = page.hasClass('hidden');
    page.removeClass('hidden');

    // sanitize the id for use with bootstrap tabs
    id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
    page.attr('id', id);

    // get the wrapper
    var wrapper = page.closest('.dashboard-page-wrapper');

    // move the id to the wrapper
    page.removeAttr('id');
    wrapper.attr('id', id);

    // add the tab-pane class to the wrapper
    wrapper.addClass('tab-pane');
    if (active)
      wrapper.addClass('active');

    // get a reference to the h1, discover it's id and title, then remove it
    var h1 = wrapper.find('h1').first();
    var title = h1.html();
    h1.remove();

    // create a navbar item
    var li = $('<li></li>');
    var a = navbarLink(icon, title, '#' + id);
    a.attr('data-toggle', 'tab');
    li.append(a);

    // add it to the navbar (or navbar menu if specified)
    var container = $('ul.navbar-left');
    if (navmenu) {
      var menuId = navmenu.replace(/\s+/g, '');
      var menu = navbarMenu(menuId, null, navmenu, container);
      menu.append(li);
    } else {
      container.append(li);
    }

    // hide it if requested
    if (hidden)
      li.addClass('hidden');
  }

  function navbarLink(icon, title, href, target) {

    var a = $('<a></a>');
    if (icon) {

      // get the name of the icon set and icon
      var dashPos = icon.indexOf("-");
      var iconSet = icon.substring(0, dashPos);
      var iconName = icon.substring(dashPos + 1);

      // create the icon
      var iconElement = $('<span class="' + iconSet + ' ' + icon + '"></span>');
      if (title)
        iconElement.css('margin-right', '7px');
      a.append(iconElement);
      // if href is null see if we can auto-generate based on icon (e.g. social)
      if (!href)
        maybeGenerateLinkFromIcon(iconName, a);
    }
    if (title)
      a.append(title);

    // add the href.
    if (href) {
      if (href === "source_embed") {
        a.attr('href', '#');
        a.attr('data-featherlight', "#flexdashboard-source-code");
        a.featherlight({
            beforeOpen: function(event){
              $('body').addClass('unselectable');
            },
            afterClose: function(event){
              $('body').removeClass('unselectable');
            }
        });
      } else {
        a.attr('href', href);
      }
    }

    // add the arget
    if (target)
      a.attr('target', target);

    return a;
  }

  // auto generate a link from an icon name (e.g. twitter) when possible
  function maybeGenerateLinkFromIcon(iconName, a) {

     var serviceLinks = {
      "twitter": "https://twitter.com/share?text=" + encodeURIComponent(document.title) + "&url="+encodeURIComponent(location.href),
      "facebook": "https://www.facebook.com/sharer/sharer.php?s=100&p[url]="+encodeURIComponent(location.href),
      "google-plus": "https://plus.google.com/share?url="+encodeURIComponent(location.href),
      "linkedin": "https://www.linkedin.com/shareArticle?mini=true&url="+encodeURIComponent(location.href) + "&title=" + encodeURIComponent(document.title),
      "pinterest": "https://pinterest.com/pin/create/link/?url="+encodeURIComponent(location.href) + "&description=" + encodeURIComponent(document.title)
    };

    var makeSocialLink = function(a, href) {
      a.attr('href', '#');
      a.on('click', function(e) {
        e.preventDefault();
        window.open(href);
      });
    };

    $.each(serviceLinks, function(key, value) {
      if (iconName.indexOf(key) !== -1)
        makeSocialLink(a, value);
    });
  }

  // layout a dashboard page
  function layoutDashboardPage(page) {

    // use a page wrapper so that free form content above the
    // dashboard appears at the top rather than the side (as it
    // would without the wrapper in a column orientation)
    var wrapper = $('<div class="dashboard-page-wrapper"></div>');
    page.wrap(wrapper);

    // if there are no level2 or level3 headers synthesize a level3
    // header to contain the (e.g. frame it, scroll container, etc.)
    var headers = page.find('h2,h3');
    if (headers.length === 0)
      page.wrapInner('<div class="section level3"></div>');

    // hoist up any content before level 2 or level 3 headers
    var children = page.children();
    children.each(function(index) {
      if ($(this).hasClass('level2') || $(this).hasClass('level3'))
        return false;
      $(this).insertBefore(page);
    });

    // determine orientation and fillPage behavior for distinct media
    var orientation, fillPage, storyboard;

    // media: mobile phone
    if (isMobilePhone()) {

      // if there is a sidebar we need to ensure it's content
      // is properly framed as an h3
      var sidebar = page.find('.section.sidebar');
      sidebar.removeClass('sidebar');
      sidebar.wrapInner('<div class="section level3"></div>');
      var h2 = sidebar.find('h2');
      var h3 = $('<h3></h3>');
      h3.html(h2.html());
      h3.insertBefore(h2);
      h2.remove();

      // wipeout h2 elements then enclose them in a single h2
      var level2 = page.find('div.section.level2');
      level2.each(function() {
        level2.children('h2').remove();
        level2.children().unwrap();
      });
      page.wrapInner('<div class="section level2"></div>');

      // substitute mobile images
      if (isPortrait()) {
        var mobileFigures = $('img.mobile-figure');
        mobileFigures.each(function() {
          // get the src (might be base64 encoded)
          var src = $(this).attr('src');

          // find it's peer
          var id = $(this).attr('data-mobile-figure-id');
          var img = $('img[data-figure-id=' + id + "]");
          img.attr('src', src)
             .attr('width', _options.defaultFigWidthMobile)
             .attr('height', _options.defaultFigHeightMobile);
        });
      }

      // hoist storyboard commentary into it's own section
      if (page.hasClass('storyboard')) {
        var commentaryHR = page.find('div.section.level3 hr');
        commentaryHR.each(function() {
          var commentary = $(this).nextAll().detach();
          var commentarySection = $('<div class="section level3"></div>');
          commentarySection.append(commentary);
          commentarySection.insertAfter($(this).closest('div.section.level3'));
          $(this).remove();
        });
      }

      // force a non full screen layout by columns
      orientation = _options.orientation = 'columns';
      fillPage = _options.fillPage = false;
      storyboard = _options.storyboard = false;

    // media: desktop
    } else {

      // determine orientation
      orientation = page.attr('data-orientation');
      if (orientation !== 'rows' && orientation != 'columns')
        orientation = _options.orientation;

      // determine storyboard mode
      storyboard = page.hasClass('storyboard');

      // fillPage based on options (force for storyboard)
      fillPage = _options.fillPage || storyboard;

      // handle sidebar
      var sidebar = page.find('.section.level2.sidebar');
      if (sidebar.length > 0)
        layoutSidebar(sidebar, page);
    }

    // give it and it's parent divs height: 100% if we are in fillPage mode
    if (fillPage) {
      page.addClass('vertical-layout-fill');
      page.css('height', '100%');
      page.parents('div').css('height', '100%');
    } else {
      page.addClass('vertical-layout-scroll');
    }

    // perform the layout
    if (storyboard)
      layoutPageAsStoryboard(page);
    else if (orientation === 'rows')
      layoutPageByRows(page, fillPage);
    else if (orientation === 'columns')
      layoutPageByColumns(page, fillPage);
  }

  function layoutSidebar(sidebar, content) {

    // get it out of the header hierarchy
    sidebar = sidebar.first();
    if (sidebar.hasClass('level1')) {
      sidebar.removeClass('level1');
      sidebar.children('h1').remove();
    } else if (sidebar.hasClass('level2')) {
      sidebar.removeClass('level2');
      sidebar.children('h2').remove();
    }

    // determine width
    var sidebarWidth = isTablet() ? 220 : 250;
    var dataWidth = parseInt(sidebar.attr('data-width'));
    if (dataWidth)
      sidebarWidth = dataWidth;

    // set the width and shift the page right to accomodate the sidebar
    sidebar.css('width', sidebarWidth + 'px');
    content.css('padding-left', sidebarWidth + 'px');

    // wrap it's contents in a form
    sidebar.wrapInner($('<form></form>'));
  }

  function layoutPageAsStoryboard(page) {

    // create storyboard navigation
    var nav = $('<div class="storyboard-nav"></div>');

    // add navigation buttons
    var prev = $('<button class="sbprev"><i class="fa fa-angle-left"></i></button>');
    nav.append(prev);
    var next= $('<button class="sbnext"><i class="fa fa-angle-right"></i></button>');
    nav.append(next);

    // add navigation frame
    var frameList = $('<div class="sbframelist"></div>');
    nav.append(frameList);
    var ul = $('<ul></ul>');
    frameList.append(ul);

     // find all the level3 sections (those are the storyboard frames)
    var frames = page.find('div.section.level3');
    frames.each(function() {

      // mark it
      $(this).addClass('sbframe');

      // divide it into chart content and (optional) commentary
      $(this).addClass('dashboard-column-orientation');

      // stuff the chart into it's own div w/ flex
      $(this).wrapInner('<div class="sbframe-component"></div>');
      setFlex($(this), 1);
      var frame = $(this).children('.sbframe-component');

      // extract the title from the h3
      var li = $('<li></li>');
      var h3 = frame.children('h3');
      li.html(h3.html());
      h3.remove();
      ul.append(li);

      // extract commentary
      var hr = frame.children('hr');
      if (hr.length) {
        var commentary = hr.nextAll().detach();
        hr.remove();
        var commentaryFrame = $('<div class="sbframe-commentary"></div>');
        commentaryFrame.addClass('flowing-content-shim');
        commentaryFrame.addClass('flowing-content-container');
        commentaryFrame.append(commentary);
        $(this).append(commentaryFrame);

        // look for a data-commentary-width attribute
        var commentaryWidth = $(this).attr('data-commentary-width');
        if (commentaryWidth)
          commentaryFrame.css('width', commentaryWidth + 'px');
      }

      // layout the chart (force flex)
      var result = layoutChart(frame, true);

      // ice the notes if there are none
      if (!result.notes)
        frame.find('.chart-notes').remove();

      // set flex on chart
      setFlex(frame, 1);
    });

    // create a div to hold all the frames
    var frameContent = $('<div class="sbframe-content"></div>');
    frameContent.addClass('dashboard-row-orientation');
    frameContent.append(frames.detach());

    // row orientation to stack nav and frame content
    page.addClass('dashboard-row-orientation');
    page.append(nav);
    page.append(frameContent);
    setFlex(frameContent, 1);

    // initialize sly
    var sly = new Sly(frameList, {
    		horizontal: true,
    		itemNav: 'basic',
    		smart: true,
    		activateOn: 'click',
    		startAt: 0,
    		scrollBy: 1,
    		activatePageOn: 'click',
    		speed: 200,
    		moveBy: 600,
    		dragHandle: true,
    		dynamicHandle: true,
    		clickBar: true,
    		keyboardNavBy: 'items',
    		next: next,
    		prev: prev
    	}).init();

    // make first frame active
    frames.removeClass('active');
    frames.first().addClass('active');

    // subscribe to frame changed events
    sly.on('active', function (eventName, itemIndex) {
      frames.removeClass('active');
      frames.eq(itemIndex).addClass('active')
                          .trigger('shown');
    });
  }

  function layoutPageByRows(page, fillPage) {

    // row orientation
    page.addClass('dashboard-row-orientation');

    // find all the level2 sections (those are the rows)
    var rows = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (rows.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      rows = page.find('div.section.level2');
    }

    rows.each(function () {

      // flags
      var haveNotes = false;
      var haveFlexHeight = true;

      // remove the h2
      $(this).children('h2').remove();

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // give it row layout semantics if it's not a tabset
      if (!isTabset)
        $(this).addClass('dashboard-row');

      // find all of the level 3 subheads
      var columns = $(this).find('div.section.level3');

      // determine figureSizes sizes
      var figureSizes = chartFigureSizes(columns);

      // fixup the columns
      columns.each(function(index) {

        // layout the chart (force flex if we are in a tabset)
        var result = layoutChart($(this), isTabset);

        // update flexHeight state
        if (!result.flex)
          haveFlexHeight = false;

        // update state
        if (result.notes)
          haveNotes = true;

        // set the column flex based on the figure width
        // (value boxes will just get the default figure width)
        var chartWidth = figureSizes[index].width;
        setFlex($(this), chartWidth + ' ' + chartWidth + ' 0px');

      });

      // remove empty chart note divs
      if (isTabset)
        $(this).find('.chart-notes').filter(function() {
            return $(this).html() === "&nbsp;";
        }).remove();
      if (!haveNotes)
        $(this).find('.chart-notes').remove();

       // make it a flexbox row
      if (haveFlexHeight)
        $(this).addClass('dashboard-row-flex');

      // now we can set the height on all the wrappers (based on maximum
      // figure height + room for title and notes, or data-height on the
      // container if specified). However, don't do this if there is
      // no flex on any of the constituent columns
      var flexHeight = null;
      var dataHeight = parseInt($(this).attr('data-height'));
      if (dataHeight)
        flexHeight = adjustedHeight(dataHeight, columns.first());
      else if (haveFlexHeight)
        flexHeight = maxChartHeight(figureSizes, columns);
      if (flexHeight) {
        if (fillPage)
          setFlex($(this), flexHeight + ' ' + flexHeight + ' 0px');
        else {
          $(this).css('height', flexHeight + 'px');
          setFlex($(this), '0 0 ' + flexHeight + 'px');
        }
      }

    });
  }

  function layoutPageByColumns(page, fillPage) {

    // column orientation
    page.addClass('dashboard-column-orientation');

    // find all the level2 sections (those are the columns)
    var columns = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (columns.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      columns = page.find('div.section.level2');
    }

    // layout each column
    columns.each(function (index) {

      // remove the h2
      $(this).children('h2').remove();

      // make it a flexbox column
      $(this).addClass('dashboard-column');

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // find all the h3 elements
      var rows = $(this).find('div.section.level3');

      // get the figure sizes for the rows
      var figureSizes = chartFigureSizes(rows);

      // column flex is the max row width (or data-width if specified)
      var flexWidth;
      var dataWidth = parseInt($(this).attr('data-width'));
      if (dataWidth)
        flexWidth = dataWidth;
      else
        flexWidth = maxChartWidth(figureSizes);
      setFlex($(this), flexWidth + ' ' + flexWidth + ' 0px');

      // layout each chart
      rows.each(function(index) {

        // perform the layout
        var result = layoutChart($(this), false);

        // ice the notes if there are none
        if (!result.notes)
          $(this).find('.chart-notes').remove();

        // set flex height based on figHeight, then adjust
        if (result.flex) {
          var chartHeight = figureSizes[index].height;
          chartHeight = adjustedHeight(chartHeight, $(this));
          if (fillPage)
            setFlex($(this), chartHeight + ' ' + chartHeight + ' 0px');
          else {
            $(this).css('height', chartHeight + 'px');
            setFlex($(this), chartHeight + ' ' + chartHeight + ' ' + chartHeight + 'px');
          }
        }
      });
    });
  }

  function chartFigureSizes(charts) {

    // sizes
    var figureSizes = new Array(charts.length);

    // check each chart
    charts.each(function(index) {

      // start with default
      figureSizes[index] = {
        width: _options.defaultFigWidth,
        height: _options.defaultFigHeight
      };

      // look for data-height or data-width then knit options
      var dataWidth = parseInt($(this).attr('data-width'));
      var dataHeight = parseInt($(this).attr('data-height'));
      var knitrOptions = $(this).find('.knitr-options:first');
      var knitrWidth, knitrHeight;
      if (knitrOptions) {
        knitrWidth = parseInt(knitrOptions.attr('data-fig-width'));
        knitrHeight =  parseInt(knitrOptions.attr('data-fig-height'));
      }

      // width
      if (dataWidth)
        figureSizes[index].width = dataWidth;
      else if (knitrWidth)
        figureSizes[index].width = knitrWidth;

      // height
      if (dataHeight)
        figureSizes[index].height = dataHeight;
      else if (knitrHeight)
        figureSizes[index].height = knitrHeight;
    });

    // return sizes
    return figureSizes;
  }

  function maxChartHeight(figureSizes, charts) {

    // first compute the maximum height
    var maxHeight = _options.defaultFigHeight;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].height > maxHeight)
        maxHeight = figureSizes[i].height;

    // now add offests for chart title and chart notes
    if (charts.length)
      maxHeight = adjustedHeight(maxHeight, charts.first());

    return maxHeight;
  }

  function adjustedHeight(height, chart) {
    if (chart.length > 0) {
      var chartTitle = chart.find('.chart-title');
      if (chartTitle.length)
        height += chartTitle.first().outerHeight();
      var chartNotes = chart.find('.chart-notes');
      if (chartNotes.length)
        height += chartNotes.first().outerHeight();
    }
    return height;
  }

  function maxChartWidth(figureSizes) {
    var maxWidth = _options.defaultFigWidth;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].width > maxWidth)
        maxWidth = figureSizes[i].width;
    return maxWidth;
  }

  // layout a chart
  function layoutChart(chart, forceFlex) {

    // state to return
    var result = {
      notes: false,
      flex: false
    };

    // extract the title
    var title = extractTitle(chart);

    // find components that apply to this container
    var components = componentsFind(chart);

    // if it's a custom component then call it and return
    var customComponents = componentsCustom(components);
    if (customComponents.length) {
      componentsLayout(customComponents, title, chart);
      result.notes = false;
      result.flex = forceFlex || componentsFlex(customComponents);
      return result;
    }

    // put all the content in a chart wrapper div
    chart.addClass('chart-wrapper');
    chart.wrapInner('<div class="chart-stage"></div>');
    var chartContent = chart.children('.chart-stage');

    // flex the content if appropriate
    result.flex = forceFlex || componentsFlex(components);
    if (result.flex) {
      // add flex classes
      chart.addClass('chart-wrapper-flex');
      chartContent.addClass('chart-stage-flex');

      // additional shim to break out of flexbox sizing
      chartContent.wrapInner('<div class="chart-shim"></div>');
      chartContent = chartContent.children('.chart-shim');
    }

    // set custom data-padding attribute
    var pad = chart.attr('data-padding');
    if (pad) {
      if (pad === "0")
        chart.addClass('no-padding');
      else {
        pad = pad + 'px';
        chartContent.css('left', pad)
                    .css('top', pad)
                    .css('right', pad)
                    .css('bottom', pad)
      }
    }

    // call compoents
    componentsLayout(components, title, chartContent);

    // also activate components on shiny output
    findShinyOutput(chartContent).on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {

          // see if we opted out of flex based on our output (for shiny
          // we can't tell what type of output we have until after the
          // value is bound)
          var components = componentsFind(element);
          var flex = forceFlex || componentsFlex(components);
          if (!flex) {
            chart.css('height', "");
            setFlex(chart, "");
            chart.removeClass('chart-wrapper-flex');
            chartContent.removeClass('chart-stage-flex');
            chartContent.children().unwrap();
          }

          // perform layout
          componentsLayout(components, title, element.parent());
        }, 10);
      });

    // add the title
    var chartTitle = $('<div class="chart-title"></div>');
    chartTitle.html(title);
    chart.prepend(chartTitle);

    // add the notes section
    var chartNotes = $('<div class="chart-notes"></div>');
    chartNotes.html('&nbsp;');
    chart.append(chartNotes);

    // attempt to extract notes if we have a component
    if (components.length)
      result.notes = extractChartNotes(chartContent, chartNotes);

    // return result
    return result;
  }

  // build a tabset from a section div with the .tabset class
  function layoutTabset(tabset) {

    // check for fade option
    var fade = tabset.hasClass("tabset-fade");
    var navClass = "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it and grab it's text
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      if (i === 0)
        li.attr('class', 'active');
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      tab.addClass('no-title');
      if (fade)
        tab.addClass('fade');
      if (i === 0) {
        tab.addClass('active');
        if (fade)
          tab.addClass('in');
      }

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // add nav-tabs-custom
    tabset.addClass('nav-tabs-custom');

    // internal layout is dashboard-column with tab-content flexing
    tabset.addClass('dashboard-column');
    setFlex(tabContent, 1);
  }

  // one time global initialization for components
  function componentsInit(dashboardContainer) {
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.init)
        component.init(dashboardContainer);
    }
  }

  // find components that apply within a container
  function componentsFind(container) {

    // look for components
    var components = [];
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.find(container).length)
        components.push(component);
    }

    // if there were none then use a special flowing content component
    // that just adds a scrollbar in fillPage mode
    if (components.length == 0) {
      components.push({
        find: function(container) {
          return container;
        },

        flex: function(fillPage) {
          return fillPage;
        },

        layout: function(title, container, element, fillPage) {
          if (fillPage) {
            container.addClass('flowing-content-shim');
            container.addClass('flowing-content-container');
          }
        }
      });
    }

    return components;
  }

  // if there is a custom component then pick it out
  function componentsCustom(components) {
    var customComponent = [];
    for (var i=0; i<components.length; i++)
      if (components[i].type === "custom") {
        customComponent.push(components[i]);
        break;
      }
    return customComponent;
  }

  // query all components for flex
  function componentsFlex(components) {

    // no components at all means no flex
    if (components.length === 0)
      return false;

    // otherwise query components (assume true unless we see false)
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++)
      if (components[i].flex && !components[i].flex(_options.fillPage))
        return false;
    return true;
  }

  // layout all components
  function componentsLayout(components, title, container) {
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++) {
      var element = components[i].find(container);
      if (components[i].layout) {
        // call layout (don't call other components if it returns false)
        var result = components[i].layout(title, container, element, _options.fillPage);
        if (result === false)
          return;
      }
    }
  }

  // get a reference to the h3, discover it's inner html, and remove it
  function extractTitle(container) {
    var h3 = container.children('h3').first();
    var title = '';
    if (!container.hasClass('no-title'))
      title = h3.html();
    h3.remove();
    return title;
  }

  // extract chart notes
  function extractChartNotes(chartContent, chartNotes) {
    // look for a terminating blockquote or image caption
    var blockquote = chartContent.children('blockquote:last-child');
    var caption = chartContent.children('div.image-container')
                              .children('p.caption');
    if (blockquote.length) {
      chartNotes.html(blockquote.children('p:first-child').html());
      blockquote.remove();
      return true;
    } else if (caption.length) {
      chartNotes.html(caption.html());
      caption.remove();
      return true;
    } else {
      return false;
    }
  }

  function findShinyOutput(chartContent) {
    return chartContent.find('.shiny-text-output, .shiny-html-output');
  }

  // safely detect rendering on a mobile phone
  function isMobilePhone() {
    try
    {
      return ! window.matchMedia("only screen and (min-width: 768px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  function isFillPage() {
    return _options.fillPage;
  }

  // detect portrait mode
  function isPortrait() {
    return ($(window).width() < $(window).height());
  }

  // safely detect rendering on a tablet
  function isTablet() {
    try
    {
      return window.matchMedia("only screen and (min-width: 769px) and (max-width: 992px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  // test whether this is a shiny doc
  function isShinyDoc() {
    return (typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings);
  }

  // set flex using vendor specific prefixes
  function setFlex(el, flex) {
    el.css('-webkit-box-flex', flex)
      .css('-webkit-flex', flex)
      .css('-ms-flex', flex)
      .css('flex', flex);
  }

  // support bookmarking of pages
  function handleLocationHash() {

    // restore tab/page from bookmark
    var hash = window.location.hash;
    if (hash.length > 0)
      $('ul.nav a[href="' + hash + '"]').tab('show');
    FlexDashboardUtils.manageActiveNavbarMenu();

    // navigate to a tab when the history changes
    window.addEventListener("popstate", function(e) {
      var hash = window.location.hash;
      var activeTab = $('ul.nav a[href="' + hash + '"]');
      if (activeTab.length) {
        activeTab.tab('show');
      } else {
        $('ul.nav a:first').tab('show');
      }
      FlexDashboardUtils.manageActiveNavbarMenu();
    });

    // add a hash to the URL when the user clicks on a tab/page
    $('.navbar-nav a[data-toggle="tab"]').on('click', function(e) {
      var baseUrl = FlexDashboardUtils.urlWithoutHash(window.location.href);
      var hash = FlexDashboardUtils.urlHash($(this).attr('href'));
      var href = baseUrl + hash;
      FlexDashboardUtils.setLocation(href);
    });

    // handle clicks of other links that should activate pages
    var navPages = $('ul.navbar-nav li a[data-toggle=tab]');
    navPages.each(function() {
      var href =  $(this).attr('href');
      var links = $('a[href="' + href + '"][data-toggle!=tab]');
      links.each(function() {
        $(this).on('click', function(e) {
          window.FlexDashboardUtils.showPage(href);
        });
      });
    });
  }

  // tweak Prism highlighting
  function initPrismHighlighting() {

    if (window.Prism) {
      Prism.languages.insertBefore('r', 'comment', {
        'heading': [
          {
            // title 1
        	  // =======

        	  // title 2
        	  // -------
        	  pattern: /\w+.*(?:\r?\n|\r)(?:====+|----+)/,
            alias: 'operator'
          },
          {
            // ### title 3
            pattern: /(^\s*)###[^#].+/m,
            lookbehind: true,
            alias: 'operator'
          }
        ]
      });

      // prism highlight
      Prism.highlightAll();
    }
  }


  // get theme color
  var themeColors = {
    bootstrap: {
      primary: "rgba(51, 122, 183, 0.4)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    cerulean: {
      primary: "rgb(47, 164, 231)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    journal: {
      primary: "rgba(235, 104, 100, 0.70)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    flatly: {
      primary: "rgba(44, 62, 80, 0.70)",
      info: "rgba(52, 152, 219, 0.70)",
      success: "rgba(24, 188, 156, 0.70)",
      warning: "rgba(243, 156, 18, 0.70)",
      danger: "rgba(231, 76, 60, 0.70)"
    },
    readable: {
      primary: "rgba(69, 130, 236, 0.4)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    spacelab: {
      primary: "rgba(68, 110, 155, 0.25)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    united: {
      primary: "rgba(221, 72, 20, 0.30)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    cosmo: {
      primary: "rgba(39, 128, 227, 0.7)",
      info: "rgba(153, 84, 187, 0.7)",
      success: "rgba(63, 182, 24, 0.7)",
      warning: "rgba(255, 117, 24, 0.7)",
      danger: "rgba(255, 0, 57, 0.7)"
    },
    lumen: {
      primary: "rgba(21, 140, 186, 0.70)",
      info: "rgba(117, 202, 235, 0.90)",
      success: "rgba(40, 182, 44, 0.70)",
      warning: "rgba(255, 133, 27, 0.70)",
      danger: "rgba(255, 65, 54, 0.70)"
    },
    paper: {
      primary: "rgba(33, 150, 243, 0.35)",
      info: "rgb(225, 190, 231)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(255, 224, 178)",
      danger: "rgb(249, 189, 187)"
    },
    sandstone: {
      primary: "rgba(50, 93, 136, 0.3)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    simplex: {
      primary: "rgba(217, 35, 15, 0.25)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    yeti: {
      primary: "rgba(0, 140, 186, 0.298039)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    }
  }
  function themeColor(color) {
    return themeColors[_options.theme][color];
  }

  FlexDashboard.prototype = {
    constructor: FlexDashboard,
    init: init,
    isMobilePhone: isMobilePhone,
    isFillPage: isFillPage,
    themeColor: themeColor
  };

  return FlexDashboard;

})();

// utils
window.FlexDashboardUtils = {
  resizableImage: function(img) {
    var src = img.attr('src');
    var url = 'url("' + src + '")';
    img.parent().css('background', url)
                .css('background-size', 'contain')
                .css('background-repeat', 'no-repeat')
                .css('background-position', 'center')
                .addClass('image-container');
  },
  setLocation: function(href) {
    if (history && history.pushState) {
      history.pushState(null, null, href);
    } else {
      window.location.replace(href);
    }
    setTimeout(function() {
        window.scrollTo(0, 0);
    }, 10);
    this.manageActiveNavbarMenu();
  },
  showPage: function(href) {
    $('ul.navbar-nav li a[href="' + href + '"]').tab('show');
    var baseUrl = this.urlWithoutHash(window.location.href);
    var loc = baseUrl + href;
    this.setLocation(loc);
  },
  showLinkedValue: function(href) {
    // check for a page link
    if ($('ul.navbar-nav li a[data-toggle=tab][href="' + href + '"]').length > 0)
      this.showPage(href);
    else
      window.open(href);
  },
  urlWithoutHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(0, hashLoc);
    else
      return url;
  },
  urlHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(hashLoc);
    else
      return "";
  },
  manageActiveNavbarMenu: function () {
    // remove active from anyone currently active
    $('.navbar ul.nav').find('li').removeClass('active');
    // find the active tab
    var activeTab = $('.dashboard-page-wrapper.tab-pane.active');
    if (activeTab.length > 0) {
      var tabId = activeTab.attr('id');
      if (tabId)
        $(".navbar ul.nav a[href='#" + tabId + "']").parents('li').addClass('active');
    }
  }
};

window.FlexDashboard = new FlexDashboard();

// empty content
window.FlexDashboardComponents.push({
  find: function(container) {
    if (container.find('p').length == 0)
      return container;
    else
      return $();
  }
})

// plot image
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('p')
                    .children('img:only-child');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// plot image (figure style)
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.figure').children('img');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// htmlwidget
window.FlexDashboardComponents.push({

  init: function(dashboardContainer) {
    // trigger "shown" after initial layout to force static htmlwidgets
    // in runtime: shiny to be resized after the dom has been transformed
    dashboardContainer.on('flexdashboard:layoutcomplete', function(event) {
      setTimeout(function() {
        dashboardContainer.trigger('shown');
      }, 200);
    });
  },

  find: function(container) {
    return container.children('div[id^="htmlwidget-"],div.html-widget');
  }
});

// gauge
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.html-widget.gauge');
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {


  }

});

// shiny output
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.children('div[class^="shiny-"]');
  }
});

// datatables
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.find('.datatables');
  },
  flex: function(fillPage) {
    return fillPage;
  }
});

// bootstrap table
window.FlexDashboardComponents.push({

  find: function(container) {
    var bsTable = container.find('table.table');
    if (bsTable.length !== 0)
      return bsTable;
    else
      return container.find('tr.header').parent('thead').parent('table');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var bsTable = element;

    // fixup xtable generated tables with a proper thead
    var headerRow = bsTable.find('tbody > tr:first-child > th').parent();
    if (headerRow.length > 0) {
      var thead = $('<thead></thead>');
      bsTable.prepend(thead);
      headerRow.detach().appendTo(thead);
    }

    // improve appearance
    container.addClass('bootstrap-table');

    // for fill page provide scrolling w/ sticky headers
    if (fillPage) {
      // force scrollbar on overflow
      container.addClass('flowing-content-shim');

      // stable table headers when scrolling
      bsTable.stickyTableHeaders({
        scrollableArea: container
      });
    }
  }
});

// embedded shiny app
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('iframe.shiny-frame');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage) {
      element.attr('height', '100%');
    } else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (!height)
        height = element.attr('height');
      if (!height)
        element.attr('height', 500);
    }
  }
});

// shiny fillRow or fillCol
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('.flexfill-container');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage)
      element.css('height', '100%');
    else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (height === "100%" || height === "auto" || height === "initial" ||
          height === "inherit" || !height) {
        element.css('height', 500);
      }
    }
  }
});

// valueBox
window.FlexDashboardComponents.push({

  type: "custom",

  find: function(container) {
    if (container.find('span.value-output, .shiny-valuebox-output').length)
      return container;
    else
      return $();
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var chartTitle = title;
    var valueBox = element;

    // add value-box class to container
    container.addClass('value-box');

    // value paragraph
    var value = $('<p class="value"></p>');

    // if we have shiny-text-output then just move it in
    var valueOutputSpan = [];
    var shinyOutput = valueBox.find('.shiny-valuebox-output').detach();
    if (shinyOutput.length) {
      valueBox.children().remove();
      shinyOutput.html("&mdash;");
      value.append(shinyOutput);
    } else {
      // extract the value (remove leading vector index)
      var chartValue = valueBox.text().trim();
      chartValue = chartValue.replace("[1] ", "");
      valueOutputSpan = valueBox.find('span.value-output').detach();
      valueBox.children().remove();
      value.text(chartValue);
    }

    // caption
    var caption = $('<p class="caption"></p>');
    caption.html(chartTitle);

    // build inner div for value box and add it
    var inner = $('<div class="inner"></div>');
    inner.append(value);
    inner.append(caption);
    valueBox.append(inner);

    // add icon if specified
    var icon = $('<div class="icon"><i></i></div>');
    valueBox.append(icon);
    function setIcon(chartIcon) {
      var iconLib = "";
      var components = chartIcon.split("-");
      if (components.length > 1)
        iconLib = components[0];
      icon.children('i').attr('class', iconLib + ' ' + chartIcon);
    }
    var chartIcon = valueBox.attr('data-icon');
    if (chartIcon)
      setIcon(chartIcon);

    // set color based on data-background if necessary
    var dataBackground = valueBox.attr('data-background');
    if (dataBackground)
      valueBox.css('background-color', bgColor);
    else {
      // default to bg-primary if no other background is specified
      if (!valueBox.hasClass('bg-primary') &&
          !valueBox.hasClass('bg-info') &&
          !valueBox.hasClass('bg-warning') &&
          !valueBox.hasClass('bg-success') &&
          !valueBox.hasClass('bg-danger')) {
        valueBox.addClass('bg-primary');
      }
    }

    // handle data attributes in valueOutputSpan
    function handleValueOutput(valueOutput) {

      // caption
      var dataCaption = valueOutput.attr('data-caption');
      if (dataCaption)
        caption.html(dataCaption);

      // icon
      var dataIcon = valueOutput.attr('data-icon');
      if (dataIcon)
        setIcon(dataIcon);

      // color
      var dataColor = valueOutput.attr('data-color');
      if (dataColor) {
        if (dataColor.indexOf('bg-') === 0) {
          valueBox.css('background-color', '');
          if (!valueBox.hasClass(dataColor)) {
             valueBox.removeClass('bg-primary bg-info bg-warning bg-danger bg-success');
             valueBox.addClass(dataColor);
          }
        } else {
          valueBox.removeClass('bg-primary bg-info bg-warning bg-danger bg-success');
          valueBox.css('background-color', dataColor);
        }
      }

      // url
      var dataHref = valueOutput.attr('data-href');
      if (dataHref) {
        valueBox.addClass('linked-value');
        valueBox.off('click.value-box');
        valueBox.on('click.value-box', function(e) {
          window.FlexDashboardUtils.showLinkedValue(dataHref);
        });
      }
    }

    // check for a valueOutputSpan
    if (valueOutputSpan.length > 0) {
      handleValueOutput(valueOutputSpan);
    }

    // if we have a shinyOutput then bind a listener to handle
    // new valueOutputSpan values
    shinyOutput.on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {
          var valueOutputSpan = element.find('span.value-output');
          if (valueOutputSpan.length > 0)
            handleValueOutput(valueOutputSpan);
        }, 10);
      }
    );
  }
});


</script>

<div id="dashboard-container">

<div id="column" class="section level2 sidebar">
<h2 class="sidebar">Column</h2>
<div id="ltima-atualizao" class="section level3">
<h3>ltima atualizao</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">2020-06-02 15:47</span>
<!-- ------------------------------------- -->
<!-- ### Trials na base americana -->
<!-- ```{r} -->
<!-- valueBox(nrow(eua)) -->
<!-- ``` -->
<hr />
</div>
<div id="total-de-trials-na-base-da-oms" class="section level3">
<h3>Total de trials na base da OMS</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">3007</span>
<p>Link para dados completos: <a href="https://www.who.int/ictrp/COVID19-web.csv" class="uri">https://www.who.int/ictrp/COVID19-web.csv</a></p>
<hr />
</div>
<div id="trials-intervencionais-na-base-da-oms" class="section level3">
<h3>Trials intervencionais na base da OMS</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<p><span class="value-output">1796</span> <!-- ### Trials na base da China --> <!-- ```{r} --> <!-- valueBox(nrow(china)) --> <!-- ``` --></p>
<!-- Extraidos da base da OMS + busca por outros mais recentes  -->
<!-- ### Protocolos na base da Unio Europeia -->
<!-- ```{r} -->
<!-- valueBox(nrow(eu_data)) -->
<!-- ``` -->
<!-- Um trial pode ter protocolos diferentes em cada pas participante -->
</div>
</div>
<div id="column-1" class="section level2 tabset tabset-fade">
<h2 class="tabset tabset-fade">Column</h2>
<div id="grupos" class="section level3">
<h3>Grupos</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-9db0d291c86c3147d65a" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-9db0d291c86c3147d65a">{"x":{"filter":"none","caption":"<caption>Grupos<\/caption>","fillContainer":true,"data":[["1","2","3","4"],["Drogas","Outros tratamentos","No identificado","Preveno"],[903,481,420,166],[31,64,61,13],[61,63,21,21],[416,138,78,31],[336,69,63,32],[105,26,35,16],[71,180,184,70],[120,61,26,20]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>grupo<\/th>\n      <th>total<\/th>\n      <th>fase0<\/th>\n      <th>fase1<\/th>\n      <th>fase2<\/th>\n      <th>fase3<\/th>\n      <th>fase4<\/th>\n      <th>faseNULL<\/th>\n      <th>multiplas_fases<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"tpi","columnDefs":[{"className":"dt-right","targets":[2,3,4,5,6,7,8,9]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="categorias" class="section level3">
<h3>Categorias</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-26d1bff1b97939318a28" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-26d1bff1b97939318a28">{"x":{"filter":"none","caption":"<caption>Categorias<\/caption>","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18"],[null,"Drogas","Drogas","Drogas","Outros tratamentos","Outros tratamentos","Preveno","Outros tratamentos","Drogas","Drogas","Outros tratamentos","Outros tratamentos","Drogas","Preveno","Drogas","Drogas","Outros tratamentos","Drogas"],["No identificado","Antimalrico","Outras drogas","Antivirais","Ventilao Pulmonar","Plasma de pessoas curadas","Testes","Medicina Tradicional Chinesa","Anticorpos monoclonais","Antibiticos","Comportamental ou atividade fsica","Clulas-Tronco","Corticides","Vacinas","Inibidores de enzimas do tipo quinases","Anti-inflamatrio","NK cells","Imunomoduladores"],[420,342,332,215,147,125,122,95,91,84,71,61,47,45,40,35,8,7],[61,4,5,23,7,9,13,32,1,0,4,11,1,0,1,4,4,0],[21,12,40,8,14,17,4,4,3,5,2,29,1,17,1,1,4,2],[78,124,192,65,40,66,14,9,61,33,0,29,16,17,26,10,2,4],[63,171,99,91,24,24,18,17,26,43,2,5,22,14,13,15,0,2],[35,54,31,31,13,2,13,12,5,4,0,0,7,3,2,3,0,1],[184,26,19,31,62,27,67,28,5,8,62,9,7,4,1,4,0,0],[26,50,54,35,14,20,8,7,11,9,0,22,7,12,5,2,2,2]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>grupo<\/th>\n      <th>categoria<\/th>\n      <th>total<\/th>\n      <th>fase0<\/th>\n      <th>fase1<\/th>\n      <th>fase2<\/th>\n      <th>fase3<\/th>\n      <th>fase4<\/th>\n      <th>faseNULL<\/th>\n      <th>multiplas_fases<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"tpi","columnDefs":[{"className":"dt-right","targets":[3,4,5,6,7,8,9,10]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="substncias" class="section level3">
<h3>Substncias</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-960246f7418c5f20debb" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-960246f7418c5f20debb">{"x":{"filter":"none","caption":"<caption>Substncias (apenas trials do grupo \"Drogas\")<\/caption>","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18"],["Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas"],["Antimalrico","Outras drogas","Antivirais","Antibiticos","Antivirais","Anticorpos monoclonais","Outras drogas","Corticides","Inibidores de enzimas do tipo quinases","Antivirais","Anti-inflamatrio","Anticorpos monoclonais","Antivirais","Antivirais","Outras drogas","Imunomoduladores","Antivirais","Antibiticos"],["cloroquina ou hidroxicloroquina","Outras drogas","lopinavir/ritonavir","azithromycin","outros antivirais","tocilizumab ou sarilumab","Interferon","corticides","Inibidores de enzimas do tipo quinases","favipiravir","Anti-inflamatrio","outros anticorpos monoclonais","remdesivir","arbidol (Umifenovir)","Anakinra","Imunomoduladores","azvudine","outros antibiticos"],[342,265,116,84,76,71,56,47,40,36,35,24,22,19,13,7,4,2],[4,0,12,0,9,1,5,1,1,5,4,0,0,5,0,0,3,0],[12,36,4,5,4,2,4,1,1,1,1,1,0,0,0,2,0,0],[124,166,38,33,20,42,20,16,26,12,10,21,4,1,8,4,0,0],[171,77,48,43,22,24,16,22,13,20,15,4,18,4,7,2,0,1],[54,18,19,4,12,5,13,7,2,2,3,0,2,8,0,1,0,1],[26,13,16,8,14,4,6,7,1,4,4,1,1,2,0,0,1,0],[50,45,21,9,6,8,8,7,5,8,2,3,3,1,2,2,0,0]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>grupo<\/th>\n      <th>categoria<\/th>\n      <th>substancia<\/th>\n      <th>total<\/th>\n      <th>fase0<\/th>\n      <th>fase1<\/th>\n      <th>fase2<\/th>\n      <th>fase3<\/th>\n      <th>fase4<\/th>\n      <th>faseNULL<\/th>\n      <th>multiplas_fases<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"tpi","columnDefs":[{"className":"dt-right","targets":[4,5,6,7,8,9,10,11]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="pases" class="section level3">
<h3>Pases</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-7c12299f5645d9f4cbb9" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-7c12299f5645d9f4cbb9">{"x":{"filter":"none","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84"],["China","United States","No identificado","Iran","France","Spain","United Kingdom","India","Germany","Italy","Canada","Australia","Brazil","Netherlands","Denmark","Belgium","Egypt","Japan","Mexico","Israel","Austria","Greece","Switzerland","Norway","Sweden","Argentina","Russian Federation","Turkey","Colombia","Pakistan","Thailand","Saudi Arabia","South Africa","Hong Kong","Ireland","Korea, Republic of, Republic of","Poland","Malaysia","Singapore","Cuba","Hungary","New Zealand","Indonesia","Nigeria","Peru","Taiwan","Bahrain","Chile","Jordan","Bangladesh","Czech Republic","Finland","Ghana","Kenya","Lebanon","Luxembourg","Portugal","Puerto Rico","Qatar","Romania","Tunisia","\n            Sri Lanka\n","Belarus","Bosnia and Herzegovina","Croatia","Ecuador","French Guiana","Gibraltar","Honduras","Iceland","Iraq","Korea, Republic of","Monaco","Mongolia","North Macedonia","Oman","Philippines","Senegal","Serbia","Slovenia","Sudan","United Arab Emirates","Vietnam","Zambia"],[390,250,215,191,140,120,69,59,55,55,47,35,33,29,27,25,24,19,18,16,14,13,13,11,11,10,10,10,9,9,9,8,8,7,7,7,7,6,6,5,5,5,4,4,4,4,3,3,3,2,2,2,2,2,2,2,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Countries<\/th>\n      <th>n<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"tpi","columnDefs":[{"className":"dt-right","targets":2},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="dados" class="section level3">
<h3>Dados</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-07a590aa0d647754ce76" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-07a590aa0d647754ce76">{"x":{"filter":"none","extensions":["Buttons"],"caption":"<caption>Variveis selecionadas; apenas trials intervencionais<\/caption>","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174","175","176","177","178","179","180","181","182","183","184","185","186","187","188","189","190","191","192","193","194","195","196","197","198","199","200","201","202","203","204","205","206","207","208","209","210","211","212","213","214","215","216","217","218","219","220","221","222","223","224","225","226","227","228","229","230","231","232","233","234","235","236","237","238","239","240","241","242","243","244","245","246","247","248","249","250","251","252","253","254","255","256","257","258","259","260","261","262","263","264","265","266","267","268","269","270","271","272","273","274","275","276","277","278","279","280","281","282","283","284","285","286","287","288","289","290","291","292","293","294","295","296","297","298","299","300","301","302","303","304","305","306","307","308","309","310","311","312","313","314","315","316","317","318","319","320","321","322","323","324","325","326","327","328","329","330","331","332","333","334","335","336","337","338","339","340","341","342","343","344","345","346","347","348","349","350","351","352","353","354","355","356","357","358","359","360","361","362","363","364","365","366","367","368","369","370","371","372","373","374","375","376","377","378","379","380","381","382","383","384","385","386","387","388","389","390","391","392","393","394","395","396","397","398","399","400","401","402","403","404","405","406","407","408","409","410","411","412","413","414","415","416","417","418","419","420","421","422","423","424","425","426","427","428","429","430","431","432","433","434","435","436","437","438","439","440","441","442","443","444","445","446","447","448","449","450","451","452","453","454","455","456","457","458","459","460","461","462","463","464","465","466","467","468","469","470","471","472","473","474","475","476","477","478","479","480","481","482","483","484","485","486","487","488","489","490","491","492","493","494","495","496","497","498","499","500","501","502","503","504","505","506","507","508","509","510","511","512","513","514","515","516","517","518","519","520","521","522","523","524","525","526","527","528","529","530","531","532","533","534","535","536","537","538","539","540","541","542","543","544","545","546","547","548","549","550","551","552","553","554","555","556","557","558","559","560","561","562","563","564","565","566","567","568","569","570","571","572","573","574","575","576","577","578","579","580","581","582","583","584","585","586","587","588","589","590","591","592","593","594","595","596","597","598","599","600","601","602","603","604","605","606","607","608","609","610","611","612","613","614","615","616","617","618","619","620","621","622","623","624","625","626","627","628","629","630","631","632","633","634","635","636","637","638","639","640","641","642","643","644","645","646","647","648","649","650","651","652","653","654","655","656","657","658","659","660","661","662","663","664","665","666","667","668","669","670","671","672","673","674","675","676","677","678","679","680","681","682","683","684","685","686","687","688","689","690","691","692","693","694","695","696","697","698","699","700","701","702","703","704","705","706","707","708","709","710","711","712","713","714","715","716","717","718","719","720","721","722","723","724","725","726","727","728","729","730","731","732","733","734","735","736","737","738","739","740","741","742","743","744","745","746","747","748","749","750","751","752","753","754","755","756","757","758","759","760","761","762","763","764","765","766","767","768","769","770","771","772","773","774","775","776","777","778","779","780","781","782","783","784","785","786","787","788","789","790","791","792","793","794","795","796","797","798","799","800","801","802","803","804","805","806","807","808","809","810","811","812","813","814","815","816","817","818","819","820","821","822","823","824","825","826","827","828","829","830","831","832","833","834","835","836","837","838","839","840","841","842","843","844","845","846","847","848","849","850","851","852","853","854","855","856","857","858","859","860","861","862","863","864","865","866","867","868","869","870","871","872","873","874","875","876","877","878","879","880","881","882","883","884","885","886","887","888","889","890","891","892","893","894","895","896","897","898","899","900","901","902","903","904","905","906","907","908","909","910","911","912","913","914","915","916","917","918","919","920","921","922","923","924","925","926","927","928","929","930","931","932","933","934","935","936","937","938","939","940","941","942","943","944","945","946","947","948","949","950","951","952","953","954","955","956","957","958","959","960","961","962","963","964","965","966","967","968","969","970","971","972","973","974","975","976","977","978","979","980","981","982","983","984","985","986","987","988","989","990","991","992","993","994","995","996","997","998","999","1000","1001","1002","1003","1004","1005","1006","1007","1008","1009","1010","1011","1012","1013","1014","1015","1016","1017","1018","1019","1020","1021","1022","1023","1024","1025","1026","1027","1028","1029","1030","1031","1032","1033","1034","1035","1036","1037","1038","1039","1040","1041","1042","1043","1044","1045","1046","1047","1048","1049","1050","1051","1052","1053","1054","1055","1056","1057","1058","1059","1060","1061","1062","1063","1064","1065","1066","1067","1068","1069","1070","1071","1072","1073","1074","1075","1076","1077","1078","1079","1080","1081","1082","1083","1084","1085","1086","1087","1088","1089","1090","1091","1092","1093","1094","1095","1096","1097","1098","1099","1100","1101","1102","1103","1104","1105","1106","1107","1108","1109","1110","1111","1112","1113","1114","1115","1116","1117","1118","1119","1120","1121","1122","1123","1124","1125","1126","1127","1128","1129","1130","1131","1132","1133","1134","1135","1136","1137","1138","1139","1140","1141","1142","1143","1144","1145","1146","1147","1148","1149","1150","1151","1152","1153","1154","1155","1156","1157","1158","1159","1160","1161","1162","1163","1164","1165","1166","1167","1168","1169","1170","1171","1172","1173","1174","1175","1176","1177","1178","1179","1180","1181","1182","1183","1184","1185","1186","1187","1188","1189","1190","1191","1192","1193","1194","1195","1196","1197","1198","1199","1200","1201","1202","1203","1204","1205","1206","1207","1208","1209","1210","1211","1212","1213","1214","1215","1216","1217","1218","1219","1220","1221","1222","1223","1224","1225","1226","1227","1228","1229","1230","1231","1232","1233","1234","1235","1236","1237","1238","1239","1240","1241","1242","1243","1244","1245","1246","1247","1248","1249","1250","1251","1252","1253","1254","1255","1256","1257","1258","1259","1260","1261","1262","1263","1264","1265","1266","1267","1268","1269","1270","1271","1272","1273","1274","1275","1276","1277","1278","1279","1280","1281","1282","1283","1284","1285","1286","1287","1288","1289","1290","1291","1292","1293","1294","1295","1296","1297","1298","1299","1300","1301","1302","1303","1304","1305","1306","1307","1308","1309","1310","1311","1312","1313","1314","1315","1316","1317","1318","1319","1320","1321","1322","1323","1324","1325","1326","1327","1328","1329","1330","1331","1332","1333","1334","1335","1336","1337","1338","1339","1340","1341","1342","1343","1344","1345","1346","1347","1348","1349","1350","1351","1352","1353","1354","1355","1356","1357","1358","1359","1360","1361","1362","1363","1364","1365","1366","1367","1368","1369","1370","1371","1372","1373","1374","1375","1376","1377","1378","1379","1380","1381","1382","1383","1384","1385","1386","1387","1388","1389","1390","1391","1392","1393","1394","1395","1396","1397","1398","1399","1400","1401","1402","1403","1404","1405","1406","1407","1408","1409","1410","1411","1412","1413","1414","1415","1416","1417","1418","1419","1420","1421","1422","1423","1424","1425","1426","1427","1428","1429","1430","1431","1432","1433","1434","1435","1436","1437","1438","1439","1440","1441","1442","1443","1444","1445","1446","1447","1448","1449","1450","1451","1452","1453","1454","1455","1456","1457","1458","1459","1460","1461","1462","1463","1464","1465","1466","1467","1468","1469","1470","1471","1472","1473","1474","1475","1476","1477","1478","1479","1480","1481","1482","1483","1484","1485","1486","1487","1488","1489","1490","1491","1492","1493","1494","1495","1496","1497","1498","1499","1500","1501","1502","1503","1504","1505","1506","1507","1508","1509","1510","1511","1512","1513","1514","1515","1516","1517","1518","1519","1520","1521","1522","1523","1524","1525","1526","1527","1528","1529","1530","1531","1532","1533","1534","1535","1536","1537","1538","1539","1540","1541","1542","1543","1544","1545","1546","1547","1548","1549","1550","1551","1552","1553","1554","1555","1556","1557","1558","1559","1560","1561","1562","1563","1564","1565","1566","1567","1568","1569","1570","1571","1572","1573","1574","1575","1576","1577","1578","1579","1580","1581","1582","1583","1584","1585","1586","1587","1588","1589","1590","1591","1592","1593","1594","1595","1596","1597","1598","1599","1600","1601","1602","1603","1604","1605","1606","1607","1608","1609","1610","1611","1612","1613","1614","1615","1616","1617","1618","1619","1620","1621","1622","1623","1624","1625","1626","1627","1628","1629","1630","1631","1632","1633","1634","1635","1636","1637","1638","1639","1640","1641","1642","1643","1644","1645","1646","1647","1648","1649","1650","1651","1652","1653","1654","1655","1656","1657","1658","1659","1660","1661","1662","1663","1664","1665","1666","1667","1668","1669","1670","1671","1672","1673","1674","1675","1676","1677","1678","1679","1680","1681","1682","1683","1684","1685","1686","1687","1688","1689","1690","1691","1692","1693","1694","1695","1696","1697","1698","1699","1700","1701","1702","1703","1704","1705","1706","1707","1708","1709","1710","1711","1712","1713","1714","1715","1716","1717","1718","1719","1720","1721","1722","1723","1724","1725","1726","1727","1728","1729","1730","1731","1732","1733","1734","1735","1736","1737","1738","1739","1740","1741","1742","1743","1744","1745","1746","1747","1748","1749","1750","1751","1752","1753","1754","1755","1756","1757","1758","1759","1760","1761","1762","1763","1764","1765","1766","1767","1768","1769","1770","1771","1772","1773","1774","1775","1776","1777","1778","1779","1780","1781","1782","1783","1784","1785","1786","1787","1788","1789","1790","1791","1792","1793","1794","1795","1796"],["ChiCTR2000029935","NCT04260594","NCT04261426","ChiCTR2000029850","NCT04252885","NCT04246242","ChiCTR2000029947","ChiCTR2000029814","NCT04261907","ChiCTR2000029941","ChiCTR2000029789","ChiCTR2000029811","ChiCTR2000029939","ChiCTR2000029869","ChiCTR2000029778","ChiCTR2000029656","ChiCTR2000029867","ChiCTR2000029849","ChiCTR2000029777","ChiCTR2000029776","ChiCTR2000029822","ChiCTR2000029742","ChiCTR2000029601","ChiCTR2000029855","ChiCTR2000029813","ChiCTR2000029741","ChiCTR2000029806","ChiCTR2000029853","ChiCTR2000029569","ChiCTR2000029542","ChiCTR2000029790","ChiCTR2000029636","ChiCTR2000029539","ChiCTR2000029788","ChiCTR2000029578","ChiCTR2000029819","ChiCTR2000029765","ChiCTR2000029438","ChiCTR2000029769","ChiCTR2000029763","ChiCTR2000029518","ChiCTR2000029436","ChiCTR2000029517","ChiCTR2000029418","ChiCTR2000029768","ChiCTR2000029495","ChiCTR2000029756","ChiCTR2000029493","ChiCTR2000029747","ChiCTR2000029432","ChiCTR2000029431","ChiCTR2000029739","ChiCTR2000030173","ChiCTR2000029639","ChiCTR2000030166","ChiCTR2000029602","ChiCTR2000029600","ChiCTR2000029572","ChiCTR2000029621","ChiCTR2000029559","ChiCTR2000030118","NCT04268537","ChiCTR2000030179","ChiCTR2000029544","ChiCTR2000029609","ChiCTR2000029541","ChiCTR2000030116","ChiCTR2000029606","ChiCTR2000029468","ChiCTR2000030093","ChiCTR2000030113","ChiCTR2000029603","ChiCTR2000030084","ChiCTR2000029435","ChiCTR2000029558","ChiCTR2000029548","ChiCTR2000029400","ChiCTR2000029461","ChiCTR2000029460","ChiCTR2000030043","ChiCTR2000029459","ChiCTR2000030041","ChiCTR2000030046","ChiCTR2000029439","ChiCTR2000030034","ChiCTR2000029381","ChiCTR2000030167","ChiCTR2000030029","ChiCTR2000030165","ChiCTR2000030027","ChiCTR2000030117","NCT04269525","ChiCTR2000030188","ChiCTR2000030090","ChiCTR2000030058","ChiCTR2000030170","ChiCTR2000030033","ChiCTR2000030138","ChiCTR2000030016","ChiCTR2000030010","ChiCTR2000030136","ChiCTR2000029996","ChiCTR2000030006","ChiCTR2000030102","ChiCTR2000030007","ChiCTR2000030089","ChiCTR2000030001","ChiCTR2000030088","ChiCTR2000029994","ChiCTR2000030000","ChiCTR2000029978","ChiCTR2000030054","ChiCTR2000029999","ChiCTR2000029960","ChiCTR2000029956","ChiCTR2000030039","ChiCTR2000029992","ChiCTR2000030020","ChiCTR2000029781","ChiCTR2000029851","ChiCTR2000029990","ChiCTR2000030003","ChiCTR2000029974","NCT04273529","NCT04273581","ChiCTR2000029803","ChiCTR2000030002","ChiCTR2000029780","ChiCTR2000029740","ChiCTR2000029989","ChiCTR2000029988","NCT04275245","NCT04279197","ChiCTR2000030442","ChiCTR2000029972","ChiCTR2000029954","ChiCTR2000030420","ChiCTR2000030424","ChiCTR2000030433","NCT04280588","ChiCTR2000030432","ChiCTR2000030398","ChiCTR2000030418","ChiCTR2000030324","ChiCTR2000030386","ChiCTR2000030261","ChiCTR2000030314","ChiCTR2000030218","ChiCTR2000030259","ChiCTR2000030260","ChiCTR2000030333","ChiCTR2000030317","ChiCTR2000030255","ChiCTR2000030219","ChiCTR2000030265","ChiCTR2000030215","ChiCTR2000030225","ChiCTR2000029761","ChiCTR2000030091","ChiCTR2000030196","ChiCTR2000030022","ChiCTR2000029759","ChiCTR2000029975","ChiCTR2000030013","ChiCTR2000030162","ChiCTR2000029899","ChiCTR2000029762","ChiCTR2000029386","ChiCTR2000029991","ChiCTR2000029760","ChiCTR2000029898","ChiCTR2000029755","ChiCTR2000029387","NCT04276987","ChiCTR2000030535","NCT04286503","NCT04281693","NCT04282902","ChiCTR2000030522","ChiCTR2000030518","ChiCTR2000030503","ChiCTR2000030487","ChiCTR2000030540","ChiCTR2000030472","ChiCTR2000030471","ChiCTR2000030490","ChiCTR2000030469","NCT04285190","ChiCTR2000030627","ChiCTR2000030578","ChiCTR2000030312","ChiCTR2000029550","ChiCTR2000029549","ChiCTR2000030481","ChiCTR2000030484","ChiCTR2000029479","ChiCTR2000030467","ChiCTR2000030475","ChiCTR2000030896","ChiCTR2000030465","ChiCTR2000030480","ChiCTR2000030479","ChiCTR2000030894","ChiCTR2000030014","ChiCTR2000029580","ChiCTR2000029993","ChiCTR2000030477","ChiCTR2000029308","ChiCTR2000030810","ChiCTR2000029757","NCT04295551","ChiCTR2000030759","ChiCTR2000030864","ChiCTR2000030855","ChiCTR2000030841","ChiCTR2000030580","NCT04296643","ChiCTR2000030329","ChiCTR2000030897","ChiCTR2000030832","ChiCTR2000030892","ChiCTR2000030187","EUCTR2018-004318-16-DK","ChiCTR2000030804","ChiCTR2000030849","NCT04293887","ChiCTR2000030779","ChiCTR2000029895","ChiCTR2000030761","ChiCTR2000029837","ChiCTR2000030853","ChiCTR2000029826","ChiCTR2000030836","ChiCTR2000030773","ChiCTR2000030835","ChiCTR2000030720","ChiCTR2000030702","ChiCTR2000030744","NCT04264533","ChiCTR2000030703","ChiCTR2000030545","ChiCTR2000030751","ChiCTR2000030718","ChiCTR2000030388","ChiCTR2000030509","ChiCTR2000030476","ChiCTR2000030417","ChiCTR2000030381","ChiCTR2000030135","ChiCTR2000030082","ChiCTR2000029818","ChiCTR2000029816","ChiCTR2000030701","ChiCTR2000030700","ChiCTR2000029984","ChiCTR2000030681","ChiCTR2000029817","ChiCTR2000030989","ChiCTR2000029812","ChiCTR2000030483","ChiCTR2000030478","ChiCTR2000030031","NCT04299724","ChiCTR2000030939","ChiCTR2000030922","NCT04302519","ChiCTR2000031023","ChiCTR2000031138","ChiCTR2000031090","ChiCTR2000030254","ChiCTR2000030224","ChiCTR2000030996","ChiCTR2000031139","ChiCTR2000030946","ChiCTR2000031089","ChiCTR2000030933","ChiCTR2000030987","NCT04263402","ChiCTR2000030944","ChiCTR2000030929","ChiCTR2000030539","ChiCTR2000030920","NCT04287686","NCT04308317","ChiCTR2000029658","ChiCTR2000029868","ChiCTR2000029573","ChiCTR2000029496","NCT04313322","EUCTR2020-000890-25-FR","NCT04304313","NCT04251767","NCT04254874","ChiCTR2000031319","NCT04255017","NCT04261270","NCT04276896","NCT04291053","NCT04264858","NCT04293692","ChiCTR2000031204","ChiCTR2000030923","NCT04316728","ChiCTR2000031271","ChiCTR2000031272","ChiCTR2000030940","ChiCTR2000030937","ChiCTR2000031328","ChiCTR2000031203","EUCTR2020-001162-12-FR","ChiCTR2000030704","ChiCTR2000030028","ChiCTR2000031196","ChiCTR2000030988","ChiCTR2000030288","NCT04290871","NCT04323332","EUCTR2020-001243-15-BE","ChiCTR2000030198","NCT04319900","NCT04323514","NCT04322344","EUCTR2020-000919-69-NL","NCT04323592","NCT04323631","ChiCTR2000031630","EUCTR2020-001023-14-GB","ChiCTR2000031540","NCT04305106","NCT04321928","ChiCTR2000031494","ISRCTN14966673","NCT04324996","ChiCTR2000031639","ChiCTR2000031503","ChiCTR2000031453","ChiCTR2000031454","ChiCTR2000031501","ChiCTR2000031430","EUCTR2020-000936-23-FR","EUCTR2020-001386-37-IT","EUCTR2020-001271-33-FR","EUCTR2020-001236-10-NL","EUCTR2020-001281-11-FR","NCT03331445","NCT04298060","NCT04275414","NCT04315298","EUCTR2020-001010-38-NO","NCT04320238","NCT04312243","NCT04316377","NCT04325867","NCT04326036","NCT04324528","NCT04328272","NCT04326075","NCT04326114","NCT04330144","NCT04326452","NCT04331613","NCT04327349","NCT04333251","NCT04330586","NCT04332666","NCT04334967","ACTRN12620000443998","NCT04335201","ACTRN12620000448943","NCT04333472","ACTRN12620000447954","ChiCTR2000031772","ACTRN12620000454976","ChiCTR2000031834","ChiCTR2000031735","ChiCTR2000031734","ChiCTR2000031781","ChiCTR2000031672","ChiCTR2000030328","ChiCTR2000030750","EUCTR2020-001250-21-FR","EUCTR2020-001381-11-FR","EUCTR2020-001301-23-FR","EUCTR2020-001435-27-FR","EUCTR2020-001333-13-FR","EUCTR2020-001366-11-ES","EUCTR2020-001335-28-NL","EUCTR2020-001409-21-ES","EUCTR2020-001421-31-ES","EUCTR2020-001188-96-FR","EUCTR2020-001492-33-FR","EUCTR2020-001606-33-ES","EUCTR2020-001373-70-FR","EUCTR2020-001194-69-ES","EUCTR2020-001457-43-FR","EUCTR2020-001039-29-GR","EUCTR2020-001565-37-ES","EUCTR2020-001445-39-ES","NCT04252274","NCT04261517","NCT04291729","EUCTR2020-001442-19-ES","NCT04317092","NCT04325672","NCT03680274","NCT04288102","EUCTR2020-001385-11-ES","NCT04328012","NCT04303299","NCT04310228","NCT04315480","EUCTR2020-001307-16-ES","NCT04324021","NCT04331470","NCT04334382","NCT04306055","NCT04331834","NCT04322773","NCT04330300","NCT04329832","NCT04332094","NCT04333407","NCT04330495","NCT04331665","NCT04334005","NCT04337788","NCT04335851","NCT04336254","NCT04338802","NCT04337216","NCT04337996","NCT04337541","NCT04336462","NCT04336904","NCT04338698","NCT04338906","NCT04340414","NCT04341207","NCT04341038","NCT04339660","NCT04339816","NCT04342221","ACTRN12620000478910","NCT04343677","ACTRN12620000473965","ChiCTR2000032098","ChiCTR2000030300","NCT04344080","ACTRN12620000477921","ACTRN12620000472976","ChiCTR2000031955","ChiCTR2000031944","ACTRN12620000470998","ChiCTR2000029976","ChiCTR2000032013","ChiCTR2000032011","NCT04344951","ACTRN12620000468921","ACTRN12620000480987","ChiCTR2000031888","ChiCTR2000029434","ChiCTR2000029433","EUCTR2020-001324-33-FR","EUCTR2020-001156-18-ES","EUCTR2020-001420-34-DK","EUCTR2020-001303-16-FR","EUCTR2020-001257-51-DK","EUCTR2020-001320-34-NL","EUCTR2020-001331-26-GB","EUCTR2020-001290-74-ES","EUCTR2020-001160-28-ES","EUCTR2020-001602-34-FR","EUCTR2020-001254-22-BE","EUCTR2019-002688-89-ES","EUCTR2020-001262-11-ES","IRCT20170117032004N3","EUCTR2020-001321-31-ES","EUCTR2020-001553-48-FR","EUCTR2020-001406-27-FR","IRCT20100228003449N29","EUCTR2020-001413-20-ES","EUCTR2020-001437-12-ES","EUCTR2020-001530-35-ES","IRCT20131113015393N6","EUCTR2020-001765-37-ES","EUCTR2020-001587-29-ES","EUCTR2020-001466-11-GR","EUCTR2020-001682-36-ES","EUCTR2020-001379-34-ES","EUCTR2020-001634-36-ES","EUCTR2020-001689-12-ES","EUCTR2020-001266-11-ES","IRCT20140911019125N6","EUCTR2020-001448-24-GB","EUCTR2020-001511-25-ES","IRCT20200310046736N1","IRCT20160316027081N1","IRCT20151113025025N3","IRCT20100228003449N30","IRCT20100228003449N28","IRCT20200324046847N1","IRCT20100228003449N27","IRCT20180923041093N3","IRCT20200316046792N1","IRCT20200317046797N1","IRCT20200325046860N1","IRCT20120826010664N6","IRCT20200128046294N2","IRCT20140528017891N8","IRCT20151227025726N12","IRCT20160625028622N1","IRCT20200321046828N1","IRCT20150914024017N1","IRCT20160310026998N10","IRCT20151227025726N13","IRCT20160310026998N11","IRCT20190727044343N1","IRCT20180923041093N4","IRCT20200324046850N1","IRCT20101219005416N2","IRCT20140617018126N2","IRCT20200324046850N5","IRCT20180610040049N3","IRCT20200324046852N1","IRCT20140907019073N4","IRCT20150704023055N2","IRCT20200317046797N2","IRCT20180802040678N4","IRCT20170611034452N11","IRCT20200325046860N2","IRCT20190917044805N2","IRCT20200319046819N1","IRCT20120225009124N4","NCT04244591","NCT04252664","NCT04276688","JPRN-JapicCTI-205238","NCT04252118","NCT04273646","NCT04280224","NCT04304690","JPRN-jRCTs031190226","NCT04315896","NCT04318015","NCT04304053","NCT04320953","NCT04324073","NCT04324190","NCT03891420","NCT04257656","JPRN-jRCTs031190227","NCT04321174","NCT04321616","NCT04326426","NCT04329650","NCT04299152","NCT04315987","NCT04323228","NCT04323345","NCT04325061","NCT04331054","NCT04333628","NCT04327401","NCT04329533","NCT04341142","NCT04334044","NCT04338568","NCT04331366","NCT04343144","NCT04343183","NCT04343690","NCT04341285","NCT04343248","NCT04344106","NCT04344210","NCT04343755","NCT04343794","NCT04344288","NCT04344236","NCT04344444","NCT04344535","NCT04344756","NCT04344782","NCT04344548","NCT04344730","NCT04345549","NCT04345406","NCT04345445","NCT03042143","NCT04320277","NCT04345887","NCT04345653","NCT04346017","NCT04346329","NCT04346355","NCT04346420","NCT04346927","NCT04347980","NCT04346953","NCT04347941","NCT04348383","NCT04348500","NCT04348513","NCT04348695","NCT04325633","NCT04333420","NCT04334434","NCT04339426","NCT04341584","NCT04342156","NCT04349371","NCT04350671","NCT04349241","NCT04350684","NCT04342169","NCT04342650","NCT04348461","NCT04351347","NCT04343001","NCT04351542","NCT04348864","NCT04348877","NCT04343963","NCT04351763","NCT04345276","NCT04345289","NCT04352400","NCT04354155","NCT04345523","NCT04345692","NCT04350593","NCT04351295","NCT04351490","NCT04354805","NCT04346368","NCT04352959","NCT04355247","NCT04347889","NCT04355026","NCT04352803","NCT04349410","NCT04349618","NCT04355676","NCT04355767","NCT04350086","NCT04357340","NCT04356495","NCT04356508","NCT04356937","ChiCTR2000032214","NCT04350281","NCT04350931","ACTRN12620000457943","NCT04351620","NCT04351789","ACTRN12620000492954","ChiCTR2000032205","NCT04353336","ChiCTR2000032165","NCT04354441","ChiCTR2000032237","ISRCTN14326006","EUCTR2020-001244-26-AT","ACTRN12620000417987","EUCTR2020-001440-26-ES","ACTRN12620000482965","EUCTR2020-001469-35-PL","ISRCTN16912075","EUCTR2020-001270-29-GB","EUCTR2020-001391-15-IE","EUCTR2020-001459-42-DK","ACTRN12620000501943","EUCTR2020-001327-13-AT","EUCTR2020-001310-38-DE","EUCTR2017-001100-30-DE","ACTRN12620000500954","ChiCTR2000032400","ChiCTR2000032399","EUCTR2020-001366-11-IT","EUCTR2020-001622-64-ES","NCT04322682","NCT04319445","NCT04329572","ChiCTR2000032367","ChiCTR2000032346","NCT04332380","NCT04332835","NCT04330638","NCT04331808","NCT04333589","NCT04335123","NCT04334980","NCT04335032","ChiCTR2000032314","EUCTR2020-001417-21-BE","ChiCTR2000032313","ChiCTR2000032242","NCT04335279","NCT04337008","NCT04339712","NCT04338009","NCT04343092","NCT04318444","NCT04343976","NCT04344431","NCT04344184","NCT04320056","NCT04321421","EUCTR2020-001329-30-AT","NCT04345861","NCT04324463","NCT04350580","EUCTR2020-001527-14-NL","NCT04351724","NCT04326920","NCT04331899","EUCTR2020-001363-85-DK","NCT04336410","NCT04352608","NCT04352946","NCT04345601","NCT04345679","NCT04355052","NCT04355429","NCT04354870","NCT04347512","NCT04355754","NCT04348929","EUCTR2020-001255-40-ES","NCT04356677","EUCTR2020-001659-42-ES","NCT04353037","NCT04353128","EUCTR2020-001536-98-ES","NCT04353518","NCT04353596","EUCTR2020-001531-27-ES","NCT04357613","NCT04358549","NCT04355351","NCT04358406","NCT04358614","NCT04359290","EUCTR2020-001224-33-DE","NCT04357782","NCT04357808","NCT04359316","NCT04359615","NCT04358809","NCT04358835","EUCTR2020-001500-41-BE","NCT04320615","NCT04359251","NCT04359095","NCT04359680","NCT04359329","NCT04359875","NCT04360356","NCT04360551","NCT04359953","NCT04360096","NCT04325906","NCT04334265","NCT04341493","NCT04346797","NCT04360811","NCT04360759","NCT04360980","NCT04348409","NCT04348474","NCT04361422","NCT04350073","NCT04361435","NCT04361448","NCT04361838","NCT04361916","NCT04362124","NCT04361461","NCT04362111","NCT04355234","NCT04362332","NCT04362358","NCT04355962","NCT04357106","NCT04363541","NCT04363372","NCT04357327","NCT04357366","NCT04363463","NCT04363528","NCT04363606","NCT04363840","NCT04357860","NCT04363749","NCT04363866","NCT04360876","NCT04361318","NCT04364022","NCT04363853","NCT04365738","NCT04361526","NCT04361552","NCT04364893","NCT04365127","NCT04365582","NCT04365699","ACTRN12620000517976","NCT04366050","ACTRN12620000516987","NCT04363736","NCT04365439","ISRCTN13311119","ISRCTN43900695","ISRCTN17898730","ISRCTN83971151","ChiCTR2000032573","ChiCTR2000032632","ChiCTR2000032487","ChiCTR2000031174","ChiCTR2000032456","ChiCTR2000032455","ChiCTR2000032459","ChiCTR2000032135","EUCTR2020-001198-55-DK","EUCTR2020-001686-36-FR","EUCTR2020-001678-31-FR","EUCTR2020-001571-32-FR","EUCTR2020-001823-15-FR","EUCTR2020-001734-36-FR","EUCTR2020-001723-13-FR","EUCTR2020-001364-29-ES","EUCTR2020-001722-66-ES","EUCTR2020-001505-22-ES","EUCTR2020-001717-20-ES","EUCTR2020-001541-39-ES","EUCTR2020-001172-15-DK","EUCTR2020-001618-39-ES","EUCTR2020-001640-26-GB","EUCTR2020-001408-41-DE","EUCTR2020-001345-38-GR","EUCTR2020-001367-88-DK","NCT04315948","NCT04321096","NCT04328285","NCT04335071","NCT04328480","NCT04329923","NCT04328441","EUCTR2020-000982-18-NO","NCT04348435","NCT04331795","NCT04334629","NCT04352465","NCT04355728","NCT04359277","NCT04273763","NCT04308668","NCT04356482","NCT04359654","NCT04359797","NCT04361643","NCT04361942","NCT04362059","NCT04334928","NCT04338958","NCT04311177","NCT04347226","NCT04349631","NCT04353271","NCT04363450","NCT04363827","NCT04359225","NCT04366063","NCT04362176","NCT04366089","NCT04343729","NCT04344457","NCT04366739","NCT04345419","NCT04345848","NCT04363060","NCT04364828","NCT04351191","NCT04356833","NCT04366323","NCT04366817","NCT04366947","NCT04367662","NCT04365231","NCT04365309","NCT04358939","NCT04359810","NCT04361396","NCT04368156","NCT04368377","NCT04366180","NCT04366856","NCT04368260","NCT04365608","NCT04367545","NCT04367636","NCT04366297","NCT04368013","NCT04368676","NCT04369066","NCT04366882","NCT04366908","NCT04369274","NCT04369469","NCT04369742","NCT04369794","NCT04371926","ACTRN12620000524998","NCT04368299","NCT04370938","EUCTR2020-001635-27-FR","NCT04368923","NCT04369365","EUCTR2020-001335-28-DE","NCT04371523","ChiCTR2000032717","NCT04369378","NCT04372186","ChiCTR2000032716","NCT04370236","EUCTR2020-001768-27-FR","EUCTR2020-001909-22-FR","ChiCTR2000032769","EUCTR2020-001449-38-GB","ChiCTR2000032737","EUCTR2020-001684-89-GB","EUCTR2020-001709-21-FR","EUCTR2020-001411-25-AT","ChiCTR2000032635","EUCTR2020-001598-66-FR","EUCTR2020-001786-36-GB","EUCTR2020-001827-15-ES","EUCTR2020-001783-28-HU","EUCTR2020-001296-33-DK","EUCTR2020-001632-10-DE","EUCTR2020-001700-42-FR","EUCTR2020-001777-71-GB","EUCTR2020-001721-31-GB","EUCTR2020-001784-88-FI","EUCTR2020-001766-11-FR","EUCTR2020-001882-36-GR","EUCTR2020-001370-30-DE","EUCTR2020-001825-29-ES","EUCTR2020-001370-30-GB","EUCTR2020-001228-32-GB","EUCTR2020-001206-35-AT","EUCTR2020-001740-26-GB","EUCTR2020-001891-14-ES","EUCTR2020-000705-86-ES","EUCTR2020-002032-69-ES","NCT04330690","EUCTR2020-001736-95-GB","EUCTR2020-001395-15-DK","EUCTR2020-001662-11-DE","EUCTR2020-001302-30-AT","EUCTR2020-001994-66-ES","EUCTR2020-001697-30-ES","NCT04358926","EUCTR2020-001275-32-DK","EUCTR2020-001603-16-ES","NCT04324489","NCT04328493","NCT04361032","NCT04366141","EUCTR2020-001474-29-ES","EUCTR2020-001696-32-ES","EUCTR2020-001953-36-ES","EUCTR2020-001375-32-NL","NCT04364815","NCT04369820","NCT04370886","EUCTR2020-001934-37-ES","EUCTR2020-002123-11-ES","NCT04370223","NCT04370288","NCT04371510","NCT04371367","NCT04371601","NCT04283461","NCT04333550","NCT04332081","NCT04372680","NCT04372030","NCT04346667","NCT04343768","NCT04345614","NCT04369456","NCT04350320","NCT04354597","NCT04371965","NCT04371978","NCT04373382","NCT04360122","NCT04372602","NCT04373005","NCT04374487","NCT04373291","NCT04373733","NCT04373824","NCT04374149","NCT04374903","NCT04371406","NCT04374474","NCT04280705","NCT04251871","NCT04333355","NCT04340232","NCT04326790","NCT04335136","NCT04313023","NCT04333225","NCT04372082","NCT04372693","NCT04336774","NCT04341688","NCT04341441","NCT04374526","NCT04374539","NCT04374552","NCT04344041","NCT04349098","NCT04344561","NCT04351581","NCT04351906","NCT04357028","NCT04363437","NCT04353674","NCT04355364","NCT04355637","NCT04375202","NCT04333732","NCT04336332","NCT04357990","NCT04360824","NCT04372004","NCT04341870","NCT04363593","NCT04370015","NCT04374019","NCT04374032","NCT04374279","NCT04343989","NCT04346082","NCT04375397","NCT04348071","NCT04354610","NCT04373161","NCT04363216","NCT04376593","NCT04364737","NCT04365972","NCT04376788","NCT04377308","NCT04374942","NCT04377334","NCT04377568","NCT04377659","NCT04371640","NCT04377750","NCT04374565","NCT04377477","NCT04377503","NCT04375098","NCT04375735","NCT04375774","NCT04377646","NCT04377672","NCT04378244","NCT04376515","NCT04376814","NCT04378257","NCT04377620","NCT04377997","NCT04377802","NCT04379336","NCT04379661","NCT04380948","NCT04379037","NCT04379154","ISRCTN50189673","NCT04379479","NCT04379518","NCT04380519","ChiCTR2000029638","ChiCTR2000032919","ChiCTR2000032915","ChiCTR2000030262","DRKS00021420","ChiCTR2000029605","DRKS00021447","ACTRN12620000566932","ACTRN12620000555954","ACTRN12620000557932","DRKS00021527","DRKS00021588","DRKS00021573","DRKS00021582","DRKS00021585","DRKS00021214","DRKS00021153","DRKS00021300","DRKS00021301","IRCT20190727044343N2","IRCT20200322046833N1","DRKS00021273","IRCT20200318046812N1","DRKS00021706","DRKS00021626","IRCT20130812014333N145","IRCT20160313027033N2","IRCT20130917014693N10","IRCT20200314046764N1","IRCT20200325046859N1","IRCT20180610040049N4","IRCT20200328046886N1","IRCT20131215015805N2","IRCT20081019001369N2","IRCT20200404046933N1","IRCT20200404046947N1","IRCT20200312046749N1","IRCT20200403046926N1","IRCT20150303021315N17","IRCT20171122037571N2","IRCT20200405046960N1","IRCT20080901001157N16","IRCT20200404046935N1","IRCT20151227025726N14","IRCT20200323046841N1","IRCT20200324046850N2","IRCT20200324046850N3","IRCT20200405046958N1","IRCT20200318046812N2","IRCT20150808023559N20","IRCT20160131026298N2","IRCT20180712040449N2","IRCT20200217046526N1","IRCT20161204031229N3","IRCT20130812014333N147","IRCT20200401046909N1","IRCT20190804044429N1","IRCT20200402046923N1","IRCT20180725040596N2","IRCT20200204046369N1","IRCT20200217046526N2","IRCT20081019001369N4","IRCT20081019001369N3","IRCT20200404046937N1","IRCT20200408046987N1","IRCT20180129038542N1","IRCT20151228025732N51","IRCT20200404046934N1","IRCT20200317046797N3","IRCT20200317046797N5","IRCT20151228025732N53","IRCT20180429039463N2","IRCT20200406046968N2","IRCT20200317046797N4","IRCT20200410047009N1","IRCT20180520039738N2","IRCT20200406046968N3","IRCT20200401046909N2","IRCT20200404046937N2","IRCT20160131026298N3","IRCT20200405046953N1","IRCT20130616013690N7","IRCT20200413047063N1","IRCT20200408046990N1","IRCT20200325046859N2","IRCT20200411047030N1","IRCT20080901001165N46","IRCT20200408046988N1","IRCT20200406046963N1","IRCT20200413047062N1","IRCT20200413047053N1","IRCT20081019001369N5","IRCT20200413047052N1","IRCT20200414047070N1","IRCT20200414047072N1","IRCT20170210032478N3","IRCT20130306012728N8","IRCT20200415047089N1","IRCT20200415047092N1","IRCT20200416047104N1","IRCT20200418047121N2","IRCT20200329046892N1","IRCT20140407017169N2","IRCT20200420047147N1","IRCT20080901001165N48","IRCT20080901001165N49","IRCT20200422047168N1","IRCT20140305016852N4","IRCT20200416047099N1","IRCT20120215009014N353","IRCT20200406046965N1","IRCT20180425039414N2","IRCT20200404046948N1","IRCT20200427047215N1","IRCT20200418047122N1","IRCT20180114038350N3","IRCT20200408046992N1","IRCT20180923041093N5","IRCT20200406046968N1","IRCT20200418047121N1","IRCT20080901001165N50","IRCT20200409047007N1","IRCT20200428047228N1","IRCT20131129015584N2","IRCT20150808023559N21","IRCT20200426047212N1","IRCT20200418047126N1","IRCT20200508047346N1","IRCT20080901001165N52","IRCT20200411047025N1","IRCT20200421047150N1","IRCT20160706028815N5","IRCT20200326046868N1","IRCT20190122042450N4","KCT0005003","IRCT20191125045492N2","IRCT20200510047383N1","IRCT20200415047082N1","IRCT20200413047056N1","IRCT20200418047116N1","IRCT20200417047113N1","JPRN-JapicCTI-205270","JPRN-jRCTs031190269","JPRN-jRCTs041190120","IRCT20151222025660N2","JPRN-UMIN000040286","IRCT20200421047155N1","IRCT20200408046990N2","IRCT20200426047206N1","IRCT20121216011763N46","IRCT20080901001165N51","JPRN-UMIN000040235","IRCT20200501047258N1","IRCT20171213037866N2","IRCT20200509047366N1","JPRN-UMIN000040401","IRCT20120215009014N354","PACTR202004693933092","PACTR202004801273802","IRCT20080901001165N53","PACTR202004761408382","RBR-3cbs3w","PACTR202004893013257","PACTR202005599385499","LBCTR2020043495","RBR-9d8z6m","RBR-658khm","JPRN-jRCT2031190264","RBR-4vm3yy","RBR-949z6v","JPRN-jRCTs031200026","TCTR20200514001","RPCEC00000306","RPCEC00000311","RPCEC00000313","RBR-8969zg","TCTR20200404004","RPCEC00000307","JPRN-UMIN000040341","RPCEC00000308","PER-010-20","RPCEC00000309","JPRN-UMIN000040407","CTRI/2020/05/024983","PACTR202005681895696","RBR-6m69fc","RBR-6w5tbk","SLCTR/2020/011","RBR-3k4wxb","CTRI/2020/04/024731","CTRI/2020/05/025069","RBR-3rdhgm","CTRI/2020/05/025068","CTRI/2020/05/025071","TCTR20200409006","CTRI/2020/04/024659","CTRI/2020/04/024773","CTRI/2020/05/025114","CTRI/2020/04/024806","CTRI/2020/04/024776","CTRI/2020/05/025162","CTRI/2020/04/024882","CTRI/2020/05/025166","CTRI/2020/03/024402","CTRI/2020/05/025178","CTRI/2020/04/024729","CTRI/2020/04/024747","CTRI/2020/04/024883","CTRI/2020/04/024479","CTRI/2020/04/024948","CTRI/2020/04/024749","CTRI/2020/04/024775","CTRI/2020/04/024804","CTRI/2020/05/024959","CTRI/2020/04/024857","CTRI/2020/04/024833","CTRI/2020/04/024846","NCT04312009","NCT04322396","CTRI/2020/04/024858","CTRI/2020/04/024904","CTRI/2020/05/024962","CTRI/2020/04/024915","NCT04333914","NCT04334512","CTRI/2020/05/024981","CTRI/2020/04/024949","CTRI/2020/04/024947","CTRI/2020/05/025013","CTRI/2020/05/024986","CTRI/2020/05/024967","CTRI/2020/05/024969","CTRI/2020/05/025067","CTRI/2020/05/025088","CTRI/2020/05/025093","CTRI/2020/05/025022","CTRI/2020/05/025161","CTRI/2020/05/025049","CTRI/2020/05/025167","CTRI/2020/05/025171","NCT04337918","NCT04346147","CTRI/2020/05/025156","NCT04346199","NCT04278963","NCT04335084","NCT02765191","NCT04273321","NCT04310865","NCT04341922","NCT04347915","NCT04340544","NCT04343651","NCT04344015","NCT04347174","NCT04346589","NCT04372589","NCT04374084","NCT04363203","NCT04347239","NCT04354389","NCT04365985","NCT04379453","NCT04379492","NCT04380818","NCT04356690","NCT04366271","NCT04373135","NCT04380376","NCT04375046","NCT04373200","NCT04376476","NCT04379271","NCT04380688","NCT04381000","NCT04382586","NCT04382625","NCT04380909","NCT04381936","NCT04382547","NCT04380935","NCT04381013","NCT04381052","NCT04382755","NCT04381377","NCT04381923","NCT04382846","NCT04381962","NCT04382092","NCT04381338","NCT04381364","NCT04382924","NCT04381858","NCT04381871","NCT04382560","NCT04382651","NCT04384549","NCT04384965","NCT04384380","NCT04382131","NCT04384588","NCT04382729","NCT04385576","NCT04340050","NCT04382950","NCT04383002","NCT04342728","NCT04292899","NCT04312997","NCT04383574","NCT04383587","NCT04344587","NCT04347538","NCT04346628","NCT04347382","NCT04328961","NCT04352933","NCT04350476","NCT04354259","NCT04334148","NCT04335097","NCT04340349","NCT04353180","NCT04348305","NCT04354831","NCT04352751","NCT04353206","NCT04384458","NCT04359901","NCT04357457","NCT04362085","NCT04364802","NCT04364009","NCT04365517","NCT04373707","NCT04374786","NCT04378712","NCT04378803","NCT04385108","NCT04368728","NCT04371029","NCT04323800","NCT04341415","NCT04380961","NCT04383535","NCT04378920","NCT04379076","NCT04343261","NCT04346446","NCT04385849","NCT04352348","NCT04356534","NCT04385095","NCT04381988","NCT04386070","NCT04386252","NCT04385199","NCT04363385","NCT04384731","NCT04385017","NCT04386239","NCT04365257","NCT04367077","NCT04385043","NCT04369599","NCT04370262","NCT04387760","NCT04385264","NCT04385771","NCT04382391","NCT04386850","NCT04389671","NCT04387955","NCT04388410","NCT04390191","NCT04384900","NCT04389294","NCT04385901","NCT04390178","ACTRN12620000580976","NCT04385940","NCT04390139","NCT04394039","ACTRN12620000445976","ACTRN12620000571976","NCT04392973","ISRCTN15254871","ACTRN12620000588998","NCT04386980","ACTRN12620000612910","ISRCTN88057279","NCT04387292","ISRCTN13447477","ISRCTN85216856","NCT04388527","ISRCTN50212645","ISRCTN86534580","ISRCTN40580903","NCT04389359","NCT04389580","ChiCTR2000033057","ChiCTR2000033056","NCT04389840","ACTRN12620000579998","NL8523","ISRCTN21363594","NL8577","NL8521","NL8578","ISRCTN90906759","ISRCTN44152751","NL8538","NL8547","NL8609","ChiCTR2000033133","ChiCTR2000033049","EUCTR2020-001886-35-GB","ChiCTR2000029589","NL8504","EUCTR2020-001759-42-GB","EUCTR2020-001805-21-GB","EUCTR2020-001614-38-BE","NL8483","EUCTR2020-001995-13-ES","EUCTR2020-001411-25-GB","NL8490","EUCTR2020-002274-28-ES","EUCTR2020-001498-63-BE","NCT03648372","EUCTR2020-001704-42-ES","EUCTR2020-001366-11-IE","EUCTR2020-001807-18-GB","NCT04292730","NCT04311697","EUCTR2020-001888-90-DK","NCT04322123","NCT04322565","NCT04303507","NCT04317040","NL8491","NCT04327206","NCT04327388","NCT04321278","NCT04331600","NCT04332107","NCT04305457","NCT04307693","NCT04327505","NCT04313127","EUCTR2020-001643-13-GB","NCT04335305","NCT04328129","NCT04321993","NCT04325893","NCT04334850","NCT04335786","NCT04332991","EUCTR2020-001770-30-BE","NCT04334460","NCT04341935","NCT04338828","EUCTR2015-002340-14-NL","NCT04344600","NCT04341389","NCT04342182","NCT04341610","NCT04341675","NCT04350736","NCT04348370","NCT04348656","NCT04345991","NCT04351243","NCT04354714","NCT04347681","NCT04355143","NCT04355533","EUCTR2020-001072-15-GB","NCT04347954","NCT04351152","NCT04355897","NCT04306393","NCT04358081","NCT04360837","NCT04351516","NCT04358003","NCT04362189","NCT04328467","NCT04361214","NCT04361253","NCT04354428","NCT04355936","NCT04361344","NCT04361474","NCT04363502","NCT04364594","NCT04329611","NCT04333654","NCT04357730","NCT04358068","NCT04338074","NCT04358783","NCT04359264","NCT04341116","NCT04363814","NCT04366115","NCT04366960","NCT04368000","NCT04342663","NCT04362137","NCT04342689","NCT04342897","NCT04363346","NCT04364763","NCT04366232","NCT04366245","NCT04371822","NCT04372979","NCT04366791","NCT04368845","NCT04368988","NCT04371952","NCT04346615","NCT04346693","NCT04373096","NCT04373460","NCT04350450","NCT04370782","NCT04372017","NCT04372628","NCT04373044","NCT04374591","NCT04374461","NCT04377100","NCT04353284","NCT04359511","NCT04375124","NCT04359537","NCT04362813","NCT04377789","NCT04377737","NCT04376684","NCT04379375","NCT04379531","NCT04380402","NCT04380532","NCT04365101","NCT04365153","NCT04385186","NCT04382066","NCT04382768","NCT04367831","NCT04370834","NCT04386291","NCT04386447","NCT04371393","NCT04371419","NCT04383613","NCT04384497","NCT04384445","NCT04388709","NCT04388826","NCT04387240","NCT04388683","NCT04389333","NCT04389450","NCT04389801","NCT04390061","NCT04389710","NCT04390152","NCT04390022","NCT04390464","NCT04390516","NCT04390217","NCT04390412","NCT04390503","NCT04377711","NCT04381884","NCT04390477","NCT04391140","NCT04382040","NCT04382053","NCT04391179","NCT04391101","NCT04391712","NCT04386616","NCT04391127","NCT04391309","NCT04386694","NCT04391829","NCT04392141","NCT04389372","NCT04389385","NCT04389411","NCT04392323","NCT04392531","NCT04392219","NCT04392232","NCT04389944","NCT04390594","NCT04393311","NCT04393051","NCT04393246","NCT04393415","NCT04393948","NCT04392128","NCT04392869","NCT04393792","NCT04393038","NCT04392414","NCT04392427","NCT04394013","NCT04394208","NCT04394169","NCT04392453","NCT04392713","NCT04394442","NCT04394377","NCT04392778","NCT04394117","NCT04393636","NCT04393727","NCT04394403","NCT04395144","NCT04393818","NCT04393961","NCT04394182","NCT04395170","NCT04394416","NCT04395911","NCT04395456","NCT04394455","NCT04394793","NCT04395716","NCT04397328","NCT04396067","NCT04395105","NCT04396106","NCT04396314","NCT04397562","NCT04398004","NCT04395807","NCT04395768","NCT04398303","NCT04395976","NCT04397523","NCT04397666","NCT04397757","NCT04397497","NCT04397510","NCT04398290","NCT04400032","NCT04400058","NCT04397692","NCT04397705","NCT04397796","NCT04400279","NCT04397718","NCT04400799","NCT04400890","NCT04400929","NCT04398147","NCT04398277","NCT04401046","NCT04399005","NCT04399252","NCT04401150","NCT04399109","NCT04399317","NCT04399356","NCT04399746","NCT04399681","NCT04399889","NCT04401475","NCT04399798","NCT04399967","NCT04399980","NCT04400305","NCT04401202","NCT04402866","NCT04402892","NCT04401579","NCT04400838","NCT04402957","NCT04402983","NCT04402203","NCT04401410","NCT04401423","NCT04402879","NCT04401293","NCT04401527","NCT04401644","NCT04402060","NCT04402918","NCT04402840","NCT04402944","NCT04403555","NCT04403100","NCT04403646","NCT04404218","NCT04404192","NCT04403243","NCT04404426","NCT04404634","NCT04403269","NCT04403477","NCT04403685","NCT04403906","NCT04404361"],["A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).","A Randomized, Open-label, Controlled, Single-center Study to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Patients With Severe 2019- nCoV Pneumonia","Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study","A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection","A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)","A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)","Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)","A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection","A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)","Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)","Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy","Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)","The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy","A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection","A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)","Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolated population","A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study","Optimization of treatment and diagnosis plan for critically ill patients","A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial","A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19)","Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial","A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)","Study for the pharmacodynamics and mechanism of traditional Chinese medicine in the treatment of novel coronavirus infection (COVID-19) based on inflammatory factor network","A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)","A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine","A prospective randomized double-blind placebo-controlled study of traditional Chinese medicine staging regimen in the treatment of novel coronavirus pneumonia (COVID-19)","The evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)","Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial","A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency","Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period","Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial","Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)","A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical study of type I macrophages therapy in the treatment of novel coronavirus pneumonia (COVID-19)","A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)","Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration","Mental health and psychological interventions on doctors, nurses and patients at the novel coronavirus pneumonia (COVID-19) designated hospitals: a prospective, open, single-center clinical study","Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial","Multicenter, randomized, open-label, controlled trial for the efficacy and safety of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)","Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)","A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)","Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients","Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy","A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)","A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)","Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","The early use of lopinavir/litonavir (LPV/r) and emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19): a real-world study","Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)","Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir","A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)","A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression","Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population","Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province","Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients","Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)","The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","Pulmonary rehabilitation to improve pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)","A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)","Combination of traditional chinese medicne and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial","A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)","Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial","A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)","Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection","Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)","A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students","A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)","Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)","A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection","A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)","The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With  Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)","Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of  Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial","Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial","An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)","A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19)","A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)","Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)","Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19)","The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)","A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)","Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)","Optimization Protocal of Integrated Traditional Chinese and Western Medicine Treatment for Novel Coronavirus Pneumonia (COVID-19)","A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)","Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19)","A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)","A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV","The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","The Application of Rehabilitation and Lung Eight-segment Exercise in  Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)","Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)","Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic","A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)","Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)","A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)","Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19): a randomized, open and controlled trial","Clinical study on novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau promoted by individualized nutritional assessment and supportive treatment","A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19)","A prospective randomized controlled trial for a Self-made Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period","Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome","Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical research program of continuous renal replacement therapy with adsorption filter for the treatment of the novel coronavirus pneumonia (COVID-19)","Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)","Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Multicenter, randomized, open clinical study of Hydroxychloroquine Sulfate tablets in the treatment of common patients with novel coronavirus pneumonia (COVID-19)","A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)","A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)","A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)","Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)","A study on the efficacy and safety of recombinant human interferon alpha 1b spray in preventing novel coronavirus (COVID-19) infection in highly exposed medical staffs.","Cancelled                         Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial","A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","A study on treatment strategies of novel coronavirus pnueumonia patients","A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial","A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)","Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia","A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia","Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine","The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study","Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection","A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection","Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)","Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial","Effecacy and safty of extracorporeal blood purification therapy for severe patients with novel coronavirus pneumonia (COVID19): a prospective cohort study","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy","An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)","To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)","A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19)","Study on the application of convalescent plasma therapy in severe COVID-19","Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)","A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)","Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)","The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)","Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population","A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","The Effect and Safety of cytokine removal therapy in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) adult patients: a Prospective Open-label Study","Clinical Application and Theoretical Discussion of Fuzheng Qingfei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)","Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)","Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)","Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial","Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients","Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial","A multicenter, randomized, open-label, parallel controlled trial for the safety and efficacy of Integrated Chinese and Western Medicine in treatment of non-critical novel coronavirus pneumonia (COVID-19): pilot study","The Effect and Safety of oXiris Membrane Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19): a Single Center Prospective Open-label Study","A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection","Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for TCM Decoction in the treatment of novel coronavirus pneumonia (COVID-19)","Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe new coronavirus pneumonia","Treatment of Acute Severe COVID-19 With Immunoglobulin From Cured COVID-19 Patients","Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19):A prospective, single-center, randomized, parallel controlled trial","Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial","Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)","Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)","Study on the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)","Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis:a prospective exploratory experimental medical study","Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects - STOP PIV - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects","Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial","Investigation on psychological status of COVID-19 rehabilitation patients in Zhengzhou City and research on coping strategies","Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon a1 in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan","A randomized, open-label, controlled trial for the efficacy and safety of  Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)","Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumon (COVID-19)ia","Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)","Novel covid-19 pneumonia combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy","Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)","Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management","Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial","Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial","A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection","Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)","Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)","Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients","Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)","Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of  Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","A randomized, parallel controlled open-label trial to evaluate the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in adult hospitalized patients with novel coronavirus pneumonia (COVID-19)","An evaluative clinical study: efficacy and safety of of Prolongin (Enoxaparin Sodium Injection) in treatment of hospitalized adult patients with common novel coronavirus pneumonia (COVID-19)","Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)","An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of SARS-CoV-2 and other infectious viruses in the operating Room","Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial","Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)","A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)","Positively Controlled Clinical Study of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)","Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine","Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia","Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection","Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period","Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)","Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)","the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study","Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)","Effect of Auricular point pressing on insomnia of 2019 new coronavirus pneumonia patients: a randomized controlled trial.","Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19)","Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia","Clinical Research on Treatment of COVID-19 (mild and moderate cases) with Toujiequwen Granules","Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in COVID-19 patients: a demonstration study for the key techniques","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia","An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia","A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)","Study for the effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus of the patients with novel coronavirus pneumonia (COVID-19)","Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.","A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19","Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19","Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19): a randomized clinical trial","Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial","A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection","A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine - SARS-CoV2quine","A Pilot Study of Sildenafi in the Treatment of COVID-19","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection: a Randomized, Double-blind, Placebo-controlled Study","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia","Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study","An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients","Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus","A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of 2019 novel coronavirus-infected pneumonia","The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)","Clinical Performance of the VivaDiag  COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19","Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)","The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak","Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)","Gu-Shen Ding-Chuan-Wan used in the recovery phase of 2019-nCoV pneumonia(FeiPiQiXuZheng): a randomized, open-label, controlled clinical trial","The protective effect of sleep psychology and music therapy in patients with new coronary pneumonia (mild and moderate type)","Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)","An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19","Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)","Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)","Clinical efficacy of novel coronavirus infection treated by combination of interferon regimen and Ritonavir Tablets","Efficacy and safety of Chinese Herb Medicine Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a prospective, randomized, controlled, open-label trial","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine","Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.","A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19","Effect of pulmonary rehabilitation on pulmonary function, exercise capacity, activity of daily living and quality of life in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia","Use of Ascorbic Acid in Patients With COVID 19","Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients","Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Gurin vaccination, a randomized controlled trial (COVID-19). - BCG-CORONA","Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)","A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19) - Phase II trial of inhaled anti-viral (SNG001) for SARS-CoV-2 infection","Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19)","The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial","Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19)","Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Evaluating the clinical impact of routine molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised pre and post implementation study (CoV-19POC)","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19","Effects of a single session internet-delivered cognitive behavioral therapy for Acute Insomnia during the pandemic of novel coronavirus pneumonia (COVID-19)","Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19)","Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial","Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)","The efficacy  of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study","Evaluation of  the safety and efficacy for human umbilical cord mesenchymal stem cells in COVID-19 induced pulmonary fibrosis","Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy","Uno studio randomizzato multicentrico in aperto per valutare lefficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19. - TOCI-RE","HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19  risque daggravation secondaire : tude prospective multicentrique randomise en double aveugle - HYCOVID","COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19  a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease - CounterCovid Study","Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit.","An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults &amp; Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections","A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection","A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)","An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19","NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION - NO-COVID-19","An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area","Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers","Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection","Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic","Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study","EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial","Effectiveness and Safety of Respiratory Training Devices in the Prevention and Severity of COVID-19: A Randomized Controlled Clinical Trial","A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection","Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS)","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19","A Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment","Home telerehabilitation for people with COVID-19: Implementing telehealth approaches to care and its effect on reintegration into the community","Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia","Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease","Piclidenoson for Treatment of COVID-19 - A Randomized Open Label Pilot Trial","Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19","Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19)","High-dose intravenous zinc (HDIVZn) as adjunctive therapy in COVID-19 positive critically ill patients: A pilot randomized controlled trial","A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19)","Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of viral pneumonia include novel coronavirus pneumonia (COVID-19)","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial","A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 years","Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19)","Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)","A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia","COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients - ONCOVID","COVID-19 - ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection: the randomized ACORES-2 study - ACORES-2","Efficacy of Addition of Naproxen in the Treatment of critically ill Patients Hospitalized for COVID-19 Infection / Enacovid Study - ENACOVID","Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety\nof several experimental treatments to reduce the risk of hospitalization or death\n(COVERAGE trial) - COVERAGE","Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial - DHYSCO","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity","A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - \"PANAMO\" - Panamo","A prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respiratory distress and cytokine release syndrome in patients with COVID-19. - DEFACOVID","Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.","Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial - COVIDAXIS","Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19 - COVID19-COVIDornase","Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. - Randomized clinical trial to evaluate the efficacy of a treatment for COVID-19 infection","IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection\r\n\r\n - IMMUNONCOVID-20","Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) - MEFLOCOVID-19","Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia - COVIDICUS","EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL - PERSONALIZED IMMUNOTHERAPY FOR SARS-CoV-2 ASSOCIATED ORGAN DYSFUCTION","PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. - PrEP_COVID","PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19","An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) - TCOVID","Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia","Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19","Lessening Organ Dysfunction With VITamin C (LOVIT)","A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination With Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence","Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial controlled with placebo - EPICOS","Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)","A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study","Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia","Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. - Steroids In Coronavirus (SIC)","A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.","Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial","Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled Trial","Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial","The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial","Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia","Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With Symptoms of Confirmed or Probable COVID-19 Disease","Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial","Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation","Dynamic Evaluation of COVID-19 Diagnostic Tests","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System","A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type","Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment","Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection","Safety and Effectiveness Study of Low Flow Extracorporeal Membrane Oxygenation(CO2 Removal) Driving by Continuous Hemofiltration Machine the Severe New Corovirus Pneumonia (NCP)","COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients","Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial","Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19","Cord Blood Therapy to prevent progression of COVID-19 related pneumonia","Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study","Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85","Clinical study for Danggui Shaoyao Powder in the treatment of novel coronavirus pneumonia (COVID-19)","Umbilical cord mesenchymal stem cells for the treatment of patients at high risk of novel coronavirus pneumonia  (COVID-19): a single-center, prospective, open clinical study","Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19","The use of a simplified negative pressure cuirass style ventilator under COVID-19 pandemic conditions in support of critically overwhelmed healthcare systems","Adapting the Decathlon Group Easybreathe snorkelling face mask for the safer administration of oxygen and/or continuous positive airway pressure and in the intra/interhospital transportation of patients with proven or suspected COVID 19 infection.","Study on the prevention of COVID-19 with Chinese medicine regulating constitution","Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19) for Returning Workers in Wuhan: a Randomized Controlled Trial","Virucidal pilot study of Nasodine Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.","Novel coronavirus pneumonia (COVID-19) emergency research project tackled by Shanghai University of Traditional Chinese Medicine","The design of a modifed N95 respirator and its protective effects against facial pressure injuries","Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Randomised Controlled Trial of Problem Management Plus versus Enhanced Treatment as Usual on Anxiety and Depression in People Distressed by Covid 19","Stress-reduction Using Probiotics to Promote Ongoing Resilience Throughout COVID-19 for Healthcare Workers: A randomised placebo-controlled trial","Clinical Research on Treatment of Novel Coronavirus Pneumonia  with ''Guangdong Pneumonia NO.1''","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Use of a respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in patients with severe confirmed COVID-19 pneumonia : a multicenter, parallel-group, open-label, randomized controlled trial - MULTI-COV","Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19","Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency\n A Randomized, Open-Label, Phase II Trial - COVIPOC","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study - COVID-Aging","The Danish Pre-HCQ Dialysis Study:\r\n Hydroxychloroquine for prevention of COVID-19 in dialysis-treated patients with end-stage renal disease -\r\nA multicenter parallel-group open randomized clinical trial\r\n - The Danish Pre-HCQ COVID19 Dialysis Study","A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease (COVID-19) - PRAETORIAN-COVID","ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial) - PROLIFIC Trial (COVID-19)","Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care - SARICOVID","A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneumonia Who Are Unresponsive to Standard Care - Tocilizumab plus Pembrolizumab in COVID-19  (COPERNICO Study)","COvid-19 and Vitamin D supplementation: a multicenter randomized controlled Trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients - CoVitTrial","A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine) in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - SARPAC","Phase 1/2 clinical study to assess the feasibility, safety, tolerability and preliminary efficacy of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome. (included patients COVID-19)","Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01","evaluation the effect of vitamin A on respiratory signs and hospitalization in patients with COVID-19","Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUF","Corticodes au cours de la pneumonie virale Covid-19 lie  linfection par le SARS-Cov-2 - CORTI-Covid","Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19","Evaluating efficacy and safety of sofosbuvir/ ledipasvir in  treatment of COVID-19","Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia","Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs","Randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts. COVID-19","Effect of Benson Relaxation on Quality of Life and job stress in nurses in intensive care units  with Covid-19 pationts","Pragmatic clinical trial to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19 infection in two cohorts: patients with oncohaematological disease and SARS-CoV-2 positive without radiological alteration and sars-cov-2 positive professionals without radiological alteration","Hydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancy","suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL","Double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV-allo) in acute respiratory failure in patients with COVID-19 pneumonia.\r\n - Treatment of COVID.19 with allogeneic mesenchymal cells  (MSV).","Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection","Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection.","COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)","Two-center, randomized, controlled clinical trial with two treatment arms to evaluate the safety and efficacy of intravenous administration of expanded allogeneic adipose tissue adult mesenchymal cells in critically ill patients COVID-19.","Study the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia","Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19\n - COVIDSurgRCT_v1.0_20200330","Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 - COL-COVID","Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients: A Clinical Trial Study","Comparison of the Effectiveness of Standard Treatment with Standard Treatment plus licorice extract in Improving Respiratory Symptoms and Survival Rate in COVID-19 Patients","Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with corona virus disease-2019 (COVID-19) referring to Sina Hospital in 2020","Evaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir/ritonavir combination  in patients with COVID-19","Evaluating efficacy and safety of interferone -1a in the treatment COVID-19 infection","Study the Efficacy and Safety of SeptimebTM in the Treatment of COVID-19   Infection in Iranian Patients: A Clinical Trial (Case Series)","Evaluating efficacy and safety of interferone -1b (IFN -1b) in the treatment of COVID-19","Efficacy of the myrtle (Myrtus Communis) syrup in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Formulation of two natural products (syrup and solution) and evaluation of their effects in patients with coronavirus disease 2019 (COVID-19): A randomized controlled trial","Effect of Camostate mesylate on clinical improvement and outcome of  Coronavirus (COVID-19)-induced pneumonia","Evaluation of Convalescent Plasma as a Potential Therapy for COVID-19 infected patients","Effect of hydroxychloroquine on prevention of covid-19 virus infection among treatment staff in Arash hospital-A double-blind clinical trial","A prospective randomized controlled trial comparing Sovodak (Sofosbuvir plus Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment","Evaluation of the efficacy and safety of cord-derived mesenchymal stem cell transplantation in the treatment of COVID-19","Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)","The effect of  NOSCOVID on pulmonary &amp; other clinical manifestations of COVID-19 patients","The effect of genetical nanocomposit drug with cell imunity level on human coronavirus (COVID-19)","the efficacy of Interferon beta 1 a (ReciGen)  in treatment of patients with Covid-19 in Sina Hospital Emergency Department","Study of the metformin effect on the survival and recovery rate of COVID-19 patients","Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)","Effect of metformin in COVID-19 mortality rate and symptom improvement","The effect of febuxostat against lung injury induced by COVID-19 virus in infected patients: A clinical trial study","Efficacy of the barley-based remedy in the treatment of suspected novel coronavirus  (COVID-19) pneumonia","Comparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients   and their effect on recovery process","Evaluation of  the effect of Traditional medicine product incorporated in the base of  Astragalus gossypinus  with food  spice on improvement of clinical menifestation of COVID -19 patients with conventional protocol","The Effect of Persian Medicine Products on the Clinical and Laboratory Symptoms of Patients With or Suspected of Covid-19","Study of the effect of Vitamin C on duration of hospital stay in patients with Covid-19","The effect of Trachyspermum copticum-based traditional medicine product on clinical manifestations and Para clinical features in patients with COVID-19: A Randomized clinical trial","Evaluation of efficacy of pharmacotherapy treatment of COVID- 19  infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease","Double blind clinical trial study on Evaluation of the effectiveness of Ipecac homeopathic remedy  in control of Clinical manifestations of COVID-19","To evaluate the effectiveness of hemoperfusion in patients with severe coronavirus disease 2019 (COVID-19)","Effect of Fingolimod for treatment of COVID-19-induced cytokine storm","Evaluation of the effects of Losartan in patients with corona virus disease 2019","Investigating the effectiveness of psychological interventions on mental health of Kerman University of Medical Sciencess mental health in hospitals and reference clinics","Mesenchymal stem cell utilization in reducing complications and enhancing pneumonia healing  in patients infected with 2019-nCoV (phase I clinical trial)","Effects of High-dose Vitamin C on Treatment, Clinical Symptoms and Laboratory Signs of Iranian COVID-19 Patients: A Double Blind Randomized Clinical Trial","Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit","Efficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19: a randomized controlled trial","Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial","A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19.","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection","Multicenter, Adaptive, Randomized, Placebo-Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia","Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19","Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19","Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus","COVID-19 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic","A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19.","Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)","Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial)","Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)","Non-contact Endoscopy at Covid-19 Outbreak","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic","A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19","A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.","A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of  lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients","ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection","Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia","Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","Exploratory Clinical Study to Assess the Efficacy of NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial","The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","Protective Role of Inhaled Steroids for Covid-19 Infection","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial","COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)","Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib","Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia","GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19-Nivolumab Trial","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection","Effectiveness of Crisis Management Coaching on Faculty and Trainee Wellness During COVID-19 Crisis","Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)","A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov)","Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial","Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection","Using Biovitals Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19","Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection","A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial","Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA Trial","Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia","Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS","Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak","Randomized Trial of ACEIs in Treatment of COVID-19","An Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression","Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (COVID-19)","Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study","The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients","Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers","Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome","Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2","An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia","Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19","Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home","Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial","Investigation Of The Effectiveness Of Video-Based Exercise Program Applied To Adult Individuals Who Experience Social Isolation At Houses Due To The Coronavirus (COVID-19) Pandemic","Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE","Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome","A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection","Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)","Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","A Pragmatic Adaptive Open Label, Randomized Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic","Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection","CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19","Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19- A Cluster Randomized Controlled Trial (SHARP COVID-19 RCT)","Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","Efficacy and Safety of Favipiravir in Management of COVID-19","Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","Hydroxychloroquine for Outpatients With Confirmed COVID-19","Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial","Two-treatment,Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19","Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment","Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial","Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial","Assessment of COVID-19 IgM/IgG Self-testing Using Virtual Point-of-care","Plasma Rich Antibodies From Recovered Patients From COVID19","Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection","Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms","An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multi-stage, 6-armed Placebo-controlled Trial in the Framework of an Adaptive Trial Platform","RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)","COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial","Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients","A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19","Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment","Impact of Zinc and Vitamin D3 Supplementation on the Survival of Institutionalized Aged Patients Infected With COVID-19","Administration of Chloropromazine as a Treatment for COVID-19","Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial","COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study","Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm","Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCT","Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia","IV Infusion of Autologous Adipose Derived Mesenchymal Cells for Abatement of Respiratory Compromise in SARS-CoV-2 Pandemic (COVID-19)","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","Open Label Randomized Controlled Trial of Ultraprotective Ventilation Without Extracorporeal Circulation in Patients With COVID 19 Pneumonia and Moderate to Severe ARDS","A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19","Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized Double-Blind, Phase 2 Study Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Placebo in Emergency Room Patients","Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection","Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia","Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19): a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)","COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1","Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19","A randomized, double-blind, placebo-controlled, multicentre clinical study on the improvement of novel coronavirus pneumonia (COVID-19) convalescent sleep mood disorder with shumian capsule","An Open-label Randomized Controlled Trial on Interferon -1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection","Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19","A Randomised, Double Blind, Placebo-Controlled Trial of the Efficacy of Hydroxychloroquine for the Community-Based Treatment of Adults With Diagnosed COVID-19\r\n","High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19","Impact of a Minimal Psychoeducational Intervention Versus Standard of Care on Anxiety Among Hospitalized COVID-19 Patients in Denmark: a Randomized Clinical Trial","Feasibility of a Facebook delivered physical activity focused group lifestyle intervention for older adults during the COVID-19 pandemic","A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia","Clinical Study Evaluating the Efficacy of Chloroquine in COVID-19 Treatment","A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period","Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial","A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence","Protecting frontline health care workers from COVID-19 with hydroxychloroquine pre-exposure prophylaxis: a randomized, placebo-controlled multi-site trial in Toronto, Canada","COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS","Multi-Site, Randomized, Open-Label, Parallel-Group, Placebo-Controlled Study to Assess the Chemoprophylactic Efficacy of Chloroquine Against SARS-CoV-2/COVID-19 in Healthcare Workers at High-Risk of Exposure","Pilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare personnel. - PrevenCOVID-19","Impact of high intensity interval training and aerobic training in on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain: a randomized controlled trial.","A multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for patients with SARS-CoV-2 infection with the risk of developing complications to reduce the risk of COVID-19-related hospitalization and death.","In adult patients with known or suspected COVID-19, does the use of Continuous Positive Airway Pressure (CPAP) or high-flow nasal oxygen (HFNO), compared with standard care reduce mortality or need for tracheal intubation?","An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19","A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.","Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study.\n - Ruxolitinib Treatment in  Patients with Severe COVID-19 Infection.A Danish Safety and Efficacy Study","Effectiveness of Prophylactic Hydroxychloroquine on incidence of COVID-19 infection in Front-line Health and Allied Health Care Workers: The COVID-SHIELD Trial","A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-19 PANDEMIC","A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 - Convalescent Plasma against COVID-19","Investigation of efficacy and tolerability of the healing water Staatl. Fachingen STILL in patients for symptomatic treatment of heartburn in comparison to placebo\n - Healing water efficacy in heartburn","A reusable personalised ventilation hood for care of patients with suspected or confirmed COVID-19 in the intensive care, emergency and respiratory healthcare settings: A phase 1 safety study of a new device (McMonty).","the efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomize, controlled trial","Xiaoyao capsule improves COVID-19 convalescence sleep mood disorder in a randomized, double-blind, placebo-controlled, multicenter clinical study","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity","OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","Mindfulness During COVID-19 - Remote Mindfulness Sessions","Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus","Rqesearch on the Application of Traditional Chinese Medicine Traditional Techniques to Prevent and Control New Coronary Pneumonia","Lingnan Fire-Needle Therapy Improves the Quality of Life in General Population Under the Pandemic of novel coronavirus pneumonia (COVID-19): A Prospective, Randomized Controlled Trial","Convalescent Plasma for Patients With COVID-19: A Pilot Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)","The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults","A Randomized Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalized Subjects With Confirmed SARS-CoV-2","A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension","An open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19 - COVIDAM","Study for efficacy and safety of Jie-Xing-Jun-Zi granules in the Treatment of convalescent patients of novel coronavious pneumonia (COVID-19)","A multicenter, randomized, open, controlled trial for the efficacy and safety of oral kolimycin in the treatment of patients with new coronavirus pneumonia (CoVID-19)","A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients","Renin Angiotensin System - CoronaVirus","Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial","The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019","Adjuvant Use of Ivermectin To Hydroxychloroquine and Azithromycin in Patients With Covid19: A Novel Double Blind Placebo Controlled Pilot Study","Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial","A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Standard Supportive Care in Subjects Infected With COVID-19","Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)","Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (EVICT-CORONA-ALI)","Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia)","Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19","Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19 - NOSARSCOVID19","Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia","Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial","Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections","COVID-19: addition of azithromycin to chloroquine treatment - CO VOR IT","A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)","A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.","A Phase 2 Randomized, Single Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19","COVID-19 Prophylaxis with hydroxychloroquine, Vitamin D, and Zinc supplementation in Danish nursing home residents  a randomized controlled trial - COVID-19 PREVENTION","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","A Randomized, Double-Blinded, Placebo-Controlled, Phase ?/? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years","Protecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Trial","Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure: A Pilot Study","Anti COVID-19 Convalescent Plasma Therapy","An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus","Efficacy of Captopril Nebulization in Covid-19 Patients Suffering of SARS CoV-2 Pneumonia. A Randomized Phase II Study","Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2","EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","Assesment of Usefulness of Ventil Device for Mechanical Ventilation in ICU Patients","Birth Experience During COVID-19 Confinement (Confinement and Fostering Intrapartum Care)","Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19.","An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19","Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19","PATCH 2 &amp; 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) An Open Label Multi-arm Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19","Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.","Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare\r\npersonnel with high risk of infection.","A Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19.","Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial","Clinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndrome","A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.","Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir v. Standard of Care in Hospitalized Subjects With COVID-19","Study of Immune Response During SARS-CoV-2 Infection","A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia","Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact","Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study","Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019  COVID-19","Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial","Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection","Efficacy and Safety of Azithromycin Compared to the Base Therapeutic Regiment of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial","Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial","A Randomized, Double-blind, Two Arm, Controlled Clinical Trial to Compare the Efficacy and Safety of Mycobacterium w (Mw) Administered Along With Standard of Care Versus Placebo Administered Along With Standard of Care, in Adult, COVID 19 Positive Patients Hospitalized But Not Critically Ill.","Keto-diet for Intubated Critical Care COVID-19 (KICC-COVID19)","A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AID","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study","Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial","A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- or Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers","Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients","Does a Systematic Phone-call by a Medical Student/General Practitioner Team in Patients Suffering From a Chronic Condition During the COVID-19 Containment Period Impact One-month Hospitalization's Rate in France? A Cluster Randomized Trial","Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope","Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19: a Randomized, Multicenter, Adaptative Study","Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19","Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study","Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic by Creation and Analysis of a Biological and Tissue Collection of Pregnancy Outcomes","Multi-centre Randomised Controlled Trial of Chloroquine/Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South Africa","Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial","Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.","Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus","Evaluation of the Safety and Efficacy of Isotretinoin in Treatment of COVID-19: Clinical Study","Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)","Comparison of Two Methods to Airway Clearance in Patients Admitted to Intensive Care Unit for COVID-19: A Pilot Corssover Randomized Controlled Trial","Comparison of the Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR","Impact of Multi-Denominational Prayer on Morbidity and Mortality of Patients Admitted to the Intensive Care Unite With Corona Virus Infection","Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino)","Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection in Medelln, Colombia, 2020","Hydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19)","Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19","Prevalence and Impact of SARS-COV-2 Infection in Pregnant Women, Fetuses and Newborns","An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","Efficacy of an Online Cognitive Behavioral Therapy (CBT) Programme Aiming at Reducing the Stress of Health Workers Involved in the Care of Patients During the Covid-19 Epidemic: a Randomized-controlled Trial","Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial","COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma","Randomized Clinical Study of Local Thermotherapy for Patients With Moderate Symptoms of COVID-19","A Pilot, Multiple Dose Study to Evaluate the Efficacy and Safety of MRx-4DP0004 in Hospitalised Patients With Symptoms of COVID-19 (SARS-CoV-2 Infection)","Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study","suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial","Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress","Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU","Chronic Fatigue Etiology and Recovery in Covid-19 Patients in Intensive Care Unit : the Role of Fatigability","The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations","Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome","Do Respiratory Control Center Anomalies Explain the Lack of Respiratory Sensations Perceptions Observed in Patients Affected by COVID-19 ?","A Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19)","Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial","Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope","Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial","Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab","Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial","Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19)","Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial","Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection (COVID-19). A Randomized Trial","A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men","A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization","A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection","A randomised controlled trial of Nebulised Heparin in critically ill mechanically ventilated patients with COVID-19 to assess the effect on  the  duration of mechanical ventilation.","A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19","Testing the efficacy of a coping skills app to support emotional wellbeing in youth during the Covid-19 epidemic","A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia","Convalescent Plasma for the Treatment of Moderate-severe COVID-19: A Proof-of-principle Study","The efficacy and safety of Siddha Treatment in Symptomatic Participants with novel coronavirus infectious disease (COVID-19): A Multicenter, Randomized, Open-Label, Active-controlled Randomised Clinical Trial","Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic (Sleep COVID-19)","Effectiveness of an expressive writing intervention in the reduction of psychological difficulties during the COVID-19 pandemic","\n                An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care\n","A randomized, double-blind, controlled trial for Bu-Fei-Huo-Xue Capsule in the treatment of novel coronavirus pneumonia (COVID-19) convalescence patient with ''Fei-Pi-Qi-Xu zhen''","The influence of COVID-19 pandemic on cardiovascular patients","Study for using sulfate in the prevention and control of novel coronavirus pneumonia (COVID-19) in high and low prevalence communities","Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19)","A Randomized Controlled Trial for the Effects of Low-Oxygen Consumption Instruction on the Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19)","A study for the mental health status of novel coronavirus pneumonia (COVID-19) convalescent patients and first-line medical staff and the intervention strategy of psychological crisis in Ningxia","Evaluation of the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) in healthy population aged 3 years and above: a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial","Efficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19)","Proactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID - ProPAC-COVID","A double-blind, randomized study versus placebo of avdoralimab (IPH5401), an anti-C5aR antibody, in patients with COVID-19 induced pneumonia\r\n - FORCE (FOR COVID-19 Elimination)","Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Gurin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Workers.\r\nCOVID-BCG\r\n - COVID BCG","Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19  LILIADE-COVID\n - LILIADE-COVID","Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study - COV-ENOX","Efficacy and safety of ANAkinra during Adult  COVID-19  with Aggravating respiratory symptoms: a multicenter open-label controlled randomized trial - ANACONDA-COVID-19","A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study\n - OUTCOV","Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia","Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation: a randomized study - REP-COVID","Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC in patients with acute respiratory distress syndrome secondary to infection by COVID-19 - COVIDMES","Prevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS)","Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19","Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 - APN01-01-COVID19","A Phase II, randomized, openlabel study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with COVID-19.","A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS: The Plasminogen Activator COVID-19 ARDS (PACA) trial\n\n - Nebulised rtPA for ARDS due to COVID-19  The PACA trial","A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia - TOC-COVID","CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL - HOPE","Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform - CCAP-RCT","Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults","The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial","CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","The ECLA PHRI COLCOVID Trial","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Gurin Vaccination, a Randomized Controlled Trial.","The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19). - N-ReCOVID 19","A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19","Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis","Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial","Treatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles: A Phase I/II Study","Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)","A Randomized Trial of Anticoagulation Strategies in COVID-19","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","DETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19","A Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19","Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone","Double-blind Randomized Controlled Clinical Trial of Low-dose Lenalidomide in the Treatment of COVID-19 Disease","Double Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)","A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19","Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo","A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation","Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization","A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19","A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease","A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics","Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)","PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19)","A Comparison of 3D and 2D Telemedicine: Communication During Covid 19","Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial","A Randomized, Controlled Clinical Trial to Test the Safety and Efficacy of Convalescent Donor Plasma to Treat COVID-19 in Hospitalized Adults","Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora","Efficacy and Safety of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.","An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms","Repurposing of Chlorpromazine in Covid-19 Treatment","The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19","Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation: a Randomized, Open-label Clinical Trial","Azithromycin With Amoxicillin/Clavulanate Versus Amoxicillin/Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA): a Superiority Open-label Randomized Controlled Trial","NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression","Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate","A Pilot, Open Label, Phase II Clinical Trial of Nebulised Recombinant Tissue-Plasminogen Activator (Rt-PA)","Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19","Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic","Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting","Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19","Efficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women: an Open-label Randomized Clinical Trial","Protective Effect of Aspirin on COVID-19 Patients","Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome","A Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19","Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum During an Emergency Laparoscopy Conducted on Confirmed or Suspected COVID-19 Patients","A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)","Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol","Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19","PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study)","Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic","Safety and Efficacy of Endotracheal Intubation by Paramedics in Suspected/Confirmed COVID-19 Patients Under Cardiac Arrest Using Vie Scope Laryngoscope","Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic","The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19: Validation of a New Online Treatment","Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial","Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial","Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness (BREATH): an RCT for Frontline Hospital and Long-term Care Home Staff Managing the COVID-19 Pandemic","COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie","Increasing Our Understanding of COVID-19: Minimal Invasive Autopsies to Investigate Clinical, Radiological, Microbiological and Histopathological Changes in Deceased COVID-19 Patients","Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)","A Repeated Measures Trial of Temporary Automated Manual Ventilation Versus Noninvasive Oxygenation or Conventional Ventilation for the Treatment of COVID-19 ARDS","A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome","Treating COVID-19 With Hydroxychloroquine: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized Adults","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk (PREVENT)","ReCOVER (Remote COVID-19 Evaluation and Response): a prospective non-randomised controlled trial to evaluate the effect of a novel smartphone application-centric model of care for the remote monitoring of COVID-19 patients in the community, on avoidable hospital presentations..","Use of Telemedicine for Follow-up of Systemic Lupus Erythematosus (\"TeleSLE\") in the COVID-19 Outbreak: a Pragmatic Randomised Controlled Trial","Exploring Provider Burnout During the COVID-19 Pandemic","A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.","Management of Covid-19 Patients During Home Isolation","A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic","A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - \"PANAMO\" - Panamo","Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers (PROVIDE): A Parallel Randomized Controlled Trial","Efficacy and safety of high-dose vitamin C combined with traditional Chinese medicine in the treatment of moderate and severe novel coronavirus pneumonia (COVID-19)","Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia","High dose intravenous vitamin C might be used as an important rescue therapy for aggravation of severe and critical novel coronavirus pneumonia (COVID-19) patients","Phase 2 Randomised Trial Using XPro1595 to Treat Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)","\"STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE\" GERONIMO 19\n - GERONIMO19","EFFICACY OF INTRAVENOUS ALMITRINE IN REDUCING THE NEED FOR MECHANICAL VENTILATION IN PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE DUE TO COVID-19-RELATED PNEUMONIA:  A RANDOMIZED CONTROLLED DOUBLE-BLIND STUDYFROM THE SKIP-ICU CONSORTIUM - AIRVM COVID","A randomized,double blinded, parallel  controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe &amp; Azithromycin &amp; Zinc vErsEs Standard CaRe - PIONEER","Clinical trial for the washed microbiota transplantation in the treatment of novel coronavirus pneumonia (COVID-19) patients suspected with gut microbiota dysbiosis","CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19","Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19)  hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE","A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection","A randomized, double-blind, placebo, parallel controlled trial for Pien-Tze-Huang Capsules in treating  convalescent novel coronavirus pneumonia (COVID-19) patient with SARS-CoV-2 positive.","Preliminary randomized controlled trial of poractant alfa (Curosurf) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 viral pneumonia. - CAARDS-1","Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection ILIAD 7 trial - ILIAD","EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS.\r\nRANDOMIZED CONTROLLED CLINICAL TRIAL - CORTIVID","REDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GURIN) VACCINATION - BACH (BCG Against COVID-19 in Hunga","Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure  a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial","A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease - RECOVER","Efficacy of captopril nebulization in Covid-19 patients suffering of SARS-CoV-2 pneumonia.\nA randomized phase II study\n - CAPTOCOVID","Ruxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts - RAVEN - RAVEN","Can a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals? - SINUS WASH pilot study","WHO SOLIDARITY Finland: The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) - SOLIDARITY Finland","Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCE","ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY: THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIAL","Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID).","CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19 - ANA-COVID-GEAS","Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID).","A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 - Investigating a Vaccine Against COVID-19 (COV002)","Stopping ACE-inhibitors in COVID-19 - a randomized, controlled clinical trial","A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2) - ATOMIC2, Version 1.0","Impact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19) - Heparin-SARS-CoV2","Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2: randomized clinical trial COVID-19","Single-center, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19","A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)","ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients","Low dose hydrocortisone in patients with COVID-19 and severe hypoxia  the COVID STEROID trial \n - COVID-STEROID trial","Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID) - RUXCOVID","A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2)\n\nACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)","Ramdomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19","PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) - COVIDNA","Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)","Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial","A RANDOMIZATION, MULTICENTRIC, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF EARLY CHOLCHICINE ADMINISTRATION IN PATIENTS OVER 70 YEARS OF AGE WITH HIGH RISK OF DEVELOPING SEVERE PULMONARY COMPLICATIONS ASSOCIATED WITH CORONAVIRUS SARS-CoV2 PNEUMONIA (COVID-19) - COLCHI-COVID","DAS181 for Severe COVID-19: Compassionate Use","A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam","Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study","The Impact of a Barrier Enclosure on Endotracheal Intubation Duration and First Pass Attempt - A Randomized Controlled Trial","Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission","A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19 - Study to Evaluate the Safety and Efficacy of High Dose IVIG in Patients with Mild/Moderate COVID19","A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19.","Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial - PreToVid","Efficacy and Safety of Hydroxychloroquine for COVID-19 Post-Exposure Prophylaxis of Healthcare Workers in the Philippine General Hospital and UP Manila National Institutes of Health: A Randomized, Double-blind, Placebo-controlled Trial","C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19","Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19","USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 - USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION","RANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. - HYDROCYCLO STUDY","A Trial of Ozone Auto-hemotherapy in Adults Hospitalized With Covid-19 Pneumonia","The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients","Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients","A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia","Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019","Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations","Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19","WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound: a Prospective, Multicenter, Randomized, Open-label, Parallel-group Clinical Trial","Utilisation de Soins Pendant la Crise Covid-19 : Recours, Report et Renoncement (US3R)","Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","A Randomized Controlled Open-Label Study of CM4620 Injectable Emulsion in Patients With Severe COVID-19 Pneumonia","Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients","Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.","A Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 Patients","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2","Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19","Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic","Impact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19","A Pilot Study of Duvelisib to Combat COVID-19","A Research Platform to Screen Patients in Oncology and Assess Impact - RESPONSE","A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications","Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial","A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir Verses HydroxycholorquiNe &amp; Azithromycin &amp; Zinc vErsEs Standard CaRe","To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study","Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)","Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients: A Pilot, Multicenter Randomized Open-Label Trial","Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients: Randomized Controlled Trial: MG-COVID","Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults","Effects of Traditional Chinese Medicines (TCMs) on Patients With COVID-19 Infection: A Perspective, Open-labeled, Randomized, Controlled Trial","Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection","Safety and Efficacy of Baricitinib for COVID-19","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2","A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures","Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities: Multicenter, Randomized, Open-labeled Controlled Trial","Unplanned Shifting the Traditional Classroom-Based to Online Distance Learning as a Result of (COVID-19) Social Distancing Measures: Nursing Students' Perception and Achievement","Use of Caption AI to Perform a Clinically Indicated Transthoracic Echocardiogram in Patients Being Evaluated for or Positive for COVID-19","A Quadruple Blind, Randomized Controlled Pilot Trial of Gargling Agents in Reducing Intraoral Viral Load Among Laboratory Confirmed COVID-19 Patients: GARGLES STUDY","Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study","Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.","Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics","COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)","A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection","UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT)","Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19","Low-flow Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform for Correction of Hypercapnia in COVID-19-associated Acute Respiratory Distress Syndrome","Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)","COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study)","Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients","Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alpha Administration in Patients With COVID19-induced Acute Respiratory Distress Syndrome (ARDS)","Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia","Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study","An International, Multi-site, Bayesian Platform Adaptive,Randomised, Double-blind, Placebo-controlled Trial Assessing the Effectiveness of Varied Doses of Oral Chloroquine in Preventing or Reducing the Severity of COVID-19 Disease in Healthcare Workers","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19","Use of a Medical Device, Kerecis Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa","COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19","Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)","Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial","Serology COVID-19 From the Cornwall Hospital Union","Efficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure: Randomised Control Trial","Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients","An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection","A Phase II Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","Feasibility and Acceptability of Online Based Mindfulness Interventions to Relieve Distress During COVID-19 Outbreak in a Chinese Population: a Proof-of-concept Trial","Treatment of Patients Hospitalized for COVID-19 Infection and Pulmonary Distress With Ibrutinib","Safety and Efficacy of Ruxolitinib for COVID-19","Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection","Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression","Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment","18F-av6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection","Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients","Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic: An Open Pilot Trial","Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19","Fluoxetine to Reduce Intubation and Death After COVID19 Infection","Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada","Prospective Phase II Study: MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS","CONCOR-KIDS: A Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children","A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection","A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)","The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation","Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial","Pilot Study on the Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy - COLOR 19)","Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial","Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial","London's Exogenous Surfactant Study for COVID19","Verification of Alternative Do-it-yourself Equipment Respirators","A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)","Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2","CORONA: A Phase 1/2 Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19","HOPE Intervention for COVID-19","Evaluation of Safety and Efficacy of Hydroxychloroquine Plus Favipiravir Drug Regimen in Comparison With Hydroxychloroquine Plus Kaletra on the Need for Intensive Care Unit Treatment in Patients With COVID-19; a Randomized, Multicenter, Parallel Groups, Open Label Study","Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic: An Open-Label 12 - Weeks Randomized Controlled Trail","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)","A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer","Safe Return to Regular Clinical Operation After COVID-19 Pandemic; (Oncology Center, Prospective Cohort)","Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Gurin Vaccination, a Randomized Controlled Trial","SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19","A Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Enhance Immune Clearance of SARS-CoV-2","Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients","Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-CoV-2: Predictive Interest in Short-term Evolution","Randomized evaluation of COVID-19 therapy","Assessment of the Clinical Effect of Dialyzable Leukocyte Extracts in Individuals With Acute Respiratory Infection (Suspected or Confirmed Cases of COVID-19) (FUTURE-T)","Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection","An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)","A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of Novel Coronavirus (2019-nCoV) Pneumonia","A multicenter, randomized, double-blind, placebo-controlled trial for Lu-Dang-Shen oral liquid in the treatment of reduced digestion function of convalescent new coronavirus pneumonia (COVID-19) patient","A randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and Abidor","Clinical study of novel coronavirus (SARS-Cov-2) infection treated with aerosol inhalation (IFN-? plus anti-inflammatory factor TFF2)","Observational clinical trial for the evaluation of an automated nasal and pharyngeal swab exam to test COVID-19 patients - SR-NOCS","A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)","CytoResc - CytoSorb Rescue for COVID-19 Cytokine Storm - CytoResc","BEAT COVID-19: A Phase III Bayesian adaptive randomisation platform controlled trial to evaluate the efficacy of drug interventions for COVID-19 on hospital admission or death in the community setting for high risk older people\r\n","Randomised controlled trial of an app-based intervention, Anchored, to support the mental health of Australians recently unemployed due to COVID-19.","Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial: The International ALLIANCE Study","Evaluation of online support during the coronavirus (COVID-19) pandemic: a group chat program in the psychiatric outpatient clinic of the Leipzig University Hospital","Naturalistic evaluation of an Internet-based psychological training program for mental strain associated with the coronavirus / COVID-19 pandemic - HelloBetter Corona","Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI","A short, animated video to improve COVID-19 hygiene uptake: an online randomized experiment with 20,000 participants - CoVideo","Lung Ultrasound in Covid-19 Pneumonia - LUCID","Improvement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease - COVit","get.calm and move.on  tackling worries and finding strength for the crisis (COVID-19) in 10 steps - get.calm_move.on","Cytokine adsorption in severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation - CYCOV","An e-Mental Health Intervention to Support burdened People in Times of the COVID-19 pandemic: CoPE It","Atorvastatin effect in Clinical and Laboratory findings of patiens with COVID-19 admitted RAZI referral hospital in Mazandaran State: A Randomized Clinical Trial","Evaluation of the efficacy and safety of Umifenovir in the treatment of hospitalized patients with covid-19: A randomized clinical trial","Effects of digital home exercise programs on physical and mental well-being during the COVID-19 pandemic: a multi-center trial - ASAP: Activity and health during the SARS-CoV2 pandemic","Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study","Evaluation of online support during the coronavirus (COVID-19) pandemic: Online cognitive behavioral therapy for obsessive-compulsive disorder (OCD NET program)","A Randomized, Controlled, Open Label, Multicentre Clinical Trial to explore Safety and Efficacy of Hyperbaric Oxygen for preventing\nICU admission, Morbidity and Mortality in Adult Patients With COVID-19 - COVID-19-HBO","Comparative assessment of the efficacy and safety of add ontreatment with Sofosbuvir plus Velpatasvir to standard of care therapeutic regimen in patients with COVID-19","Evaluation of the effect of oral intermediate chain triglyceride on prognosis and course of disease in suspected outpatients with COVID-19","Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis","The evaluation of pirfenidone effects on prevention and treatment of pulmonary fibrosis and acute respiratory distress syndrome caused by COVID-19","Evaluation of the efficacy of intravenous immunoglobulin (IVIg) in patients with severe  COVID-19 (Before intubation phase) who have not responded to treatment with the standard three-drug protocol (hydroxychloroquine / chloroquine + lupinavir / ritonavir + ribavirin)","The comparison of effectiveness of Tanacetum parthenium (L) Sch. syrups on clinical and paraclinical features of inpatients infected with 2019 novel coronavirus COVID-19, Parallel randomized trial","Evaluation of efficacy and safety of Sovodak (Sofosbuvir+Daclatasvir) in combination with Ribavirin for mild to moderate hospitalized Covid-19 patients compared to standard care regimen (a randomized controlled trial)","Assessment of effect of levamisole on pneumonia caused by COVID-19","Clinical trial of berberine against COVID-19","Evaluation the effect of aqueous extract of licorice on coronavirus outpatients: A randomized, double-blind, placebo-controlled clinical trial","Study of Methylprednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian ?COVID-19 patients: a clinical trial study","Evaluation the efficacy of Tumor Necrosis Factor alpha inhibitor in COVID-19 outcomes: a prospective clinical trial study.","The effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients: A Clinical Trial Study","Evaluation of the safety and efficacy of tocilizumab (AryoGen ?Pharmed Co., Iran) in patients with severe COVID-19?","A single-arm multicenter clinical trial to evaluate the safety and efficacy of Remdesivir in COVID-19 patients with progressive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Evaluating efficacy of Kelofan syrup, a traditional Iranian medicine product, on pulmonary and other clinical and laboratory manifestations of patients with probable or confirmed COVID-19","Evaluation of the effect of IMFLUNA herbal compound on the improvement of covid-19 pneumonia symptoms in patients referred to Baqiyatallah Hospital","Evaluation of the effect of herbal medicine containing Saatar, Hofarigon and Fennel on reduction of pulmonary complications of COVID-19 in patients: a clinical trial","Evaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patients","Efficacy evaluation of an herbal compound Fluherb on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients: a controlled randomized clinical trial.","Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms","The effect of naproxen on the healing process of patients with COVID-19","Effect of Hydroxychloroquine on Novel Coronavirus Disease (COVID-19) prevention in cancer patients under treatment","Safety and efficacy of Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone and Hydroxychloroquine + Azithromycin + Naproxen regimens in comparison with Hydroxychloroquine + kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study","Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in  hospitalized patients with COVID-19","Assessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in  pulmonary problems of the patients with Covid-19","Formulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.","Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection : A Phase 1 and 2 clinical trial","Study of the Efficacy of Teicoplanin on mortality rate of patients with  COVID-19 Infection: A randomized clinical trial","Comparative assessment of the efficacy and safety of addon treatment with Sofosbuvir-Daclatasvir, Lithium,and Trifluoprazine to standard of care in three groups of patients with COVID-19","The efficacy of oral 25-hydroxyvitamin D3 on  COVID-19 treatment in adults: A Randomized, Controlled Double-Blind Clinical Trial.","Efficacy and safety evaluation of therapeutic regimen of lopinavir/ritonavir and interferon beta 1b in patients with COVID-19","Effects of Viroherb capsule and Fenugreek syrup derived from traditional Persian medicine on clinical and paraclinical outcomes and survival of patients with mild to moderate COVID-19 hospitalized in medical centers of Tehran University of Medical Sciences","Evaluation of the effect of Arbidol drug in the treatment of hospitalized patients with COVID-19","Evaluation of Methylprednisolone Administration as a Therapeutic Option in the 2019 Novel Coronavirus (COVID-19): A Non-Randomized Controlled Study","Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial","Clinical trial of minocycline against COVID-19","Clinical trial of the effect of crocetin in improving the clinical and laboratory symptoms of patients with COVID-19","Evaluating the therapeutic effect of a mixed herbal drink of Marshmallow and Licorice on COVID 19 patients, A double blind clinical trial","Dose-Finding study of Ivermectin treatment on patients infected with Covid-19:A clinical trial","The comparison between early tracheostomy and orotracheal intubation in critically ill COVID-19 patients.","Effect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris, Lepidium sativum supplements on the Severity and Consequences of Coronavirus 19 disease (COVID-19)","Investigation of the effect of Zufa syrup on clinical symptoms in the with suspected  Corona(COVID-19)","To evaluate the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of COVID-19-induced cytokine storm","Treatment of COVID-19-induced cytokine storm with filter hemoperfusion HA330","Evaluation of the therapeutic effects of Convalescent Plasma (CP) of recovered people from Covid-19 in improving clinical and laboratory symptoms of hospitalized patients","The effect of family-centered empowerment model on stress, anxiety and family satisfaction in patients with Covid-19","Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patients","Effect of Bromhexine Hydrochloride on clinical improvement and outcome of  COVID-19-induced pneumonia","Evaluation of the role of naproxen as adjunctive therapy with standard therapies and its efficacy in the early improvement and reduced mortality rate of COVID-19 patients","Comparison of the effectiveness of standard treatment with stand treatment plus Vitamin A in treatment in covid19 patients","effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital","Investigating preventive effects of oral 25-hydroxyvitamin D3 on COVID-19 in adults: A  Randomized, Controlled Double-Blind Clinical Trial.","Evaluating the therapeutic effect of Phyllanthus Emblica on COVID 19 patients, A double blind clinical trial","Evaluation of the effect of Iranian medicine product, Algro, on the symptoms of patients with covid-19 (Coronavirus 19 disease)","Randomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trial","Comparison of interactive psycho-educational interventions via social networks with placebo on anxiety and self-efficacy of patients infected with COVID-19 and lived in home quarantine","Placental Mesenchymal Stem cells for treatment of ARDS in Coronavirus infection, Phase 1 and 2 Clinical Trials","Evaluation of SinaCurcumin as a complementary therapy in mild to moderate COVID-19: An open label non-randomized clinical trial","evaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections: A  non-randomized interventional study in Imam Reza Hospital, Mashhad.","Evaluation of adding melatonin to routine treatment on outcomes and quality of sleep in COVID-19 patients","Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19","Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings: A double-blind randomized and placebo controlled trial","Evaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with ARDS","Evaluating the efficacy of Atorvastatin in clinical improvement, prognosis and hospitalization course in patients with COVID-19 infection","Evaluation the effect of  asafoetida on coronavirus outpatients: A randomized, double-blind, placebo-controlled clinical trial","Clinical trial of lithium in improving the clinical and laboratory symptoms of patients with COVID-19","The effectiveness of educational-treatment package based on psychological flexibility in burnout, quality of working life, work-family conflict and mental health of the care team working in medical centers for patients with COVID-19","Determining the effect of skin test  purified protein derivative (PPD) on the recovery process of patients with COVID 19 in patients with this disease","Experimental Use of COVID-19 Convalescent Plasma for the Purpose Of Passive Immunization in Current COVID-19 Pandemic","The efficacy of inhaled formoterol on symptom improvement  in covid 19 patients","Prospective post-exposure hydroxycloroquine prophylaxis for Covid 19 (PROSCLOROCOV 19)","The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases","Safety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial study","The effect of pomegranate tea on symptom relief of COVID-19 patients: a double-blind randomized clinical trial study","Investigation the adipose and placenta-derived mesenchymal stem cells effect on the respiratory distress syndrome in patients with COVID-19: a pilot study","Evaluation of Trifluoperazine Effectiveness in Treatment Process, Survival rate and Cure rate of COVID-19 Patients","The Effect of a Persian Natural Medicine Product based on Tahini Oil on Clinical Signs in Suspected Patients with COVID-19","Evaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19","Investigating the efficacy of Zofa (a herbal medicine) in symptom management of patients with COVID-19","Evaluation efficacy  of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19","Comparison of the Effectiveness of  Tenofovir antiviral drug beside (Kaletra and Chloroquine) with  routine drug regime (Kaletra and Chloroquine) in  COVID-19 patients","Comparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test (Kovid-19)","Use of convalescent plasma in the treatment of patients with severe COVID-19 pneumonia","Effect of plasma of patients recovered from covid-19 versus control group on treatment of covid-19: a randomized clinical trial","A comparison of Elderberry (Sambucus nigra) extract syrup and placebo against COVID-19 symptoms in outpatients and home quarantined patients: A randomized double-blind clinical trial","The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)","Randomized, parallel-controlled and multi-center clinical study evaluating the efficacy and safety of convalescent  plasma, in the treatment of patients with severe SARS-CoV-2 infection (COVID-19)","Efficacy and safety  of  oral indomethacin for treatment of covid 19 induced pneumonia","Evaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection: A Clinical Trial","Investigating the effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)","Evaluation of the Effect  of  Trifluoperazin in Treatment of   Patients with Confirmed 2019 Novel Coronavirus(COVID- 19): An Open-Label Randomized Clinical Trial","Investigating the effect of hot foot-bath on controlling the symptoms of hospitalized patients with COVID-19 and accelerating the recovery process","The  effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure","Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19","Investigating the efficacy and safety of Azithromycin inhaled spray in controlling the symptoms of patients with COVID-19","The effect of plasma administration of COVID-19 survivors in patients with acute respiratory distress syndrome due to COVID-19","Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19","Evaluation of the effect of herbal oral product (thyme syrup) in patients with COVID-19","The Effect of Convalescent Plasma Therapy on the Outcomes of Patients with 19-COVID","The Effect of Inhalation of Thyme Oil with Standard Nationwide Medication on Respiratory Markers and Laboratory Findings in Patients with COVID-19","Evaluation of the therapeutic effect of colchicine plus chloroquine in comparison with chloroquine in patients with COVID-19","Evaluation of the efficacy and safety of Rabbit polyclonal antibody (CoviGlobulin) in patients with coronavirus COVID-19 virus moderate to severe","Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19","Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital: a clinical trial ?","Assessment of safety, efficacy and effective dose determination of human umbilical cord Whartons jelly mesenchymal stem cell transplantation on treatment of COVID-19 (coronavirus)  pneumonia and complications in humans","The effect of addition of selenium to treatment regimen of hospitalized patients with COVID-19 on the outcome of disease compared with control group","The effect of propolis supplementation on clinical manifestations and inflammatory biomarkers in patients with COVID-19","Prevention of COVID-19 disease after contact with an infected patient with coronavirus after taking hydroxychloroquine in the community","Treatment effect of Nafamostat mesilate in patients with COVID-19 pneumonia: open labelled randomized controlled clinical trial","Comparison of the effectiveness of Ozone therapy with conventional therapy in improving patient outcomes in Covid-19 patients","Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19, determining indications within the paradigm of host-directed therapy","Effect evaluation of herbal supplementation from the combination of sugarcane, black myrobalan and mastic along with the treatment protocol of the Ministry of Health on the course of COVID-19 disease","Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19: A randomized clinical trial","Effect of Intravenous immunoglobulin (IVIG) versus Kaletra (lopinavir and ritonavir) tablets in patients with acute respiratory infection (COVID-19): A clinical trial studies","Evaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trial","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia in Japan","A multicenter, open-label, randomized controlled trial to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 - RACCO trial","Multicenter, open-label, randomized trial of favipiravir in asymptomatic and minimally symptomatic patients infected with SARS-CoV2 to evaluate viral load reduction","The prophylactic effect of Hydroxychloroquine on Novel Corona virus (COVID-19) in health care providers","Study on risk perception and behavioral change related to COVID-19 - Study on risk perception and behavioral change related to COVID-19","Therapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19","Evaluation of colchicine tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad: A triple-blind randomized placebo controlled clinical trial","Evaluation of the effect of Nutrition Bio-Safety (NBS) powder on immune system function and clinical manifestations in patients with  COVID-19","Effect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus(COVID-19): A randomized, double-blind, placebo-controlled clinical trial study","Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19","Examination of test accuracy of COVID-19 rapid antibody kit - Examination of test accuracy of COVID-19 rapid antibody kit","Investigation of the effects of COVID-19 convalescent plasma in acute respiratory distress syndrome due to COVID-19","Efficacy of jujube product in accelerating the recovery process of Covid -19 patients","Assessment of adding low dose pulmonary radiotherapy to the national protocol of COVID-19 management: A pilot trial.","A feasibility study of remote rehabilitation using a wearable biological monitoring device in the patients with COVID-19 - A feasibility study of remote rehabilitation using a wearable device in COVID-19 patients","Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19: A double blind randomized clinical trial","Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate and Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients in Lagos State","Investigating the efficacy and safety of Interferon Beta1a nasal spray in controlling the symptoms of patients with COVID-19","Efficacy and safety of IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) for treatment of Corona virus disease 2019 (COVID-19): a pilot placebo-controlled randomized trial","Randomized, pragmatic, open study evaluating Hydroxychloroquine for prevention of Hospitalization and Respiratory Complications in outpatients with confirmed or presumptive diagnosis of Infection by (COVID-19)","PROTECT-Surg","The host Epigenetic methylation repair in COVID-19 using Folic acid: A new suggested prevention and treatment.","An international randomised trial of additional  treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY","Open and controlled trial of hydroxychloroquine and azytromicyn use to prevent complications in patients infected by new coronavirus (COVID-19): a randomized controlled trial - Brazil COVID Coalition I Trial","Evaluation of patients treated by telemedicine in the Covid-19 pandemic in Brazil\r\nin a medical clinic in the supplementary health sector in So Paulo, Brazil - : MAZZEI MEDICAL CENTER","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT)","Use of convalescent plasma submitted to pathogen inactivation for the treatment of patients with severe COVID-19","Full versus prophylactic heparinization for the treatment of severe forms of SARS-Covid-19: clinical, randomized, open and controlled study - HeSAcovid trial","Multicenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia","An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia ?? An open-label randomized controlled study ??","Randomized control clinical trial of CIGB 2020 in contacts and SARS-CoV-2 infection suspects (COVID-19)","Treatment of patients with severe SARS-CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab. (COVID-19) - VICTORIA","Administration of the CIGB-258 peptide in patients with COVID-19 under intensive therapy regimen (COVID-19)","Clinical Trial using N-acetylcysteine for treatment of 2019-nCoV Pneumonia","Comparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patients","Evaluation of the effect and safety of HeberFERON versus Heberon alfa in patients infected with the SARS-CoV-2 coronavirus (COVID-19).","Immunological efficacy of Qing Fei Pai Du Tang for COVID-19: an open-label, single-arm trial - COVID-19/Qing Fei Pai Du Tang","Pharmacodynamics and safety of recombinant interferon alfa 2b, by different routes of administration, in healthy volunteers (COVID-19).","SOLIDARITY: AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTS","Evaluation of the effect of 0.002% sodium chloride saline (activated) administered intravenously and / or mists in patients with covid-19. (COVID-19) - TX-COVID19","Immunological efficacy of Jinhua Qinggan Granule for COVID-19: an open-label, single-arm trial - COVID-19/Jinhua Qinggan Granule","Usage of topical lignocaine to decrease the gag reflex\nwhile sampling for Covid-19: Does it affect the yield of\n\nspecimen?","A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya","Therapeutic Pulmonary Telerehabilitation Protocol in patients affected by COVID-19, confined in their homes: Randomized Control Trial","Effectiveness of a protocol based on rt-pcr and serology tests for sars-cov-2 for the preservation of the healthcare workforce during covid-19 pandemia in Brazil: a parallel group, randomized clinical trial","Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel: a placebo-controlled, randomized, clinical trial","Evaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19: randomized clinical trial","Evaluation of Effect of Composite AYUSH Treatment as Prophylaxis of COVID 19","Impact of Ayurvedic Interventions in prevention of COVID-19 infection in containment areas of Delhi- A community based study","The role of early acute renal support in the prognosis of patients diagnosed of COVID 19: a randomized clinical trial","A Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection - Not applicable","Driving pressure guided positive end expiratory pressure (PEEP) strategy Vs physician guided PEEP (ARDSnet protocol) in mechanical ventilation for Acute respiratory distress syndrome (ARDS) in COVID-19 patients: a prospective randomised controlled trial.","Efficacy of HA330 Hemoperfusion in Critically Ill Patients with Severe COVID-19","An open labelled trial to evaluate safety and efficacy of SSV Formulation to boost immunity in quarantine patients of COVID-19","An international randomised trial of additional treatments for COVID-19 in\nhospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL","A Randomized, Open-label, multicenter study to evaluate the efficacy and safety of Favipiravir combined with STANDARD  supportive care in adult Indian patients with mild to moderate COVID-19","Efficacy of Imatinib in mild SARS CoV2 infection: A randomized study","Novel Artificial Intelligence Algorithm to screen COVID-19 patients from X-Ray and CT-Scan of Thorax and Voice Sampling through Android App and storage through Cloud","Effect of alternate nostril breathing and guided meditation practice on sleep quality, psychological distress and coping skills of healthcare workers during COVID-19 pandemic","Effect of an Ayurvedic Formulation as add-on to standard of care in COVID-19 positive patients in a tertiary hospital","Observational Study of ASHWAGANDHA TABLET intake as a preventive measure in pandemic of COVID-19 ?? An open label, Randomized, Controlled, Prospective, Interventional, Community-based Clinical study on healthy subjects\n\n","Hydroxy Chloroquine, in open labelled, Randomised intervention for prevention of new infection and adverse outcomes following COVID-19 infection- A Tertiary Hospital based study - CORONA study","Evaluation of the Immuno- stimulatory Potential (Shareera Bala) of an Ayurveda management protocol in Cohort of Quarantined Delhi police under Covid-19 care centers- An Exploratory clinical study - APCOVIDA","Topical Chloroquine Nasal Drops in Early Stage Covid 19-\nImpact on Viral load and cure rates\n","EFFECTIVENESS OF SIMULATION BASED TEACHING OF VENTILATORY MANAGEMENT AMONG NON-ANAESTHESIOLOGY RESIDENTS TO MANAGE COVID 19 PANDEMIC.","Randomized controlled Single blinded prospective multi centre clinical trial to\ninvestigate the safety and efficacy of ZingiVir-H as an adjuvant therapy in hospitalized adults\ndiagnosed with coronavirus disease 2019 (COVID-19)","Open labelled Randomised controlled trial to study the effect of Chloroquine in addition to standard therapy in COVID-19 patients","EFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS: AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVID","A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subjects","A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. - PLACID","Evaluation of safety and efficacy of convalescent plasma in COVID-19 patients","A Multi-Centre, Open label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications","Proving the efficacy of Homeopathic treatment in prevention and cure of COVID-19.","Effect of BCG-Denmark (Green Signal) on prevention of COVID 19 infection in health care workers ?? a double blind randomized controlled trial","A clinical trial to evaluate the safety and efficacy of Mycobacterium W in critically ill patients suffering from COVID 19 infection","Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization","Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19","??To study the effectiveness of Ivermectin with standard of care treatment\nversus standard of care treatment for COVID 19 cases. A Pilot Study","Randomised Controlled Trial to compare efficacy of  hydroxychloroquine alone and in combination with azithromycin  in treatment of COVID-19\n - HAZES","Effectiveness of topical povidone iodine (PVP-I) oropharyngeal and intranasal application during the current coronavirus pandemic amongst COVID-19 positive patients in Andhra Pradesh, India","A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications","Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti PD-1 (Nivolumab) and an Anti-interleukine-6 Receptor (Tocilizumab) vs Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection","A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection","??Clinical evaluation of Dabur Chyawanprash (DCP) as a preventive remedy in pandemic of COVID-19 ?? An Open label, Multi centric, Randomized, Comparative, Prospective, Interventional Community based Clinical Study on Healthy individuals.?? - NIL","EFFICACY OF ORAL NICLOSAMIDE IN TREATMENT OF MILD AND VERY MILD COVID-19 CASES: AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL - EONIC-COVID","Drug Proving &amp; checking its effectiveness in treatment of COVID 19","Phase 2 Clinical Trial for the Evaluation of BCG as potential therapy for CoVID-I9 - COVID-19 BCG","EFFECTIVENESS OF ARSENICUM ALBUM 30C IN PREVENTION OF COVID-19 IN INDIVIDUALS RESIDING IN HOSPOTS OF RED ZONES IN DELHI?? A  PROSPECTIVE COHORT STUDY","A Prospective, Open label observational clinical study to evaluate the efficacy and safety of MyVir tablets to improve immunity in quarantine patients of COVID-19","Effect of adjuvant homoeopathy with standard treatment protocol in management of covid-19: a randomised, open label, placebo controlled, parallel  group study\n\n","A randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19","Observational Study of GUDUCHI TABLET intake as a preventive measure in pandemic of COVID-19 ?? An open label, Randomized, Controlled, Prospective, Interventional, Community-based Clinical study on healthy subjects","Observational Study of YASHTIMADHU TABLET intake as a preventive measure in pandemic of COVID-19 ?? An open label, Randomized, Controlled, Prospective, interventional, Community-based Cclinical study on healthy subjects\n\n","An open label randomised  controlled trial to assess the efficacy of Hydroxychloroquine in patients with mild COVID -19  illness with risk factors for severe disease.","A Randomized and Comparative Study to assess Safety and Efficacy of Supplemental Treatment of a herbal formulation - Aayudh Advance comprising essential oils in patients with Corona Virus 2019 (Covid-19)","PROVING THE EFFICACY OF HOMOEOPATHIC TREATMENT IN PREVENTION AND CURE OF COVID 19","Evaluation of Efficacy and Safety of Thymoquinone compared to Best supportive care in Patients with COVID-19.","Evaluation of the Immuno-stimulatory(Shareera Bala) potential of Ayurveda management protocol in Cohort of Delhi Police - An Exploratory clinical Study - EBAMD","Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection","Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia","Evaluation of Efficacy and Safety of Ayurveda Intervention (Ayush-64) add-on therapy for patients with COVID-19 infection (Stage I)-A Randomized controlled clinical trial","A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19","Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19","A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","MR-Evaluation of Renal Function In Septic Patients","Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails","An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial","The Randomized, Open, Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)","Collection of COVID-19 Convalescent Plasma","A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection","A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19)","Antithrombotic Therapy to Ameliorate Complications of COVID-19","Moxibustion Plus Cupping in Convalescent Patients With COVID-19: A Randomized Clinical Trial","VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)","A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","DAS181 for COVID-19: A Phase II/III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study","Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses","Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection","Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19: Multi-central Prospective Study","A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection","Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19","A Study to Evaluate Health Behavior and Access Impacts Due to COVID-19 and for Community Engagement of Stakeholders Surrounding Scarce Resource Allocation Policy.","Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19","A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Bacterial ACE2 Receptors -Like Enzyme 2 (rbACE2) and Isotretinoin Adult Patients With COVID-19","Human Ab Response &amp; immunoMONItoring of COVID-19 Patients","Host-pathogen Interactions During Paediatric and Adult SARS-CoV-2 Infection (COVID-19)","A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19","A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19","The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.","A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress","Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial","Randomized Controlled Trial (RCT) to Evaluate the Efficacy of an Internet-based Self-help Program for People With Psychological Distress Due to Covid-19","Randomized Evaluation of COVID-19 Therapy","Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells","Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia","Emergency Ventilator Splitting Between Two or More Patients Using a Single Ventilator to Address Critical Ventilator Shortages During a Pandemic","A Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure","A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of Polyoxidonium, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).","High Flow Nasal Oxygen Versus Continuous Positive Airway Pressure Helmet Evaluation: A Randomized Crossover Trial in COVID-19 Pneumonia","Novel Treatment Regimens in Treatment of COVID-19","A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2)","Co-infections in COVID-19 Critically Ill and Antibiotic Management","Pulmonary and Motor Rehabilitation for People With COVID-19 in Intensive Care Units to Reduce Length of Stay in Hospital","Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)","A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients","Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial","Phase II ,III Randomized Double Blind Parallel Arms Clinical Trial of Potential Role of Gum Arabic ( Acacia Senegal) as Immunomodulatory Agent Among COVID 19 Patients in Sudan","Resting Heart Rate Variability as a Predictor of Coping Strategies and Responsiveness to a Brief Online Intervention During Forced Quarantine","A Phase 2, Randomized, Placebo-controlled, Participant and Investigator Blinded, Multi-center Study to Assess Efficacy and Safety of MAS825 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function","Randomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and Gurin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care Workers","A Novel and Practical Accelerated Intermittent Theta Burst Protocol as a Substitute for Depressed Patients Needing Electroconvulsive Therapy During the COVID-19 Pandemic","A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment","Hypertonic Saline Nasal Irrigation and Gargling With Hypertonic Saline for Suspected or Confirmed COVID-19: Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial","Investigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria: FALP 001-2020 Trial (FALP-COVID)","Effects of Neuromuscular Electrical Stimulation Therapy on Physical Function in Patients With COVID-19 Associated Pneumonia: Study Protocol of a Randomized Controlled Trial","Taiwan \"Aerosol Box\" Versus UMMC \"Intubation Box\" : Clinical Evaluation of the \"Intubation Box\" for Ease of Intubation","Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center","Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2","Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19","Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe COVID-19","A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","A Randomized, Double-Blinded, Placebo-Controlled, Phase ?/? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged =60 Years","Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers","Awake Prone Position for Early Hypoxemia in COVID-19","Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19","A Phase 2 Randomized, Open Label Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19","The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Lahore, Pakistan","Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study","ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)","Remote Monitoring in Patients With Coronavirus Disease (COVID-19)","Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)","Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study","Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)","Isotretinoin in Treatment of COVID-19 (Randomized)","Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial","An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection","Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020","A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19","COVID-19 Prophylaxis With Hydroxychloroquine Associated With Zinc For High-Risk Healthcare Workers Involved In Suspected, or Confirmed Cases of COVID-19.","Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design","Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia: a Randomized Controlled Double-blind Study From the Skip-icu Consortium","Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)","Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic","Efficacy and Safety of ANAkinra During Adult \" COVID-19 \" With Aggravating Respiratory Symptoms: a Multicenter Open-label Controlled Randomized Trial","The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients","Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE","Effects of a Mobile App on Health and Well-being During COVID-19 Pandemic in House Staff at Banner University Medical Center Phoenix","Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial","Mindfulness Training for Older Adults During the COVID-19 Pandemic","Identification of Predictive Immune Biomarkers Based on the Understanding of COVID-19 Pathogenesis to Influence Therapeutic Management","A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS","Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS","Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.","Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease","Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria","A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease","A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK","Convalescent Plasma in the Treatment of COVID 19","Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial","Phase 1b, Randomized, Blinded, Placebo-controlled Study of the Safety of Therapeutic Treatment With an Immunomodulary Agent (N-803 in Adults With COVID-19","Cohort of Patients Infected With SARS-CoV2 or Suspected of Being (COVID-19 in Ile-de-France)","Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial","A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection","A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID)","Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19","Adaptive Phase IB-II Trial Of Vaccine Consisting Of Autologous Dendritic Cells Loaded With Antigens From Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), With Or Without GM-CSF, In Frontline Healthcare Providers And Responders","The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease","Cohort of Patients With Covid19: Constitution of Blood Samples Collections With Clinical Characterization","Randomized Controlled Phase II Trial of Poractant Alfa (Curosurf) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral Pneumonia","Role of Inflammasomes in COVID-19 Disease","Pilot Study on the Use of Sarilumab in Patients With COVID-19 Infection","Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection","A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStem Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)","Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection","Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest","A Multi-site, Randomized, Double-Blind, Multi-Arm Historical Control, Comparative Trial of the Safety and Efficacy of Hydroxychloroquine, and the Combination of HCQ and Famotidine for the Treatment of COVID-19","Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial","#StayHome: Efficacy of Early Hydroxychloroquine in Outpatients to Reduce Secondary Hospitalisation and Household Transmission of COVID-19 in Switzerland: A Double-blind, Randomised, Placebo-controlled Trial","Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation - Randomized, Controlled, Open-label Intervention, Multi-center Trial (CYCOV-II-study)","A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII)","Preventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults","A Multicenter, Single-Treatment Study to Assess the Safety and Preliminary Efficacy of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury","Analysis of Chilblains Profile During COVID-19 Epidemic","Phase 2b/3 Trial to Evaluate the Safety and Efficacy of Plasma Transfusion From Convalescent Patients With SARS-CoV-2 Infection on Severity and Mortality of COVID-19 in Hospitalized Patients.","Early Continuous Positive Airway Pressure (CPAP) in COVID-19 Confirmed or Suspected Patients","Accelerated Prone Position Ventilation of Patients With COVID-19","Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020","Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth","Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease","Tocilizumab for the treatment of COVID-19 in intensive care patients: effect on days free of ventilatory support.","Improving Vitamin D Status in the Management of COVID-19","A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19","Effects of COVID-19-Related Self-isolation on Psychological Response to Different Outdoor Environments in Singapore - Before &amp; After Brain and Behavior Study","Australasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care","Evaluation of Shift, a smartphone application for New South Wales Junior Medical Officers, on depression and anxiety during the COVID-19 epidemic.","A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19","Online parent training for reducing parenting stress during the COVID-19 pandemic: a randomized controlled trial","The safety and efficacy of STC3141 in patient with COVID-19 ARDS require intensive care","A Phase 3, Randomized, Multi-center, Blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin (RTX) Versus Placebo to Manage Pain in Patients With Osteoarthritis of the Knee Whose Total Knee Replacement Surgery is Delayed Due to the COVID-19-related Moratoria on Elective Procedures","A pilot, open-label, randomised controlled clinical trial to investigate early efficacy of CYP-001 in adults admitted to intensive care with COVID-19","PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT)","Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic","A pilot study of virucidal activity of povidone-iodine (PVP-I) 0.5% aqueous solution oral/nasal spray and mouthwash in people with COVID-19 and confirmed oral/nasal shedding of SARS-CoV-2","Investigating the use of convalescent plasma from patients who have recovered from COVID-19 in the management of Ecuadorian patients infected with SARS-CoV-2 with clinical deterioration: IMPACT","An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2","A Phase III prospective, interventional, cohort, superiority study to evaluate the benefit of rapid COVID-19 genomic sequencing (the COVID-19 GENOMICS UK Project) on infection control in preventing the spread of the virus in UK NHS hospitals","Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE)","A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.","PROphylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT): a Basket Trial of Prophylactic Interventions Amongst At-risk Patients","Combination Therapy With Isotretinoin and Tamoxifen May Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus","A randomized controlled trial for determination of the clinical effect of Internet-assisted pulmonary rehabilitation on patients with novel coronavirus pneumonia (COVID-19)","Convalescent Plasma in the treatment of 6 COVID-19 Patients","A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure","Simulation time taken amongst consultant anaesthetists to perform spinal anaesthesia or general anaesthesia for COVID-19 patients requiring an emergency category 1 caesarean delivery","Volatile agents for sedation in patients with COVID-19-associated acute respiratory distress syndrome  a pilot study","A pilot randomized clinical trial of therapeutic plasma exchange (TPE) in serious SARS CoV-2 disease (COVID-19)","Randomized controlled trial of Digital Cardiac Counseling in patients with delayed cardiac surgical treatment due to Covid-19 pandemic (DCC trial)","Continuous positive airway pressure in severe Covid-19 pneumonia: a feasibility and physiological end-point study","Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19)","A phase II/III study to determine the efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19","The School Opening in the Age of Pandemic (SOAP) study: a cluster-randomised re-introduction of school activities in Norway","Sleep position related to hospital length of stay in admitted COVID-19 patients","REDUCING HOSPITAL ADMISSION OF ELDERLY IN SARS-CoV-2 PANDEMIC VIA THE INDUCTION OF TRAINED IMMUNITY BY BACILLUS CALMETTE-GURIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL","Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine: a possible preventive approach against COVID-19 (BCG-PLUS)","A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)","A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients","A clinical trial of nebulized surfactant for the Treatment of moderate to severe COVID-19 in adults - COVID-19 Surfactant Clinical Trial","An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)","Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial","A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease. - OSCAR","Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 - IONIC study -IMU838 and Oseltamivir in treatment of Novel Coronavirus","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19    DAWN AZITHRO","The use of (social) media","A multicentre, open-label clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab for treating patients with COVID-19 pneumonia: the BREATH-19 Study","A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection - Low Dose Oral Selinexor in Patients with Severe COVID-19 Infection","An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19\n","Usefulness of vitamin D on morbidity and mortality of SARS-COV-2 virus infection (Covid-19) at the Central University Hospital of Asturias - Vitamin D and COVID-19","Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterioration in hospitalized patients with COVID-19 pneumonia (severe stage)","An Open Label, Dose-Escalation, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019","Controlled and randomised trial to assess the safety and efficacy of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in hospital healthcare personnel (Sanitarios sin COVID-19 -SANsinCOVID-19). - Sanitarios sin COVID -SANsinCOVID-","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated with COVID-19 - TD-0903 for acute lung injury associated with COVID-19","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial. - BCG-DENMARK-COVID","An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients","Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)","A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment","Countering Lung Damage in COVID-19 infection (CounterCovid) study","BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers Following Coronavirus Exposure (BRACE) Trial","An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19","Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients","Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications","Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19","Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial","Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","A Randomized, Controlled, Open Label, Multicentre Clinical Trial to Explore Safety and Efficacy of Hyperbaric Oxygen for Preventing ICU Admission, Morbidity and Mortality in Adult Patients With COVID-19","A Single-center,Open-label,Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 - STOP-COVID19: Superiority Trial Of Protease inhibition in COVID-19","A Multicenter, Randomized, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Checkpoint Blockade in Patients With Coronavirus Disease 2019 (COVID-19)-Related Mild Acute Respiratory Syndrome Nonresponsive to Frontline Therapy","Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in French Guiana","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial","PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","COVID 19: Experimental use of tocilizumab (Roactemra) in severe SARS-CoV-2 related pneumonia.","Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment","Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) - REMAP-CAP","Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19","Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial)","A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses","A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS","A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.","A Pilot Study of Ruxolitinib to Combat COVID-19","A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)","Seroprevalence and Antibody Profiling Against SARS-CoV2 in Children and Their Parents","A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers - A phase I/II trial of a candidate COVID-19 vaccine (COV001)","Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers","A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia","Convalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 Disease","Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.","A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease","PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill COVID-19 Patients Under Electric Impedance Tomography (EIT)","Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients","Plasma Adsorption in Patients With Confirmed COVID-19 Infection","A Randomized, Placebo-Controlled, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19","Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19","A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity","Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial","Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial","Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection - MARNEVO-Covid","A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.","A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.","A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19","Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial","A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19","Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients","Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia","Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial (DISTANSE COVID-19 RCT)","A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","A Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19","A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study Evaluating AVM0703 in Patients With COVID-19","Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial","Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)","The Role of Resistant Starch in COVID-19 Infection","A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19","Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia","A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)","Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation: Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib","Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection","Efficacy of Based MRI Contrast Media Against Covid-19","Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.","The RESCUE 1-19 Trial: Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19","A Telerehabilitation Approach to Improve Long-term Physical Ability and Quality of Life in Patients With Severe Acute Respiratory Syndrome Coronavirus (SARSCoV-2, COVID-19) Immediately After Hospitalization. The ATHLOS Study","A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M Adjuvant In Healthy Subjects","Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria: Prospective, Multicenter, Randomized, Double-blind Study","BHV3500-203: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Vazegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen","An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19)","Development of a Novel Hood Shield to Enhance PPE Security and Minimize COVID-19 Transmission to Front-line Health Care Workers Performing High-risk Procedures","Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19.","Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore: a Review of Process Feasibility, Safety, and Clinical Outcomes","A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting","Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection","Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-18","A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19","Home-based Treatment of Computed Tomography and Clinically Suspected Novel COVID-19 With Adjuvant Inhalable Sodium Bicarbonate: A Preliminary Case Series","Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection","Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses","The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial","Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion France","Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19","Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel","Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)","The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19","Incidence of Covid-19 in School Children During the Pandemic Period in Nice","A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease","Using Behavioral Nudges to Improve Preventive Health Behaviors That Limit COVID-19 Spread","Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study","Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19","Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill","A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19","Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury and Hyperinflammation","Inactivated Convalescent Plasma as a Therapeutic Alternative in Hospitalized Patients CoViD-19","Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization","Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.","Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID)","Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)","Meditation and Yoga for Heightened Anxiety Related to COVID-19","Phase II, Multicenter, Open-label, Rct With an Adaptive Design, to Assess Efficacy of Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19","Mesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome","COVID-19 Health Messaging to Underserved Communities","Prone Positioning for Patients on General Medical Wards With COVID19: A Multicenter Pragmatic Randomized Trial [COVID-PRONE]","Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study","A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Organicell Flow for the Treatment of Moderate to SARS Related to COVID-19 Infection vs Placebo","A Randomized Phase 2 Trial of Peginterferon Lambda-1a (Lambda) for the Treatment of Hospitalized Patients Infected With SARS-CoV-2 With Non-critical Illness","Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)","Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19","Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.","Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic: a Prospective, Open-label, Pilot, Randomized Trial","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19","The Use of Desferal and Adjuvants for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection: A Randomized Controlled Trial","TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia:a Multicenter Randomized Controlled Open Label Trial","Convalescent Plasma for the Treatment of Patients With COVID-19","Safety and Efficacy of Intravenous Infusion of Wharton's Jelly Derived Mesenchymal Stem Cell Plus Standard Therapy for the Treatment of Patients With Acute Respiratory Distress Syndrome Diagnosis Due to COVID 19: A Randomized Controlled Trial","Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)","Respiratory Decompensation and Model for the Triage of COVID-19 Patients: a Prospective Study","A Phase 2 Study to Evaluate LB1148 for the Treatment of Pulmonary Dysfunction Associated With COVID-19 Pneumonia","Assessment of Adding Low Dose Pulmonary Radiotherapy to the National Protocol of COVID-19 Management: A Pilot Trial","A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection","A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19","The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection","Effectiveness of Prone Positioning Combined With High-flow Nasal Cannula for Patients With COVID-19 Induced ARDS","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19","Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia and Impaired Respiratory Function","Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19","Efficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection: A Randomized, Open Label Clinical Trial","Multiwave Locked System (MLS) Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia","Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial","Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)","Is Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) Able to Decrease the Intensive Care Unit (ICU) Length of Stay for Patients With COVID-19?","Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males","Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19","Feasibility and Effectiveness of Mindfulness Program by Smartphone for Patients With Chronic Migraine and Medication Overuse During Covid-19 Emergency","Aerosol Inhalation of the Exosomes Derived From Allogenic COVID-19 T Cell in the Treatment of Early Stage Novel Coronavirus Pneumonia","Repurposing Montelukast for the Attenuation and Prophylaxis of Severe COVID-19 Symptoms: The COvid-19 Symptom MOntelukast (COSMO) Trial","Incidence of COVID-19 Test Conversion in Post-surgical Patients","Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers","A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection","Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19)","Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal","A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients","BARICIVID-19 STUDY: MultiCentre, Randomised, Phase IIa Clinical Trial Evaluating Efficacy and Tolerability of Baricitinib as add-on Treatment of In-patients With COVID-19 Compared to Standard Therapy","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)","the Effect of PRP and Cord Blood in Improving the Symptoms of Covid-19","Pilot Study of Low-Dose Single or Bilateral Whole Lung Irradiation for SARS-CoV-2 Pneumonia","Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies","Testing the Effects of Two Mindfulness-based Programs on Well Being and Academic Performance of Undergraduate Students of Translation and Interpreting: An Interventional Study","Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?","A Phase 2/3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged = 65 and Patients Aged =18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2.","Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease","Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: a Pilot Sequential Clinical Trial","A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period","Trial of Silymarin in Adults With COVID-19 Pneumonia","Early Care, Therapeutic Education, and Psychological Intervention for the Management of Post-intensive Care Syndrome and Chronic Pain After Coronavirus Disease 2019 Infection. Simple-blind, Controlled, Randomized Trial.","Upper Limb Robotic Rehabilitation in Stroke Survivors Using a Portable Device During the COVID-19 Outbreak. A Feasibility Study","Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial","Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial","Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial","What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study)","Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","Randomized Controlled Trial of Digital Cardiac Counseling in Patients With Delayed Cardiac Surgical Treatment Due to Covid-19 Pandemic (DCC Trial)","Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2: a Multicenter Open Label Randomized Control Trial","Pilot Internet-based Self-Help Program for Managing Corona Stress vs. Waitlist Control","Randomized-controlled Trial of HFNC Alone vs HFNC and Awake Self-proning for Treatment of Severe COVID-19","A Double-blinded Randomized Controlled Trial to Examine the Effectiveness of a Mobile-based Intervention to Reduce Mental Health Problems in Healthcare Workers at the Frontline Against COVID-19 in Spain: the PsyCovidApp Trial","At-Home COVID-19 Antibody Test Usability Assessment &amp; Behavior Change Study","Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia: Prospective Multicentric Study in Radiation Oncology Centers","A Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment in Hospitalized Patients","Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19","A Multi-Center Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Patients Developing Acute Kidney Injury (AKI) or Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 Infection","A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 (SAVE)","Effects of Cognitive Behavariol Brief Therapy on Perceived Stress Level and Anxiety, Depression and Post Trauamatic Stress Symptoms in Medical Residents and Medical Staff During CoVID 19 Pandemics","Low Dose Radiation Therapy for Covid-19 Pneumonia: A Pilot Study","A Phase I Study of ResCure to Treat COVID-19 Infection","Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial","Combination With Inhibitor of Neutrophil Elastase (All-trans Retinoic Acid ) and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines","Dexamethasone Versus Usual Care for the Treatment of COVID-19 Related ARDS: a Multicenter and Randomized Open-label Clinical Trial","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19","Effectiveness of Basic Body Awareness Therapy in Survivors of Covid-19 and Health Workers Regarding Post-traumatic Stress Disorders","A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19","Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial","Helmet Continuous Positive Airway Pressure Versus High-Flow Nasal Cannula in COVID-19: A Pragmatic Randomised Clinical Trial","Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The International ALLIANCE Study","A Phase 1/2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 Pneumonia","Effect of Ayurveda as Prophylaxis for Suspected Covid-19 Patients: Randomised Controlled Trial","Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety","RT-PCR on Conjunctival Sample for the Detection of SARS-Cov-2 in Patients With Covid-19","An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.","A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial)","Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury","Randomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental Oxygen","Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19) the Vanguard Study","EFFICACY AND SAFETY OF OCTAGAM 10% THERAPY IN COVID-19 PATIENTS WITH SEVERE DISEASE PROGRESSION","Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)","Remote Monitoring of Cancer Patients Presenting With Symptoms Suggestive of Covid-19 - Pilot Phase.","Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical Ventilation","COvid-19 Pandemic and Exercise (COPE) Trial: A Randomized Study Examining Physical Activities and Wellbeing in Individuals Mandated to Stay at Home","Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix","Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial","Randomized Double-Blind Placebo-Controlled Proof-of-Concept Trial of Resveratrol for the Outpatient Treatment of Mild Coronavirus Disease (COVID-19)","Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial","A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to &lt;85 Years of Age in Canada","A Daily Coping Toolkit for Medical Personnel and First-Responders During the COVID-19 Pandemic","COVID-19 EPIDEMIC Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder","The Efficacy Comparing Daily and After-each-case Room Disinfection in the Endoscopy Unit During the COVID-19 Pandemic.","A Randomized Trial of the Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19","Lessening Organ Dysfunction With VITamin C - COVID","ReCOVER (Remote COVID-19 Evaluation and Response): a Prospective Non-randomised Controlled Trial to Evaluate the Effect of a Novel Smartphone Application-centric Model of Care for the Remote Monitoring of COVID-19 Patients in the Community.","Flow Controlled Ventilation in ARDS Associated With COVID-19","Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)","A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol","The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19 at Emergency Department","Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With Moderate to Severe COVID-19 Pneumonia","A proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related Pneumonia","Building Capacity and Promoting Smoking Cessation in the Community Via \"Quit to Win\" Contest 2020: a Single-blind Randomized Controlled Trial on COVID-19 Related Brief Advice and Personalized Chat-based Intervention for Smoking Cessation","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation","\"Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention\"","Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19","SARS-CoV-2 Specific Memory B and T- CD4+ Cells","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II)","A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19","Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Other Organ Injuries in Patients Infected With SARS-CoV-2 (COVID-19)","The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients","Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh","BAT IT: Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19","Randomized Controlled Trial of Angiotensin 1-7/ TXA127 for the Treatment of Moderate COVID-19","A Prospective Randomized Trial of Prone Positioning Versus Usual Care for Patients With Do-not-intubate Goals of Care and Hypoxemic Respiratory Failure During the Coronavirus SARS-CoV-2 (COVID-19) Pandemic","Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)","Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Study","Laser Interferometry of Single Virus Particles Flowing Through Glass Microcapillaries to Detect Novel Coronavirus COVID-19","A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19","Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 During Pregnancy","Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)","Pulmozyme to Improve COVID-19 ARDS Outcomes","The Efficacy of Ivermectin and Doxycycline in COVID-19 Treatment","Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: \"The Hope Coalition\"","Efficacy of Tannin Specific Natural Extract for Coronavirus Disease (COVID-19): Randomized Controlled Trial","Randomized Clinical Trial of Aa Palm Berry Extract as an Intervention in Patients Diagnosed With COVID-19","A Phase 2a Open-label Study of the Efficacy and Safety of PRN PH94B Neuroactive Nasal Spray in the Treatment of Adjustment Disorder With Anxiety (AjDA) Associated With COVID-19","COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial","CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome","CONVALESCENT PLASMA TO LIMIT CORONAVIRUS ASSOCIATED COMPLICATIONS: A RANDOMIZED BLINDED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF ANTI-SARS-COV-2 PLASMA TO PLACEBO IN COVID-19 HOSPITALIZED PATIENTS","\"STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE\" GERONIMO 19","Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT","Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers: a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS)","Evaluation of the PCL Rapid Point of Care Antigen Test for Severe Acute Respiratory Syndrome Coronavirus 2","A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer"],["China",null,null,"China","China",null,"China","China",null,"China","China",null,"China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,null,"China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China",null,"China",null,"China","China","China","China","China","China","China","China","China",null,"China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China",null,"China","China",null,"China","China",null,"China","China","France;United States;Hong Kong;Taiwan;Belgium;Spain;Australia;Denmark;Germany;Italy;China;Korea, Republic of, Republic of","China","China",null,"China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,null,"China","China",null,"China",null,"China",null,"China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","Jordan","France","China","China","China","China","China","China","China",null,"China","China","China","China","Italy","China","China","China","China","China","China","France;Canada;Spain;Russian Federation;Israel;Germany;Japan;Italy","China","China","China","China","China",null,"China","Belgium","China","China","Italy","Italy","Netherlands","Italy",null,"China","United Kingdom","China","China",null,"China","United Kingdom","China","China","China","China","China","China","China","France;Belgium;Luxembourg;Netherlands;Germany;United Kingdom;Spain","Italy","France","Netherlands","France","Canada","China","China;Italy;China;Italy","United States","Norway","China",null,"Norway","Romania","United States","Germany","Pakistan",null,null,null,"United States","China","Iran",null,null,null,"United States","Australia",null,"Australia","Israel","Australia",null,"Australia","China","China","China","China","China","China","China","France","France","France","France","France","Spain","Netherlands","Spain","Spain","France","France","Spain","France","Spain","France","Greece","Spain","Spain","China","China","China","Spain","Italy","United States","Canada","China","Spain","United States","Thailand","China","Italy","Spain","Italy","Iran","United States","China","Spain","Denmark","Ireland","United States","Spain","United Kingdom",null,"Canada","Spain",null,"Turkey","China",null,"United States",null,"Denmark","China","Italy",null,null,"China","France","Spain","China",null,"Germany","Australia","United States","Australia","China","China","Germany","Australia","Australia","China","China","Australia","China","China","China","Greece","Australia","New Zealand","China","China","China","France","Spain","Denmark","France","Denmark","Netherlands","United Kingdom","Spain","Spain","France","Belgium","Spain","Spain","Iran","Spain","France","France","Iran","Spain","Spain","Spain","Iran","Spain","Spain","Greece","Spain","Spain","Spain","Spain","Spain","Iran","Ghana;Nigeria;South Africa;United Kingdom;India","Spain","Iran","Iran;Iran;Iran;Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran;Iran;Iran","Iran","Iran;Iran;Iran;Iran","Iran","Iran;Iran;Iran;Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran;Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","China","China","Hong Kong","Japan","China","China","China","France","Japan","Mexico","Mexico","Spain","China","France","Germany","Brazil","China","Japan","Canada","Norway","United States","Spain",null,"Brazil",null,"Egypt","Spain","France",null,"Brazil","United States","France","Mexico","Belgium","United States","France","United States","United States","Germany",null,"France","Brazil","United States","Hong Kong","France","United States","United States","United States","France",null,"Colombia","France","United Kingdom","Egypt","Malaysia","United Kingdom","Italy","Turkey","United States","Belgium","Colombia","Italy","Belgium",null,"France",null,"Ireland","Spain",null,"Greece","Spain",null,"Netherlands","Turkey","United States",null,null,"United States","Iran","Egypt","Iran","United States","Brazil",null,"Egypt","Nigeria;Pakistan;Nigeria;Pakistan","United Kingdom","United States","Egypt","Mexico","Poland","China","Denmark",null,"United States","Spain","United States","United States","Egypt",null,"Egypt","China",null,"Puerto Rico",null,"Slovenia",null,"United States","France",null,"United States","France","Iran","France",null,"United States","China","Hong Kong","Egypt","New Zealand","United States",null,"Australia","China","Egypt","China",null,null,"Canada","Austria","Australia","Spain","Spain","Poland","United Kingdom","France;Hungary;Czech Republic;Denmark;Germany;United Kingdom","Ireland","Denmark","Australia","Austria","Germany","Germany","Australia","China","China","Spain;Thailand;Indonesia;Italy;Switzerland;Canada;Argentina;Brazil;Iran;Peru;South Africa;Germany;Norway","Spain","United States;Canada;Spain;Canada;Spain;United States","United States","Brazil","China","China","Colombia","Colombia","Belgium","France","China","United States","Canada",null,"China","Belgium","China","China","Canada","France","Greece","United States","Iraq","United States","United States","France","United States","Canada","Italy","United States;Austria;China","France","Canada","France","Netherlands","Austria","Belgium;Italy","United States","Denmark","United States","China","United States","United States",null,"Israel","France","United States",null,"Poland","France","Spain",null,"Spain","United States",null,"Spain",null,"Austria;Germany;Austria;Germany","Spain","France","United States","France",null,"Italy",null,"Germany","United States","Spain","Iran","Iran",null,null,"Belgium","United States;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States","China","Colombia",null,"United States","France",null,"United States","France",null,"United States","China","Mexico","France","France","South Africa","Iran","Brazil","Brazil",null,"United States",null,"Belgium",null,"Italy","Colombia","Brazil",null,null,"Netherlands",null,"Switzerland","Mexico",null,null,"Italy","Greece","France","France","France",null,"Spain",null,"United States",null,null,"Switzerland","Mexico","Turkey","Spain","United States","Brazil","United States","France","United States","Australia",null,"New Zealand",null,null,"India","United Kingdom","Serbia","Indonesia;Iran;Ireland;Israel;Italy;Kenya;Lebanon;Malaysia;Norway;Peru;Philippines;Qatar;Saudi Arabia;South Africa;Spain;Switzerland;Thailand;Argentina;Brazil;Canada;Germany;Honduras;India","China","China","China","China",null,"China","China","China","Denmark","France","France","France","France","France","France","Spain","Spain","Spain","Spain","Spain","Austria;Denmark","Spain","United Kingdom","Germany","Greece","Denmark","France;Luxembourg;France;Luxembourg","Denmark","France","Switzerland","Argentina","United States","Netherlands","Norway","United States","United States",null,"Brazil","United States","United States","China","United States;Canada;United States","Mexico","United Kingdom","United States","Spain","Spain",null,"Spain","Germany","United States","United States","United States","United States","United States","Italy","United Kingdom","Iran","United States","Italy","Brazil","United States","France","Egypt","Switzerland","France",null,"Pakistan","United Kingdom",null,"France","Poland","France","France","China","France","United States","France","Spain","Italy","Spain","France","United States","Poland","France","Belgium","Poland","Sweden","Canada","France","Belgium",null,null,null,"United States","Brazil",null,"Australia",null,"United States","France","Egypt","Austria","Netherlands;Germany","Canada","China",null,null,"China",null,"France","France","China","United Kingdom","China","United Kingdom","France","United States;Spain;Austria;Israel;Italy;United Kingdom;India;France;Canada;Belgium;Malaysia;Australia;Germany","China","France","United States;France;Spain;Belgium;Italy;United Kingdom","Spain","Hungary","Denmark","Germany","France","United Kingdom","United Kingdom","Finland","France","Greece","United States;France;Spain;Germany;United Kingdom;Italy","Spain","United States;France;Spain;Germany;Italy;United Kingdom","United Kingdom","Austria","United Kingdom","Spain","Spain","Spain","Canada;Canada","United Kingdom","Denmark","United States;France;Spain;Germany;United Kingdom;Italy","Austria","Spain","Spain","Israel;Israel","Denmark","Spain","China;China","Vietnam;Vietnam","Tunisia;Tunisia",null,"Spain","Spain","Spain","Netherlands",null,"France;France","China;China","Spain","Spain","Spain;Spain","Iran;Iran","France;France","France;France","China;China","United States;United States","Iran;Iran","United States;United States","France;France",null,"Pakistan;Pakistan","Iran;Iran","United States;United States","France;France","Spain;Spain","Jordan;Jordan","France;France","Israel;Israel","Canada;Canada","Egypt;Egypt","United States;United States","Canada;Canada","India;India",null,"United Kingdom;United Kingdom","India;India",null,"Jordan;Jordan",null,"Canada;Canada","United States;Denmark;Germany;Greece;Japan;Korea, Republic of, Republic of;Mexico;Singapore;Spain;United Kingdom;Denmark;Germany;Greece;Japan;Korea, Republic of, Republic of;Mexico;Singapore;Spain;United Kingdom;United States","China","Mexico","United States","Gibraltar","Austria;Denmark;Germany;Austria;Denmark;Germany","United States","United States",null,"Egypt;Egypt","United States",null,"United States","Italy;Italy","Spain;Spain","United States;United States","France","United States;Austria;France;Israel;Spain;United Kingdom;Austria;France;Israel;Spain;United Kingdom;United States",null,"Denmark","Germany","Egypt","United States","Canada","France","Spain","Italy;Italy","United States;Canada;Ireland;South Africa;United Kingdom;Zambia;Canada;Ireland;South Africa;United Kingdom;United States;Zambia;Australia","United States","Iceland",null,null,"France","France",null,"United States","Bosnia and Herzegovina","United States","United States","Hong Kong",null,null,"France","United States",null,"United States","United States","Israel","Egypt","United States","Canada","Germany","Canada","United States","United States","Israel","United States","Italy",null,"Chile",null,"Belgium","Tunisia",null,null,"United States","Iran",null,"United States",null,"Saudi Arabia","South Africa","United States","United States",null,"France","United Kingdom","Mexico","United States","Russian Federation","China","China","China","China","Germany","China","Germany","Australia","Australia","Australia;United States;Germany","Germany","Germany","Germany","United States;United Kingdom;Germany;Mexico;Spain;France","Germany","Germany","Germany","Germany","Germany","Iran","Iran","Germany;Argentina;France;Austria;Italy;Spain;Chile;Brazil;Singapore","Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran","Germany","Germany;Sweden;United States","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran;Iran;Iran","Iran","Iran","Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran","Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran;Iran;Iran;Iran","Iran","Iran","Iran;Iran;Iran","Iran;Iran","Iran","Iran","Iran;Iran;Iran;Iran;Iran","Iran","Iran;Iran;Iran","Iran","Iran;Iran","Iran;Iran","Iran","Iran","Iran;Iran;Iran","Iran;Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran;Iran","Iran","Iran;Iran;Iran;Iran","Iran;Iran;Iran","Iran","Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran;Iran","Iran","Iran;Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Pakistan","Iran","Iran;Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran;Iran;Iran;Iran","Iran;Iran","Iran;Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Iran","Korea, Republic of, Republic of","Iran","Iran","Iran","Iran","Iran","Iran","Japan","Japan","Japan","Iran;Iran","Japan","Iran","Iran","Iran","Iran","Iran","Japan","Iran","Iran","Iran","Japan","Iran","Egypt","Nigeria","Iran","Nigeria;Nigeria","Brazil","Ghana","Egypt","Lebanon","Brazil","Brazil","United States;Korea, Republic of;Japan","Brazil","Brazil","Japan","Thailand","Cuba","Cuba","Cuba","Brazil","Thailand","Cuba","Japan","Cuba","India;Iran;Thailand;Spain;Norway;Switzerland;South Africa;Argentina;Peru;Bahrain","Mexico","Japan","India","Kenya","Spain","Brazil","\n            Sri Lanka\n","Brazil","India","India","Brazil","India","India","Thailand","India","Argentina;Brazil;Canada;Germany;India;Indonesia;Iran;Norway;Peru;Qatar;South Africa;Spain;Switzerland;Thailand","India","India","India","India","India","India","India","India","India","India","India","India","India","India","India","India","India","India","India","India","United States","Denmark","India","India","India","India","France","United States","India","India","India","India","India","India","India","India","India","India","India","India","India","India","India","Canada","Spain","India","France;Italy;Spain;France;Italy;Spain","China","United States","Sweden","China","China","Sweden","Korea, Republic of, Republic of","Germany","United States","United States","India","Italy","Canada",null,"United States","United States","Italy","United States","Brazil","United States","Spain","United States","Spain","United States","Russian Federation",null,"France","France",null,"United States","Greece","United States","United States","Switzerland","United Kingdom","Belarus","Indonesia","United States","United States","Belgium","Russian Federation",null,null,null,"Belgium","Italy","Sweden",null,"Mexico","Sudan","Italy",null,"France","Canada","Taiwan","United Kingdom","Chile","Italy","Malaysia","United States",null,null,"United States","United States;China;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;China;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States","United States","China","United States","United States","United States","United States","Pakistan","United States","United Kingdom","United States","Canada","United States","Norway","Mexico","Egypt","Denmark","United States","Pakistan","United States","Brazil","United States","France","Canada","United States","France","Italy","France","United States","China","United States","France","United States","France",null,"France","United States",null,"France","United Kingdom","United States","India",null,"France","Bahrain","United Kingdom","United States",null,null,"United States","France",null,"France",null,"United States","United States","Italy","United States","United States","Bahrain","Switzerland","Germany","United States","Iran",null,null,null,"United States","Denmark","United States","United States","Sweden","Australia",null,"Spain","Singapore","Australia;New Zealand","Australia","Saudi Arabia","Hungary","Australia",null,"Australia","United Kingdom","France","United Kingdom","Ecuador","United States","United Kingdom","United Kingdom","United Kingdom",null,null,"China","China",null,"Australia","Netherlands","Oman;Saudi Arabia;United Arab Emirates","Netherlands","Netherlands","Netherlands","United Kingdom","Norway","Netherlands","Netherlands","Netherlands","China","China","United Kingdom","China","Netherlands","United States;France;Spain;United Kingdom","United Kingdom","Belgium","Netherlands","Spain","United States;Spain;Austria;Israel;United Kingdom;Italy;India;France;Canada;Belgium;Malaysia;Australia;Germany","Netherlands","Spain","United States;France;Belgium","United States","Spain","Portugal;France;Canada;Spain;Ireland;Australia;Norway;Italy;India","United Kingdom","United States;China;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;China;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;Iran","United States;Israel;United States","Denmark","Brazil","Italy","Thailand","United States","Netherlands","Australia","Canada;France;Germany;Israel;Italy;Japan;Russian Federation;Spain;Canada;France;Germany;Israel;Italy;Japan;Russian Federation;Spain","Brazil","Poland","United States","United States","Korea, Republic of, Republic of","Germany;Sweden;Germany;Sweden","China","United Kingdom","Spain","French Guiana","Canada","France;Monaco;France;Monaco","France","Netherlands","United States","Belgium","United States","United States","United States","Portugal;Greece;Finland;Spain;Ireland;United Kingdom;France;Czech Republic;Hungary;Belgium;Romania;Croatia;Australia;Denmark;Netherlands;Germany;New Zealand","United States","China","Netherlands","Denmark","United States","United Kingdom","United States","Canada","France","United States","United States","Saudi Arabia","United States","France","United Kingdom","United States","United States","United States","United States","United States","Hungary","Germany","United States","United States","United States","United States","United States","United States","Argentina","France","France","United States","Italy","Canada","United States;Belgium;France;Netherlands;Belgium;France;Netherlands;United States","United States","United States;Puerto Rico;United States","United States","Mexico","Canada","United States",null,null,"Italy","United States","United States","United States;Germany;Spain;United Kingdom;Germany;Spain;United Kingdom;United States",null,"United States","United States",null,"France","Spain","Egypt","France","United States","Greece","Australia","France","United States","Russian Federation",null,null,"United States","United States","United States","United States","United States","Egypt","United States","United States",null,null,"Turkey","Pakistan","United States;Germany;Spain;United Kingdom;Germany;Spain;United Kingdom;United States","Turkey","France",null,null,"Russian Federation",null,"Canada;Mongolia;Canada;Mongolia","United States","United States","Colombia","Spain","Argentina","United States",null,"United States","France;Italy;France;Italy","United States","United States","Canada","Sweden","United States","United States","United States","Saudi Arabia","United States","China","United States;Israel;United States",null,null,"United States","Colombia","Spain","United Kingdom","United States",null,"Iran","United States",null,"Argentina","Spain","Spain","Israel","Denmark","United States","Colombia","United States","United States","Mexico","United States","Brazil",null,"Iran","Italy","Turkey",null,"United States","Spain","United States;United Kingdom;United States","United States","Switzerland","Senegal","United States","Italy","United Kingdom","Egypt",null,"France","Spain","United Kingdom","France","Russian Federation","Egypt","Malaysia","Egypt",null,null,"Pakistan","Saudi Arabia",null,"Turkey","Australia",null,"Italy","Israel","Canada",null,"United States","Spain",null,null,null,null,null,"India","United States",null,null,"Argentina","United States",null,"Russian Federation","Greece","Sweden",null,null,"United Kingdom","North Macedonia","France","United States","Italy",null,"United States","Canada",null,"United States","United Kingdom",null,null,"United States",null,null,null,"Canada","United States",null,"China","United States","Canada","Australia",null,null,"Mexico","Turkey",null,null,null,"China","United States","Canada","Saudi Arabia","United Kingdom",null,"United States;Japan;Singapore;Japan;Singapore;United States","United Kingdom",null,"Turkey","Bangladesh","United States",null,"Canada","United States",null,"United Kingdom","United States","France","United States",null,"Egypt","Brazil",null,null,"United States","Russian Federation","France",null,"France","Bangladesh","Brazil","United Kingdom",null],["Case series:Treated with conventional treatment combined with Chloroquine Phosphate;","Other: basic treatment;Drug: Arbidol","Drug: Intravenous Immunoglobulin;Other: Standard care","experimental group:standardized comprehensive treatment combined with convalescent plasma treatment;control group:standardized comprehensive treatment;","Drug: Arbidol;Drug: Lopinavir and Ritonavir Tablets","Drug: arbidol,400mg,tid;Drug: arbidol,200mg,tid;Drug: Conventional treatment group","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment;control group :western medicine symptomatic treatment  ;","control group:Western Medicine;experimental group:Integrated Traditional Chinese and Western Medicine;","Drug: lopinavir/ritonavir group;Drug: ASC09/ritonavir group","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment ;control group:western medicine symptomatic treatment ;","Experimental group:TCM based on symptomatic treatment;Control group:Placebo TCM based on symptomatic treatment;","Experimental group:Conventional treatment+Anti-aging Active Freeze-dried Powder Granules;Control group:Conventional treatment;","Conventional treatment group:The conventional treatment group will be treated according to the guidance of the Diagnosis and Treatment Scheme of COVID-19 published by the National Health Commission.;Experimental group:conventional treatment combined with Chloroquine Phosphate.;","experimental group:Truncated Torsion' Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","TCM Group:herbal medicine and conventional treatment;QFPD decoction group:QFPD decoction and conventional treatment;SFJD capsuale group:SFJD capsuale and conventional treatment;control group:conventional treatment;","control group:Standard treatment;experimental group:Standard treatment and methylprednisolone for injection;","Experimental group:Carrimycin;Control group:Lopinavir and Ritonavir Tablets;","Experimental group:Regulating intestinal flora + conventional treatment;Control group:conventional treatment;","experimental group:Truncation and Torsion Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","experimental group:Polyinosinic-Polycytidylic Acid Injection and conventional therapy;control group:conventional therapy;","Experimental group:honeysuckle decoction;Control group:placebo;","General patients treated with normal treatment:Normal Treatment;General patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;Severe patients control group 1:Normal treatment plus hormonotherapy;Severe patients control group 2:Normal Treatment;Severe patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;","Control group:Health education+Basic treatment of western medicine;Experimental group:Health education+Basic treatment of Western medicine+Dialectical?treatment of traditional Chinese medicine;","Chinese traditional medicine group 1:Traditional Chinese medicine qingfei prescription treatment;Chinese traditional medicine group 2:Traditional Chinese medicine clear lung prescription and compound houttuynia mixture treatment;Control group:Conventional treatment;","Experimental group:Conventional Treatment &amp; Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day);Control Group:Conventional Treatment;","experimental group:Chloroquine Phosphate;control group:Lopinavir / Ritonavir;","Thymosin treatment group:Thymosin for injection 1.6 mg sc qd for 5 days;PD-1 treatment group:Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion;Conventional treatment group:Conventional treatment;","Experimental group:Oral administration of 5 tablets of 1mg Azvudine tablets daily;Control group:According to the \"Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Version 5)\" issued by National Health Commission of People's Republic of China, the subjects were given corresponding treatment.;","control group :Conventional treatment ;Experimental group :conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group;","Experimental group:chloroquine;control group:conventional management;","Control group:Western medicine basic treatment;Experimental group:Western medicine basic treatment combined with traditional Chinese medicine;","Case series:Conventional standardized treatment and vMIP atomized inhalation;","experimental group:conventional standardized treatment and Lopinavir-Ritonavir;control group:Conventional standardized treatment;","Control group :Western medicine routine treatment plan;Intervention group :Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","Treatment group:Integrated Traditional Chinese and Western Medicine;","Experimental group:Conventional treatment + take Ba-Bao-Dan;Control group:Conventional treatment;","control group:conventional therapy;Experience group:conventional  therapy+tocilizumab;","control group:western medical therapies;Experimental group:Conventional medicine + TCM;","Experimental group:Routine treatment + Babaodan 6 capsules, bid orally;Control group:Conventional treatment;","experimental group:TCM and general treatment;control group:general treatment;","(ordinary) Western medicine group:Use the (ordinary)  western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(ordinary) Chinese and Western Medicine Group:Use the (ordinary)   TCM clinical prescription combined with the western medicine  treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(severe) Western medicine group:Use the (severe) TCM clinical prescription combined with the western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(severe) Chinese and Western Medicine Group:Use the(severe)TCM clinical prescription combined with the western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;","Group 1:TCM syndrome differentiation treatment+ Western medicine treatment;Group 2:Western medicine treatment;","treament group:Chinese medicine decoction;placebo group:placebo;","Experimental Group:Combined Treatment of Chinese medicine and western medicine;Control Group:Western medicine treatment;","experimental group:Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment;control group:clinical standard antiviral treatment;","experimental group:Traditional Chinese Medicine+psychological intervention;\t Control group:Traditional Chinese Medicine;Control group:psychological intervention;","experimental group:Xiyanping injection;control group:alpha-interferon;","experimental group \t:TCM decoctions+basic western medical therapies ;control group :basic western medical therapies ;","Experimental group:Traditional Chinese Medicine;control group:Basic treatment of modern medicine;","Case series:Add 500ml of 5% glucose injection or 0.9% sodium chloride injection into Tanreqing injection, intravenous drip, control the number of drops no more than 60 drops per minute, 1-2 times a day; the dosage is determined by the doctor,but no more than 80ml / day, 40ml / day is recommended.;","A:Critical Treatment in Critical Period + Ankylosaurus;B:Critical Treatment in Critical Period + Ankylosaurus+M1 suppression therapy;C:Critical Treatment in Critical Period;","Experimental group:Hydrogen-Oxygen Nebulizer;Control group:Oxygen concentrator;","Experimental group:umbilical cord mesenchymal stem cells;control group:convention treatment;","doctors group:Psychological intervention;nurses group:Psychological intervention;suspected cases group:Psychological intervention or drug intervention;cases group:Psychological intervention or drug intervention;","Control group:Routine treatment (Pure western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection;Investigation group:(Integrated Chinese and western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection(routine treatment)+Qing-Wen Bai-Du-Yin formula granules;","Experimental group:health education, follow-up condition management by team of family doctors, Chinese medicine treatment;Control group:health education, follow-up condition management by team of family doctors;","Group A:alpha-Interferon atomization;Group B:Lopinavir and Ritonavir + alpha-Interferon atomization;Group C:Favipiravir + alpha-Interferon atomization;","control group:Conventional treatment;experimental group:conventional treatment combined with umbilical cord blood mononuclear cells group;","Experimental group:Arbidol tablets + basic treatment;Control group:Basic treatment;","experimental group 1:Hydroxychloroquine 0.1 oral 2/ day;experimental group 2:Hydroxychloroquine 0.2 oral 2/ day;Placebo control group:Starch pill oral 2/ day;","Experimental group:Traditional Chinese medicine soup;Control group:Western antiviral;","Other: standard treatment;Drug: Thymosin+standard treatment;Drug: PD-1 blocking antibody+standard treatment","Experimental group:Routine treatment + plasma treatment;Control group:Routine treatment;","Experimental group 1:current antiviral treatment+Baloxavir Marboxil  tablets;Experimental group 2:current antiviral treatment+fabiravir tablets;Control group:current antiviral treatment;","mild-moderate chloroquine group:oral chloroquine phosphate;mild-moderate Lopinavir/ritonavir group:oral Lopinavir/ritonavir;mild-moderate combination group:chloroquine phosphate plus Lopinavir/ritonavir;severe-chloroquine group :oral chloroquine phosphate  ;severe- Lopinavir/ritonavir group:oral Lopinavir/ritonavir;","DRV/c group:DRV/c (800mg/150mg QD) + Conventional treatment containing thymosin (1.6 mg SC QOD) ;LPV/r group:LPV/r (400mg/100mg bid) + Conventional treatment containing thymosin (1.6 mg SC QOD);other group:Conventional treatment containing thymosin (1.6 mg SC QOD) ;","Two groups:Different stem cell doses;","experimental group A:Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations;control gorup A:Conventional treatment;Experimental Group B1:Artificial liver therapy+conventional treatment;Experimental Group B2:Artificial liver therapy followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations+conventional treatment;Control Gorup A:Conventional treatment;","experimental group:Lopinavir/litonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination;Historical Control:LPV/r;","1:Simplify cognitive behavior;2:Supportive psychotherapy;","Control group:Keep ritonavir/ritonavir treatment;Experimental group:Favipiravir;","Experimental group:Conventional standardized treatment and ASC09/Ritonavir;Control group:Conventional standardized treatment and Lopinavir/Ritonavir;","Psychological Intervention Group:\"Intelligent Psychosomatic Regulation System\" Intervention;Control Group :General Treatment ;","Community exposure TCM intervention group:TCM intervention;Community exposure control group:Placebo;Hospital exposure TCM intervention group:TCM intervention;Hospital exposure control group:Placebo;Community suspected TCM intervention group:TCM intervention;Community suspected control group:Placebo;Hospital suspected TCM intervention group:TCM intervention;Hospital suspected control group:Placebo;","single arm:Chinese medicine treatment combined with western medicine treatment;","A:BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.;B:Favipiravir: 600 mg tid with 1600mg first loading dosage for no more than 14 days.;C:Lopinavir-Ritonavir: 2# (200mg/50 mg), twice daily, for 14days.;","Group A:traditional Chinese medicine treatment;Group B:Lopinavir / Ritonavir;Group C:traditional Chinese medicine treatment and Lopinavir / Ritonavir;","experimental group:TCM decoctions+basic conventional therapy;Control group:basic conventional therapies;","experimental group:shadowboxing +conventional treatment;Control group:conventional treatments;","Experimental:Conventional treatment and Shenfu injection;control:Conventional treatment;","experimental group:Pulmonary rehabilitation+Conventional treatment;control group:Conventional treatment;","Case series:FNC;","Case series:Anti-2019-nCoV virus inactivated plasma;","control group:basic western medical therapies;experimental group:TCM standard decoctions+basic western medical therapies;","Experimental group:TCM+Routine treatment of Western Medicine;Control group:Routine treatment of Western Medicine;","Group 1:Xuebijing Injiection;Group 2:Conventional treatment;","Experimental Group:Conventional Treatment &amp; Low Dose  Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks);Control Group:Conventional Treatment+Placebo  i.m.(once another day, 3 times per week, 2 weeks);","Case series:Suramin( IV.);","control group:conventional treatment;mild ill patients:conventional treatment and ozonated autohemotherapy;severe/critical ill patients:conventional treatment and ozonated autohemotherapy;","Case series:Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","Combination therapy group:Xiyanping injection+ conventional treatment;Conventional treatment group:Lopinavir / Ritonavir tablets, alpha-interferon;","Biological: UC-MSCs","Experimental group:Syndrome differential treatment of Chinese Medicine + Western medicine basic treatment;Control group:Western medicine basic treatment;","Exercise prescription group:Exercise prescription;Control group:None;","Experimental group :Oral leflunomide;Control group:Oral placebo;","severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;Acute exacerbation NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;","Intervention group 1:Oral antiviral oral solution (Xiangxue Pharmaceutical);Intervention group 2:Oral \"Wu-Zhi-Fang-Guan-Fang\" decoction;Control group:Routine quarantine measures;","Experimental group:Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC);Control group:Routine treatment + placebo;","1:inhalate the mycobacterium vaccae for injection;2:inhalate  Physiological saline;","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Humanistic care:Humanistic care+routine regimen;Control group:routine regimen;","Low-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 1600 mg per time on first day; the duration of treatment will be 10 d.;Middle-dose group:Tablets; 200mg; orally; twice a day;The adult dose is 1800 mg per time on first day; the duration of treatment will be 10 d.;High-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 2400 mg per time on first day; the duration of treatment will be 10 d.;","Experimental group:ozonated autohemotherapy;Control group:Standard medical treatment;","control group with common NCP:conventional treatment;experimental group with common NCP:conventional treatment combined with ozone therapy;experimental group with severe NCP:conventional treatment combined with ozone therapy;control group with severe NCP:conventional treatment;experimental group with critical NCP:conventional treatment combined with ozone therapy;control group with critical NCP:conventional treatment;","Experimental group:rhG-CSF, 5ug/kg, combinated with standard treatment;Control group:standard treatment;","Experimental group:Conventional treatent and adalimumab;Control group:conventional treatment ;","Experimental group:Basic treatment combined Triazavirin;Control group:Basic treatment combined Triazavirin placebo;","Experimental group:Iv injection of Wharton's Jelly mesenchymal stem cells (110^6/kg), cell suspension volume: 40ml;Control group:Iv 40ml saline;","Control group:Conventional treatment;Experimental group:Conventional treatment +acupressure+Liuzijue qigong;","Ganovo / ritonavir group:Ganovo/ ritonavir oral;Pegasys group:Pegasys injection;Novaferon group:Novaferon  intramuscular injection+Spray inhalation;Coriolus group:Coriolus  oral;Comparator:TCM+Spray inhalation;","Control group:Conventional treatment;Experimental group:Conventional treatment pius Dao Yin;","Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days a day ;Chloroquine phosphate gloup:The first dose of chloroquine phosphate was 1gx2 days, and the third day was 0.5gx12 days ;Control group:Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan ;","Mild Group:probiotics;Severe Group:probiotics;","Control group:Conventional medicine;Experimental group:integrated Chinese and conventional medicine;","Experimental group:Health Guidance + Guixi Regulating Lung Gong Method + Shenling Baizhu Powder + Moxibustion Treatment;Control group:Health Guidance + Guixi Regulating Lung Gong Method ;","Experimental group:conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended;control group:conventional therapy;","Chloroquine phosphate gloup:Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day   ; Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days;Routine treatment group:Recommended treatment plan for novel coronavirus pneumonia severe and critical cases;","Case series:mesenchymal stem cells therapy;","experimental group:routine treatment and Kangbingdu granules;control group:routine treatment ;","control group:conventional therapy and placebo;Experience group:conventional therapy and ALA;","experimental group:mesenchymal stem cells;control group:saline;","Group 1:Traditional Chinese Medicine prescription No. 1 and 2;Group 2:Gankeshuangqing capsule;Group 3:Shuanghuanglian oral liquid;","Experimental group:atic treatment medicines;Control group:Symptomatic treatment medicines;","Drug: placebo;Drug: thalidomide","Drug: placebo;Drug: Thalidomide","A1:Hydroxychloroquine, small dose;A2:Hydroxychloroquine, high dose;B1:Abidol hydrochloride, small dose;B2:Abidol hydrochloride, high dose;","control group:conventional therapy;Experience group:conventional therapy and Tranilast;","experimental group:Routine treatment and Shenqi Fuzheng Injection;control group:Routine treatment ;","hydroxychloroquine group:oral intake hydroxycholoroquine 0.2 twice a day;control group:conventional therapy;","experimental group.:Recombinant Human Interferon a1b Eye Drops ;Control group:placebo drop;","Experimental group:Chloroquine Phosphate;Control group:No;","Drug: Meplazumab for Injection","Drug: N-acetylcysteine+ Fuzheng Huayu Tablet;Drug: N-acetylcysteine+Placebo","Case series:Combination of Tocilizumab, IVIG and CRRT;","Experimental group:ultra short wave  Electrotherapy;control:standard medical therapy;","Control group:Treated according to the New Protocol for Diagnosis and Treatment of NCP(5th edition), without using traditional Chinese medicine;Experimental group 1:Basic treatment+Low dose of honeysuckle oral liquid 60ml each time, tid;Experimental group 2:Basic treatment + high dose of honeysuckle oral liquid 180 ml each time, tid;","Control group:Conventional integrated traditional Chinese and western medicine treatment and western medicine psychological intervention treatment;Experimental group:Conventional integrated traditional Chinese and western medicine treatment, western medicine psychological intervention therapy and traditional chinese medicine psychological intervention therapy;","Case series:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment;","one group:Rehabilitation Lung Health Eight - Stage Exercise ;","Drug: Fingolimod 0.5 mg","Case series:rehabilitation and Lung eight-segment exercise;Control group:Keep the initial life style;","Experimental group:Capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;Control group:Simulated capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;","Group 1:Eight lung exercises for rehabilitation;Group 2:Free activities;","Two groups:Chinese massage versus control;","Case series:moxibustion;","Exocrine group:Aerosol inhalation of exosomes;Control group:Blank;","Case series:Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San;","Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment;Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;","Experimental group:Danorevir sodium tablets,/ritonavir oral;Control group:Symptomatic treatment;","Experimental group:enteral nutrition emulsion, tpf-t 200ml Bid;Control group:No intervention;","Pirfenidone group:Conventional standard treatment + Pirfenidone 400mg three times a day;Control group:Conventional standard treatment;","The experimental group:Wear a self-made \"gastroscope mask\" during gastroscopy;Control group:Without self-made \"gastroscope mask\" during gastroscopy;","Routine treatment +  Jing-Yin Granule:Jing-Yin Granule 2 bags / time, 3 times a day \t;Routine treatment :Treat as prescribed in the sixth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","Case series:Integration of traditional Chinese and Western Medicine;","High inflammation oXiris CRRT treatment group:oXiris CRRT treatment;High inflammation Conventional treatment group:Conventional treatment;Low inflammation conventional treatment group:Conventional treatment;","Experimental group 1:Routine treatment + Kanguan No. 1;Control group (Mild patients):Routine treatment;Experimental group 2:Routine treatment + Kanguan No. 2;Control group (general patient):Routine treatment;Experimental group 3:Routine treatment + Kanguan No. 3;Control group (severe patients):Routine treatment;","Experimental group:Conventional treatment &amp; Acupuncture;Control Group:Conventional treatment;","Low-dose group:Low-dose hydroxychloroquine and conventional therapy;Medium-dose group:Medium-dose hydroxychloroquine and conventional therapy;High-dose group:High-dose hydroxychloroquine and conventional therapy;control group:conventional therapy;","Experimental group:Exercise prescription;Control group:none;","Case series:conventional therapy+tocilizumab;","Experimental group:Conventional therapy and Pediatric Huatanzhike granules;Control group:Conventional therapy;","control group 1:Lopinavir / Ritonavir (Kaletra)  and IFN aerosol inhalation;control group 2:Abidol and IFN aerosol inhalation.;Experimental group:ASC09/ Ritonavir (ASC09F)  and IFN aerosol inhalation;","Experimental group:Chloroquine phosphate;","Experimental group:recombinant human interferon a1b spray;Control group:Blank;","","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day1-3:500mg,BID Day4-5:250mg,BID;","Experimental group:Conventional treatent and hydroxychloroquine;Control group:Conventional treatment;","Experimental group:Methylprednisolone, intravenous injection, 1-2mg/kgd for 3 days.;Control group:Without any glucocorticoid therapy;","Kesuting syrup group:conventional therapy and Kesuting syrup, p.o., 20ml, three times a day;Keqing capsule group:conventional therapy and Keqing capsule, p.o., three pills once, three times a day;control group:conventional therapy;","Experimental group:Hydroxychloroquin;Control group:Lopinavir /Ritonavir;","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day 1-3:500mg BID; Day 4-5:250mg BID;","experimental group:routine treatment, Jinyebaidu granule, po, 1-2 bags once, 3 times a day;;control group:routinel treatment, treatment according to the fifth version  of the diagnosis and treatment protocol, no use of traditional Chinese medicine.;","arm A:Ribavirin + Interferon alpha-1b;arm B:lopinavir / ritonavir + interferon alpha-1b;arm C:Ribavirin + LPV/r+Interferon alpha-1b;","Biological: MSCs-derived exosomes","experimental group:ebastine 10mg bid, nterferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid;control group:interferon-alpha aerosol inhalation 5million U  bid and Lopinavir 200 mg, 2 capsules at a time, bid;","Drug: basic treatment;Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate;Drug: Carrimycin","Diagnostic Test: New screening strategy;Diagnostic Test: Standard screening strategy","Drug: pirfenidone","experimental group:Ma-Xing-Gan-Shi decoction and Conventional Western Medicine Treatment;control group:placebo and Conventional Western Medicine Treatment;","Experimental group:Intravenous drip, 0.2 g (4 vials) once daily for adults; slow drip after dilution with 250 ml of 5% Glucose Injection or 0.9% Sodium Chloride Injection, not less than 120 minutes or 30-40 drops/minute. Continuous administration for 7 days, observation until 21 days or discharge;Control group:Conventional treatment, no control drug;","Experimental group:Hemadsorption+conventional treatment;Control group:conventional treatment;","Azvudine Plus Symptomatic treatment:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment&amp;#32;","CRRT group:CRRT;Control group:Routine treatment, CRRT only when there are emergency indications;","Experimental group:Ganovo/ ritonavir oral+conventional treatment;Control group:Conventional treatment;","Lipoic acid group:Routine Therapy and administration of Lipoic acid injection;Blank control group:Routine Therapy and administration of placebo;","Case series:diammonium glycyrrhizinate enteric-coated capsule combined with hydrogen-rich water;","Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;","Drug: T89","Experimental group:Convalescent plasma therapy + routine treatment;Control group:routine treatment;","Experimental group:Lung rehabilitation training+Conventional treatment;Control group:Conventional treatment;","Case series:Anti-SARS-CoV-2 virus inactivated plasma;","Experimental group 1 (mild):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g,  tid,with warm water;Experimental group 1 (moderate):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, q4hwith warm water;","Experimental group:Western medicine routine treatment combined with traditional Chinese medicine treatment;Control group:Western medicine routine treatment;","Early corticosteroid intervention group:Early corticosteroid intervention;Middle-late corticosteroid intervention group:Middle-late corticosteroid intervention;Control group:No corticosteroid;","treatment group1:HUMSCs: intravenous infusion, 5  10E7 cells / time, once / week, twice / course;treatment group 2:HUMSCs: intravenous infusion, 5  107 cells / time, 1 time / week, 2 times / course, a total of 2 courses;            Exosomes: intravenous administration, 180mg / time, 1 time / day, 7 days / course, 2 courses in total;control group:The control group was given the same amount of placebo (stem cell solvent);","Experimental group:1. Jinhao Artemisia Antipyretic Granules 8g / time, bid, take it with warm water after meals; 2. Huoxiangzhengqi oral liquid 10ml / time, bid, orally after meals.;blank cntrol group:non-intervention;","Control group:TCM + Conventional medicine treatment + conventional medicine's psychological intervention;Experimental group:Integrated Chinese and Conventional medicine treatment + conventional medicine's psychological intervention + TCM psychological intervention;","Case series:cytokine removal therapy with Cytosorb;","Case series:traditional Chinese medicine and Western medicine treatment;","Group 2:SMO Assisted tracheal intubation;Group 1:Assisted tracheal intubation via nasal high-flow oxygen inhalation;","Interferon Therapy Group:Standard treatment + cerrokin (recombinant human interferon alpha 1beta) 10UG BID is administered by nebulization for 10 days.;Control group:Standard treatment + blank;","Control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan.;Experimental group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of western medicine + Yiqi Huashi Jiedu Fang (same as above), decoction of decoction machine, 300mL;","Group 1:Favipiravir Combined With Tocilizumab;Group 2:Favipiravir;Group 3:Tocilizumab;","Experimental group:pulmonary training;control group:Conventional medication;","Experimental group:Ruxolitinib combined with mesenchymal stem cell;control group:  Routine treatment;","group A:Arbidol Hydrochloride Tablets, Liushen Capsule, standard therapy;control group:standard therapy;","Case series:oXiris membrane;","intervention group:Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and  50 mg of ritonavir), twice a day, 2 tablets at a time;Control group:Conventional standardized treatment;","Experimental group:oral medicine(trditional medicine);control group:oral medicine( anti virious);","Experimental group:Conventional treatment and convalescent plasma therapy;Control group:Conventional treatment;","Drug: Lopinavir/ritonavir treatment;Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection","control group:Routine supportive treatment;experimental group:TCM decoction intervention + routine supportive treatment;","Case series:Western medicine plus Qingfei Paidu decoction;","Case series:external diaphragmatic pacing;","Experimental group:Immunoglobulin of cured patients;Control group:gama-Globulin;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of tozumab and adamumab was used;control group:Follow the guidelines for standard treatment;","Device: N95 respirator;Device: Medical Mask","Control group:conventional therapy;CIK group:Umbilical cord blood CIK cells (1.610E8/kg) were injected twice every other day.;NK group:Umbilical cord blood NK cells (1.610E8/kg) were injected twice every other day.;","Control group:Routine medicines and food;Experimental group:Taking Newgen beta-gluten probiotic composite powder;","Group 1:mindfulness therapy;Group 2:cognitive behavioral therapy;Group 3:exercise therapy;Group 4:Without treatment, online assessment per two weeks;","Experimental group:Pirfenidone;Control group:Blank;","Experimental group:Lopinavir and Ritonavir Tablets;control group:Routine symptomatic support treatment;","&lt;br&gt;                Product Code: DAS181&lt;br&gt;                Pharmaceutical Form: Inhalation solution&lt;br&gt;                INN or Proposed INN: Farbefusp&lt;br&gt;                Current Sponsor code: DAS181&lt;br&gt;                Concentration unit: mg milligram(s)&lt;br&gt;                Concentration type: equal&lt;br&gt;                Concentration number: 4.5-&lt;br&gt;                Pharmaceutical form of the placebo: Inhalation solution&lt;br&gt;                Route of administration of the placebo: Inhalation use&lt;br&gt;&lt;br&gt;","Exocarpium Citri Grandis Group:Oral Administration of Exocarpium Citri Grandis Phlegm Cough Solution;Placebo Group:Oral Administration of Placebo;","Case series:Psychological intervention;","Drug: Recombinant human interferon a1","Experimental group:Conventional treatent and Ulinastatin;Control group:Conventional treatent ;","Case series:Routine treatment+GD31, GD31: D1: 200mg QD, dissolved in 100ml of saline, intravenous drip, about 60 minutes; D2 ~ 10: 100mg QD, dissolved in 100ml of saline, intravenous drip, 30 minutes.;","Case series:CRRT;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);","Case series:dexmedetomidine;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)\";Placebo:2 tablets placebo BID;","Group 2:Truncated Torsion' Formula and Routine treatment of Western Medicine;Group 1:Routine treatment of Western Medicine;","Case series:Early initiation of blood purification;","High dose group:routine treatment + MSc (2 x10^6 / kg / time);Low dose group:routine treatment + MSc (1x10^6 / kg / time);","Group 2:Western medicine conventional treatment;Group 1:TCM treatment;","eperimental group:Conventional treatment and convalescent plasma therapy;control group:conventional treatment;","ECMO group:ECMO therapy;the conventional treatment group:no;","Drug: Sterile Water for Injection;Drug: VC","experimental group:Ixekizumab and antiviral therapy;control group:antiviral therapy;","Control group:Basic treatment refers to the treatment according to the diagnosis and treatment plan of the health care Commission (Sixth Edition). (after three days of medication, if the symptoms cannot be controlled in time and effectively, the patients can be sent out of the group immediately to receive the treatment&amp;#;Experimental group 1:Basic treatment + honeysuckle oral liquid at a low dose of 60ml / time, three times a day;Experimental group 2:Basic treatment + honeysuckle oral liquid high dose group, honeysuckle oral liquid120ml / time, three times a day.;","Case series:Traditional Mongolian Medicine;","Experimental group:chloroquine phosphate ;Control group:none;","Experimental group:On the basis of routine treatment, add 100ml of normal saline and 50ml of Xuebijing injection twice a day;;Control group:conventional therapy;","experimental group:Intravenous infusion of NK cells on day 0,3 and 6 , 1*1071*108/kg body weight of NK cells each day.;control group:Sodium Potassium Magnesium Calcium and Glucose Injection.;","1:meditation+Standard treatment of traditional Chinese and Western Medicine;2:Standard treatment of traditional Chinese and Western Medicine;","Experimental group:Combined standard therapy of chloroquine phosphate aerosol inhalation solution;control group:Water for injection atomization inhalation combined with standard therapy;","Experimental group:Conventional treatment and anti-SARS-CoV-2 virus inactivated plasma;Control group:Conventional treatment and Ordinary plasma;","Experimental group:High-dose Vitamin C;Control group:Routine treatment;","experimental group:dihydroartemisinin piperaquine tablets combined with antiviral treatment.;control group:antiviral treatment was selected as: a-interferon and Ardibdol;","Experimental group :Conventional treatment followed by Intravenous infusion of Umbilical Cord Blood Plasma preparations;Control group:Conventional treatment ;","Experimental group:Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations ;Control group :Conventional treatment ;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","Experimental group:Routine treatment +biological preparation of human placenta;Control group:conventional therapy;","Group A:Sevoflurane anesthesia maintenance, common extubation;Group B:Sevoflurane anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;Group C:Propofol anesthesia maintenance, common extubation;Group D:Propofol anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;","High dose group:High-dose NK cells (&gt;5x10^9)and mesenchymal stem cells(&gt;5x10^9),Intravenous infusion once every two days for a total of five times;Conventional dose group:Conventional dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every two days for a total of three times;Preventive dose group:Preventive dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every week for a total of one time;","SFBT group:Internet based SFBT;Waiting Group:Wait ;","Experimental group:Conventional treatment followed by Intravenous infusion of  Umbilical Cord Blood Mononuclear Cells preparations;Control group:Conventional treatment;","treatment group :Ba duanjin;","Positive drug control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of Western medicine + Lianhua Qingwen Capsule (0.35 g per capsule) orally, 4 capsules each time;Compound Yuxingcao Mixture Group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of western medicine + compound Yuxingcao mixture orally, 30mL each time, 3 times a day.;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);","Biological: Pathogen-specific aAPC","Case series:oral CSA0001;","A:Long-acting interferon alpha-2a (135ug) + ribavirin;B:Abidol + ribavirin;","Biological: Dental pulp mesenchymal stem cells","Group 2:thymosin;Group 1:BaZhen soup;","Pirfenidone group:Support treatment with oral taken Pirfenidone capsule;Support treatment group:Support treatment ;","Group 1:psychological support;Group 2:cognitive behavioral therapy;","Experimental group:Farpiravir tablets;Control group:Abidole tablets;","1 the critical group :injecting Mesenchymal stem cells;2 the severe group:injecting Mesenchymal stem cells;3 the control group of the critical group:injecting normal saline;4 the control group of the severe group:injecting normal saline;","Experimental group:normal treatment and auricular point pressing;control group:normal treatment;","Case series:The cell dose was 3*10^6 cells / kg. It was intravenously infused twice in a row, and the interval between each infusion was 1 week (+/-2 days). If the investigator considered it necessary, an additional infusion could be performed. Infusion interval 1 week (+/-2 days) from the last time.;","1:7/5000   Low molecular weight heparin therapy;2:The mechanical prevention;","experimental group:Toujiequwen Granules and basic treatment ;control group:basic treatment with or without antiviral therapy ;","Group 1:Liuzijue exercise;Group 2:Respiratory muscle training;Group 3:Liuzijue exercise combined with respiratory muscle training;","Experimental group 1:the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group;Experimental group 2:the oral trial drug favipiravir tablets;Control group:the oral placebo treatment;","Drug: Methylprednisolone;Drug: Methylprednisolone","Experimental group:On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased;Control group:current clinical treatment of SNCP;","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","control group:None;Experimental group (mild and normal type in patients with new coronavirus pneumonia):3% hydrogen peroxide gargle;","Tricholoma matsutake group:Taking tricholoma matsutake ;Cannabis sativa capsule group:Taking cannabis sativa capsule ;Dendrobium candidum group:Taking dendrobium candidum;Routine treatment group:Taking routine drugs and food;","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Drug: Tetrandrine","experimental group:high-fow therapy by nasal cannulae (HFNC);control group:bag- valve mask oxygenation (SMO);","Experimental group:oral hydroxychloroquine sulfate tablets;Control group:Conventional treatment meet the Guideline;","Mild Type Group A:antiviral therapy and Chinese medicine treatment;Mild Type Group B:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;Common and Heavy Type Group C:antiviral therapy and Chinese medicine treatment;Common and Heavy Type Group C:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;","Intervention A:On the basis of routine medical treatment, the patients were given Novaferon Atomization inhalation, 20ug each time, twice a day, 7-14 days.;intervention B:On the basis of routine medical treatment, the patients were given lopinavir / ritonavir tablets (Kaletra) twice a day, twice each time, 7-14 days.;intervention C:On the basis of routine medical treatment, combined with Novafron and Kaletra, the usage and course of treatment are the same as above.;","Biological: WJ-MSCs","&lt;br&gt;Trade Name: Plaquenil 200 mg, comprim pellicul&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;","Drug: Sildenafil citrate tablets","Other: placebo;Other: washed microbiota transplantation","Drug: Abidol hydrochloride;Drug: Abidol Hydrochloride combined with Interferon atomization","hDPSCs group:Routine treatment + Intravenous injection of human dental pulp stem cells;Control group:Routine treatment + Placebo;","Drug: Abidol hydrochloride;Drug: Oseltamivir;Drug: Lopinavir/ritonavir","Drug: Oseltamivir;Drug: Ritonavir+Oseltamivir;Drug: ASC09F+Oseltamivir","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Drug: Huaier Granule","Drug: Immunoglobulin of cured patients;Drug: ?-Globulin","Biological: UC-MSCs;Other: Placebo","Experimental treatment group:Oral chloroquine phosphate tablets (treatment group);control group:Oral placebo group (control group);","Suspected case treatment group:TCM formula 1 or TCM formula 2;Suspected case control group:null;Confirmed case  treatment group:Western medicine+(TCM formula 3 or TCM formula 4 or TCM formula 5 or TCM formula 6);Confirmed case control group:Western medicine;","Device: VivaDiag COVID-19 lgM/IgG Rapid Test","Control group:regular treatment;Experimental group:Compound amino acid combined with routine treatment;","mindfulness intervention group:Mindfulness practice;control group:mind-wandering practice;","Experimental group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment + acupoint application (Zusanli + Feishu);control group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment;","Experimental group:On the basis of rehabilitation treatment, the subjects in the experimental group take Gu-Shen Ding-Chuan-Wan;Control group:standard treatment;","Group M:Play sleep-aid music on the cell phone at the same time as basic therapy, listen to it once every night at 22 o'clock, and the patient falls asleep with the music. A total of 2 weeks of treatment.;Group C:No music, the use of basic treatment, in accordance with the \"new coronavirus infection pneumonia diagnosis and treatment program\" trial fifth, sixth, seventh version of the provisions of the implementation.;","1:Blank;2:Moxibustion treatment;","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Current Sponsor code: SAR153191&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Experimental group:Bufonis venenum injection;Control group:0.9% N.S.;","Experimental group:PD-1 mAb + Standard treatment;Control group:Standard treatment;","treatment group:combination of  Lopinavir/ritonavir (Kaletra) Tablets and interferon;control group:Routine medical treatment,;","Experimental group:Hua-Shi Bai-Du granules;control group:conventional treatment of western medicine;","experimental group:TCM formula and general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);control group:general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);","Drug: Nitric Oxide Gas","Drug: Traditional Chinese Medicine Prescription","&lt;br&gt;Product Name: itraconazole&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: ITRACONAZOLE&lt;br&gt;CAS Number: 84625-61-6&lt;br&gt;&lt;br&gt;Product Name: itraconazole&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: ITRACONAZOLE&lt;br&gt;CAS Number: 84625-61-6&lt;br&gt;&lt;br&gt;","experimental group:Health education+ pulmonary rehabilitation;control group:Health educatio;","Drug: favipiravir tablets+chloroquine phosphatetablets tablets;Drug: Favipiravir tablets;Drug: Placebo","Dietary Supplement: Vitamin C","Drug: Escin;Drug: standard therapy","&lt;br&gt;Trade Name: BCG vaccine (BCG-Vaccin SSI [Nederlands VaccinStatens Serum Instituut]) Danish strain 1331.&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Concentrate and solvent for solution for injection&lt;br&gt;Route of administration of the placebo: Intradermal use&lt;br&gt;&lt;br&gt;","Other: standard care;Drug: Methylprednisolone","Drug: Hydroxychloroquine;Other: The control group will not receive hydroxychloroquine","Experimental group:Celebrex capsules 200mg / time twice a day for 7 days;control group:routine treatment;","&lt;br&gt;Product Name: Interferon beat-1a (IFN-1a)&lt;br&gt;Product Code: SNG001&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;Current Sponsor code: SNG001&lt;br&gt;Concentration unit: million IU million international units&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;Pharmaceutical form of the placebo: Nebulisation solution&lt;br&gt;Route of administration of the placebo: Inhalation use&lt;br&gt;&lt;br&gt;","Experimental group:Rehabilitation Nursing Program;Control group:Routine rehabilitation care;","Drug: Bevacizumab","Behavioral: General health education;Behavioral: Personalized health education","Experimental group:Conventional medication + Infusion of mesenchymal stem cells;Control group:Conventional medication;","Patients will have a nose and throat swab collected and tested immediately using the QIAstat-Dx Respiratory n-CoV Panel. Results are available in one hour and will be communicated immediately to clinical and infection control teams. There is no patient follow up but clinical outcome data are collected retrospectively from case notes and hospital information systems for the duration of hospitalisation, up to 30 days post-intervention.","Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Group 1:single-shot CBT-I;Group 2:Sleep Hygiene;","Control:NA;Noninvasive cardiopulmonary monitoring group:Wear non-invasive multi-channel cardiopulmonary monitor;","Nintedanib group:Nintedanib;Control group:Placebo;","experimental group:Rabeprazole plus chloroquine;control group :Lopinavir + rabeprazole;","Group 1:Routine treatment + Infusion of convalescent plasma;Group 2:Routine treatment;","Experimental group:Conventional treatment regimen + MSC treatment;Control group:Conventional treatment regimen;","&lt;br&gt;Trade Name: MYLAN&lt;br&gt;Product Name: lopinavir/ritonavir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;&lt;br&gt;Trade Name: REBIF&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: Remdesivir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 20 ml (400 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 20 ml (400 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 10 ml (200 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 10 ml (200 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 4 ml (80 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 4 ml (80 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Imatinib mesilate &lt;br&gt;Product Name: Imatinib mesilate&lt;br&gt;Product Code: L01XE01&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Sulfate d'hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-800&lt;br&gt;&lt;br&gt;","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Drug: DAS181;Drug: Placebo","Drug: Bevacizumab Injection","Drug: Placebo;Drug: Sarilumab","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: hydroxychloroquine sulfate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Drug: recombinant human interferon Alpha-1b;Drug: thymosin alpha 1","Drug: Inhaled nitric oxide gas","Drug: Hydroxychloroquine Sulfate","Other: Tele-medicine platform","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF);Device: Centricyte 1000;Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution;Drug: Liberase Enzyme (Roche);Drug: Sterile Normal Saline for Intravenous Use","Device: vv-ECMO only (no cytokine adsorption);Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)","Dietary Supplement: Glucose tablets;Drug: Azithromycin 500Mg Oral Tablet;Drug: Hydroxychloroquine 200 Mg Oral Tablet","Device: CPAP treatment","Device: Inspiratory training device;Device: Expiratory training device","Drug: Hydroxychloroquine as post exposure prophylaxis;Other: Others(No intervention)","Device: bidirectional oxygenation mouthpiece","Biological: CAStem","Biological: Convalescent Plasma","Biological: high-titer anti-Sars-CoV-2 plasma;Other: oxygen therapy","Drug: Hydroxychloroquine;Drug: Ciclesonide Metered Dose Inhaler [Alvesco]","Drug: Placebos;Drug: Angiotensin 1-7","Drug: Hydroxychloroquine;Dietary Supplement: Vitamin C","The primary aim of this study is to evaluate the efficacy and efficiency of two telerehabilitation interventions. The intervention consists of a rehabilitation intervention which focuses more on participation in usual activities and is offered via a coaching model to a virtual group of people. The intervention components are: identifying patient goals with therapist (1:1); and participation in virtual groups (up to 4 participants per session) with physiotherapist and occupational therapists which focus on increasing participation in life roles and usual activities. &lt;br&gt;The 1:1 session will last for approximately 45 minutes and will be followed by commencement of group sessions within 5 days.&lt;br&gt;Groups adopt a coaching model where the therapist talks about common challenges, facilitates discussion and sharing of experiences and ideas and the group brainstorm and plan next steps together. The group sessions will last approximately 45 minutes and will be delivered 3 times per week for up to 4 weeks. &lt;br&gt;Adherence will be measured using attendance logs. &lt;br&gt;&lt;br&gt;","Drug: Defibrotide Injection","Expressive/gratitude writing intervention  This group will participate in the adapted evidenced-based 4-day writing program (Pennebaker 1997). Participants will meet with the facilitator (a researcher with a Psychology degree) using Zoom in a group format four times in one week for approx. 30 minutes (25 minutes of writing time). Daily e-mail reminders will be sent during the 4 days of writing. Session structure  1 min to complete the distress VAS measure (before), 5 minutes write any reflection from last session, 15 minutes spent writing about your thoughts and feelings, 5 minutes writing about the things you are grateful for, 1 min to complete the distress VAS measure (after). The instruction each day will be (adapted from Pennebaker): &lt;br&gt;Please write about your thoughts and feelings about your IBD and the recent situation with COVID-19. Try to select something that you had a strong reaction to  perhaps this was a thought that was challenging or unpleasant. Feel free to really let go and explore your very deepest emotions and thoughts. You might tie your topic to your relationships with others, including parents, lovers, friends or relatives, to your past, your present, your future, or to who you have been, who you would like to be, or who you are now. All of your writing will be completely confidential. Please dont worry about spelling, sentence structure, or grammar. Feel free to type or write by hand. &lt;br&gt;Participants will not be asked to share their writing with the study investigators, to ensure free expression.&lt;br&gt;","Drug: Piclidenoson","Based on preclinical and non-randomised studies, the Royal Brisbane and Womens Hospital Intensive Care Unit clinical Consultant Medical Staff, in agreement with the Infectious Diseases Department and the Pharmacy Department, have decided that all patients admitted to the ICU with COVID-19 infection should receive hydroxychloroquine as standard care. Therefore, hydroxychloroquine is NOT considered a trial intervention for the purpose of this study.&lt;br&gt;&lt;br&gt;The dose of hydroxychloroquine used for COVID-19 infection is extrapolated from that in common use for malaria and other approved indications. However, the organ dysfuction that accompanies critical illness suggests dosing is likely to require adjustment. This study will adjust the dose of hydroxychloroquine using therapeutic drug monitoring (TDM) to a goal concentration known to be safe. The observation period for TDM will be a total of up to 10 days or until the time of ICU discharge, which ever is sooner.&lt;br&gt;&lt;br&gt;As is routine practice at the RBWH ICU, TDM will be led by the senior ICU pharmacist after initiation of therapy. Trough venous blood samples (3 ml) will be taken via an indwelling arterial cannula. The first TDM should ideally occur before the administration of the FIRST MAINTENANCE DOSE, provided the appropriate loading dose schedule has been completed. Sampling thereafter can occur every 24-48 hours to confirm the appropriateness of ongoing dosing as guided by the Pharmacy and Medical Team. Blood samples will be transported to Queensland Pathology on the Herston Campus for drug analysis. Prescribing of initial and ongoing/revised dosing will remain the responsibility of medical officers, whilst fidelity of the intervention will be maintained through pharmacy dosing adjustment notes which are subjected to","Experimental group:WeChat-based parenting education;Control groop:Electronic Manual + Teaching Plan;","COVID-19 symptomatic confirmed hospitalized adult patients will be enrolled as soon as possible after fulfilling the criteria for randomisation. Patients will be allocated in a 1:1 ratio to either the treatment group receiving intravenous zinc chloride (0.5mg/kg/d) or to control group, receiving saline placebo alone. &lt;br&gt;Pharmaceutical grade Zinc Chloride stock solution obtained from an Australian company (Phebra Pty Ltd) will be diluted in 250ml of normal saline and infused, resulting in a final dosage of 0.5mg/kg/d. Patients will be administered zinc for seven days. To standardise administration time, zinc infusions will commence around 9am but anywhere between 8am to 12pm in the morning is adequate. Zinc chloride will be administered via central venous or peripheral access over 3-6 hrs.&lt;br&gt;We will monitor fidelity to the intervention by review of nursing documentation in the intravenous fluid given section of the electronic fluid balance chart. Note will be made of what was given, time commenced, volume given, time completed.&lt;br&gt;","Experimental group:exercise rehabilitation under remote monitoring;Control group:patient education;","NK cell group:NK cells were injected by intravenous drip once a day for 2 to 3 times in total, each dose was 4 10^7 pieces /kg body weight,100ml normal saline suspension;Control group:100ml normal saline intravenous drip;","Case series:Danorevir sodium tablets,/ritonavir oral;","1:Middle dose (1E11vp);2:Low dose (5E10vp);3:placebo;","Experimental Group:Xiaotan Sanjiefang granule;Control Group:placebo (contain 5% test drug);","Experimental group:Acetylcysteine inhaled via tracheal tube;Control group:Placebo (saline) inhaled via tracheal tube;","common type :Immunotherapy with recombinant chimeric DC vaccine;Latent period group:Immunotherapy with recombinant chimeric DC vaccine;Normal control group:Immunotherapy with recombinant chimeric DC vaccine;Blank vaccine control group:0.9%NS;","&lt;br&gt;Trade Name: Plaquenil 200mg&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;Trade Name: Azithromycine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: NAPROXEN&lt;br&gt;Other descriptive name: NAPROXEN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: PLAQUENIL 200 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Imatinib Teva 400 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: IMATINIB&lt;br&gt;CAS Number: 152459-95-5&lt;br&gt;Other descriptive name: IMATINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: AVIGAN 200mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: FAVIPIRAVIR&lt;br&gt;Other descriptive name: FAVIPIRAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: MICARDIS 20mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: TELMISARTAN&lt;br&gt;CAS Number: 144701-48-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: DEXAMETHASONE MYLAN 20mg/5mL &lt;br&gt;Product Name: DEXAMETHASONE&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;&lt;br&gt;Trade Name: PLAQUENIL 200MG&lt;br&gt;Product Name: HYDROXYCHLOROQUINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;Current Sponsor code: REMDESIVIR&lt;br&gt;Other descriptive name: REMDESIVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Chloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Chloroquine&lt;br&gt;CAS Number: 54-05-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Lopinavir/Ritonavir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Interfern b 1A&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;CAS Number: 220581-49-7&lt;br&gt;Current Sponsor code: Interferon beta-1a&lt;br&gt;Other descriptive name: Interferon beta-1a&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 152-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: IFX-1&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: -&lt;br&gt;CAS Number: -&lt;br&gt;Current Sponsor code: IFX-1&lt;br&gt;Other descriptive name: -&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: DEFITELIO&lt;br&gt;Product Name: DEFITELIO&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: DEFIBROTIDE&lt;br&gt;CAS Number: 83712-60-1&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Hidroxicloroquina Aristo&lt;br&gt;Product Name: Hidroxicloroquina sulfato&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: 81939&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Hidroxicloroquina Aristo&lt;br&gt;Product Name: Hidroxicloroquina sulfato&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: 81939&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Lopinavir/Ritonavir&lt;br&gt;Product Name: Lopinavir/Ritonavir&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Pulmozyme 2500 U/2,5ml, solution pour inhalation par nbuliseur&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ibuprofen&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: IBUPROFEN&lt;br&gt;CAS Number: 15687-27-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;Trade Name: Hidroxicloroquina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Azitromicina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Azithromycin&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;Other descriptive name: AZITHROMYCIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Paracetamol&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Paracetamol&lt;br&gt;CAS Number: 103-90-2&lt;br&gt;Other descriptive name: PARACETAMOL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: GNS561&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Not available&lt;br&gt;CAS Number: 1914148-72-3&lt;br&gt;Current Sponsor code: GNS561&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 50 - 200-&lt;br&gt;&lt;br&gt;Trade Name: Opdivo&lt;br&gt;Product Name: Nivolumab&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: NIVOLUMAB&lt;br&gt;CAS Number: NIVOLUMAB&lt;br&gt;Current Sponsor code: ET17-093&lt;br&gt;Other descriptive name: NIVOLUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Lariam&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: MEFLOQUINE&lt;br&gt;CAS Number: 53230-10-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dexamethasone 20 mg/5mL&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: DEXAMETHASONE&lt;br&gt;CAS Number: 50-02-2&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: Medicinal Oxygen&lt;br&gt;Product Name: Medicinal Oxygen&lt;br&gt;Pharmaceutical Form: Medicinal gas, liquefied&lt;br&gt;INN or Proposed INN: Medicinal Oxygen&lt;br&gt;Other descriptive name: Medicinal Oxygen&lt;br&gt;Concentration unit: % (V/V) percent volume/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Anakinra&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine Sulfate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Metilprednisolona&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 20-125&lt;br&gt;&lt;br&gt;Trade Name: Modigraf&lt;br&gt;Pharmaceutical Form: Powder for oral suspension&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.1-0.2&lt;br&gt;&lt;br&gt;","Drug: Darunavir and Cobicistat","Drug: Hydroxychloroquine","Drug: Ganovo+ritonavir+/-Interferon nebulization","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 648-&lt;br&gt;&lt;br&gt;","Drug: Tocilizumab Injection","Biological: Convalescent Plasma","Other: Control;Drug: Vitamin C","Biological: MSCs;Biological: Saline containing 1% Human serum albumin(solution of MSC)","&lt;br&gt;Trade Name: Truvada&lt;br&gt;Product Name: Truvada&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: TENOFOVIR DISOPROXIL FUMARATE&lt;br&gt;CAS Number: 202138-50-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: EMTRICITABINE&lt;br&gt;CAS Number: 143491-57-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 245-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Hydroxychloroquine&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Drug: lopinavir/ritonavir;Drug: Hydroxychloroquine Sulfate;Drug: Losartan;Drug: Placebos","Drug: Oral","Drug: Favipiravir Combined With Tocilizumab;Drug: Favipiravir;Drug: Tocilizumab","Drug: Tocilizumab","&lt;br&gt;Trade Name: Solu-Modern 1 g polvo y disolvente para solucin inyectable&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection/infusion&lt;br&gt;INN or Proposed INN: Metilprednisolona (como succinato de sodio)&lt;br&gt;CAS Number: 2375-03-3&lt;br&gt;Current Sponsor code: Pfizer, SL&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;","Biological: Emapalumab;Biological: Anakinra","Drug: Levamisole Pill + Budesonide+Formoterol inhaler;Drug: Lopinavir/Ritonavir + hydoxychloroquine","Drug: Hydroxychloroquine;Drug: Azithromycin","Other: Questionnaire with precaution information;Other: Experimental: Questionnaire without precaution information","Drug: Hydroxychloroquine;Drug: Placebos","Drug: RoActemra iv;Drug: RoActemra sc;Drug: Kevzara sc;Other: Standard medical care","Drug: Thiazide or Thiazide-like diuretics;Drug: Calcium Channel Blockers;Drug: ACE inhibitor;Drug: Angiotensin receptor blocker","Drug: Hydroxychloroquine;Drug: Azithromycin","Drug: Tocilizumab;Drug: Hydroxychloroquine;Drug: Azithromycin","Drug: Aspirin 75mg;Drug: Clopidogrel 75mg;Drug: Rivaroxaban 2.5 MG;Drug: Atorvastatin 40mg;Drug: Omeprazole 20mg","Drug: Hidroxicloroquina;Drug: Control group","Drug: Ruxolitinib","Dietary Supplement: Vitamin D","Other: telehealth applications","Other: Video based aerobic exercise","Other: Intravenous saline injection (Placebo);Biological: allogeneic human dental pulp stem cells (BSH BTC &amp; Utooth BTC)","Drug: Nintedanib 150 MG;Other: Placebo","Drug: Mavrilimumab","Diagnostic Test: COVID-19 diagnostic test","Other: Surgical facial mask","Device: oxyhydrogen;Device: Oxygen","Drug: Favipiravir;Other: Placebo","Drug: Hydroxychloroquine;Drug: Oseltamivir;Drug: Azithromycin","Drug: Camostat Mesilate;Drug: Placebo;Drug: Hydroxychloroquine","Device: Low flow ECMO driving by CVVH machine","Drug: Azithromycin;Drug: Hydroxychloroquine","Drug: Tacrolimus;Drug: Methylprednisolone","Biological: UC-MSCs;Other: Placebo","Drug: Azithromycin;Drug: Hydroxychloroquine;Drug: Placebo","Drug: Placebo;Drug: Hydroxychloroquine Sulfate","Cord blood therapy (expanded cord blood cells) + standard supportive management&lt;br&gt;5 million expanded umbilical cord blood cells (max -500 million cells) given intravenously over an hour by hospital staff under observation by research team&lt;br&gt;Single administration sourced from off the shelf CB units","Drug: Hydroxychloroquine;Dietary Supplement: Placebo","Study design: parallel group, wait list design, with treatment delayed by 3 months.&lt;br&gt;Open label OM85 one capsule (7.0mg) daily for 3 months with 3 months follow-up off treatment. &lt;br&gt;Adherence assessed by participant diary and blister pack return.","Case series :Western medicine plus Danggui Shaoyao Power ;","Case series:mesenchymal stem cells therapy;","Device: CytoSorb-Therapy","This study is an unblinded trial of a cuirass based negative pressure ventilator. &lt;br&gt;The device consists of a plastic casing (cuirass) placed over the thorax with negative pressure of -200cmH2O applied by a household vacuum cleaner.The negative pressure in the cuirass facilitates inspiration. The device cycles back to atmospheric pressure allowing expiration.&lt;br&gt;Following confirmation of fit by the research team, application of ANZCA standard monitoring (Australian and New Zealand College of Anaesthetists, 2017) and trial of the device in an awake volunteer, the study will use sedation to simulate an unwell patient.  &lt;br&gt;Baseline data before intervention will include AVPU level of consciousness, HR, SpO2 and Vt on room air, then HR and SpO2 on 4L/min via Hudson mask.  &lt;br&gt;The patient will be ventilated using the device with supplemental oxygen via Hudson face mask at 4L/min for one hour. Tidal volumes will be recorded every 15 minutes. The Hudson mask will be removed and a face mask connected to a GE Anaesthetic Machine running FiO2 at 30%, 4L/min will be used to record Vt for 3 consecutive breaths.  &lt;br&gt;Sedation will be provided by an accredited Consultant Anaesthetist and targeted to maintain an AVPU score of V, that is, rousable to command. The level of sedation will be targeted to not require direct airway intervention. Sedation will be provided using propofol and Total Intravenous Anaesthesia (TIVA) using the Marsh algorithm. An initial bolus of Lignocaine will be included with the propofol to minimise patient discomfort as per accepted practice. &lt;br&gt;An anaesthetic record will be maintained as per ANZCA Guidelines (Australian and New Zealand College of Anaesthetists, 2019). &lt;br&gt;The trial will be conducted in an operating theatre environment with full resuscitati","We are testing the feasibility and comfort of the use of a novel mask (the Decathlon group EasyBreathe snorkel mask) for the transport of patients between locations at our health service.&lt;br&gt;The Decathlon mask is a non-TGA approved device used for recreational snorkelling.  It has been adapted for use in COVID-19 patients by Italian engineers (see https://www.isinnova.it/easy-covid19-eng/)&lt;br&gt;In this trial we propose to apply the Decathlon mask in place of standard delivery systems for oxygen and positive airway pressure.  The Decathlon mask will be applied by clinicians in the hospital setting.&lt;br&gt;The mask is worn over the entire face and has advantages over conventional delivery methods in that it is thought to reduce the risk of virus aerosolization (a common problem with conventional delivery systems) and therefore increase safety for healthcare workers and other patients at the hospital.&lt;br&gt;We will test mask comfort and tolerability with daily questionnaires.&lt;br&gt;The mask will be applied to suspected or confirmed COVID-19 patients during transfer between the emergency department and other locations such as radiology department, ward and high dependency unit.&lt;br&gt;We anticipate the mask will be worn for several hours at a time depending on patient tolerability (early data from overseas suggests superior tolerability to conventional mask setups).  The mask may be used intermittently for the entire patient admission to hospital pending the clinical needs and preference of the patient. We anticipate, based on how conventional treatments are applied, that the patient will use the mask in 3 hour sessions with potential breaks in between to be determined by clinical need and patient tolerability.","control group:General basic epidemic prevention measures;sachet group:General basic epidemic prevention measures + Traditional Chinese medicine sachet;Oral and nasal spray group:General basic epidemic prevention measures + Oral and nasal spray;Oral Chinese medicine group:General basic epidemic prevention measures + Traditional Chinese medicine for epidemic prevention in high risk groups;","experimental group:Chinese herbal tea;control group:drinking water;","Intervention is an aqueous buffered solution of 0.5% povidone-iodine (PVP-I) contained in a 30 mL bottle closed with a traditional nasal spray pump.&lt;br&gt;Subjects will receive a single dose to their nasal passages, administered by the investigator. &lt;br&gt;The amount a subject receives consists of 6 x 140L pump actuations (3 into each nostril), being 0.84 mL total volume.","In-hospital rehabilitation group: A. the patients took Qigong lung-nourishing exercise twice a day, once in the morning and afternoon, about 15 minutes each time. B, through online WeChat group patient communication, functional guidance, health counseling, psychological comfort.;Discharge follow-up rehabilitation group: A. the patients were given fitness Qigong lung-nourishing exercise twice a day, once in the morning and afternoon, about 15 minutes each time. B, through online one-to-one patient communication, functional guidance, health counseling, psychological comfort.;","Two groups:modified respirator versus conventional respirator;","1.5ATA:1.5ATA HBO;2.5ATA:2.5ATA HBO;Control group:Routine treatment;","Drug: UNIKINON (Chloroquine phosphate) 200mg tablets","There are two arms to this trial. Arm 1: Problem Management Plus. Arm 2: Enhanced Treatment as Usual. Therapy is administered once-weekly 60 minute sessions by clinical psychologists over 6 weeks delivered via teleconferencing to groups of 4 people at a time. Problem Management Plus is a program developed by the World Health Organization. Across sessions the clinical psychologist will teach the following stress coping strategies: anxiety reduction, problem solving, behavioral activation, and accessing social support. This will occur will via educational sessions, group discussions via teleconference, and handouts. The duration of the study for any participant will conclude after a 2-month follow-up assessment, resulting in participation duration of 15 weeks.","Participants who are randomly assigned to the intervention group will  receive capsules containing the probiotic Lactobacillus rhamnosus HN001 (6X109 colony forming units). &lt;br&gt;&lt;br&gt;Participants will be instructed to take one capsule a day for a period of 12 weeks.&lt;br&gt;&lt;br&gt;Adherence will be assessed by asking participants to enter the number of remaining capsules they have in the bottle at the post-intervention data collection phase.","experimental group:''Guangdong Pneumonia NO.1''+basic treatment;\t control group:basic treatment and(or) antiviral therapy;","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan;","&lt;br&gt;Trade Name: Antimicrobial therapy (antibiotics)&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dolquine 200 mg comprimidos recubiertos.&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Buccal use&lt;br&gt;&lt;br&gt;Trade Name: azitromicina cinfa 500 mg comprimidos&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;&lt;br&gt;Trade Name: Kaletra&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Senicapoc&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Telmisartan EG&lt;br&gt;Product Name: Telmisartan&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Azithromycine EG&lt;br&gt;Product Name: Azithromycine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Curcumin C3&lt;br&gt;Product Name: Curcumin&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Valsartan or matched placebo&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: VALSARTAN&lt;br&gt;CAS Number: 137862-53-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 80-160&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Product Name: Kevzara&lt;br&gt;Product Code: 1171196003&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Other descriptive name: EU/1/17/1196/012&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Azitromicina&lt;br&gt;Product Name: Azitromicina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: hidroxicloroquina&lt;br&gt;Product Name: Hidroxicloroquina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: KEYTRUDA&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Pembrolizumab&lt;br&gt;Current Sponsor code: MK3475&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: ZYMAD 200 000 UI&lt;br&gt;Product Name: ZYMAD 200 000 UI&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;&lt;br&gt;Trade Name: ZYMAD 50 000 UI&lt;br&gt;Product Name: ZYMAD 50 000 UI&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Leukine&lt;br&gt;Product Name: Leukine&lt;br&gt;Pharmaceutical Form: Powder for nebuliser solution&lt;br&gt;INN or Proposed INN: SARGRAMOSTIM&lt;br&gt;CAS Number: 123774-72-1&lt;br&gt;Concentration unit: g microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Leukine&lt;br&gt;Product Name: Leukine&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: SARGRAMOSTIM&lt;br&gt;CAS Number: 123774-72-1&lt;br&gt;Concentration unit: g microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: HCR040&lt;br&gt;Product Code: HCR040&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;INN or Proposed INN: HCR040&lt;br&gt;Current Sponsor code: HCR040&lt;br&gt;Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED&lt;br&gt;Concentration unit: million organisms million organisms&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-2&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: DARUNAVIR&lt;br&gt;CAS Number: 206361-99-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Chloroquine&lt;br&gt;CAS Number: 54-05-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: SPIRONOLACTONE&lt;br&gt;Other descriptive name: SPIRONOLACTONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: INTERFERON BETA-1B&lt;br&gt;CAS Number: 145155-23-3&lt;br&gt;Other descriptive name: INTERFERON BETA-1B&lt;br&gt;Concentration unit: g/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","Intervention 1: Intervention group: 50000 Vitamin A daily for two weeks. Intervention 2: Control group: common treatment.","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Dolquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Kaletra versus Aluvia&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Imatinib&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Imatinib&lt;br&gt;CAS Number: 152459-95-5&lt;br&gt;Other descriptive name: IMATINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-300&lt;br&gt;&lt;br&gt;Trade Name: Olumiant&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: BARICITINIB&lt;br&gt;Other descriptive name: Olumiant&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 4-2&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: prednisone&lt;br&gt;Product Name: prednisone&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: PREDNISONE&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: azithromycin&lt;br&gt;Product Name: azithromycine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 121470-24-4&lt;br&gt;Other descriptive name: AZITHROMYCIN MONOHYDRATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (Tab hydroxychloroquine 400 mg twice daily at day 1 then 200 mg twice daily plus Tab lopinavir/ritonavir 200/50 mg two tablets twice daily for at least 5 days), patients will receive one tablet of sofosbuvir/ledipasvir 400/100 mg (Danesh Pharmaceutical Development Company) daily for 10 days. Intervention 2: Control group: Patients will receive the national corona treatment recommendation (Tab hydroxychloroquine 400 mg twice daily at day 1 then 200 mg twice daily plus  Tab lopinavir/ritonavir 200/50 mg two tablets twice daily for at least 5 days).","&lt;br&gt;Trade Name: Sylvant&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Siltuximab&lt;br&gt;CAS Number: 541502-14-1&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 11-&lt;br&gt;&lt;br&gt;Trade Name: Urbason&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Sandimmun&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-15&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 800-1200&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: CIRCADIN 2 mg&lt;br&gt;Product Name: CIRCADIN 2mg&lt;br&gt;Product Code: EMEA/H/C/000695&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CIRCADIN&lt;br&gt;CAS Number: 73-31-4&lt;br&gt;Other descriptive name: MELATONIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Intervention 1: Intervention group: experimental group will receive supportive intervention and get education of Benson relaxation with video tape and every nurse will get one CD and pamphlet for use in home. nurses in experimental group will do Benson relaxation for 15 minute, twice a day during one month. Job Stress and Quality of working life questionnaire will complete by experimental group before, and 4 week after intervention. Intervention 2: Control group: no intervention in control group.","&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-800&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Anakinra&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;&lt;br&gt;Trade Name: Bactrimel&lt;br&gt;Product Name: Sulfamethoxazole and Trimethoprim&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Clulas mesenquimales troncales adultas alognicas de mdula sea expandidas en suspensin&lt;br&gt;Product Code: MSV-allo&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;INN or Proposed INN: clulas mesenquimales troncales adultas alognicas de mdula sea expandidas mediante procedimiento IBGM&lt;br&gt;Current Sponsor code: MSV_allo&lt;br&gt;Concentration unit: U/ml unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10000000-&lt;br&gt;Pharmaceutical form of the placebo: Injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: SEVOFLURANE&lt;br&gt;Pharmaceutical Form: Inhalation vapour, liquid&lt;br&gt;INN or Proposed INN: SEVOFLURANE&lt;br&gt;CAS Number: 28523-86-6&lt;br&gt;Other descriptive name: SEVOFLURANE&lt;br&gt;Concentration unit: ml millilitre(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;Product Name: PROPOFOL&lt;br&gt;Pharmaceutical Form: Emulsion for suspension for injection&lt;br&gt;INN or Proposed INN: PROPOFOL&lt;br&gt;Other descriptive name: PROPOFOL&lt;br&gt;Concentration unit: mg/kg/h milligram(s)/kilogram/hour&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;CAS Number: 1189541-98-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: COLCHICINA SEID 0,5 mg comprimidos&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: COLCHICINE&lt;br&gt;CAS Number: 64-86-8&lt;br&gt;Other descriptive name: COLCHICINE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Allogeneic mesenchymal stromal cells isolated from adipose tissue&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Allogeneic adipose-derived mesenchymal stromal cells in vitro expanded&lt;br&gt;Other descriptive name: Allogeneic adipose-derived mesenchymal stem cells in vitro expanded&lt;br&gt;Concentration unit: million organisms/ml million organisms/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","Intervention group:  The extracted tooth is brought to the lab . After tooth extraction, it is enzymatically digested and cultured. After the cells have reached the required level, 40 million cells are injected intravenously at one time. Patients receive common medications at the same time..","&lt;br&gt;Trade Name: Lopinavir-Ritonavir &lt;br&gt;Product Name: Lopinavir-Ritonavir &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Lopinavir&lt;br&gt;Other descriptive name: Antiretroviral&lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: Ritonavir&lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Hydroxychloroquine (Plaquenil) &lt;br&gt;Product Name: Hydroxychloroquine (Plaquenil) &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine sulfate&lt;br&gt;Other descriptive name: Antimalarial, Aminoquinoline&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: COLCHICINE&lt;br&gt;Product Name: COLCHIMAX&lt;br&gt;Product Code: M04AX&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: COLCHICINA&lt;br&gt;CAS Number: 64-86-8&lt;br&gt;Other descriptive name: COLCHICINE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: .5-&lt;br&gt;&lt;br&gt;","Intervention 1: In this  intervention group COVID-19 patients who do not reply to routine treatments and are in a critical stage and prolonged hospitalization  will be treated with convalescent plasma (obtained from fully recovered patients according to inclusion criteria) {200 cc/day intravenous (IV) administration for 1 to 4 hours} for 1-4 days. Intervention 2: The second intervention group will be treated with Plasma-derived Immunoglobulin-enriched solution {IV, 0.2 _0.4 g/kg/day based on the patient's physiological tolerance}. Intervention 3: The control group will only receive routine care without any new therapeutic interventions.","Intervention 1: Intervention group: In this group of patients with COVID-19, in addition to standard treatment introduced by the Ministry of Health, the second drug is also prescribed. It is a licorice-based herbal extract that contains licorice, Rheum palmatum, Rosa damascene, Crocus sativus, and Ziziphus jujube. In order to prepare this extract, simple substances of these herbal are first prepared from the pharmaceutical market and after identification in the herbarium of the Faculty of Pharmacy of Tehran University of Medical Sciences, a herbarium code is assigned to each one. Then, a herbal syrup is extracted from these herbs by the maceration method. The syrup is standardized based on glycerol content, the total phenolic, and flavonoids compounds by HPLC method. Microbial controls are performed on the syrup. The syrup is packaged in 240 cc dark pets and given to the patient and at a dose of 10 cc every 8 hours for up to 8 days. Intervention 2: Control group: Patients in this group receive only standard treatment provided by the Ministry of Health for COVID-9.","Intervention 1: Intervention group: Discontinuation of agents inhibiting renin-angiotensin-aldosterone system substituting by calcium channel blocker with or without beta-blocker. Intervention 2: Control group: Continuation of renin-angiotensin-aldosterone inhibiting agents.","Intervention group: Patients in this group will receive drug regimen including Tab hydroxychloroquine 400 mg twice daily on day 1 then 200 mg twice daily + Tab lopinavir/ritonavir 200/50 mg two tablets twice daily or Tab atazanavir/ritonavir 300/100 mg daily for at least 5 days..","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir), patients will receive interferon beta, sub type 1a (CinnaGen Company) with dose of 44 mcg subcutaneously every other day for 14 days. Intervention 2: Control group: Patients will receive the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir) for at least 5 days.","Intervention group: Patients who suffer from sever (ARDS patients who are not admitted in ICU) or very severe (ARDS or related symptoms and signs who are admitted in ICU) complications of COVID-19, received 150 mg of SeptimebTM in 500 ml of DW 5%, infused over 1.5 hours on the first day. All hemodynamic data are monitored during the infusion and in case of any negative hemodynamic deterioration, dermal rash, urticaria or anaphylactic reaction, the infusion discontinued. In absence of the mentioned complications the treatment is continued by administration of 300 mg of the drug that will be infused in 500 ml of DW5%, every day for up to 14 days (the duration of treatment will be adjusted based on the severity of symptom and sign of the patients)..","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir), patients will receive interferon , sub-type 1b (Zist Daru Daneh Company) with dose of 250 mcg subcutaneously every other day for 14 days. Intervention 2: Control group: Patients will receive the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir) for at least 5 days.","Intervention 1: Intervention group: Patients in this group receive medication for treatment of Covid-19 based on Fifth Edition of the Novel Corona Virus Guidelines, in addition they recieve myrtle syrup for 5 days  (Patients daily boil the contents of a pack containing 10 grams of myrtle fruit and 10 grams of sugar in 3 glasses of water gently to stay 2 glasses, then smooth it and drink one glass in the morning and one glass in the evening.). Intervention 2: Control group: Patients in this group receive medication according to the novel Corona virus country guideline version 5.","Intervention 1: Intervention group: Hospitalized patients will receive 10 cc Corostop solution and 30 cc Coroguard syrup three times daily for 10 days in addition to receiving standard treatments recommended by the corona county committee. Intervention 2: Control group: Hospitalized patients will receive standard treatment according to the national guidelines for the treatment of COVID-19. Intervention 3: Intervention group:  Outpatients (self-quarantine at their home) will receive 10 cc Corostop solution and 30 cc Coroguard syrup three times daily for 10 days in addition to receiving standard treatments recommended by the corona county committee.","Intervention 1: Intervention group: Twenty patients with Coronavirus (COVID-19)-induced pneumonia in addition to standard regimen of covid-19, will receive Camostate mesylate tablets for 3 days (200 mg three times daily). Intervention 2: Control group: they will receive standard regimen for COVID-19 patients.","Intervention 1: Treatment group: Patients with confirmed COVID-19 infection who in addition to their current treatment will be infused with 500 Ml convalescent plasma in 4 hrs. Intervention 2: Control group: Patients hospitalized with COVID-19 disease who are receive routine treatment.","Intervention 1: Intervention group:   Hydroxychloroquine 200 mg tablet of Amin Pharmaceutical, 400 mg daily and once a week for one to three months. (Based on the duration of corona virus epidemic). Intervention 2: Control group: placebo which is completely similar in form and taste to 200 mg hydroxychloroquine tablet and is manufactured by the same factory (Amin Pharmacy)is given.The dosage is two tablet daily , once a week for one to three months (based on duration of Corona virus epidemic in Tehran).","Intervention 1: Control group: Standard of care treatment according to the national guidelines for the treatment of COVID-19. Intervention 2: Intervention group: Sovodak, Company: Rojan, Daily single oral tablet containing 400mg of Sofosbovir and 60mg of Daclatasvir plus Standard of care treatment.","Intervention 1: Intervention group: In this group, mesenchymal stem cells will be injected at an initial dose of 0.5-1 milion/ kg. This process will be performed on the first, third and sixth days. This intervention will be done along with other treatments for this type of patients, varying in severity of COVID Infectious, and in accordance with national and international guidelines. Mesenchymal Stem Cell is GMP-approved by SinaCell. Intervention 2: Control group:This group, like the intervention group, will receive all routine medication according to national and international guidelines, depending on the severity of COVID-19. But on the first, third and sixth day, placebo (normal saline) will be injected.","Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus Interferon beta-1a 44 mg every other day S.C for 10 days.","Intervention 1: Intervention group: Treatment group which received Noscapine   mg, tds. Intervention 2: Control group: Group receiving Placebo with no API.","Intervention 1: Control group 1: Positive people with corona virus infection after laboratory tests are classified according to expert diagnosis and based on the patient's symptoms and history as well as laboratory results with primary infection in the first control group. This spectrum of patients is treated by the Ministry of Health's pharmacological and medical regimen, which is monitored by relevant specialists. Intervention 2: Intervention group 1: In this group, patients will be diagnosed with corona virus primary infection  after the corona virus infection is confirmed. The symptoms and level of virus infection is categorized with specialist. For this group the same dose of 2 puffs is used every 12 hours. An estimate of 400 ug / ml is considered for each dose of drug. The drug is given 8 days every two days for the patient to have optimal efficacy. The chemical formula is reserved for the RNA Biotechnology company, but according to the ethics committee, no harm can be expected to consumers. The new drug has FDA-approved components. Intervention 3: Intervention group 2: . Once the corona virus infection is confirmed positive and the clinical symptoms are diagnosed according to the specialist's diagnosis, the secondary level of corona virus infection is defined.  The application of drugs for this group is same as group 1.  the same dose of 2 puffs is used every 12 hours. An estimate of 400 ug / ml is considered for each dose of drug. The period  time for treatment of the drug is 8 days and the drug application is for every two days and a resting day for the patient to be optimal for effectiveness. The chemical formula for the RNA Biotechnology company is protected, but according to the ethics committee, there is no compensation for consumer users. The new drug h","Intervention 1: Intervention group: subcutaneous injection of Recigen (44mcg) daily until 5 days or the discharge day (which ever come sooner) in addition to standard treatment (based on the Ministry of Health protocol: chloroquine, etc .. ). Intervention 2: Control group: subcutaneous injection of placebo daily until 5 days or the discharge day (which ever come sooner) in addition to standard treatment (based on the Ministry of Health protocol: chloroquine, etc .. ).","Intervention 1: Intervention group: in addition to standard regimen of covid-19 patients will be administered Metformin 500 mg BID orally for 2 weeks. Intervention 2: Control group: standard regimen of covid-19 patients.","Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus Tocilizumab (Actemra) 400 mg I.V infusion as a single dose.","Intervention 1: Intervention group: in addition to standard regimen of covid-19 patients will be administered Metformin 500 mg BID  orally for 2 weeks. Intervention 2: Control group: standard regimen of covid-19 patients.","Intervention 1: Intervention group: Acetaminophen + Febuxostat. Intervention 2: Control group: Acetaminophen + Hydroxychloroquine.","Intervention 1: Intervention group: Patients in this group receive the treatment according to the protocol of the Ministry of Health, in addition they should daily boil the contents of one drug pack with 8 glasses of water slowly to stay two glasses, then smooth and the content of the sachet will be added for 5 days. They drink a glass in the morning and a glass in the evening. Intervention 2: Control group: Patients in this group receive medication according to the Ministry of Health protocol.","Intervention 1: Group I: Receivers of standard national protocol drugs. Intervention 2: Intervention group: Group II: Drug recipients of National Medicines Standard Protocol + (Perl Vitamin D3 50,000 units) once a week. Intervention 3: Intervention group: Group III: National standard drug + N acetylcysteine (NAC) tablets receiving 600mg every 12 hours for 14 days. Intervention 4: Intervention group: Group IV: National standard protocol drug + (Perl vitamin D3 50,000 units) once a week + N acetylcysteine (NAC) tablet 600mg every 12 hours for 14 days.","Intervention 1: Intervention group: Patients admitted to hospital in addition to receiving standard treatments of the Corona Country Committee, received a traditional  product based on Astragalus gossypinus  of 10 cc daily for 2 hours and food spice based on Ferula assa-foetida  of 2 grams once a day with apple juice. Traditional protocol duration is 5 days. Intervention 2: Control group:  Hospitalized patients are receiving standard corona treatment.","Intervention 1: Intervention group: In the intervention group, in addition to the standard treatment, medicinal herbal products will be prescribed. The drug will be given in two combination forms. One in the form of a syrup containing the following medicinal herbs: Zattaria multiflora, Punicagranatum, Marticaria chamomilla, Zizyphus sativa and Mentha spp, and the other in the form of a capsule containing the following medicinal herbs: Rheum officinale, nigella Sativa andnepeta bracteata . In addition to the usual treatment, the intervention group, will receive a capsule every 8 hours and 10 cc of of Iranian medicine syrup every 8 hours for one week. The capsule will be taken at least half an hour after taking the syrup. Intervention 2: Control group: Get standard treatment.","Intervention 1: Control group: Standard Protocol Drugs (Hydroxychloroquine Sulfate Tablet 200mg Two Single Dose Pills  or Chloroquine Phosphate 150mg Pill Two Single Dose Pills, Coltra Pills (Lupinavir / Ritonavir)(50/ 200)+A placebo (in terms of appearance and color similar to vitamin C) every 12 hours. Intervention 2: Intervention group: Standard Protocol Drugs (Hydroxychloroquine Sulfate Tablet 200mg Two Single Dose Pills (Tehran Drug) or Chloroquine Phosphate 150mg Pill Two Single Dose Pills (Pars), Coltra Pills (Lupinavir / Ritonavir)) 200) + Vitamin C 500mg every 12 hours for 5 days.","Intervention 1: \"Intervention group:\" This group consumes the Trachyspermum copticum syrup. The Trachyspermum copticum plant is a member of the Umbrella family. The total extract of this plant is used.The concentration of this syrup is 10% of the aqueous extract of Trachyspermum copticum. This syrup is administered three times daily for two weeks, 5 ml each time, a total of 15 ml daily. The syrup is made by Shahid Beheshti School of Pharmacy. Intervention 2: \"Control group:\" This group is taking placebo. Placebo syrup have the same size and shape as the drug.The placebo syrup contains all the basic ingredients of a syrup without the addition of herbal medicine.  The placebo syrup is made by Shahid Beheshti School of Pharmacy.","Intervention 1: Intervention group:In this group along with the standard drugs according to the national guideline of treatment for COVID-19, patients will take Levamisole 50 mg TDS for 3-7 days, made by Poursina pharmaceutical Company and Budesonide+Formoterol 1 Puff every 12 hours made by Astra Zenca Company for 3-7 days. Brand name of  Budesonide+Formoterol is Symbicort and it has two strength ; 160/4.5 and 320/9 mcg respectively. Decision about the used strength and dose of drug depends on the situation of the disease and will be made by physician. Intervention 2: Control group: This group just take standard drugs consist of Kaletra and Hydroxychloroquie. This national  protocol would be taken as below: 1- Hydroxychloroquine sulfate 200 mg as a single dose. 2- Kaletra tablet ( Lopinavir/ Ritonavir) 200/50 mg 2 tablets every 12 hoursfor atleast 5 days which can be extended to 14 days.","Intervention 1: The one globule of  (Ipecac)homeopathy remedy with C30 potency produced by Hellios homeopathy pharmacy distilled in 20 ml. 10 degree alcohol which will be administered at a dose of 15 drops every 2 hours for 6 hours and then every 6hours at 15 drops for 3 days. Intervention 2: The one placebo(Sac-lac) distilled in 20 ml. 10 degree alcohol which will be administered at a dose of 15 drops every 2 hours for 6 hours and then 15 drops every 6 hours  for 3 days. remedy and placebo have both common bases and are similar in taste, color, odor and taste.","Intervention group: Patients undergo extracorporeal blood purification on three sessions. Each session conducts in six hours per day, using hemoperfusion filters (HA280 and HA230) manufactured by the Jafron Company, China. The second course of hemoperfusion is performed 12-24 hours after the first and the third session 24 hours after the second time..","Intervention 1: Intervention group:  Twenty patients with Coronavirus (COVID-19)-induced pneumonia addition to standard regimen of covid-19? will receive Fingolimod for 1 day (50 mg one time). Intervention 2: Control group: standard regimen of covid-19 patients.","Intervention 1: Intervention group: In the case group, patients will receive 25 mg losartan tablets two times daily. Intervention 2: Intervention group: Patients will receive 5 mg amlodipine daily.","Intervention 1: Intervention group:Intervention is used to Psychological counseling program consisting of 10 daily virtual sessions through virtual networks such as WhatsApp or Skype For 30 to 45 minutes. Intervention 2: Control group: There is no intervention for the control group.","Treatment group: Patients with confirmed COVID-19 infection who in addition to their current treatment will be infused with 70 million mesenchymal stem cell day 0, 3 6 , infusion time 30 min 4..","Intervention 1: Intervention group: this group adjunct to standard treatment will receive intravenous infusion of 12 grams of vitamin C in Dextrose 5% serum to the total volume of 200 ml  over 24 hours for 4 days. Intervention 2: Control group: infusion of serum containing 120 ml distilled water in Dextrose 5% serum to the total volume of 200 ml over 24 hours for 4 days beside receiving standard treatment.","Intervention 1: Intervention group: Vitamin supplementation in order (ampoules): 25,000 international units of vitamin A daily, 600,000 international units of vitamin D once during the intervention time, 300 international units of vitamin E, 2 times a day, 500 mg of vitamin C, 4 times a day and B vitamins in the form of one Soluvit ampoule in a day. The control group does not receive any supplement or placebo. In this study, the duration of supplementation and evaluation of patients is one week .Except for Soluvit (Fresenius Kabi New Zealand) , all supplements are made in Iran. Soluvit: Thiamine nitrate 3.1 mg, Sodiumriboflavine phosphate 4.9 mg(corresponding to Vitamin B2 3.6mg), Nicotinamide 40 mg,Pyridoxine hydrochloride 4.9 mg(corresponding to Vitamin B6 4.0mg), Sodium pantothenate 16.5 mg(corresponding to Pantothenic acid15 mg), Sodium ascorbate 113 mg(corresponding to Vitamin C 100mg), Biotin 60 g, Folic acid 400 g,Cyanocobalamin 5 g,. Intervention 2: Control group: no placebo.","Intervention 1: Control group: Receive standard treatment for COVID19 according to the protocol of MOH of Iran (antiviral drugs and hydroxychloroquine). Intervention 2: Intervention group 1: Receive standard treatment for COVID19 and combination of dexamethadone, IV-IG and Interferon beta at admission. Intervention 3: Intervention group 2: Receive standard treatment for COVID19 and combination of dexamethasone, IV-IG and Interferon beta 48 hours after admission.","Other: Standard care;Drug: methylprednisolone therapy","Drug: Remdesivir;Drug: Remdesivir placebo","Drug: Lopinavir/ritonavir;Drug: Ribavirin;Drug: Interferon Beta-1B","Intervention name : Favipiravir (T-705)&lt;br&gt;INN of the intervention : Favipiravir&lt;br&gt;Dosage And administration of the intervention : Oral Multiple Dose&lt;br&gt;Control intervention name : -&lt;br&gt;INN of the control intervention : -&lt;br&gt;Dosage And administration of the control intervention : -","Biological: MSCs","Biological: UC-MSCs;Drug: Placebo","Biological: NK Cells","Other: blood sample","oral administration of favipiravir","Drug: Placebo oral tablet;Drug: Hydroxychloroquine","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Drug: Treatment and prophylaxis;Other: Standard Public Health measures","Device: Non-contact MCE system","Drug: Sarilumab","Behavioral: Guided online support program;Behavioral: WHO recommendations (waiting condition)","Drug: Galidesivir;Drug: Placebo","Drug: Remdesivir placebo;Drug: Remdesivir","oral administration of lopinavir, ritonavir and hydroxychloroquine with or without oseltamivir","Drug: Lopinavir/ritonavir","Drug: Hydroxychloroquine;Drug: Remdesivir;Other: (Standard of Care) SoC","Drug: Tradipitant;Drug: Placebo","Drug: Methylprednisolone;Drug: Siltuximab","Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis","Biological: NestCell","Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants;Dietary Supplement: isocaloric/isonutrigenous ONS","Dietary Supplement: Natural Honey;Other: Standard Care","Drug: Dexamethasone","Drug: 2: Usual practice + SYMBICORT RAPIHALER;Other: 1: Usual practice","Drug: chloroquine;Other: standard care","Drug: Dexamethasone","Other: \"Calm\" is a mindfulness meditation mobile app","Diagnostic Test: Serological tests will be applied on patients blood sampling","Drug: Ruxolitinib Oral Tablet","Diagnostic Test: Lung ultrasound","Device: GO2 PEEP MOUTHPIECE","Drug: Nivolumab Injection","Device: Hyperbaric Oxygen Therapy","Behavioral: Crisis management coaching","Procedure: ECMO Implantation","Drug: Nitazoxanide;Drug: Placebo","Procedure: Prone positioning","Behavioral: Tele-interventions related to diabetes management and mental well-being","Biological: Convalescent Plasma","Device: BIOVITALS","Drug: Prednisone;Other: Control group","Drug: Saline oral/nasal rinse;Drug: 0.5% Povidone/Iodine oral/nasal rinse;Drug: 0.12% Chlorhexidine oral/nasal rinse","Drug: Hydroxychloroquine;Drug: Azithromycin","Biological: Convalescent Plasma;Biological: Standard Donor Plasma","Drug: Tinzaparin or unfractionated heparin","Drug: Bevacizumab Injection","Biological: Allogeneic NK transfer","Drug: Dexamethasone injection;Drug: placebo;Procedure: conventional oxygen;Procedure: CPAP;Procedure: HFNO;Procedure: mechanical ventilation","Other: Individualised Ayurveda","Drug: ACEIs;Drug: Conventional treatment","Drug: Tocilizumab;Drug: Methylprednisolone","Biological: Placebo (Plasma-Lyte 148);Biological: Human umbilical cord derived CD362 enriched MSCs","Drug: Baricitinib","Drug: Spironolactone 100mg;Drug: Placebo oral tablet","Drug: Hydroxychloroquine Sulfate (HCQ)","Diagnostic Test: Cytokines dosage;Diagnostic Test: Complement dosage","Drug: Placebo oral tablet;Drug: Hydroxychloroquine","Drug: Tocilizumab","Other: Standard interface;Device: Double-Trunk Mask","Other: Telerehabilitation;Other: exercise brochure","Drug: Dexamethasone and Hydroxychloroquine;Drug: Hydroxychloroquine","Behavioral: Video based exercise","Procedure: Prone Positioning;Procedure: Standard of care.","Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days;Drug: Placebo 250 cc 24 hours continuous infusion for 15 days","Drug: Clazakizumab","Drug: Placebo;Drug: T3 solution for injection","Drug: Ruxolitinib plus simvastatin;Other: Standard of Care","Drug: 1: Naproxen;Drug: 2: Standard of care","Drug: Best supportive Care (BSC) + IFX-1;Drug: Best supportive care only","Other: Telerehabilitation","Drug: Atovaquone/Azithromycin","Drug: Anakinra","Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab","Drug: Placebo oral tablet;Drug: Chloroquine","Drug: Interferon Beta-1A;Drug: Lopinavir / Ritonavir;Drug: Single Dose of Hydroxychloroquine","Drug: favipiravir;Drug: Standard of care therapy","Drug: Umifenovir;Drug: Interferon- 1a;Drug: Lopinavir / Ritonavir;Drug: Single Dose of Hydroxychloroquine;Drug: Standards of Care","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Drug: Chloroquine Diphosphate;Drug: Placebo oral tablet","Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells","Drug: Chloroquine;Drug: Nitazoxanide;Drug: Ivermectin","Drug: Aspirin;Drug: Losartan;Drug: Simvastatin","Dietary Supplement: Ayurveda;Other: Usual Care","Diagnostic Test: COVID-19 IgM/IgG Rapid Testing, mobile device image capture and telemedicine support;Other: Telemedicine","Other: Antibody-Rich Plasma from COVID-19 recovered patients","Drug: Pyridostigmine Bromide;Drug: Placebo","Drug: Amiodarone;Drug: Verapamil","Drug: Danoprevir+Ritonavir","Biological: Convalescent anti-SARS-CoV-2 plasma;Drug: Sarilumab;Drug: Baricitinib;Drug: Hydroxychloroquine;Other: Injective placebo;Other: Oral placebo","Drug: Placebo;Drug: Nafamostat Mesilate","Drug: Enoxaparin Prefilled Syringe [Lovenox]","Other: Blood and derivatives.;Drug: Standard of Care","Drug: Hydroxychloroquine","Drug: Dapagliflozin 10 MG;Drug: Placebo","Drug: Favipiravir;Drug: Placebos","Dietary Supplement: Zinc gluconate;Dietary Supplement: 25-OH cholecalciferol","Drug: Chlorpromazine Injection","Biological: BM-MSCs;Biological: Placebo","Device: mouthrinse with bta-cyclodextrin and citrox;Device: mouthrinse without bta-cyclodextrin and citrox","Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension","Drug: Hydroxychloroquine;Other: Vitamin C","Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet","Biological: Autologous Adipose MSC's","Drug: Hydroxychloroquine, Azithromycin;Drug: Hydroxychloroquine, Doxycycline;Drug: Hydroxychloroquine, Clindamycin;Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.;Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.;Drug: Remdesivir;Drug: Tocilizumab;Drug: Methylprednisolone;Drug: Interferon-Alpha2B;Drug: Losartan;Drug: Convalescent Serum","Other: PROTECTIVE VENTILATION;Other: ULTRAPROTECTIVE VENTILATION","Drug: Selinexor","Biological: Convalescent Plasma;Biological: Standard Plasma","Drug: Treatment with Dexmedetomidine","Other: Pulmonary Physiotherapy Techniques","Dietary Supplement: Vitamins;Drug: Hydroxychloroquine;Drug: Imatinib;Drug: Favipiravir;Drug: Telmisartan","Drug: Nivolumab","Drug: Tocilizumab;Drug: Placebos","Experimental group:Shumian capsule;Control group:Shumian capsule placebo;","Drug: Interferon Beta-1B;Drug: Hydroxychloroquine","Biological: intradermal injection of BCG Vaccine;Other: placebo","Oral administration of Hydroxychloroquine capsules for five days. &lt;br&gt;Day 1: 800mg (4 capsules) Hydroxychloroquine stat&lt;br&gt;Days 2 - 5: 400mg (2 capsules) Hydroxychloroquine once daily&lt;br&gt;Adherence to trial treatment will be assessed through the study diaries which will require the participant to complete the time of administration and number of tablets taken each day. Participants will not be required to return used study treatments to the research office but encouraged to dispose of any unused medication via their community pharmacy or general practice.","Drug: Hydroxychloroquine","Other: Psychoeducational intervention","This study will recruit older adults (aged 60 years and older) during the COVID-19 pandemic to a 6-week, group based physical activity promotion intervention delivered online through a private Facebook group. The group will allow members to receive information and contribute to weekly conversations on pre-specified topics related to physical activity eg. sedentary behaviour, goal setting, benefits of physical activity and support. Different topics will be covered each week with 2-3 Facebook posts on the topic each week. The content of each topic is designed specifically for this study but will also make use of existing videos, pictures and information sources. An exercise physiologists and dietitian will deliver the program. The purpose of the Facebook group is to facilitate social support and provide participants with a platform to exchange personal experiences including barriers and facilitators to commencing and maintaining a physical activity program. While discussion topics will be pre-determined, discussion will change weekly based on the participants posts for example someone may ask for examples of workouts or different ways overcome barriers. Participants will also be able to join a group video call via zoom two times per week. These calls will last for 20-30mins. The facilitator will lead the call and provide education on the topic for the week. This will also give the facilitator the chance to check in on participants and allow them to ask questions. The intervention itself will go for 6 weeks however there is the option for participants to remain in the Facebook group and continue to use it for support without the input from the facilitators. All 20 participants will be included in the one Facebook group and encouraged to check the Facebook weekly. The page","Experimental group:Shengmai Decoction;Control group:Shengmai Decoction simulant;","Drug: Chloroquine","Control Group:Qimaifeiluoping Mixture Simulator + Respiratory Training + Rehabilitation Education Guidance;Experimental group:Qimaifeiluoping Mixture  + Respiratory Training + Rehabilitation Education Guidance;","Drug: hydroxychloroquine sulfate 200 MG;Drug: Placebo oral tablet","experimental group:Xiangsha Liujun Pill;Control group:Placebo;","&lt;br&gt;                Intervention: Hydroxychloroquine 400 mg orally once a day as pre-exposure prophylaxis against COVID-19.&lt;br&gt;                Control: Placebo.&lt;br&gt;                Randomization details: Fixed 1:1 allocation ratio produced by a computer-based random number generator. Randomly permuted blocks of varying size will be used to ensure equal allocation to each group, stratified by site.&lt;br&gt;","&lt;br&gt;Product Name: Solnatide&lt;br&gt;Pharmaceutical Form: Powder for nebuliser suspension&lt;br&gt;INN or Proposed INN: Solnatide&lt;br&gt;CAS Number: 259206-53-06&lt;br&gt;Current Sponsor code: AP301&lt;br&gt;Other descriptive name: human tumour necrosis factor alpha-derived peptide Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Solvent for...&lt;br&gt;Route of administration of the placebo: Inhalation use&lt;br&gt;&lt;br&gt;","Oral 500mg chloroquine phosphate tablets prophylactic weekly regimen against COVID-19 over 10 week trial period followed with plasma chloroquine levels.","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","A home-based intervention based on high-intensity interval training (HIIT). A physical therapist, with more than 5 years of experience, will provide a video session upload to YouTube. A WhatsApp message will individually send to each participant with a session link, that they will have to complete.&lt;br&gt;Frequency, duration of the sessions and overall duration of the intervention: 45 min of HIIT session, six days per week during all the self-isolation period (6 weeks estimated). &lt;br&gt;Each session will have: &lt;br&gt;1) A warm-up (10 min): Joint mobility exercises. &lt;br&gt;2) Main part: CORE, arms and legs exercises, with 10-12 sets of 30-90 seconds with 15-60 seconds of rest between sets (ie. push ups, squats, splits or dead lifts). All the exercises will be performed with their own weight. &lt;br&gt;3) Cold down: Flexibility exercises.&lt;br&gt;Adherences will daily be monitored through WhatsApp message.","&lt;br&gt;Trade Name: Arechin&lt;br&gt;Product Name: Chlorine phosphate (Arechin) &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CHLOROQUINE PHOSPHATE&lt;br&gt;CAS Number: 50-63-5&lt;br&gt;Other descriptive name: CHLOROQUINE PHOSPHATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;                Patients will be randomised in a 1:1:1 ratio to:&lt;br&gt;                Arm 1: Continuous positive airway pressure (CPAP), administered according to local protocol/guidelines. Administration will be left to clinical discretion.&lt;br&gt;                Arm 2: High flow nasal oxygen (HFNO) will be administered according to local protocol/guidelines. Administration will be left to clinical discretion.&lt;br&gt;                Arm 3: Standard care. Standard oxygen therapy according to local protocol/guidelines.&lt;br&gt;","&lt;br&gt;Trade Name: PLAQUENIL 200 mg, comprim pellicul&lt;br&gt;Product Code: SAR390530&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: SAR321068&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Prolastin&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: HUMAN ALPHA1-PROTEINASE INHIBITOR&lt;br&gt;CAS Number: 9041-92-3&lt;br&gt;Other descriptive name: HUMAN ALPHA1-PROTEINASE INHIBITOR&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ruxolitinib (JAKAVI)&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: ruxolitinib (phosphate)&lt;br&gt;CAS Number: 1092939-17-7&lt;br&gt;Current Sponsor code: INCB018424 phosphate&lt;br&gt;Other descriptive name: RUXOLITINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-40&lt;br&gt;&lt;br&gt;","a) Hydroxychloroquine or placebo to match will be administered orally once daily; 400mg (&gt;=65kg body weight) or 200mg (&lt;65kg body weight);&lt;br&gt;b) the duration of administration will be for 4 months total;&lt;br&gt;c) the mode of administration oral capsule;&lt;br&gt;d) adherence to medication administration will be done via a daily reminder text message. At the completion of the study, study drug accountability will be performed and blood analysis for  Hydroxychloroquine at baseline and completion.","&lt;br&gt;Trade Name: Zithromax&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;Current Sponsor code: OnCoVID19&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Fresh frozen plasma (FFP) with marketing authorisation in Germany issued by PEI&lt;br&gt;&lt;br&gt;Product Name: For example \"Gefrorenes Frischplasma / Apherese DRK Blutspendedienst\"&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Staatl. Fachingen STILL&lt;br&gt;Product Name: Staatl. Fachingen STILL &lt;br&gt;Product Code: 6959688.00.00&lt;br&gt;Pharmaceutical Form: Oral liquid&lt;br&gt;INN or Proposed INN: Healing water&lt;br&gt;Other descriptive name: HYDROGEN CARBONATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2.769-&lt;br&gt;Pharmaceutical form of the placebo: Oral liquid&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Phase 1 medical device trial investigating the use of a personalised ventilation hood (McMonty hood device) for use by patients with suspected or proven infectious respiratory diseases (primarily COVID-19 suspected or confirmed patients).  This non-invasive device provides a physical barrier to droplet and aerosol spread, as well as utilising a ventilation system to reduce aerosol spread from COVID-19 or other infectious diseases.  The hood has a skirt that drapes down the sides of the bed and over the patients waist and does not seal around the patient. The hood relies upon air being drawn up the sides of the bed and from the front near the patients legs etc. up to the rear, i.e. away from the healthcare worker who is principally at the front/sides of the patient. The air passes through the fan and on through a High Efficiency Particulate Air (HEPA) filter, thereafter returning to the hospital air environment.  The device will be used continuously for 7 days or until the patient has been declared COVID-19 negative, is discharged from hospital, or elects to withdraw from the study.  Use of the device is entirely voluntary, and patients may elect to cease use of the device at any time either temporarily, or permanently.  Staff will be asked to complete simple data for each clinical shift about device compliance use.  In addition, measures to capture technical product adverse events and complaints will be captured by forms available to clinical staff and checked daily by the investigator team.  Technical product complaint data will be submitted to an independent data safety monitor team.","HDIVC group:100mg/kg/day;Control group:normal saline;","Control  group:xiaoyao capsule;Experimental group:xiaoyao capsule;","&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;CAS Number: 1809249-37-3&lt;br&gt;Current Sponsor code: GS-5734&lt;br&gt;Other descriptive name: REMDESIVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Chloroquine difosfato&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Chloroquine difosfato&lt;br&gt;CAS Number: 54-05-7&lt;br&gt;Current Sponsor code: Clorochina&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Product Name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Lopinavir/Ritonavir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Interfern b 1A&lt;br&gt;Product Name: Interfern b 1A&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;CAS Number: 220581-49-7&lt;br&gt;Current Sponsor code: Interferon beta-1a&lt;br&gt;Other descriptive name: Interferon beta-1a&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 152-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dacortin&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Prednisone&lt;br&gt;CAS Number: NA&lt;br&gt;Current Sponsor code: NA&lt;br&gt;Other descriptive name: PREDNISONE&lt;br&gt;&lt;br&gt;","Drug: Placebo oral tablet;Drug: Colchicine","Behavioral: Mindfulness session(s)","Drug: Hydroxychloroquine Sulfate;Drug: Azithromycin Tablets","Group 2:Conventional treatment;Group 2:Conventional treatment plus liu-zi--jue exercisee therapy;","Intervention group:Lingnan Fire-Needle Therapy;Control:Health and life guidance;","Drug: Plasma","Drug: Plasma;Drug: Hydroxychloroquine","Other: Usual Care;Drug: Anakinra;Drug: Siltuximab;Drug: Tocilizumab","Drug: Tocilizumab","Drug: Favipiravir","Drug: Losartan","Biological: bacTRL-Spike;Other: Placebo","Drug: Eicosapentaenoic acid gastro-resistant capsules","Group 2:Aliskiren with Standard Care;Group 1:Nifedipine with Standard Care;","&lt;br&gt;Trade Name: PLAQUENIL&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Experimental group:Jiexingjunzi granules ;control group:placebo;","Experimental group:Basic treatment + kolimycin;Control group:Basic treatment;","Other: SPIN-CHAT Program","Other: blood draw","Drug: Anakinra;Drug: Tocilizumab","Other: Discontinuation of ARB/ACEI;Other: Continuation of ARB/ACEI","Drug: Ivermectine;Drug: Hydroxychloroquine Sulfate;Drug: Placebos;Drug: Azithromycin 500 mg","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Drug: Pegylated interferon lambda","Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)","Drug: L-ascorbic acid;Other: Placebo","Other: Standard administration of oxygen flow;Device: Automated oxygen administration - FreeO2","Other: hyperimmune plasma","&lt;br&gt;Product Name: Inhaled nitric oxide&lt;br&gt;Product Code: n.a.&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;INN or Proposed INN: NITRIC OXIDE&lt;br&gt;CAS Number: 10102-43-9 &lt;br&gt;Other descriptive name: Nitrogen monoxide&lt;br&gt;Concentration unit: PPM part per million&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-80&lt;br&gt;&lt;br&gt;","Drug: Hydroxychloroquine + placebo;Drug: hydroxychloroquine + azithromycin","Drug: Azithromycin;Drug: Hydoxychloroquine or Chloroquine;Drug: Interferon-Beta","Drug: Human immunoglobulin;Drug: Placebo","&lt;br&gt;Product Name: chloroquine&lt;br&gt;Product Code: RVG 106659&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: azithromycin&lt;br&gt;Product Code: RVG 117670&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","Drug: placebo for clazakizumab;Drug: Clazakizumab;Drug: non-RAS blocking antihypertensives;Drug: Candesartan;Drug: Thromboprophylaxis;Drug: Rivaroxaban;Other: Best standard of care;Drug: Lopinavir/Ritonavir;Drug: Chloroquine or Hydroxychloroquine","Drug: Sargramostim;Other: Control","Drug: Peginterferon Lambda-1a;Other: Placebo","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Drug: INO-4800;Device: CELLECTRA 2000","Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule;Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule;Biological: Two doses of placebo at the emergency vaccination schedule;Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule;Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule;Biological: Two doses of placebo at the routine vaccination schedule","Drug: Hydroxychloroquine Pre-Exposure Prophylaxis;Drug: Placebo oral tablet","Genetic: Mesenchymal Stromal Cells","Biological: anti-SARS-CoV-2 convalescent plasma","Drug: hydroxychloroquine in combination with camostat mesylate;Drug: Hydroxychloroquine in combination of Azithromycin","Drug: captopril 25mg","Drug: Hydroxychloroquine (HCQ)","Drug: Hydroxychloroquine and azithromycin treatment arm.;Drug: Hydroxychloroquine;Drug: Control arm","Device: Ventil - a gas flow divider","Other: Self-administered questionnaires","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Pharmaceutical Form: Solution for infusion in pre-filled syringe&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;CAS Number: 1189541-98-7&lt;br&gt;&lt;br&gt;","Drug: 100 mg/mL Virazole;Drug: 50 mg/mL Virazole","&lt;br&gt;Trade Name: Anbinex&lt;br&gt;Product Name: HUMAN ANTITHROMBIN&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Antithrombin III&lt;br&gt;Other descriptive name: HUMAN ANTITHROMBIN&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;","Drug: Group A HCQ;Drug: Group B Control","Drug: Melatonin 2mg;Drug: Placebo oral tablet","&lt;br&gt;Trade Name: hidroxicloroquine&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 747-42-3&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 5-200&lt;br&gt;&lt;br&gt;","Drug: Suspension of heat killed (autoclaved) Mycobacterium w;Other: Placebo","Drug: ACE inhibitor, angiotensin receptor blocker","&lt;br&gt;Trade Name: Kevzara 200mg&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;CAS Number: 1189541-98-7&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 175-&lt;br&gt;&lt;br&gt;Trade Name: Kevzara 400mg&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;CAS Number: 1189541-98-7&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 175-&lt;br&gt;&lt;br&gt;","Drug: Experimental drug","Drug: Standard of Care;Drug: Favipiravir + Standard of Care","Other: blood sampling;Other: additional blood tubes","Drug: Recombinant human plasma gelsolin (Rhu-pGSN);Other: Placebo","Drug: Baricitinib 4 MG Oral Tablet","Drug: Ruxolitinib administration","&lt;br&gt;Trade Name: Quensyl&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Drug: L-ascorbic acid","Drug: Sarilumab;Other: Standar of care","Drug: Hydroxychloroquine;Drug: Azithromycin","Drug: Hydroxychloroquine;Drug: Favipiravir","Drug: Suspension of heat killed (autoclaved) Mycobacterium w;Other: Placebo","Dietary Supplement: Ketogenic diet;Other: standard of care","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Kineret&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: ANAKINRA&lt;br&gt;CAS Number: 143090-92-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 162-&lt;br&gt;&lt;br&gt;Trade Name: SYLVANT&lt;br&gt;Product Name: SYLVANT&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Siltuximab&lt;br&gt;CAS Number: 541502-14-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;","Drug: Tocilizumab (TCZ);Drug: Placebo","Other: Gas exchanges at different PEEP;Other: lung mechanics at different PEEP;Other: Hemodynamics changes at different PEEP","Drug: Hydroxychloroquine;Drug: Lopinavir / Ritonavir Pill;Drug: Azithromycin;Other: Standard treatment","Drug: Nitazoxanide;Drug: Placebo","Drug: Estradiol patch","Behavioral: Phone-call screening and management by a medical student/general practitioner tandem","Other: Standard Care;Combination Product: Ivermectin plus Nitazoxanide","Drug: Telmisartan 40mg;Drug: Placebo","Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Telmisartan","Drug: Aviptadil (VIP);Drug: Placebo","Device: high flow nasal cannula (HFNC);Procedure: Prone positioning (PP)","Drug: Anluohuaxian","Drug: Nitazoxanide 500 MG;Drug: Hydroxychloroquine","Drug: Eculizumab","Diagnostic Test: COVID 19 diagnostic test by PCR","Drug: Chloroquine or hydroxychloroquine","Drug: Colchicine Tablets","Drug: Nitazoxanide Tablets;Drug: Placebo","Drug: Hydroxychloroquine Sulfate;Drug: Azithromycin Tablets","Drug: Isotretinoin Only Product in Oral Dose Form","Device: Q-NRG Metobolic Cart Device;Device: MuscleSound Ultrasound;Device: Multifrequency Bioimpedance Spectroscopy","Procedure: Chest physiotherapy using a non-invasive oscillating device","Other: samling of oropharynx and nasopharynx","Behavioral: prayer","Other: home care monitoring","Biological: vaccine BCG;Other: Placebo","Drug: Hydroxychloroquine Sulfate;Drug: Hydroxychloroquine Sulfate + Azythromycin","Drug: Anakinra;Drug: Normal saline","Diagnostic Test: identify SARS-CoV-2 infection by serology;Biological: collection of biological samples","Drug: Chloroquine Sulfate;Drug: Hydroxychloroquine;Other: Standard supportive care","Behavioral: Online cognitive behavioral therapy (CBT);Behavioral: Online bibliotherapy programme","Drug: Sevoflurane;Drug: Intravenous drug","Biological: Convalescent plasma","Device: Electric pad for human external pain therapy","Drug: MRx-4DP0004;Drug: Placebo","Diagnostic Test: rapid salivary test","Drug: Anakinra;Drug: trimethoprim/sulfamethoxazole","Other: prone position","Other: Doppler Echo","Other: Questionnaires;Biological: blood test;Other: Maximal effort test;Device: actigraphy;Device: Neuromuscular evaluation","Dietary Supplement: Vitamin D;Drug: Aspirin 81 mg","Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA];Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA];Drug: Best available treatment","Other: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint","Drug: Hydroxychloroquine;Drug: Placebo","Drug: Dexamethasone injection;Drug: Placebos","Combination Product: Hydroxychloroquine plus Nitazoxanide;Other: Standard care","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil];Drug: Lopinavir/ritonavir","Drug: Tocilizumab","Other: Rehabilitation","Device: Cytokine Adsorption","Other: Best Practice;Biological: Tocilizumab","Other: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors","Drug: Progesterone 100 MG","Drug: Azithromycin;Drug: Hydroxychloroquine;Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab","Drug: AT-001","Nebulised (Vibrating mesh nebuliser) heparin sodium 25,000 IU in 5 ml 6-hourly to day 10 while invasively ventilated in addition to standard care.&lt;br&gt;The medication will be prescribed and administration documented in the medical record.&lt;br&gt;","Drug: Ramipril 2.5 MG Oral Capsule;Drug: Placebo oral capsule","The app includes seven modules that can be completed within a week to learn evidence-based coping skills based on CBT, psychoeducation and positive psychology techniques. The seven modules are: (1) identifying and rating emotions, (2) relaxation, (3) self-compassion, (4) gratitude, (5) staying connected, (6) physical care, and (7) goal setting. The app uses short videos and interactive activities to allow participants to practice the coping strategies that are taught in each module (e.g. a relaxation technique). Participants are asked to complete one module per day and to complete the modules in one week. Each module takes approximately 15 minutes to complete. Participants will be asked to complete module 1 first, but the other modules can be completed in any order. Adherence will be assessed via app analytics and also using self-report.","Drug: Tociliuzumab","Biological: Blood plasma","&lt;br&gt;                The study consists of the following periods/assessments for participants in both the intervention and control arms.&lt;br&gt;                1. Screening period: -3 to -1 days. This will involve taking informed consent, assessing eligibility and comorbidity (e.g. Hypertension, Diabetes, Cardiovascular disease, etc.) through taking a medical and surgical history, smoking history, previous medication history, demographic history, physical examination, serology, 12-lead ECG, and vital signs.&lt;br&gt;                2. Treatment period: 0 to 14 days&lt;br&gt;                3. Follow-up period: 0 to 28 days. Patients will attend five study assessments at 0 (baseline assessment), 2, 8, 15 and 29 days. If nasal swabs taken at 15 days are negative participants will be invited to return 24 h later on day 16 for a second swab.&lt;br&gt;                4. Safety Follow-up assessment: 28 days after the last dose of the Siddha treatment was received in the event of early termination&lt;br&gt;&lt;br&gt;                The patients selected for participation will be assigned randomly to one of the two treatment groups, Siddha treatment regimen + Standard of Care, or Standard of Care only, in 1:1 ratio balancing the stratification factor of co-morbidity status.&lt;br&gt;&lt;br&gt;                The stratified permuted block randomization design will be used to randomize the patients in 1:1 ratio among the two treatment groups.&lt;br&gt;&lt;br&gt;                Siddha treatment regimen + Standard of care will involve Siddha treatment with Kabasura kudineer and Brammanandha bairavam where indicated in addition to standard care as per local/government guidance. Kabasura kudineer will be given in the dose of 60 ml, twice a day for 7 days taken 90 minutes before food. Brammanandha bairavam will be given in the dose of 100 mg, three times a day for 7 days, ta","&lt;br&gt;                This is an interventional study where good sleepers will be recruited as a wait-list control, where they will receive the treatment after a delay of one week. An additional group of good sleeper participants will be recruited who will not receive the intervention. An equal number of participants will be recruited to each group and healthy good sleepers and individuals with sleep problems will be recruited at a 2:1 ratio (estimated n = 40:20 participants).&lt;br&gt;&lt;br&gt;                The study is single-centre and the study will be run entirely online.&lt;br&gt;&lt;br&gt;                Participants who are in the two intervention groups (poor sleep and wait-list control good sleepers) will be provided with an online version of a self-help leaflet. A printed version of this leaflet has been used in previous treatment studies conducted by our research group. Briefly, this self-help leaflet aims to improve sleep by identifying and addressing sleep-related dysfunctional thinking by providing education about sleep, providing techniques to distract from intrusive worrisome thoughts at night, and providing guidelines for sleep-related stimulus control.&lt;br&gt;&lt;br&gt;                The duration of treatment will be one week and the follow-up period is at the end of the treatment period. Participants will be randomised using online software (where good sleepers will be randomised to treatment or no treatment).&lt;br&gt;","&lt;br&gt;                The participants are randomized across experimental and control groups and blinded for group allocation.&lt;br&gt;                Following recruitment, the researcher who was blind to participants identities and baseline assessment results performed randomisation into groups using random number generating software.&lt;br&gt;                Intervention: Expressive writing  (20 minutes, 5 sessions during 2 weeks), participants are instructed to write about any experiences and thoughts on their life during the pandemic.&lt;br&gt;                Control: Treatment as usual (TAU), i.e. informal support through families, friends, and networks (face-to-face, telephone and online) as well as support participants could get using available services in the community during the state of emergency (e.g. online counseling, hotlines, available self-help manuals)&lt;br&gt;","&lt;br&gt;                Adults (aged =18 years) recently hospitalized, or already in the hospital, with definite COVID-19 and, in the view of the responsible doctor, no contra-indication to any of the study drugs will be randomly allocated between five groups:&lt;br&gt;                1. Local standard of care alone&lt;br&gt;                OR local standard of care plus one of&lt;br&gt;                2. Remdesivir (daily infusion for 10 days)&lt;br&gt;                3. Chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)&lt;br&gt;                4. Lopinavir + ritonavir (orally twice daily for 14 days)&lt;br&gt;                5. Lopinavir + ritonavir ((orally twice daily for 14 days) plus interferon-beta (daily injection for 6 days)&lt;br&gt;&lt;br&gt;                Follow-up is until death or discharge from hospital.&lt;br&gt;                Randomization is performed at one central global location through an online portal.&lt;br&gt;","Control:conventional therapy;Experimental group:Bufei Huoxue Capsule, 1.4g/day, three times a day, three months of treatment;","Case series:Nil;","Experimental group:Administration of hydroxychloroquine sulfate;control group:Placebo given;","Experimental group vs control group:Hydroxychloroquine versus Placebo;","Experimental group:Treatment according to the seventh edition of the diagnosis and treatment guidelines + continuous implementation of health education and low oxygen consumption and rest behavior guidance for 5 days;Control group:Treatment according to the seventh edition of the diagnosis and treatment guidelines;","COVID-19 convalescent patients:Psychological crisis intervention;First-line medical staff:Psychological crisis intervention;","Phase I A1:Low dosage;Phase I A2:Placebo;Phase I A3:medium dosage;Phase I A4:Placebo;Phase I A5:high dosage;Phase I A6:Placebo;Phase I F1:Low dosage;Phase I F2:Placebo;Phase I F3:medium dosage;Phase I F4:Placebo;Phase I F5:high dosage;Phase I F6:Placebo;Phase I G1:low dosage;Phase I G2:placebo;Phase I G3:medium dosage;Phase I G4:placebo;Phase I G5:high dosage;Phase I G6:placebo;Phase I H1:low dosage;Phase I H2:placebo;Phase I H3:medium dosage;Phase I H4:placebo;Phase I H5:high dosage;Phase I H6:placebo;Phase I M1:low dosage;Phase I M2:placebo;Phase I M3:medium dosage;Phase I M4:placebo;Phase I M5:high dosage;Phase I M6:placebo;phase II A1:low dosage;phase II A2:placebo;phase II A3:medium;phase II A4:placebo;phase II A5:high dosage;phase II A6:placebo;phase II B1:medium;phase II B2:placebo;phase II C1:medium dosage;phase II C2:placebo;phase II D1:medium dosage;phase II D2:placebo;phase II E1:high dosage;phase II E2:placebo;phase II F1:low dosage;phase II F2:placebo;phase II F3:medium dosage;phase II F4:placebo;phase II F5:high dosage;phase II F6:placebo;phase II G1:low dosage;phase II G2:placebo;phase II G3:medium dosage;phase II G4:placebo;phase II G5:high dosage;phase II G6:placebo;phase II H1:low dosage;phase II H1:placebo;phase II H3:medium dosage;phase II H4:placebo;phase II H5:high dosage;phase II H6:placebo;phase II M1:low dosage;phase II M2:placebo;phase II M3:medium dosage;phase II M4:placebo;phase II M5:high dosage;phase II M6:placebo;","Experimental group: mild cases:Ulinastatin 300,000 IU, Q12H;Experimental group: severe or critical cases:Severe cases: 1 million IU of ulinastatin, Q8H; Critical cases: ulinastatin 1.6 million IU, Q8H;Control group: mild cases:conventional therapy;Control group: severe or critical cases :conventional therapy;","&lt;br&gt;Trade Name: Azithromycin&lt;br&gt;Product Name: Azithromycin&lt;br&gt;Product Code: Azithromycin&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Azithromycin&lt;br&gt;CAS Number: 121470-24-4&lt;br&gt;Other descriptive name: AZITHROMYCIN MONOHYDRATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-500&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Product Code: Hydroxyghloroquine&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: avdoralimab&lt;br&gt;Product Code: IPH5401&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: avdoralimab&lt;br&gt;CAS Number: 2226393-85-5&lt;br&gt;Current Sponsor code: IPH5401&lt;br&gt;Other descriptive name: NNC0215-0384&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: VACCIN BCG AJVaccines&lt;br&gt;Product Name: VACCIN BCG AJVaccines&lt;br&gt;Pharmaceutical Form: Powder and solvent for dispersion for injection&lt;br&gt;Other descriptive name: BCG VACCINE, FREEZE-DRIED&lt;br&gt;Concentration unit: CFU/ml colony forming unit(s)/millilitre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 2-8&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intradermal use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Aldesleukin&lt;br&gt;Product Code: ILT101&lt;br&gt;Pharmaceutical Form: Concentrate for cutaneous solution&lt;br&gt;CAS Number: 110942-02-4&lt;br&gt;Current Sponsor code: ILT101&lt;br&gt;Other descriptive name: ALDESLEUKIN&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;Pharmaceutical form of the placebo: Concentrate for cutaneous solution&lt;br&gt;Route of administration of the placebo: Subcutaneous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Enoxaparine sodique&lt;br&gt;Product Name: enoxaparine sodique&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: ENOXAPARIN SODIUM&lt;br&gt;CAS Number: 9041-08-1&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Kineret&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: PLAQUENIL 200 MG CPR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: KALETRA 200MG/50MG CPR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Current Sponsor code: LOPINAVIR&lt;br&gt;Other descriptive name: LOPINAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;Current Sponsor code: RITONAVIR&lt;br&gt;Other descriptive name: RITONAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: ZITHROMAX 250MG CPR&lt;br&gt;Product Name: AZITHROMYCIN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN&lt;br&gt;CAS Number:  83905-01-5&lt;br&gt;Current Sponsor code: AZITHROMYCIN&lt;br&gt;Other descriptive name: AZITHROMYCIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED&lt;br&gt;Product Code: CMTAd&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;INN or Proposed INN: EXPANDED HUMAN ALLOGENEIC MESENCHYMAL ADULT STEM CELLS EXTRACTED FROM ADIPOSE TISSUE&lt;br&gt;Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED&lt;br&gt;Concentration unit: Other&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 80000000-160000000&lt;br&gt;&lt;br&gt;Trade Name: Treatment according to clinical practice by COVID-19&lt;br&gt;Product Name: Treatment according to clinical practice (Hydroxychloroquine + Azithromycin or Lopinavir / ritonavir&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: not less then&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Product Name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED&lt;br&gt;Product Code: CMTAd&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;INN or Proposed INN: EXPANDED HUMAN ALLOGENEIC MESENCHYMAL ADULT STEM CELLS EXTRACTED FROM ADIPOSE TISSUE&lt;br&gt;Other descriptive name: EXPANDED HUMAN ALLOGENEIC MESENCHYMAL ADULT STEM CELLS EXTRACTED FROM ADIPOSE TISSUE&lt;br&gt;Concentration unit: DF dosage form&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 160000000-320000000&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Albutein 5% solutin for infusion&lt;br&gt;Product Name: Human Albumin&lt;br&gt;Product Code: B05AA01&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: HUMAN SERUM ALBUMIN&lt;br&gt;Other descriptive name: ALBUMIN NORMAL HUMAN SERUM&lt;br&gt;Concentration unit: g/ml gram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;Trade Name: Flebogamma DIF/100 Human Inmunoglobulin normal&lt;br&gt;Product Name: Human Immunoglobuline normal&lt;br&gt;Product Code: Flebogamma DIF 50 mg/ml solucin para perfusin&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Human normal immunoglobulin&lt;br&gt;Other descriptive name: HUMAN NORMAL IMMUNOGLOBULIN&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: XCEL-UMC-BETA&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: EX VIVO EXPANDED WHARTON'S JELLY DERIVED MESENCHYMAL STEM CELLS&lt;br&gt;Current Sponsor code: XCEL-UMC-BETA&lt;br&gt;Other descriptive name: EX VIVO EXPANDED WHARTON'S JELLY DERIVED MESENCHYMAL STEM CELLS&lt;br&gt;Concentration unit: IU/kg international unit(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 700000-1000000&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Hidroferol 0,266 mg cpsulas blandas&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CALCIFEDIOL&lt;br&gt;CAS Number: 19356-17-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.266-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Avastin&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: BEVACIZUMAB&lt;br&gt;CAS Number: 216974-75-3&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Recombinant human angiotensin-converting enzyme 2&lt;br&gt;Product Code: APN01&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: APN01 / GSK2586881&lt;br&gt;Other descriptive name: GSK2586881&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Vafidemstat&lt;br&gt;Product Code: ORY-2001&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: VAFIDEMSTAT&lt;br&gt;CAS Number: 1357247-95-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.2-2.4&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Actilyse &lt;br&gt;Product Name: Actilyse &lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection/infusion&lt;br&gt;INN or Proposed INN: Alteplase&lt;br&gt;CAS Number: 0105857-23-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Roactemra&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Roactemra&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: UNIKINON Tablets 200mg/tab&lt;br&gt;Product Name: UNIKINON Tablets 200mg/tab&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CHLOROQUINE PHOSPHATE&lt;br&gt;Other descriptive name: CHLOROQUINE PHOSPHATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Olumiant&lt;br&gt;Product Name: Olumiant&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: BARICITINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Product Name: Kevzara&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Subcutaneous use&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: Olumiant&lt;br&gt;Product Name: Olumiant&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: BARICITINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Other: Standard of care;Drug: Hydroxychloroquine;Drug: Interferon Beta-1A;Drug: Lopinavir/ritonavir;Drug: Remdesivir","Drug: Camostat Mesilate;Drug: Placebo oral tablet","Drug: Hydroxychloroquine;Drug: Placebo of Hydroxychloroquine;Drug: Lopinavir and ritonavir;Drug: Placebo of LPV/r Tablets","Drug: Placebo;Drug: Tocilizumab (TCZ)","Drug: Colchicine;Other: Local standard of care","Drug: Hydroxychloroquine Sulfate 400 mg twice a day;Drug: Hydroxychloroquine Sulfate 600 mg twice a day;Drug: Hydroxychloroquine Sulfate 600 mg once a day;Drug: Placebo oral tablet","Drug: BCG Vaccine;Drug: Placebo","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: hydroxychloroquine sulphate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;Other descriptive name: Remdesivir&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","Drug: Placebos;Drug: HB-adMSCs","Drug: Tocilizumab;Drug: Tocilizumab","Drug: Ibuprofen","Drug: Methotrexate;Drug: Methotrexate;Drug: Methotrexate","Biological: Umbilical Cord Mesenchymal Stem Cells;Other: Standard of Care","Drug: Enoxaparin Higher Dose;Drug: Lower-dose prophylactic anticoagulation","Drug: Bromhexine Hydrochloride Tablets;Drug: Arbidol Hydrochloride Granules;Drug: Recombinant Human Interferon a2b Spray","Drug: Hydroxychloroquine;Other: Placebo","Biological: convalescent plasma","Drug: Dornase Alfa Inhalation Solution [Pulmozyme]","Other: Prone;Other: Usual Care","Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.;Drug: Placebo","Biological: Mesenchymal Stromal Cells;Other: Placebo","Device: COVSurf Drug Delivery System;Other: Standard of Care","Drug: Emtricitabine/tenofovir disoproxil;Drug: Hydroxychloroquine;Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo;Drug: Placebo: Hydroxychloroquine","Drug: Ruxolitinib","Drug: Losartan;Other: Placebo","Drug: BMS-986253","Drug: HB-adMSCs","Drug: Hydroxychloroquine;Other: Placebo","Drug: Placebo;Drug: Hydroxychloroquine","Drug: Hydroxychloroquine","Other: 3D Telemedicine;Other: 2D Telemedicine","Biological: Cell therapy protocol 1;Biological: Cell therapy protocol 2","Biological: pathogen reduced SARS-CoV-2 convalescent plasma;Biological: Placebo","Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care;Dietary Supplement: SivoMixx (200 billion);Drug: Azithromycin;Drug: hydroxychloroquine","Drug: Methylprednisolone Sodium Succinate;Drug: Placebo solution","Drug: Hydroxychloroquine;Drug: Indomethacin;Drug: Zithromax Oral Product","Combination Product: Standard of Care (SOC);Drug: CHLORPROMAZINE (CPZ)","Drug: Chloroquine;Drug: Favipiravir;Drug: Nitazoxanide;Drug: Ivermectin;Drug: Niclosamide;Drug: Other drugs","Drug: Enoxaparin","Combination Product: Azithromycin with amoxicillin/clavulanate;Drug: amoxicillin/clavulanate","Genetic: Whole Genome Analysis;Genetic: T-cell receptor (TCR) repertoire;Genetic: SARS-CoV-2 viral composition","Drug: Hydroxychloroquine Sulfate Regular dose;Drug: Hydroxychloroquine Sulfate Loading Dose;Drug: Chloroquine;Drug: Placebo","Drug: nebulised recombinant tissue-Plasminogen Activator (rt-PA)","Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS","Behavioral: psychological assessment","Device: NIO (Intraosseous access);Device: Standard of Care (Intravenous access)","Procedure: blood sampling","Drug: Hydroxychloroquine and azithromycin treatment;Other: conventional management of patients","Drug: Aspirin 100mg","Other: Prone decubitus","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma);Biological: Non-convalescent Plasma (control plasma)","Other: Collection of samples","Device: gammaCore (Vagus nerve stimulation)","Drug: Tirofiban Injection;Drug: Clopidogrel;Drug: Acetylsalicylic acid;Drug: Fondaparinux","Dietary Supplement: Probiotic;Dietary Supplement: Control","Behavioral: 1: Prone positioning;Behavioral: 2: No instruction regarding positioning","Device: Control swab;Device: Prototype swab","Procedure: Direct laryngoscopy;Procedure: Vie Scope laryngoscopy","Diagnostic Test: Saliva collection","Behavioral: Behavioral: OCAT-sham;Behavioral: Behavioral: OCAT;Other: psycho-education video","Device: Intravenous access;Device: Intraosseous access","Procedure: Extended sampling and procedures","Other: Sudarshan Kriya Yoga (SKY);Other: Health Enhancement Program","Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube)","Procedure: CT-scan with minimal invasive autopsy","Drug: BAT + Calcifediol;Drug: BAT","Device: Mechanical ventilation with the automated BVM compressor","Biological: Ravulizumab;Other: Best Supportive Care","Drug: Hydroxychloroquine (HCQ);Other: Pacebo: Calcium citrate","Biological: BCG;Biological: Placebo","Drug: Hydroxychloroquine Sulfate","TCC-COVID is an app-based model of care which includes a smartphone app and a pulse oximeter that measures oxygen saturation, pulse rate and collects symptoms. &lt;br&gt;Patients place their index finger in the pulse oximeter to measure their oxygen saturation and pulse rate twice a day, which will take approximately 5 minutes each time. Patients then enter the results into the TCC-COVID app twice daily, and complete a symptom questionnaire via the TCC-COVID app once daily, which will take approximately 5 minutes. The symptom questionnaire was designed specifically for this study. The measurements and information are directly connected to a clinician interface (KIOLA database) which provides the data of all patients in aggregate and an easy to use responsive format with customisable alerts. The alerts identify if the oxygen saturation levels are low or the pulse rate is out of range. The alerts also identify if a measurement has not been completed in a timely manner and the central monitoring service will contact the patient to check on their safety or if they are experiencing any technical issues. The overall duration of participation will be 14 days.","Other: Telemedicine;Other: Standard care","Behavioral: Coping strategies video","&lt;br&gt;Product Name: Masitinib&lt;br&gt;Product Code: AB1010&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Masitinib mesilate&lt;br&gt;CAS Number: 790299-79-5&lt;br&gt;Current Sponsor code: AB1010&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Masitinib&lt;br&gt;Product Code: AB1010&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Masitinib mesilate&lt;br&gt;CAS Number: 790299-79-5&lt;br&gt;Current Sponsor code: AB1010&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Isoquercetin &lt;br&gt;Product Code: IQC950AN &lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;&lt;br&gt;Trade Name: Plaquenil 200 mg&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: SAR321068&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Device: Oxygen Therapy;Procedure: Physical Therapy","Drug: Azithromycin 500 milligram (mg) oral Tablet;Drug: Placebo","&lt;br&gt;Product Name: IFX-1&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: IFX-1&lt;br&gt;CAS Number: 2250440-41-4&lt;br&gt;Current Sponsor code: IFX-1&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","Drug: Matched Placebo;Drug: Apo-Hydroxychloroquine","Control group 1:western medicine treatment;Integrated traditional Chinese and western medicine treatment group 1:(2)traditional Chinese medicine treatment, western medicine treatment, and intravenous administration of 5% glucose (control);Integrated traditional and western medicine treatment + high-dose vitamin C group 1:traditional Chinese medicine treatment, western medicine treatment, and intravenous administration of high-dose vitamin C (control);Control group 2:western medicine treatment;Integrated traditional and western medicine treatment group 2:(5)traditional Chinese medicine treatment, western medicine treatment, and intravenous administration of 5% glucose (control);Integrated traditional and western medicine treatment + high-dose vitamin C group 2:(6)traditional Chinese medicine treatment, western medicine treatment, and intravenous administration of high-dose vitamin C (control);","Behavioral: Meditation app usage","Drug: Placebo;Drug: Tocilizumab","severe group:high dose intravenous vitamin C;critical group:high dose intravenous vitamin C;","Drug: XPro1595","&lt;br&gt;Trade Name: Immunoglobulines Humaines Normales&lt;br&gt;Pharmaceutical Form: Solution for injection/infusion&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: VECTARION INJECTABLE, lyophilisat et solution pour prparation injectable&lt;br&gt;Product Name: Almitrine (DCI) bis msilate&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Experimental Group:FNC+Standard of Care;Control Group:FNC dummy tablet+ Standard of Care;","&lt;br&gt;Product Name: Favipiravir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Favipiravir&lt;br&gt;CAS Number: 259793-96-9&lt;br&gt;&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;&lt;br&gt;Product Name: Azithromycin&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Azithromycin&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;&lt;br&gt;","Routine treatment group:Routine treatment;WMT group:Washed microbiota transplantation;","&lt;br&gt;Trade Name: Mylotarg&lt;br&gt;Product Name: Mylotarg&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Gemtuzumab ozogamicin&lt;br&gt;CAS Number: 220578-59-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Enoxaparin (LOVENOX or other specialties)&lt;br&gt;Product Name: Enoxaparin (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: enoxaparin&lt;br&gt;CAS Number: 9005-49-6&lt;br&gt;Other descriptive name: ENOXAPARIN&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 14000-&lt;br&gt;&lt;br&gt;Trade Name: Tinzaparine (INNOHEP)&lt;br&gt;Product Name: Tinzaparine (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: Tinzaparin&lt;br&gt;Other descriptive name: TINZAPARIN SODIUM&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 14000-&lt;br&gt;&lt;br&gt;Trade Name: Dalteparin (FRAGMINE)&lt;br&gt;Product Name: Dalteparin (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: dalteparin&lt;br&gt;Other descriptive name: DALTEPARIN SODIUM&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 12500-&lt;br&gt;&lt;br&gt;Trade Name: Nadroparin (FRAXIPARINE)&lt;br&gt;Product Name: Nadropanine (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: NADROPARIN CALCIUM&lt;br&gt;Other descriptive name: NADROPARIN CALCIUM&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 114000-&lt;br&gt;&lt;br&gt;Trade Name: Enoxaparin (LOVENOX or other specialities)&lt;br&gt;Product Name: Enoxaparin (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: ENOXAPARIN SODIUM&lt;br&gt;CAS Number: 9041-08-1&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 8000-&lt;br&gt;&lt;br&gt;Trade Name: Tinzaparin (INNOHEP)&lt;br&gt;Product Name: Tinzaparin (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: Tinzaparin&lt;br&gt;Other descriptive name: TINZAPARIN SODIUM&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up","&lt;br&gt;Product Name: Selinexor&lt;br&gt;Product Code: KPT-330, XPOVIO&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Selinexor&lt;br&gt;CAS Number: 1393477-72-9&lt;br&gt;Current Sponsor code: KPT-330&lt;br&gt;Other descriptive name: SELINEXOR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Control group:the basic treatment withThymosin enteric capsule  + Pien Tze Huang Capsules placebo;Experimental group:the basic treatment with Thymosin enteric capsule +Pien Tze Huang Capsules;","&lt;br&gt;Trade Name: Curosurf&lt;br&gt;Pharmaceutical Form: Endotracheopulmonary instillation&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: CYT107 &lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intramuscular use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Methylprednisolone&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;CAS Number: 2375-03-3&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 125-&lt;br&gt;&lt;br&gt;Trade Name: HYDROXYCHLOROQUINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: LOPINAVIR/RITONAVIR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR/RITONAVIR&lt;br&gt;Other descriptive name: LOPINAVIR/RITONAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-100&lt;br&gt;&lt;br&gt;Trade Name: TOCILIZUMAB&lt;br&gt;Pharmaceutical Form: Powder and solvent for suspension for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 162-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: SSI BCG powder and solvent for suspension for injection&lt;br&gt;Product Name: BCG vaccine (Danish strain 1331, SSI, Denmark)&lt;br&gt;Product Code: OGYI-T-9001/02&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intradermal use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ilomedin&lt;br&gt;Product Name: Ilomedin&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: Iloprost&lt;br&gt;CAS Number: 78919-13-8&lt;br&gt;Concentration unit: g/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Rekonvaleszentenplasma COVID-19 Apherese (HD)&lt;br&gt;Product Code: CP COVID19&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: CAPTOPRIL&lt;br&gt;Pharmaceutical Form: Concentrate for nebuliser solution&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Jakavi tablets&lt;br&gt;Product Name: Jakavi Tablets&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Vedine/Betadine&lt;br&gt;Product Name: Vedine/Betadine&lt;br&gt;Pharmaceutical Form: Oromucosal solution&lt;br&gt;INN or Proposed INN: iodonated Povidone&lt;br&gt;CAS Number: 9003-39-8&lt;br&gt;Current Sponsor code: nil&lt;br&gt;Other descriptive name: betadine/videne&lt;br&gt;Concentration unit: % (V/V) percent volume/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Nasal wash&lt;br&gt;Route of administration of the placebo: Nasal use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: OXIKLORIN&lt;br&gt;Product Name:  OXIKLORIN&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: hydroxychloroquine sulphate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;Other descriptive name: Remdesivir&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: LOSARTAN ARROW 50 mg, comprim pellicul scable&lt;br&gt;Product Name: Losartan&lt;br&gt;Product Code: Losartan&lt;br&gt;Pharmaceutical Form: Pillules&lt;br&gt;INN or Proposed INN: LOSARTAN&lt;br&gt;CAS Number: 114798-26-4&lt;br&gt;Current Sponsor code: losartan&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: SPIRONOLACTONE ARROW 25 mg,&lt;br&gt;comprim pellicul scable&lt;br&gt;Product Name: SPIRONOLACTONE&lt;br&gt;Product Code: SPIRONOLACTONE&lt;br&gt;Pharmaceutical Form: Pillules&lt;br&gt;INN or Proposed INN: SPIRONOLACTONE&lt;br&gt;Current Sponsor code: SPIRONOLACTONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Klaricid&lt;br&gt;Product Name: Clarithromycin&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ilaris&lt;br&gt;Product Name: Canakinumab&lt;br&gt;Product Code: ACZ885&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: CANAKINUMAB&lt;br&gt;CAS Number: 914613-48-2&lt;br&gt;Current Sponsor code: CACZ885D2310&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: ANAKINRA&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: ANAKINRA&lt;br&gt;CAS Number: 143090-92-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: HYDROXYCHLOROQUINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: LOPINAVIR/RITONAVIR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR/RITONAVIR&lt;br&gt;Other descriptive name: LOPINAVIR/RITONAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 800-200&lt;br&gt;&lt;br&gt;Trade Name: AZYTHROMICINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;Other descriptive name: AZITHROMYCIN DIHYDRATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ilaris&lt;br&gt;Product Name: Canakinumab&lt;br&gt;Product Code: ACZ885&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: CANAKINUMAB&lt;br&gt;CAS Number: 914613-48-2&lt;br&gt;Current Sponsor code: CACZ885D2310&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: ChAdOx1 nCoV-19&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Nimenrix&lt;br&gt;Product Name: Nimenrix&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Menveo&lt;br&gt;Product Name: Menveo&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;&lt;br&gt;","&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Zithromax&lt;br&gt;Product Name: Zithromax&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Azithromycin dihydrate&lt;br&gt;CAS Number: 117772-70-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: ENOXAPARIN SODIUM&lt;br&gt;CAS Number: 9041-08-1&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: SMOFLIPID&lt;br&gt;Product Name: TPN with emulsions enriched with omega-3 fatty acid&lt;br&gt;Pharmaceutical Form: Emulsion for infusion&lt;br&gt;INN or Proposed INN: aceite de soja, triglicridos de cadena media, aceite de oliva y aceite de pescado&lt;br&gt;CAS Number: 66581&lt;br&gt;Other descriptive name: LONG-CHAIN TRIGLYCERIDES&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: CLINOLEIC&lt;br&gt;Product Name: TPN with emulsions enriched with omega-3 fatty acid&lt;br&gt;Pharmaceutical Form: Emulsion for infusion&lt;br&gt;INN or Proposed INN: Aceite de oliva purificado y aceite de soja purificado&lt;br&gt;CAS Number: 66971&lt;br&gt;Other descriptive name: LONG-CHAIN TRIGLYCERIDES&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: OMEGAVEN&lt;br&gt;Product Name: TPN with emulsions enriched with omega-3 fatty acid&lt;br&gt;Pharmaceutical Form: Emulsion for infusion&lt;br&gt;INN or Proposed INN: Acidos grasos omega-3&lt;br&gt;Other descriptive name: OMEGA-3-FATTY ACIDS 90&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: NUTRIFLEX LIPID SPECIAL&lt;br&gt;Product Name: NUTRIFLEX LIPID SPECIAL&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Solucion de aminoacidos&lt;br&gt;CAS Number: 62987&lt;br&gt;Other descriptive name: ESSENTIAL AMINO ACIDS&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 56-&lt;br&gt;INN or Proposed INN: Solucion de glucosa anhidra&lt;br&gt;CAS Number: 62987&lt;br&gt;Other descriptive name: GLUCOSE ANHYDROUS PH EUR&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 158-&lt;br&gt;INN or Proposed INN: Aceite de soja refinado y MCT&lt;br&gt;CAS Number: 62987&lt;br&gt;Other descriptive name: LONG-CHAIN TRIGLYCERIDES&lt;br&gt;Concentration unit: % (W/V) p","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","Drug: remdesivir;Drug: Hydroxychloroquine;Drug: Lopinavir/ritonavir;Drug: remdesivir;Drug: Hydroxychloroquine;Drug: Lopinavir/ritonavir","&lt;br&gt;Product Name: Bemcentinib&lt;br&gt;Product Code: BGB324&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: bemcentinib&lt;br&gt;CAS Number: 1037624-75-1&lt;br&gt;Current Sponsor code: BGB324&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: MEDI3506&lt;br&gt;Product Code: MEDI3506&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;CAS Number: 2376858-66-9&lt;br&gt;Current Sponsor code: MEDI3506&lt;br&gt;Other descriptive name: human immunoglobulin (Ig) G1 monoclonal antibody (mAb)&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Product Name: acalabrutinib&lt;br&gt;Product Code: ACP-196&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: acalabrutinib&lt;br&gt;CAS Number: 1420477-60-6&lt;br&gt;Current Sponsor code: ACP-196&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Zilucoplan&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: Zilucoplan&lt;br&gt;CAS Number: 1841136-73-9&lt;br&gt;Current Sponsor code: RA101495&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Solu-Cortef&lt;br&gt;Product Name: Solu-Cortef&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection/infusion&lt;br&gt;INN or Proposed INN: hydrocortisone&lt;br&gt;Other descriptive name: HYDROCORTISONE SODIUM SUCCINATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;Pharmaceutical form of the placebo: Infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: Isotonic Sodium Chloride (0.9%)&lt;br&gt;Product Name: Sodium Chloride&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;INN or Proposed INN: Sodium Chloride&lt;br&gt;Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9%&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.9-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Jakavi 5mg Tabletten&lt;br&gt;Product Name: ruxolitinib&lt;br&gt;Product Code: INC424&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: ruxolitinib&lt;br&gt;CAS Number: 1092939-17-7&lt;br&gt;Current Sponsor code: INC424&lt;br&gt;Other descriptive name: RUXOLITINIB PHOSPHATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Quensyl&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Kaletra&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Xarelto&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: RIVAROXABAN&lt;br&gt;CAS Number: 366789-02-8&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Candesartan&lt;br&gt;Other descriptive name: CANDESARTAN CILEXETIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: STROMECTOL 3 mg&lt;br&gt;Product Name: STROMECTOL 3 mg&lt;br&gt;Product Code: 34009 352 388 5 6&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: HYDROXYCHLOROQUINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: Bq/mg becquerel(s)/milligram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Device: Normobaric oxygen therapy;Device: Hyperbaric oxygen therapy;Device: Normobaric oxygen therapy;Device: Hyperbaric oxygen therapy","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: Roactemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 162-&lt;br&gt;&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Product Name: Sarilumab&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Other descriptive name: Kevzara&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: COLCHICINA&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: COLCHICINE&lt;br&gt;CAS Number: 64-86-8&lt;br&gt;Current Sponsor code: COLCHICINE&lt;br&gt;Other descriptive name: COLCHICINE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,5-&lt;br&gt;&lt;br&gt;","Drug: DAS181;Drug: DAS181","Drug: Chloroquine phosphate;Drug: Chloroquine phosphate","Drug: Tocilizumab Injection;Drug: Deferoxamine;Drug: Tocilizumab Injection;Drug: Deferoxamine","Device: COVID-19 barrier box;Device: COVID-19 barrier box","&lt;br&gt;Trade Name: Stromectol&lt;br&gt;Product Name: Ivermectina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Ivermectin&lt;br&gt;CAS Number: 70288-86-7&lt;br&gt;Other descriptive name: IVERMECTIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Flebogamma 5% DIF&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Human normal immunoglobulin (IVIg)&lt;br&gt;Other descriptive name: HUMAN NORMAL IMMUNOGLOBULIN (IV)&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Flebogamma 10% DIF&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Human normal immunoglobulin (IVIg)&lt;br&gt;Other descriptive name: HUMAN NORMAL IMMUNOGLOBULIN (IV)&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Prolastina 1000 mg, polvo y disolvente para solucin para perfusin&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: Alpha1-Proteinase Inhibitor (Human)&lt;br&gt;Other descriptive name: HUMAN ALPHA1-PROTEINASE INHIBITOR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Roactemra&lt;br&gt;Product Name: roactemra&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Current Sponsor code: L04AC07&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 8-16&lt;br&gt;&lt;br&gt;","Drug: Hydroxychloroquine plus standard preventive measures;Drug: Placebo plus standard preventive measures;Drug: Placebo plus standard preventive measures;Drug: Hydroxychloroquine plus standard preventive measures","Other: draw blood;Other: draw blood","Behavioral: blood donation SMS;Behavioral: blood donation SMS","&lt;br&gt;Trade Name: Urbason/Metilprednisolona&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;CAS Number: 83-43-2&lt;br&gt;Current Sponsor code: -&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 20-40&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Sandimmun Neoral 25 mg cpsulas blandas&lt;br&gt;Sandimmun Neoral 50 mg cpsulas blandas&lt;br&gt;Sandimun Neoral 100 mg cpsulas blandas&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 25-100&lt;br&gt;&lt;br&gt;Trade Name: Dolquine 200 mg comprimidos recubiertos&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Dolquine 200 mg comprimidos recubiertos&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Biological: Ozone auto-hemotherapy;Biological: Ozone auto-hemotherapy","Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine);Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)","Other: blood sample;Other: blood sample","Biological: avdoralimab;Other: Placebo;Biological: avdoralimab;Other: Placebo","Drug: Oseltamivir;Drug: hormones;Device: oxygen therapy;Procedure: mesenchymal stem cells;Drug: Oseltamivir;Drug: hormones;Device: oxygen therapy;Procedure: mesenchymal stem cells","Biological: mRNA-1273;Biological: mRNA-1273","Drug: Deferoxamine;Drug: Deferoxamine","Device: hyperbaric oxygen therapy (HBOT);Device: hyperbaric oxygen therapy (HBOT)","Diagnostic Test: CTUS examination;Diagnostic Test: CTUS examination","Other: Online questionnaire;Other: Online questionnaire","Drug: Placebo;Drug: Chloroquine;Drug: Hydroxychloroquine Sulfate Loading Dose;Drug: Hydroxychloroquine Sulfate Regular dose;Drug: Hydroxychloroquine Sulfate Loading Dose;Drug: Hydroxychloroquine Sulfate Regular dose;Drug: Placebo;Drug: Chloroquine","Drug: Hydroxychloroquine;Drug: Lopinavir / Ritonavir;Drug: Interferon Beta-1A;Drug: Interferon Beta-1B;Drug: Interferon Beta-1B;Drug: Interferon Beta-1A;Drug: Lopinavir / Ritonavir;Drug: Hydroxychloroquine","Drug: CM4620-Injectable Emulsion;Drug: CM4620-Injectable Emulsion","Other: blood sample;Other: blood sample","Drug: Colchicine Tablets;Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.;Drug: Colchicine Tablets;Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.","Drug: HCQ &amp; AZ;Drug: HCQ &amp; AZ","Drug: Povidone-Iodine;Drug: Povidone-Iodine","Drug: Linagliptin 5 MG;Drug: Linagliptin 5 MG","Behavioral: Peer Resilience Champion;Behavioral: Peer Resilience Champion;Behavioral: Enriched Survey Feedback;Behavioral: Enriched Survey Feedback","Drug: Levamisole;Drug: Isoprinosine;Drug: Levamisole and Isoprinosine;Drug: Levamisole;Drug: Isoprinosine;Drug: Levamisole and Isoprinosine","Drug: Duvelisib;Procedure: Peripheral blood draw;Drug: Duvelisib;Procedure: Peripheral blood draw","Diagnostic Test: Nasopharyngeal (NP) swab;Diagnostic Test: Nasopharyngeal (NP) swab","Other: Standard Care Therapy;Drug: Convalescent Plasma;Other: Standard Care Therapy;Drug: Convalescent Plasma","Biological: BCG-Denmark;Biological: Saline;Biological: BCG-Denmark;Biological: Saline","Drug: Favipiravir;Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Zinc Sulfate;Other: Standard of care management;Drug: Favipiravir;Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Zinc Sulfate;Other: Standard of care management","Drug: Ivermectin;Drug: Ivermectin","Procedure: Therapeutic Plasma Exchange;Drug: Ruxolitinib;Procedure: Therapeutic Plasma Exchange;Drug: Ruxolitinib","Drug: HCQ &amp; AZ vs HCQ+SIR;Drug: HCQ &amp; AZ vs HCQ+SIR","Drug: Hydroxychloroquine and Azithromycin;Dietary Supplement: Azinc;Drug: Hydroxychloroquine and Azithromycin;Dietary Supplement: Azinc","Other: Olfactory retraining;Drug: corticosteroid nasal irrigation;Other: smell household Items;Other: Nasal Irrigation;Other: Olfactory retraining;Drug: corticosteroid nasal irrigation;Other: smell household Items;Other: Nasal Irrigation","Other: Placebo;Drug: Remdesivir","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir);Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules","Biological: Convalescent Plasma","Drug: Baricitinib","Drug: Colchicine;Drug: Standard treatment","Drug: RhACE2 APN01;Drug: Physiological saline solution","Drug: Placebo;Drug: PUL-042 Inhalation Solution","Drug: Hydroxychloroquine","Other: Standard of care (SOC);Drug: Hydroxychloroquine;Drug: Association of diltiazem and niclosamide;Other: Standard of care (SOC);Drug: Hydroxychloroquine;Drug: Association of diltiazem and niclosamide","Other: impliminting Online Distance Learning;Other: impliminting Online Distance Learning","Device: Caption AI","Drug: Gargle/Mouthwash","Drug: Hydroxychloroquine - Daily Dosing;Drug: Hydroxychloroquine - Weekly Dosing;Other: Placebo oral tablet;Diagnostic Test: Monitoring Visit - Baseline;Diagnostic Test: Monitoring Visit - Week 4;Diagnostic Test: Monitoring Visit - Week 8;Other: Weekly Assessment","Biological: COVID-19 Convalescent Plasma;Biological: COVID-19 Convalescent Plasma","Biological: Plasma exchange;Drug: Standar medical treatmen;Biological: Plasma exchange;Drug: Standar medical treatmen","Drug: Hydroxychloroquine sulfate &amp;Azithromycin;Drug: Placebo;Drug: Hydroxychloroquine sulfate &amp;Azithromycin;Drug: Placebo","Drug: cholecalciferol 200,000 IU;Drug: cholecalciferol 50,000 IU","Other: Placebo;Drug: Selinexor","Other: Postural Positioning","Other: Discontinuation of ACEi/ARB;Other: Continuation of ACEi/ARB","Device: ECCO2R","Drug: Placebos;Drug: Measles-Mumps-Rubella Vaccine","Drug: Usual Care;Drug: Colchicine","Device: Control group;Device: SLEDD with a L-MOD","Drug: Dornase Alfa Inhalation Solution [Pulmozyme];Procedure: standard procedure","Drug: Inhaled budesonide","Drug: Colchicine 1 MG Oral Tablet;Drug: Colchicine 1 MG Oral Tablet","Drug: Low-dose chloroquine;Drug: Mid-dose chloroquine;Drug: High-dose chloroquine;Drug: Placebo","Combination Product: Hydroxychloroquine Sulfate + Azithromycin;Drug: Hydroxychloroquine Sulfate","Device: Kerecis Oral and Nasal Spray;Other: Placebo","Drug: Intermediate dose thromboprophylaxis;Drug: Standard of Care thromboprophylaxis","Diagnostic Test: diagnostic tests for COVID-19 infection","Drug: Sarilumab;Drug: Azithromycin;Drug: Hydroxychloroquine","Biological: Serological test;Biological: Serum test","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Drug: Camostat Mesilate;Drug: Hydroxychloroquine and Ivermectin;Drug: Hydroxychloroquine and Azithromycin;Drug: Hydroxychloroquine","Drug: The standard of care;Drug: metenkefalin + tridecactide","Drug: Bicalutamide 150 Mg Oral Tablet;Drug: Ivermectin 3Mg Tab","Drug: Clazakizumab 25 mg;Drug: Clazakizumab 12.5 mg;Other: Placebo","Behavioral: online mindfulness group","Drug: Ibrutinib;Drug: Placebo","Drug: Ruxolitinib","Procedure: Biological samples specific to research;Procedure: Clinical examination;Procedure: Telephone follow-up","Device: Home Pulse Oximetry Monitoring","Drug: Ascorbic Acid","Drug: 18F-av6-BP","Biological: Convalescent Plasma;Biological: Lactated ringer's solution or sterile saline","Behavioral: Attention Bias Modification (ABM)","Biological: exchange blood transfusion from normal donor;Biological: plasma from convalescent patients with COVID-19;Drug: Methylene Blue 5 MG/ML","Drug: Fluoxetine","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Biological: MSC","Biological: Convalescent plasma (CP)","Drug: Tocilizumab","Drug: Sirolimus 1 MG/ML;Drug: Placebo","Drug: Tocilizumab","Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma","Radiation: Single fraction whole lung radiotherapy","Drug: Tocilizumab 180 MG/ML;Drug: Methylprednisolone Sodium Succinate","Biological: COVID-19 convalescent plasma","Drug: Bovine Lipid Extract Surfactant","Device: FFP2;Device: Facial mask;Device: MFS","Drug: Hydroxychloroquine;Drug: Hydroxychloroquine (placebo);Drug: Zinc;Drug: Zinc (Placebo)","Biological: Anti-SARS-CoV-2 Human Convalescent Plasma","Drug: DeltaRex-G","Behavioral: HOPE intervention","Drug: Favipiravir;Drug: Hydroxychloroquine;Drug: Kaletra","Behavioral: Therapist Guided E-Therapy;Behavioral: Self-Help Therapy","Drug: Placebo;Drug: Ruxolitinib","Drug: Enoxaparin","Diagnostic Test: molecular testing for virus RNA using RT-PCR","Biological: Bacille Calmette-Gurin (BCG);Other: Placebo Comparator","Behavioral: Online support Group","Biological: NT-17;Drug: Placebo;Other: Supportive care;Procedure: Peripheral blood draw","Device: Transcutaneous Auricular Vagus Nerve Stimulation","Device: Volatile Organic Compounds analysis","&lt;br&gt;                Current interventions as of 07/05/2020:&lt;br&gt;&lt;br&gt;                RECOVERY is a randomised trial among people hospitalised for COVID-19. Eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs lopinavir + ritonavir vs corticosteroids vs hydroxychloroquine vs azithromycin. The study allows a second randomisation for patients with progressive COVID-19 (evidence of hypoxia and a hyper-inflammatory state): No additional treatment vs Tocilizumab. For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.&lt;br&gt;&lt;br&gt;                RECOVERY has an adaptive trial design. The interim trial results will be monitored by an independent Data Monitoring Committee (DMC). The DMC will assess whether the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform the Trial Steering Committee who will make the results available to the public and amend the trial arms accordingly. New trial arms can be added as evidence emerges that other candidate therapeutics should be evaluated.&lt;br&gt;&lt;br&gt;                Drug dosage and duration&lt;br&gt;                First (main) randomisation:&lt;br&gt;                1. Lopinavir 400 mg + ritonavir 100 mg: by mouth (or nasogastric tube) every 12 hours for 10 days or until discharge&lt;br&gt;                2. Corticosteroid in the form of dexamethasone: administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or b","Drug: Dialyzable Leukocyte Extract;Drug: Placebo oral","Biological: Recombinant Interferon Alfa-2b;Drug: Rintatolimod","Drug: Placebo;Drug: Olokizumab 64 mg;Biological: RPH-104 80 mg","Treatment group:baseline antiviral treatment (lopinavir / ritonavir or abidol) and inhaled with rSIFN-co;Control group:baseline antiviral treatment  (lopinavir / ritonavir or abidol) and inhaled with interferon-a;","Experimental group:Lu-Dang-Shen oral solution 10ml / time, 2 times a day;Control group:Placebo 10ml / time, 2 times a day;","Experimental group:Taking artemisinin-piperaquine;Control group:Symptomatic treatment with non-antiviral drugs;","Group 1:Standard therapy plus aerosol inhalation for 3 times (once for every day);Group 2:Standard therapy plus aerosol inhalation for 3 times (once for every 2 days);Third group:Standard therapy;Fourth group:Standard therapy plus aerosol inhalation for 6 times (once for every day);","Intervention 1: robotic autonomous naso-oropharyngeal swab collection Intervention 2: manual naso-oropharyngeal swab collection","Low dose group:Shuanghuanglian 2 bottles/time, 3 times a day; Routine treatment.;Medium dose of group:Shuanghuanglian 4 bottles/time, 3 times a day; routine treatment.;High dose of group:Shuanghuanglian 6 bottles/time, 3 times a day; routine treatment.;Control group:Routine treatment;","Intervention 1: CytoSorb treatment initiated within 24 hours after fullfilling the inclusion criteria persued for 3-7 days Intervention 2: Standard of care without CytoSorb treatment","Initial treatment is hydroxychloroquine 200 mg orally twice a day for 7 days compared with placebo.  Participants will record drug compliance in a provided electronic study diary for assessment centrally by study team.&lt;br&gt;&lt;br&gt;Further interventions may be added during the course of the trial.  Bayesian adaptive randomisation and analysis methodology BEAT-COVID-19 will  accelerate the acquisition of evidence about the effectiveness and safety of proposed new treatments ensure rapid implementation of new treatments.&lt;br&gt;&lt;br&gt;&lt;br&gt;","'Anchored' is a smartphone application-based intervention that includes therapeutic content centred on behavioural activation (BA), mindfulness, and cognitive behavioural tasks. It was adapted from HeadGear, an existing smartphone application designed for individuals working in male-dominated industries. Anchored is more broadly aimed at all adults, and has a more gender-neutral look and feel, achieved through use of colour scheme, imagery, font/typography, inclusion of male and female characters, and delivery of in-app content by both male and female presenters. The Anchored app is designed for self-directed use by an individual on a smartphone device. It features interactive content, delivered by on-screen text, audio, static and interactive image displays and videos. The app can be accessed by the participant on their smartphone at a time and location of their choosing. This app/intervention has been used previously in a pilot study: Pilot-testing of a mobile phone application to support the mental health of Australian workers (ACTRN12619000761167); and is being currently being evaluated in a large scale randomised controlled trial (ACTRN12620000178943). Due to the unexpected changes to the workforce brought about by COVID-19 (coronavirus) the present study seeks to evaluate the efficacy of the Anchored app in individuals who are unemployed as a consequence of COVID-19. &lt;br&gt;&lt;br&gt;The main therapeutic component of the Anchored app takes the form of a 30 day intervention in which users complete one challenge daily (5- 10 minutes per day). These 'challenges' feature a variety of evidence-based therapeutic techniques delivered using a range of formats including: psychoeducational videos (on coping skills and resilience, mindfulness, and behavioural activation); min","2 trial arms:&lt;br&gt;1) Hydroxychloroquine plus zinc plus Vit D3/B12 plus azithromycin plus IV Vitamin C&lt;br&gt;2) Hydroxychloroquine plus zinc plus Vit D3/B12 plus azithromycin&lt;br&gt;&lt;br&gt;Dosing &lt;br&gt;Trial arm 1+2: &lt;br&gt;Hydroxychloroquine: 400mg oral tablet twice a day for 1 day, followed by 200mg oral tablet two times a day for 6 days&lt;br&gt;Azithromycin: 500 mg oral tablet on day 1 followed by 250 mg oral tablet once daily for 4 days &lt;br&gt;Zinc Citrate: 30mg elemental zinc oral tablet daily for 14 days&lt;br&gt;Vitamin D3: 5,000iu oral capsule daily for 14 days&lt;br&gt;Vitamin B12 (Methylcobalamin): 500mcg oral tablet daily for 14 days &lt;br&gt;&lt;br&gt;Plus Trial arm 2 only:&lt;br&gt;Inpatients: IV Vitamin C (Sodium Ascorbate) &lt;br&gt;50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x day, 400mg/kg/day) for 7 days (average 28g.day; maximum dose of 50g/24hrs for those weighing more than 125kg). &lt;br&gt;Outpatients: Vitamin C (Sodium Ascorbate)&lt;br&gt;200mg/kg x1 IV, then 1 gram oral tablet three times per day for 7 days&lt;br&gt;&lt;br&gt;All treatments will be administered by medical staff briefed on the trial protocol. Adherence and fidelity will be assessed and recorded on the trial specific electronic data collection sheet by medical staff providing the trial treatment &lt;br&gt;","Intervention 1: Study participants (patients of the outpatient clinic, age 18 or over, N = 100) will be offered to participate in therapist-guided group chats depending on the individual patients diagnosis (anxiety disorders, obsessive-compulsive disorders, depression, and ADHD, respectively), with several weekly group chat appointments over the course of four weeks. The aim of this study is to examine the feasibility and acceptance of the group chat program and evaluate its effect on the patients quality of life. Paper-and-pencil questionnaires will be completed at the beginning of the intervention and at the end of the intervention after four weeks.","Intervention 1: Online training \"HelloBetter Corona\", consisting of 8 weekly sessions. Each session will be completed in approximately 45-60 minutes. Contents of the online training refer to problem- and emotion-focused coping for potentially solvable or unsolvable stressors. Concepts and contents are based on the intervention \"Get.On Fit im Stress\". Contents were adapted to the special conditions and stressors in the context of the \"Corona crisis\".","Intervention 1: PPI-Arm: Treatment with pantoprazole in addition to the trial medication hydoxychloroquine, midazolam and yohimbine Intervention 2: Control-Arm: no pantoprazole in addition to the trial medication","Intervention 1: Participants first receive a 2.30 minute video about the COVID-19 outbreak (CoVideo). The CoVideo is animated with sound effects, but has no words, speech, or text. It shows how the virus is spread (airborne, physical contact) and recommends best hygiene practices to prevent onward transmission (staying at home, not congregating in public spaces, and sanitizing hands/surfaces). It also covers the mass media coverage of the outbreak and the publics response to this media coverage, which includes a subplot on the stockpiling of essential goods, and the impact thereof on health-care services (e.g., doctors being unable to access protective equipment). After the video, participants answer COVID-19 related questions. Intervention 2: The participants first receive the COVID-19 questions, and then receive the CoVideo. Intervention 3: The participants first receive an attention placebo control (PAC) video, which is animated, has the same duration as the CoVideo, and deals with the impact of daily life choices and health outcomes. After the PAC, participants will receive the COVID-19 questions.","Intervention 1: Lung Ultrasound Intervention 2: CT thorax","Intervention 1: Nicotinamide, 1,000 mg/day p.o. (2 x 500-mg tablets), for 4 weeks Intervention 2: Silica, 245 mg/day p.o., for 4 weeks","Intervention 1: Interventiongroup, direct access to the internet intervention Intervention 2: Waitlist controlgroup, delayed access to the internet intervention","Intervention 1: vv-ECMO with cytokine adsorption using a CytoSorb adsorbers for 72 hours Intervention 2: vv-ECMO without cytokine adsorption","Intervention 1: All participating subjects conduct the web-based psychological CoPE It training over a period of two weeks. Every 48 hours a new session ( 30 minutes) is activated for the patients. The CoPE It training can be conducted on the PC, tablet or smartphone of the participating person.&lt;br&gt;&lt;br&gt;The four modules of the CoPE It training include stress-related sessions with instructional videos, audio files, interactive worksheets, personal skills box, and the resulting final material for everyday use.&lt;br&gt;&lt;br&gt;The contents of the modules are based on established elements and methods from cognitive behavioural therapy and the field of mindfulness teaching.","Intervention 1: Intervention group: Oral Atorvastatin 40 mg for 5 days. Intervention 2: Control group: Routine Care.","Intervention 1: Intervention group: Hydroxychloroquine 400 mg every 12 hours for the first day then 200 mg every 12 hours Atazanavir / ritonavir 300/100 mg once daily. Arbidol 100 mg(manufactured by Pharmstandard)2 capsules every 6 hours. Intervention 2: Control group: Hydroxychloroquine 400 mg every 12 hours for the first day then 200 mg every 12 hours Atazanavir / ritonavir 300/100 mg, two placebo capsules (hand made) every 6 hours.","Intervention 1: Home-based exercise training&lt;br&gt;&lt;br&gt;Participants in the intervention group receive a 4-week, digital (video livestream) home exercise program. In each country various course with different durations and contents (e.g. strength or endurance training, balance training or relaxation exercises) will be offered. They can be freely used.&lt;br&gt;&lt;br&gt;After the 4 weeks, the participants have another 4-week access to a digital archive containing pre-recorded exercise sesisons. Intervention 2: inactive wait-control group &lt;br&gt;&lt;br&gt;The members of the wait-control group do not exercise during the initial 4 weeks.&lt;br&gt;&lt;br&gt;After the 4 weeks, the participants have a 4-week access to a digital archive containing pre-recorded exercise sesisons.","Intervention 1: Intervention group: Group receiving Favipiravir plus Hydroxychloroquine. Stat dose of eight 200 mg Favipiravir tablets (total 1600 mg) followed by Favipiravir 600 mg three times a day for 7 days plus Hydroxychloroquine 200mg two times per day for 7 days. This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups. Intervention 2: Control group: Group receiving Kaletra plus Hydroxychloroquine regimen. Stat dose of two 200 mg Hydroxychloroquine tablets (total 400 mg) followed by Kaletra(Lopinavir/Ritonavir) 200/50 mg two times a day for 7 days. This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups.","Intervention 1: Study participants (patients with obsessive-compulsive disorder, age 18 or over, N = 40) will be offered to participate in the therapist-guided online program OCD NET over the course of 10 weeks. The aim of this study is to examine the feasibility and acceptance of the OCD NET program and evaluate its effect on the patients symptoms of obsessive-compulsive disorder and their quality of life. Online questionnaires will be completed at the beginning of the intervention, after completing each module, and at the end of the intervention (after completing the program).","Intervention 1: Intervention: &lt;br&gt;Hyperbaric oxygen therapy (HBO) in addition to the best possible therapy COVID-19 pneumonitis &lt;br&gt;Product, dosage: HBO, HBO 1.6-2.4 ATA for 30-60 min, maximum 5 treatments in the first 7 days Intervention 2: Best possible therapy for COVID-19 pneumonitis","Intervention 1: The intervention group in addition to standard treatment  (400 mg of hydroxychloroquine and 100 to 400 mg of Lupinavir-ritonavir at a time), will receive 100 to 400 mg of Sofosbuvir-Velpatasvir for 10 days. Intervention 2: The control group will receive standard treatment including 400 mg of hydroxychloroquine and 100 to 400 mg of lupinavir-ritonavir for 10 days at a time.","Intervention 1: Intervention group: Patients in this group in addition to drug treatment according to the Ministry of Health protocol, take 2 tablespoons of medium-chain triglyceride (MCT) to cure fever with each meal. Both group are thought to take the following advice base on traditional medicine instructions:During this period, avoid consuming carbohydrate including sweet and eat less starch food.skim snacks and start eating when they're starving.avoid eating before satiating.eat slowly and chew well.walk for 15 minutes after eating. Intervention 2: Control group: Patients in this group receive medication according to the Ministry of Health protocol. Both group are thought to take the following advice base on traditional medicine instructions:During this period, avoid consuming carbohydrate including sweet and eat less starch food.skim snacks and start eating when they're starving.avoid eating before satiating.eat slowly and chew well.walk for 15 minutes after eating.","Intervention 1: Intervention group: Participants receive Hydroxychloroquine (Amin Pharmaceutical company, Isfahan) at dose of 200 mg TDS up to 7 days. Intervention 2: Control group:  Participants receive no medicines.","Intervention 1: Intervention group: Pirfenidone 200 mg ,three times daily in addition to standard treatment (according to the national protocol)  containing Coltra Lupinavir / Ritonavir twice daily, Chloroquine 250 mg twice daily, and Osiltamivir 75 mg twice daily, in critically ill patients with ribavirin 1200 twice daily. ). Intervention 2: Control group: In the control group, standard treatment according to the national protocol containing Coltra (Lupinavir / Ritonavir) 100mg/400mg twice daily, chloroquine 250 mg twice daily, and siltamivir 75 mg twice daily in critically ill patients with ribavirin 1200 twice daily.","Intervention group: Patients with severe clinical symptoms for whom the standard three-drug protocol (hydroxychloroquine / chloroquine + lupinavir / ritonavir + ribavirin) was not responsive receive intravenous immunoglobulin (IVIg) before entering the intubation phase. They will receive 0.4-0.5/g/kg/day of IVIg in 3-5 doses with each dose being equal to about 30g with a weight of 60 kg. Also patients under prophylaxis from thrombosis, in the case of the absence of contraindication, will receive heparin with prophylaxis dose..","Intervention 1: \"Intervention group:\" This group consumes the Trachyspermum copticum syrup. The total extract of this plant is used.The concentration of this syrup is 10% of the aqueous extract of Tanacetum parthenium (L) Sch. This syrup is administered three times daily for two weeks, 7 ml each time, a total of 21 ml daily. The syrup is made by Shahid Beheshti School of Pharmacy. Intervention 2: \"Control group:\" This group is taking placebo. Placebo syrup have the same size and shape as the drug.The placebo syrup contains all the basic ingredients of a syrup without the addition of herbal medicine. The placebo syrup is made by Shahid Beheshti School of Pharmacy.","Intervention 1: Intervention group: sovodak+ribavirin. Intervention 2: Control group: standard care regimen.","Intervention 1: Intervention group: Intervention group: 50 mg three times daily for levamisole for 5 days. Intervention 2: Control group: Like levamisole, placebo will be given three times a day.","Intervention 1: In addition to the standard treatment regimen for COVID-19, the berberine hydrochloride capsule (Pharmaceutical grade)  300 mg will be given three times a day for 2 weeks. Berberine capsule (300 mg) is formulated at the School of Pharmacy with the inert ingredients of aerosol and avicel. Intervention 2: Control group: Patients on the standard treatment regimen for COVID-19 will receive placebo capsules three times a day for 2 weeks. The placebo is formulated in capsules of the same shape and size as the drug capsules and contains avicel and aerosil.","Intervention 1: Intervention group: In addition to the standard treatment regimen  for covid-19,  capsules which have aqueous licorice extract  containing 80 mg of the active ingredient glycyrrhizin will be given three times a day for 2 weeks. Licorice capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. Intervention 2: Control group: ]n addition to general drugs for  treatment of corona, the patients take placebo capsule 3 times a day for 14 days.","Intervention 1: Intervention group: Patients hospitalized with COVID-19 disease who in addition to their standard treatment will be received 250mg/day Methylprednisolone? for 3 days. Intervention 2: Control group: Patients hospitalized with COVID-19 disease who are received standard treatment.","Intervention 1: Intervention group: altebrel 50mg by aryogen company subcutaneously in two dose with2-3 days duration in one week. Intervention 2: Control group: In control group, supportive care and protocol without any injection.","Intervention 1: Intervention group: COVID-19 Patients receiving hydroxychloroquine + SOVODAK. Intervention 2: Control group: COVID-19 Patients receiving hydroxychloroquine.","Intervention group: Subcutaneous (two PFS injections of 162 mg Tocilizumab for ?patients &lt;100 kg and three PFS injections of 162 mg Tocilizumab for patients &gt;100 kg) in addition to the standard treatment. In case of inadequate response, Tocilizumab would be re-administered with a 12-hour interval between injections..","Intervention group: In addition to standard treatment:(two-drug regimen including 500 mg chloroquine phosphate / 400 mg hydroxychloroquine sulfate; single-dose and lopinavir/ritonavir 400/100 mg BID for at least 5 days or alternatively, atazanavir OR three-drug regimen including 500 mg chloroquine phosphate / 400 mg hydroxychloroquine sulfate; single-dose and lopinavir/ritonavir 400/100 mg BID for at least 5 days and ribavirin 1200 mg BID for at least 5 days)Remdesivir is also prescribed for 5 days (for patients over 40 kg or more: Amp Remdesivir 200 mg IV infusion over 30 minutes once-daily dose, followed by 100 mg iv infusion over 30 minutes once-daily maintenance doses for next 4 days.For patients weighing less than 40 kg: Amp Remdesivir 5 mg/kg IV infusion over 30 minutes loading dose on day 1, followed by 2.5 mg/kg iv infusion over 30 minutes once-daily maintenance doses for next 4 days).","In the intervention group, in addition to the standard treatment, medicinal herbal products will be prescribed. The drug will be given in syrup form. The syrup will contain the following medicinal herbs: Nepeta bracteata?  Adiantum capillus veneris?  Glycyrrhi za glabra, Foeniculum vulgare? Viola odorata,  Ziziphus jujube,  Malva sylvestris, Nigella sativa . The intervention group will receive 7.5 cc of Kelofan syrup every 12 hours for one week..","Intervention 1: Intervention group: patients in this group in addition to receiving standard medications, take two 500 mg capsules of the herbal compound three times a day after meals. The herbal capsule contains a mixture of medicinal plant extract powder and is manufactured by the HomaPharmed Pharmaceutical Company. The herbal capsule is given as a supplement to patients for two weeks along with standard medications. Intervention 2: Control group: patients in this group in addition to receiving standard medications, take two 500 mg capsules of the placebo three times a day after meals. The placebo capsule contains a toasted powder is manufactured by the HomaPharmed Pharmaceutical Company. The placebo capsule is given as a supplement to patients for two weeks along with standard medications.","Intervention 1: Intervention group: Kaletra 200 mg/50 mg tablet every 12 hours + hydroxychloroquine 200 mg tablets every 12 hours + herbal medicine containing sage, hofariqun and fennel (5 ml 3 times a day). Intervention 2: Control group: Kaletra 200 mg/50 mg tablet every 12 hours + hydroxychloroquine 200 mg tablets every 12 hours.","Intervention 1: Intervention group: Favipiravir (Toliddaru-Sobhan Oncology company, Iran) at dose of 1600 mg BID for one day and then 600 mg BID for totally 7 days with the standard and supportive care. Intervention 2: Control group: Lopinavir-ritonavir (Heterd company, India) at dose of 200/50 mg two tablets BID for 7 days with the standard and supportive care.","Intervention 1: Intervention group: This group will receive routine treatments for COVID-19 disease and will receive a suspension of extract of five herbs. Patients will receive a combination consisted of aqueous extract of 10 grams of hyssop leaf, 5 grams of Plantain seed, 10 grams of purslane seed , 10 grams of licorice root and 5 grams of turmeric, orally, in three divided doses daily. The intervention duration is five days. Intervention 2: Control group: This group receive routine treatments for COVID-19 disease and placebo. Placebo will be given as an oral syrup, three servings a day. For the placebo syrup, a non-absorbable sweetened drop of stevia (a product from a pharmaceutical company), authorized oral dyes are used to make the color and taste relatively similar to the original drug.","Intervention 1: lopinavir (50 mg) ritonavir (200 mg) 2 tablets every 12 hours until the patient's clinical symptoms improve + hydroxychloroquine (200 mg) two tablets one dose  + sofosbuvir (400 mg)- daclatasvir (60 mg) take one tablet daily until clinical symptoms improve. Intervention 2: Intervention group 2: lopinavir (50 mg) ritonavir (200 mg) 2 tablets every 12 hours until the patient's clinical symptoms improve + hydroxychloroquine (200 mg) two tablets one dose + ribavirin (200 mg) 6 tablets every 12 hours until clinical symptoms improve.","Intervention 1: Control group: Standard drugs of the national protocol (hydroxychloroquine sulfate 200mg, two single-dose tablets (Tehran Daru) , two single-dose tablets (Pars), Kaletra tablets (Lupinavir / Ritonavir) every 12 hours 2 tablets 50/200)+ A placebo every 12 hours (in terms of appearance and color similar to 500 mg naproxen). Intervention 2: Intervention Group: Standard Protocol Drugs For 5 days (Hydroxychloroquine Sulfate 200mg Two Single Dose tablets (Tehran Daroo) , Kaletra tablets (Lupinavir / Ritonavir)  every 12 hours, 2 tablets 50/200) + Naproxen 500 mg every 12 hours (Pars Daru) For 5 days.","Intervention 1: Intervention arm: Patients in this group receive 200 mg of hydroxychloroquine tablets (manufactured by Amin Pharmaceutical Company, Isfahan) every other day for 2 months. At the same time, specific cancer treatments are given. Intervention 2: Control arm: Patients receive the placebo, which is similar to Amin's hydroxychloroquine tablets, one every other day. Cancer treatment of these patients is done according to the standard during this period.","Intervention 1: Intervention group: Intervention group: Group 1: Patients in this group will first receive hydroxychloroquine as two 200 mg tablets with a total of 400 mg of stat; then the following regimen will be continued for 5 days - azithromycin two 250 mg tablets on the first day. And then 250 mg daily for 5 days - 5 mg prednisolone tablets in the amount of 5 tablets (25 mg) daily for 5 days - 250 mg naproxen tablets twice a day for 5 days. Also, patients in this group to prevent complications. Digestive patients will receive 40 mg of pentoprazole tablets or capsules daily during treatment. According to the attending physician, this treatment protocol can be continued for 10 days, depending on the clinical symptoms, if necessary. The patient will be discharged from the protocol. In this case, all the patient's information will be collected until the end of the study. If treatment is needed in the intensive care unit, all treatment methods will be used according to the patient's clinical needs and the decision of the treating physician. Prednisolone in this group will continue to be cleared and gradually reduced to 5 mg each week to be discontinued. The weekly dose will be as follows: -First week after clearance: 20 mg per day -Second week after clearance: 15 mg per day- Third week after clearance: 10 mg per day -Fourth week after clearance 5 Mg per day and finally discontinued. Intervention 2: Intervention group: Patients in this group will first receive hydroxychloroquine in the form of two 200 mg tablets with a total of 400 mg of stat; then the following diet will be continued for 5 days.- Azithromycin two 250 mg tablets on the first day and then 250 mg daily for 5 days- Naproxen tablets 250 mg twice daily for 5 daysIn addition, patients in this group will rec","Intervention 1: Intervention group: Group receiving Favipiravir (Nafas farmed Co, Iran) plus Hydroxychloroquine (Iran daroo Co, Iran). This group will receive stat dose of eight 200 mg Favipiravir tablets (total 1600 mg) followed by Favipiravir 600 mg three times a day for 7 days plus Hydroxychloroquine 200mg two times per day for 7 days.This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups. Intervention 2: Control group: Group receiving Kaletra (Bakhtar bioshimi Co, Iran) plus Hydroxychloroquine (Iran daroo Co, Iran) regimen. This group will receive Stat dose of two 200 mg Hydroxychloroquine tablets (total 400 mg) followed by Kaletra(Lopinavir/Ritonavir) 50/200 mg two times a day for 7 days,This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups.","Intervention 1: Intervention group:The group  uses the following herbal medicine in addition to the current medicine for Covid-19: Drug Name: Pinene-Hydronoplactone-Ribonucleoic-Abbreviation: PHR160 - Drug Form: Inhaler Spray --- Ingredients: Sineol Menthol Crocin Safranol Alpha Tojun Oleic Acid Linoleic Acid Linolenic AcidIt was extracted from natural products found in 7 plant species by steam distillation method. These herbs have previously had a single, double or triple human consumption history. Effectives per puff: 160 micrograms How to use PHR160: Determine the dosage approach for the above product based on the following: 1. Due to the volume of the nozzle output and pump MDIs and the presence of propylant (HFA gas) and alcohol in the product concentration of essential oils and herbal compounds in the total MDI is about 0.3%. Therefore, the total amount of soluble natural substances available per puff is less than 300 nL or 270 mg, which, of course, reaches a limited proportion in the lungs. 1-20 g / kg of human body weight and these compounds are considered very safe and high dosage is much lower than the toxic range indicated and is 1/100 toxic in the case of essential oils.3. Products available on the market such as Eucalyptus Barrage incense, Eucalyptus dyne incense Pulmonary doses of essential oils are similar to our product compounds in excess of 30mg. Of the amount in each puff investigated product is less than 1/100 of the amount above 0.4. External products mainly used in Aroma Therapy Ascents, MBC Aerosol, Primatene Mist are examples of those with higher doses of essential oil.5.Refruitment time to discuss the use or inhalation of the above product 30-45 In this case, the maximum time interval of 1 hour of awakening has been suggested for this product to","Intervention 1: Intervention group: 34 patients receive herbal treatment including 150 ml of decoction (Matricaria chamomilla L., Zataria multiflora Boiss., Glycyrrhiza glabra L., Ziziphus jujuba Mill., Ficus carica L., Urtica dioica L., Althaea officinalis L., Hyssopus officinali L.) 3 times a day and capsule (Lyophilized powder from hydroalcoholic 70% extracts of Punica granatum L., Rheum palmatum L. and seed powder of Nigella sativa L.) 2 times a day with routine interventions based on the instructions of the Ministry of Health for 2 weeks. Intervention 2: Control group:34 patients receive routine interventions according to the instructions of the Ministry of Health for 2 weeks.","Intervention group: (n=6). Patients will receive three doses of MSCs. Three doses of 20010e6 (10%) cells will intravenously infuse as a normally dropped single dose over 10-12 minutes at the infusion speed of 4-5 mL/minute in day 0, day 2, day 4. The cells will inject in 50 ml saline containing 1% human serum albumin..","Intervention 1: Intervention group:  Tab Hydroxychloroquine 200 mg two tablet P.O. BID for first day then 200 mg BID seven days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for seven days or Tab atazabavir-ritonavir 100/300 mg P.O one tablet daily for seven days plus Teicoplanin IV 400 mg daily for 1 weeks. Intervention 2: Control group: Tab Hydroxychloroquine 200 mg two tablet P.O. BID for first day then 200 mg BID seven days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for seven days or Tab atazabavir-ritonavir 100/300 mg P.O one tablet daily for seven days.","Intervention 1: The first group will receive the standard treatment consisted of 200 mg Tab Hydroxychloroquine 2 times every 12 hours on the first day and then one every 12 hours up to 10 days). Intervention 2: The second group will receive 60 to 400 mg daily of Tab Sofosbuvir-Daclatasvir for 10 days with standard treatment ( 200 mg Tab Hydroxychloroquine 2 times every 12 hours on the first day and then one every 12 hours up to 10 days). Intervention 3: The third group will receive 300 mg Tab Lithium every 8 hours for 10 days with standard treatment ( 200 mg Tab Hydroxychloroquine 2 times every 12 hours on the first day and then one every 12 hours up to 10 days). Intervention 4: The fourth group will receive 5 mg Tab Trifluoprazine every 8 hours and 2 mg Tab Trihexyphenidyl every 8 hours with standard treatment  ( 200 mg Tab Hydroxychloroquine 2 times every 12 hours on the first day and then one every 12 hours up to 10 days).","Intervention 1: Intervention group: containing 25OHD soft gelatin capsular 1000 IU , Producer: Dishmen. the case group will receive 1000 IUs of 25(OH)D daily for 8 wks. The subjects will receive a bottle containing 30 capsules in first and second visits that will contain the 25(OH)D. The bottles will be returned to be checked at each visit. Intervention 2: Placebo: containing white to off white color suspension oil. Producer: Dishmen Company. The control group will receive placebo daily for 8 wks..The subjects will receive a bottle containing 30 capsules in first and second visits that will contain the placebo. The bottles will be returned to be checked at each visit.","Intervention 1: Intervention group: National therapeutic guideline including hydroxychloroquine 400 mg stat and lopinavir/ritonavir plus 250 mcg interferon beta 1 b subcutaneous injection every other day for at least 3 doses. Intervention 2: Control group: Patients with inclusion criteria and received national therapeutic guideline within two weeks before proposal approval.","Intervention 1: Intervention group: Medications in national guideline+ Viroherb capsule 500 mg 2 caps every 12 h + Fenugreek syrup 10 cc every 6 h. Intervention 2: Control group: Medications in national guideline.","Intervention 1: Intervention group: 50 patients with COVID-19 will be included in this group and their treatment regimen includes oral Hydroxychloroquine 400 mg single dose and Arbidol orally at a dose of 50 mg 4 times a day for 5 to 10 days. Intervention 2: Control group: Sixty COVID-19 patients in the control group will be given a treatment regimen of two Kaletra 200/50 mg tablets every 12 hours and two Hydroxychloroquine sulfate 200 mg tablets as a single dose for 5 to 10 days.","Intervention 1: Intervention group: An initial dose of 1mg/kg will be started for all patients in the case group. The patients will receive the mentioned dose for 5 days, which will then be halved for 5 days and repeated until reached a dose of under 20mg/day, which will then be converted into oral tablet form of prednisolone. Also, patients will receive the national treatment protocol for COVID-19. Intervention 2: Control group: Patients in the control group will receive the standard treatment based on the National protocol.","Intervention 1: Intervention group: The intervention group 1, Patients will receive three doses of MSCs. Two doses of 10010e6 (10%) cells will intravenously infuse as a normally dropped single dose over 10-12 minutes at the infusion speed of 4-5 mL/minute in day 0 and day 2. Intervention 2: The intervention group 3, Patients will receive two doses of MSCs intravenously and EVs. Two doses of 10010e6 (10%) MSCs will intravenously infuse as a normally dropped single dose over 10-12 minutes at the infusion speed of 4-5 mL/minute in day 0 and day 2. In days 4 and 6, the patients will receive two times the infusion of MSCs-EVs. Intervention 3: Control group: Patients will receive conventional therapy.","Intervention 1: Intervention group: In addition to the standard treatment regimen forCOVID-19, the minocycline capsule 100 mg will be given two times a day for 2 weeks. Intervention 2: Control group: Patients on the standard treatment regimen for COVID-19 will receive placebo capsules two times a day for 2 weeks. The placebo is formulated in capsules of the same shape and size as the drug capsules and contains avicel and aerosil.","Intervention 1: Intervention group: In addition to the standard treatment regimen for COVID-19, the crocetin capsule 22.5 mg (7.5 mg, three times a day) will be given for 2 weeks. Intervention 2: Control group: Patients on the standard treatment regimen for COVID-19 will receive placebo capsules 3 times a day for 2 weeks. The placebo is formulated in capsules of the same shape and size as the drug capsules and contains inert ingredients.","Intervention 1: Intervention group:After routine treatment , the main group will be received the drug of the study . drugs are in the sacher form. every sacher contain 2.5 gram of Marshmallow and 2.5 gram of Licorice. For 10 days Patients should infuse the contents of one packet with 250 cc of boiling water for 10 minutes every 12 hours, then strain and sip. Intervention 2: Control group: after routine treatment, the control group willl be received the placebo. they are in the sacher form. The contents of each package of placebo is 5 grams of starch powder. For 10 days,  patients should infuse the contents of one packet with 250 cc of boiling water for 12 minutes every 12 hours, then strain and sip.","Intervention 1: Control group: Standard regimen based on Iran health ministry. Intervention 2: Intervention group: Standard regimen based on Iran health ministry plus low dose Ivermectin(200 mcg/kg , PO, Once). Intervention 3: Intervention group: Standard regimen based on Iran health ministry plus high dose Ivermectin(200 mcg/kg , PO, interval days:1,2,5). Intervention 4: Control group: Standard regimen based on Iran health ministry plus Placebo,Once in first day. placebo is a simple tablet containing only fillers without any active ingredient and is made by Alborz Darou company.","Intervention 1: Intervention group: Patients in this group received medications for the treatment of COVID-19 based on the Fifth Edition of the Novel Corona Virus Guidelines, in addition they indicated for mechanical ventilation and the  airway management was selected using the tracheotomy tube within 3 days from intubation. Intervention 2: Control group: Patients in this group received medications for the treatment of COVID-19 based on the Fifth Edition of the Novel Corona Virus Guidelines, in addition they indicated for mechanical ventilation and the  airway management was selected using the Orotracheal tube.","Intervention 1: Intervention group: In addition to the treatment protocol, patients are given four daily doses of 300 mg of Vulgaris.C supplemented with Herbal tea (2g Pennyroyal; 2g chamomile, 1.4g Hollyhocks and 0.6g Mallow). Intervention 2: Control group: Treatment is according to the protocol and is for comparison only with the intervention group.","Intervention 1: Intervention group: under treatment with Zufa syrup 6 times a day (every 4 hours) and 7.5 cc each time for 10 days made by Bouali Daru  Pharmaceutical Company. Intervention 2: Control group: under treatment with placebo syrup 6 times a day (every 4 hours) and 7.5 cc each time for 10 days made by Bouali Daru   Pharmaceutical Company.","Intervention 1: Intervention group: 50 patients with Coronavirus (COVID-19)-induced moderate or severe pneumonia in addition to the standard regimen of covid-19? will receive IVIG for 2 days (100-200 mg two-wise a day). Privigen, Behring company, Switzerland. Intervention 2: Control group: will receive a standard regimen of covid-19 based on national protocol including Hydroxychloroquine, Ribavirin and Kaletra).","Intervention group: Patients undergo hemodialysis on 2 sessions, each session will be conducted in 4 hours using hemoperfusion HA330 filter (JAFRON BIOMEDICAL.CO.LTD, China). The second round will be performed 18-24 hours after the first time. Protocol: a blood flow 150cc/minute, Heparin 10-12 unit per kg per hour..","Intervention 1: Intervention group: Administration of 2 units of CP (Convalescent Plasma obtained from COVID-19 recovered people thorough plasmapheresis) (IV). Each unit of plasma that is collected from one different donor will be given over 2h with an interval of 1h between the two units. Intervention 2: Control group: Patients with COVID-19 will receive conventional treatment.","Intervention group: The Family-Based Empowerment Model, which will include four empowerment training sessions (2 45-minute sessions per week)..","In 30 patients with respiratory failure and ARDS caused by COVID-19 undergoing mechanical ventilation or oxygen therapy, antivirals and supportive care  therapies will be continued, and 200-400 cc of convalescent plasma will transfused for them..","Intervention 1: Intervention group:30 patients with COVID-19 in addition to a standard regimen will receive Bromhexine  8 mg tablets every 8 hours for 14 days from the beginning of hospitalization. Intervention 2: Control group: 30 patients will receive only standard regimen of COVID-2019.","Intervention 1: Intervention group: A group of COVID-19 patients who will receive 500 mg Naproxen tablets 3 times a day for 10 days orally, in addition to the standard treatment provided in the latest national guide which the control group receives. Intervention 2: Control group: A group of patients will be treated according to the standard treatment provided in the latest national COVID-19 guide:Two-drug regimen: Oseltamivirwith hydroxychloroquine / chloroquine- Three-Phase Diet: Oseltamivir with Hydroxychloroquine / Chloroquine and Lopinavir / RitonavirFour-Phase Diet:Oseltamivir with Hydroxychloroquine / Chloroquine and Lopinavir / Ritonavir and Ribavirin.","Intervention 1: Intervention group:25000 IU vitamin A per day for ten days, the plus, the standard national treatment for COVID 19. Intervention 2: Control group: the standard national treatment for COVID19 ,and placebo.","Intervention 1: Intervention group:  30 COVID-19 patients with inclusion criteria  will be treated with  250 micro grams of betafron (Zifron Zist Darou Danesh)  Subcutaneously every other day up to 10 days or 5 dosages in addition to antivirals including hydroxychloroquine 400 mg,bid stat. and Kaletra 2 tablet bid for 10 days. Intervention 2: Control group: 30 COVID-19 patients will be treated only with antivirals including hydroxychloroquine 400 mg,bid stat and Kaletra 2 tablet bid for 10 days.","Intervention 1: Intervention group: containing 25OHD soft gelatin capsular 1000 IU , Producer: Dishmen. the case group will receive 1000 IUs of 25(OH)D daily for 8 wks. The subjects will receive a bottle containing 30 capsules in first and second visits that will contain the 25(OH)D. The bottles will be returned to be checked at each visit. Intervention 2: Placebo: containing white to off white color suspension oil. Producer: Dishmen Company. The control group will receive placebo daily for 8 wks..The subjects will receive a bottle containing 30 capsules in first and second visits that will contain the placebo. The bottles will be returned to be checked at each visit.","Intervention 1: Intervention group: After routine treatment, the main group will be received the drug of the study. Drugs are in the sacher form. Every sacher contain 2 gram of Phyllanthus Emblica powder. For 10 days Patients should infuse the contents of one packet with 250 cc of boiling water for 10 minutes every 12 hours, then strain and sip. Intervention 2: Control group: After routine treatment, the control group willl be received the placebo. They are in the sacher form. The contents of each package of placebo is 2 grams of starch powder. For 10 days, patients should infuse the contents of one packet with 250 cc of boiling water for 12 minutesevery 12 hours, then strain and sip.","Intervention 1: Intervention group: The medicinal product includes a capsule composed of two herbs(salix ,lambs quarter). The amount of each of these substances in the capsule is 250 mg. The dosage of the product is three capsules a day, which is half an hour before each meal. This product is prepared by Armaghan Sabz Araz Teb Pharmaceutical Company.In this group, common medical drug is also consumed according to the latest protocol of the Ministry of Health. Intervention 2: Control group: Patient in control group use  common medicine based on the latest protocol of the Ministry of Health and placebo.","Intervention 1: Intervention group: local standard of care plus Remdesivir (daily infusion for 10 days). Intervention 2: Intervention group: local standard of care plus Chloroquine or Hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days). Intervention 3: Intervention group: local standard of care plus Lopinavir with Ritonavir (orally twice daily for 14 days). Intervention 4: Intervention group: local standard of care plus Lopinavir with Ritonavir (ditto) plus Interferon (daily injection for 6 days). Intervention 5: Control group: local standard of care.","Intervention 1: \"Intervention group:\" The patients in the intervention group are enrolled in a WhatsApp group. They will receive numerous videos, audio files, and educational texts regarding mental health, coping strategies, positive thinking, hope, spiritual well-being, and some enjoyable activities such as relaxation music. Other psychological interventions are included encouraging the patients to apply trained psychological techniques, sharing good memories of their lives, gratitude and thanking God, and expressing their positive abilities in a variety of areas in the group.The intervention is performed for eleven days from morning to 9 pm, and the files are entered in the WhatsApp group every two hours during the day. Intervention 2: Control group: This group would receive the routine care and would not receive any of the interventions of the intervention group.","Intervention 1: Intervention group:Intervention group: The intervention group 1, Patients will receive three doses of MSCs. Two doses of 10010e6 (10%) cells will intravenously infuse as a normally dropped single dose over 10-12 minutes at the infusion speed of 4-5 mL/minute in day 0 and day 2 and day 4. Intervention 2: Control group:Patients will receive conventional therapy.","Intervention 1: Intervention group: nanocurcumin capsule 40mg, two capsule twice daily for two weeks then 1 capsule twice daily for 2 weeks. Intervention 2: Control group:all standard measures will be performed for patient.","Intervention 1: Intervention group: In this group, patients with moderate symptoms of COVID-19 take the  two-drug diet of 200 mg Hydroxy chlorquine (Made by Amin Pharmaceutical Company) with 2 tablets every 12 hours in the first day and 1 every 12 hours up to 7 days in addition to 100 mg Arbidol (Made in Russia (received from the Ministry)) every 8 hours 2 tablets for at least 7 days. Intervention 2: Control group: patients in this group routinely receive 200 mg Hydroxy chlorquine (Made by Amin Pharmaceutical Company) with 2 tablets every 12 hours in the first day and 1 every 12 hours up to 7 days.","Intervention 1: Intervention group: COVID-19 patients receiving hydroxychloroquine (200 mg every 12 hours), azithromycin (500 mg daily) and melatonin tablets (3 mg every night before bedtime) for up to 7 days. Intervention 2: Control group: COVID-19 patients receiving hydroxychloroquine (200 mg every 12 hours) and azithromycin (500 mg daily)  for up to 7 days.","Intervention 1: Intervention group: Capsule Umnifenovir 100 mg, 2 capsuls every 6 hours, for 7 days. (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: routine treatment according to the latest national guideline for the treatment of new corona-virus.","Intervention 1: Intervention group: Melatonin 3 mg tablets will be given every eight hours for all patients undergoing standard treatment for Qovid 19 (Hydroxychloroquine 200 tablets every 12 hours). Intervention 2: Control group:  All patients will be given the standard treatment for Qovid 19 (Hydroxychloroquine 200 tablets every 12 hours). Then placebo tablets with the same shape as the melatonin tablets will be prescribed every 8 hours.","Intervention 1: Intervention group: Patients hospitalized with COVID-19 disease who in addition to their standard treatment ( Hydroxychloroquine 400mg daily) will be received 1000mg/day Methylprednisolone? for 3 days. Intervention 2: Control group: Patients hospitalized with COVID-19 disease who are received standard treatment ( Hydroxychloroquine 400mg daily).","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation + Atorvastatin 20 mg daily for full course of therapy. Intervention 2: Control group: Only national corona treatment recommendation.","Intervention 1: Intervention group1: In addition to the standard treatment regimen for covid-19, capsules which have aqueous 300 mg of Khorasan asafoetida will be given once a day for 2 weeks. asafoetida capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine. Intervention 2: Intervention group2: n addition to the standard treatment regimen for covid-19, capsules which have aqueous 300 mg of Fars asafoetida will be given once a day for 2 weeks. asafoetida capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine. Intervention 3: control group: this group receive placebo capsules exactly with similar characteristics to real drugs in intervention group. All patients in this group receive typical treatment including azithromycin and hydroxychloroquine.","Intervention 1: Intervention group: In addition to the standard treatment regimen for COVID-19, the lithium carbonate  tablets (300 mg/day to  900 mg/day)  will be given for 2 weeks. Intervention 2: Control group: Patients on the standard treatment regimen for COVID-19 will receive placebo tablets once a day for 2 weeks. The placebo is formulated in tablets of the same shape and size as the drug tablets and contains inert agents.","Intervention 1: The intervention team will receive a training package based on psychologically developed flexibility for 8 two-hour sessions using educational facilities such as blackboards.This educational-therapeutic package is based on a qualitative research of the theoretical theory and has been prepared after interviewing and observing the treatment staff in the special sections of Corona and Codex based on psychological flexibility. Intervention 2: Control group: They will not receive any intervention.","Intervention 1: Intervention group: People with covid 19 Patients after accidental registration of personal information including name and surname, gender, age, weight, place of residence, job, the presence of underlying diseases and disease profile in one of the two intervention groups and Control based on AB and BA random block design. In addition to treatment with the common drugs Chloroquine and Lopinavir / Ritonavir, the intervention group (PPd (purified protein derivative) is also performed for them in the intervention group. We evaluate and evaluate by an infectious disease specialist through daily tests for patients and CT Scan of the chest on days 0, 3 and 7, and Corona testing on days 7 and 14 for patients to relieve fever. Intervention 2: Control group: People with Covid 19 Patients after random registration of personal information including name and surname, gender, age, weight, place of residence, occupation, the presence of underlying diseases and disease profile randomly in one of the two groups tested And control based on AB and BA random block design. They are only routinely treated with chloroquine and Lopinavir / Ritonavir, and are evaluated by an infectious disease specialist through daily tests for patients and CT Scan of the chest on days 0, 3 and 7, and Corona testing on days 7 and 14 for patients, fever relief, face Accept.","Intervention group:  Convalescent Plasma, Frozen Solution for infusion (FFP) for the prevention and treatment of Covid-19. Human plasma protein. The dosage depends upon the clinical situation and underlying disorder, use within 24 hours, administration based on ABO-blood group compatibility. Avoid shaking.  It should be frozen within 8 hours after collection, stored at -18C or colder and have an expiration date one year from the date of collection. Not to exceed IV infusion rate of 1 mL/kg/min, emergency IND (eIND) approved by FDA. provided by Blood bank of the hospital mentioned in the IRB..","Intervention 1: Intervention group:  Inhaled Formoterol? In this group along with the standard regiment according to the national guideline of treatment for COVID-19, patients will take Formoterol 1 Puff every 12 hours made by Medochemie Company for 7 days. Intervention 2: Control group: standard treatment according to protocol.","Intervention 1: Intervention group: Hydroxychloroquine200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days. Intervention 2: Control group: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days.","Intervention group: In this study, 2 herbal medicines (in addition to standard treatment) will be used as follows. 1. Vomigone 500 tablets (containing ginger) 2 TDS a day (after meals) With drug registration number: 9406633051781240 Dineh Pharmaceutical Company        .2 Rucoldup tablets 750 (containing echinacea) 1 tablet TDS day with drug registration number: 6563916081842893 Company: Ghaem Daru.","Intervention 1: Intervention group: These patients receive daily azithromycin 500 mg, bi-daily oseltamivir 75, bi-daily lopinavir/ritonavir or in case of adverse gastrointestinal effects daily atazanavir (Kaletra) 400/100 mg and daily 400 mg of hydroxychloroquine; all for 5 days. Intervention 2: Control group: These patients receive bi-daily oseltamivir 75, bi-daily lopinavir/ritonavir or atazanavir (Kaletra) 400/100 mg and in case of adverse gasterointestinal effects, daily atazanavir (Kaletra) 400/100 mg and daily 400 mg of hydroxychloroquine; all drugs are administered for five days.","Intervention 1: Intervention group:  Participants in the intervention group receive 4 times a day (after each meal and before bedtime) and 10 ccs of pomegranate syrup for 21 days each time, in addition to standard treatment. Pomegranate tea is prepared by dilution 10 ccs of pomegranate syrup in 50 to 100 cc of warm boiled water and kept in the mouth for a while before swallowing. Intervention 2: Control group: In addition to standard treatment, the control group receives a placebo in completely similar conditions. The placebo will be produced in terms of taste and color similar to the original drug and will be used in completely similar conditions.","Intervention 1: Intervention group: Three Patients suffering from COVID-19 with acute respiratory infections and severe lung involvement will be allocated to this group under the supervision of the medical staff. Those patients with severe symptoms (pneumonia and ARDS) will be suggested to join this pilot study and after obtaining the written informed consent, they participate in this investigation at Emam Reza hospital (at transplantation ward). Afterward, 1  106 cells/Kg of weight are prepared for transplantation in addition to common treatment protocol. Cell transplantation is repeated once every 3-4 days during a 14-day period (totally three doses). After cell transplantation, patients are assessed for two weeks, all the symptoms and side effects such as allergic reactions and secondary infections also the level of the cytokines variation, the level of CRP and the oxygen saturation, lymphocyte count, the chest CT and the respiratory rate will be assessed and compared with control group. Intervention 2: Control group: just receive the common treatment. Patients are assessed for two weeks, all the clinical symptoms such as the level of the cytokines, the level of CRP and the oxygen saturation, lymphocyte count, the chest CT and the respiratory rate are  examined.","Intervention 1: Intervention group: Recommended standard care for COVID-19 patients + Trifluoperazine, 2 mg tablet PO (manufactured by Sobhandarou, Iran) q12hr for 21 days. Intervention 2: Control group: Recommended standard care for COVID-19 patients.","Patients in the two intervention and control groups, in addition to treatment according to the protocol, will rub the ointment and placebo 2 and 1 times five times a day for four hours in the amount of one tablespoon of jam (2 g) of the combined product on the back and chest..","Intervention 1: Intervention group: Patients in Sitagliptin group receive Sitagliptin (Dr.Abidi Pharmaceuticals, Iran)  at dose of 50 mg BID twice a day for totally 10 days and the other standard and supportive treatment (including Lopinavir and ritonavir at dose of 200/50 mg two tablets BID and Hydroxychloroquine sulfate 400 mg one dose) will be administered. Intervention 2: Standard and supportive treatment (including Lopinavir and ritonavir at dose of 200/50 mg two tablets BID and Hydroxychloroquine sulfate 400 mg one dose) will be administered.","Intervention 1: Intervention group: Syrup Zofa 10 ml every 8 hours, for 7 days. (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: Routine treatment according to the latest national guideline for the treatment of new corona-virus.","Intervention 1: Intervention group: Herbal nasal spray 1 puff every 8 hours, for 7 days (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: Routine treatment according to the latest national guideline for the treatment of new corona-virus.","Intervention 1: Intervention group: On the first day, patients will receive chloroquine at a dose of 200 mg, and from the second day for six consecutive days, they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg. In addition to the above drugs, Alfamed Tenofovir is given to 25 mg daily for 7 days. Intervention 2: Control group:  On the first day, patients will receive chloroquine at a dose of 200 mg, and from the second day for six consecutive days, they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg.","Intervention 1: Intervention group: In this group, untreated COVID-19 patients are treated with routine treatments and 50,000 units of vitamin D daily for one week. Intervention 2: Intervention group: In this group, untreated COVID-19 patients are treated with routine and vitamin C-containing treatments containing 500 mg daily for one week. Intervention 3: Control group: The control group includes patients who are under routine care only.","Intervention group: Convalescent plasma from patient who recovered from COVID-19,2 to 3 injections,injection volume of 250-300 milliliter every other day.","Intervention 1: Intervention group: Routine care (For outpatients: 250 mg chloroquine tablets every 12 hours for the first day and then every day for up to 6 days; for inpatients: tablet Lupinavir 200 mg and tablet Ritonavir 50 mg every 12 hours for 14 days) plus plasma of patients recovered from covid-19 500 U every week for at least 3 weeks. Intervention 2: Control group: Just routine care (For outpatients: 250 mg chloroquine tablets every 12 hours for the first day and then every day for up to 6 days; for inpatients: tablet Lupinavir 200 mg and tablet Ritonavir 50 mg every 12 hours for 14 days).","Intervention 1: Intervention group:The patients will receive 10 ml of elderberry extract syrup 3 times daily (2.6 g of elderberry extract per day equivalent to 15.76 g of fresh elderberries) beside the standard treatment regimen for COVID-19 according to the Ministry of Health protocol. This treatment will continue for 2 weeks. The syrup is formulated according to the United States Pharmacopoeia description. This syrup is preservative-free and remains stable for up to 1 month. The syrups will be prepared freshly at the School of Pharmacy, Mashhad University of Medical Sciences. Intervention 2: Control group: The patients will receive the placebo syrup beside the standard treatment regimen for COVID-19 according to the Ministry of Health protocol with the same order as the intervention group.The placebo consists of USP syrup formula with food-grade coloring agents with the same shape and size containers as the elderberry syrup. This syrup is preservative-free and will be prepared freshly at the School of Pharmacy, Mashhad University of Medical Sciences.","Intervention 1: Intervention group: Includes 40 patients with COVID-19 which for 5 days, who are given two 200 mg hydroxychloroquine sulfate tablets every 12 hours on the first day and then 200 mg every 12 hours. In addition to the above, zinc tablets with a dose of 220 mg twice a day orally during the patient's hospitalization will be prescribed. Intervention 2: Control group: Includes 40 patients with COVID-19 which for 5 days, who are given two 200 mg hydroxychloroquine sulfate tablets every 12 hours on the first day and then 200 mg every 12 hours.","Intervention 1: Intervention group: patients in this group  (Laboratory confirmed COVID-19 by PCR), will receive conventional therapy with Infusion of convalescent plasma, 200-500ml, two IV infusions during two consecutive days. Intervention 2: Control group: Laboratory confirmed COVID-19 by PCR only receive conventional therapy.","Intervention 1: Intervention group:??Slow release Indomethacin tablets, 75 mg daily for five days. Made by Aria Pharmaceutical Company. Intervention 2: Control group: A placebo similar to indomethacin tablets is given daily for five days.","Intervention 1: Intervention group: This group includes inpatient cases with mild to moderate respiratory problems that are confirmed for corona infection. In phase II non-randomized clinical trial, at first, 5 patients confirmed with COVID-19 and non-serious presentations are included in a pilot study from which informed consents have been gotten. The current standard treatments are given to the patients in an open-labeled approach and combinative drug including: two capsules and two spoonfuls of syrup per day including Niacin-Tannin in capsule and Apocynin in syrup with Bid consumption of Tannin(125mg) + Niacin(5mg) and one spoonful apocynin (2.5mg) up to 14 days. The control group only receives current treatment. . Then the side-effects and efficacies will be evaluated. If no side-effects are observed and therapeutic outcomes are positive, the results will be reported to the RCT assessment committee. If the permission is given, the trial will continue with more patients up to 20% of all experimental cases. Then the evaluation will be repeated. If the results are approved again, the study will continue on all the cases according to the following statement. In this clinical trial we will finally recruit 80 patients infected by COVID19 in two groups of experimental and control. Except in the pilot phase that the control group is not included, in the following, the control group will be also added with just standard treatment until 14 days follow-up and clinical assessment. If a patient is discharged from the hospital, his/her follow-up of the treatment and clinical evaluation will continue at home via daily interview by phone. The necessary education will be presented for all the patients and their families before discharging. Intervention 2: Control group: This group i","Intervention 1: Intervention group: Oral Deferiprone  is added to drugs used to treat Covid 19 (approved by the National Committee). Intervention 2: Control group: Patients receive only the drugs used to treat Quaid 19 (approved by the National Committee).","Intervention 1: Intervention group:35 participants in the investigational treatment group will receive trifluoprazine at a dose of 5 mg twice daily for 14 days on admission in addition to standard treatment consisting of hydroxychloroquine. If necessary, according to the approved treatment protocol, kaletra and ribavirin would be added to the treatment. Intervention 2: Control group:35 participants in control group, would receive standard treatment protocol consisting hydroxychloroquine and , if necessary, according to the approved treatment protocol, kaletra and ribavirin would be added to the treatment.","Intervention 1: Intervention group: They receive both usual treatments and foot bath (warm water at 42 C for 20 minutes and then kept warm for 5 minutes once a day for 7 days). Intervention 2: Control group: They receive only usual treatments based on classical medicine.","Intervention 1: Intervention group: Patients with COVID-19, in addition to the usual treatment, receive Tocilizumab IL-6 at a dose of 400 mg diluted in 155 cc of normal saline for one hour as a single dose, and monitoring is improved. Oxygenation status and subsequent complications will occur in vital organs of the heart, kidneys, CNS, hemodynamic disturbances, duration of mechanical ventilation, and eventual mortality. Intervention 2: Control group: Patients with COVID-19 disease who have not received the Tocilizumab IL-6 medication are routinely treated.","Intervention 1: The intervention group will receive 250 mg of azithromycin daily for up to five days, 100 mg of doxycycline twice daily, 1.5 g of vitamin C every 6 hours, and 500 mg of metformin daily for one week. Intervention 2: The control group will receive the usual medication.","Intervention 1: Intervention group: Azithromycin inhaled spray (500g/ml) 1 puff every 12 hours, for 7 days (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: Routine treatment according to the latest national guideline for the treatment of new corona-virus.","Intervention 1: Intervention group: In the intervention group, patients, in addition to the current standard treatments, also receive survivors plasma 500 cc each time. This treatment is started as soon as possible after the patient enters the ICU and within a week and is performed up to 3 times a day. For the preparation of fresh plasma products, survivors with 18 to 60 years old were contacted and tested for CRP, CBC, HBS Ag, HCV Ab, HIV Ab, HTLV1 Ab and COVID 19 PCR if they were without symptoms for at least 10 days.  If all tests are normal, 500 cc plasma will be taken from them and are prescribed to patients in the ICU in less than 12 hours. Survivors should have a positive initial PCR test for coronavirus, be male, or have no history of pregnancy if they are female. The donor and the patient must be the same in blood group and Rh. Intervention 2: Control group: In the control group, patients benefit from all available supportive and specific therapies based on existing standards. Survivors plasma is not prescribed in this group.","Intervention 1: Intervention group: On the first day, 1600 mg of Favipiravir BD, and on the second to fifth day, 600 mg of Favipiravir  BD and concurrent hydroxychloroquine, 400 mg  BD on the first day and 200 mg hydroxychloroquine BD daily on the second to fifth day. The two groups will receive standard treatment (oxygen and, if necessary, antibiotics). Intervention 2: Control group: hydroxychloroquine, 400 mg  BD on the first day and 200 mg hydroxychloroquine BD daily on the second to fifth day. Increasing the duration of treatment to 10 days, according to the doctor's order. The control group will receive placebo instead of Favipiravir.","Intervention 1: Intervention group: standard treatment of COVID-19 + herbal syrup (Iranian medicine product made by the research team): 100 cc of the syrup is mixed with 100 cc of hot water and eaten 30 minutes after a meal (three times a day). Intervention 2: Control group: standard treatment of COVID-19(Kaletra+ Azitromycine).","Intervention 1: Intervention group: Patients in the intervention group, in addition to routine treatment, will receive convalescent Plasma extracted from improved patients from 19-COVID in the amount of 500 ml over a period of 4 hours. Intervention 2: Control group: They only receive routine treatment.","Intervention 1: Intervention group: The intervention group in addition to receiving a standard nationwide medication [2 tablets of Hydroxychloroquine sulfate 200 mg as a single dose and 2 tablets of Kaletra(Lopinavir/Ritonavir) 200/200 mg every 12 hours], receives pure thyme oil every 8 hours (8 am, 4 pm, 12 pm) for 30 minutes through a nebulizer for 5 days. So that 4 drops of pure thyme oil with 10 cc of distilled water were prepared for each nebulization. Intervention 2: Control group: The control group in addition to receiving a standard nationwide medication [2 tablets of Hydroxychloroquine sulfate 200 mg as a single dose and 2 tablets of Kaletra(Lopinavir/Ritonavir) 200/200 mg every 12 hours], receives 10 cc of distilled water (placebo) every 8 hours (8 am, 4 pm, 12 pm) for 30 minutes through a nebulizer for 5 days.","Intervention 1: Intervention group: A 1 mg tablet of colchicine daily for 10 days. Intervention 2: Control group: A placebo tablet daily for 10 days.","Intervention 1: The intervention group includes patients with moderate to severe COVID-19 symptoms who have been diagnosed with coronavirus by PCR: (1) CoviGlobulin (rabbit polyclonal antibody) intake of 1-3 mg per kg body weight Body (1-3 mg / kg / d) for 2-4 days. (2) Receive the basic COVID-19 treatment based on the protocol approved by the Ministry of Health. Intervention 2: Control group: Receive basic COVID-19 treatment based on protocol approved by the Ministry of Health.","Intervention 1: Intervention group: At Day 1: Amp. Methylprednisolone 500mg IV infusion over 1 hour. At Day 2 and 3, Amp. Methylprednisolone 250mg IV infusion over 1 hour. At Day 4 and 5, Amp. Methylprednisolone100mg IV infusion over 1 hour. Then, Tab. Prednisolone 25mg, per oral, daily, until the day of discharge, then Tab. Prednisolone will gradually taper off over during 1 month. All patients will receive routine treatment according to the latest national guideline. Intervention 2: Control group: Includes patients who will not receive high-dose of glucocorticoids during hospitalization. All patients will receive routine treatment according to the latest national guideline.","Intervention 1: Intervention group: case group 55 patients treat with intravenous  vitamin c 1.5 gram 4 times a day  and   Hydroxychloroquine ??400 mg in the ?first day and then 200 mg BID plus Atazanavir / Ritonavir 300/100? daily  5 days. Every vitamin c vial content of 500 mg and is from Darou Pakhsh factory. The patients receive 3 vials slow infusion (1-2 hours)  with normalsaline.  Duration of treatment base of clinical response is 3-5 days. Renal function with BUN and CR monitor every other day. Intervention 2: Control group: control group 55 patients treat with    Hydroxychloroquine ??400 mg in the ?first day and then 200 mg BID plus Atazanavir / Ritonavir 300/100? daily  5 days.","Intervention 1: Intervention group: In this group, umbilical cord Whartons jelly mesenchymal stem cells are infused at an initial dose of 0.5-2 milion/ kg. This process is performed on the first, third and sixth days. This intervention is done along with other standard treatments for this type of patients, varying in severity of COVID-19 Infectious, and in accordance with national and international guidelines. Intervention 2: Control group: This group, like the intervention group, will receive all standard medication according to national and international guidelines, depending on the severity of COVID-19. But on the first, third and sixth day, placebo (normal saline) is infused.","Intervention 1: Intervention group: Intervention group until discharge, in addition to antiviral treatments according to the national protocol, injectable selenium will be prescribed in the form of 1000 micrograms every 12 hours on the first day and then 500 micrograms every 12 days from the second day onwards. Intervention 2: Control group: the control group until discharge will receive antiviral treatments according to the national protocol.","Intervention 1: Intervention group: The propolis supplement is taken as a 500 mg capsule twice a day for 1 month. Intervention 2: Control group: The placebo is taken as a capsule twice a day for 1 month.","Intervention 1: Intervention group: hydroxychloroquine  Ruzdarou 200mg;  This group take 2 hydroxychloroquine tablet (400 mg) for the first day and From the second day, take one tablet (200 mg) daily for two weeks. Intervention 2: Control group: Domestic quarantine for 14 days.","Drug : 1. Control group: Conventional treatment&lt;br&gt; * Conventional treatment: Treatments with Lopinavir / ritonavir, Hydroxychloroquine, Oxygen therapy, Non-invasive and invasive ventilaton, antibiotic therapy, renal-replacement therapy (e.g. CRRT, HD),  extracorporeal membrane oxygenation (ECMO), etc. can be applied as a standard treatment for patients eligible for this study.&lt;br&gt;&lt;br&gt;2. Intervention group: Conventional treatment + Nafamostat IV&lt;br&gt; * Nafamostat injection&lt;br&gt;- Dosage: The researcher administers a dose of 0.1 to 0.2 mg / kg / hr (2.4 to 4.8 mg / kg / day), taking into account the severity and underlying disease of the clinical trial patient.&lt;br&gt;- Method of administration: Nafamostat injection is mixed with 1,000 ml of 5&amp;#37; DW infusion, followed by continuous infusion over 24 hours.&lt;br&gt;- Duration of administration: The researcher administers for 10-14 days considering the severity and underlying disease of the clinical trial patient.","Intervention 1: Intervention group:  In addition to the conventional treatments for Covid-19, patients will undergo a cycle of Ozone Major Autohemotherapy. In this method, a specific volume of patient's blood is drawn (100 to 200 cc in mild to moderate cases and 200 cc in severe cases). Then, a corresponding volume (100 to 200cc) of the oxygen-ozone gas mixture is added to the blood (initially with an ozone concentration of 35 micrograms/ml and gradually increasing it up to 45micrograms/ml in mild to moderate cases and up to 50micrograms/ml in severe cases). After mixing the blood with the gas mixture for at least 5 minutes with gentle rotating movements, the blood is reinfused to the patient. Mild to moderate cases will be treated daily for 4 days. Severe cases will be treated twice daily for at least 7 days. Intervention 2: Control group: Patients of this group, will just get the conventional treatments for COVID-19.","Intervention 1: Intervention group: Take tocilizumab. This group is given a dose of 8 mg per kilogram of body weight tocilizumab up to a maximum dose of 800 mg. If the symptoms worsen or do not improve, another dose is injected. If side effects occur, the complication is recorded and then the patient is removed from the study. Intervention 2: Control group: Receive standard multi drug protocol.","Intervention 1: Intervention group: herbal supplement taking from a combination of 1000 mg of black myrobalan and 2000 mg of mastic and 3000 mg of sugarcane twice a day without water. The duration of herbal supplement taking is one week. Intervention 2: Control group: Placebo taking twice a day Without water. The duration of placebo taking is one week.","Intervention 1: Intervention group: In addition to the common national protocol, this group will receive convalescent plasma of recovered individuals twice and 200 cc each time. Intervention 2: Intervention group: In addition to the common national protocol, this group will receive intravenous immunoglobulin (400mg/kg/d). Intervention 3: Control group: This group will receive common national protocol.","Intervention 1: Intervention group: intravenous immunoglobulin (IVIG), brand name Intratect , 400 mg/kg/day  in 3 doses will be administered by slow intravenous infusion. Intervention 2: Control group: Lopinavir/ritonavir, brand name Kaletra, two tablet of 200/50 mg dose every 12 hours will be administered orally.","Intervention 1: Intervention group 1: treatment group A, 0.1 * 107 NK cells per kilogram of patient weight. The lowest dose of cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after cell injection for safety and efficacy effects. Intervention 2: Intervention group 2: treatment group B, 0.5 * 107 NK cells per kilogram of patient weight. The middle dose of the cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after injection for safety and efficacy effects. Intervention 3: Intervention group 3: treatment group C, 1 * 107 NK cells per kilogram of patient weight. The middle dose of the cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after injection for safety and efficacy effects. Intervention 4: Intervention group 4: treatment group D, 1.5 * 107 NK cells per kilogram of patient weight. The middle dose of the cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after injection for safety and efficacy effects. Intervention 5: Intervention group 5: treatment group E, 2 * 107 NK cells per kilogram of patient weight. The highest dose of cells will be injected into this treatment cohort. These patients will also be examined at intervals of 1, 3, 7, 14, 28 days in terms of safety and effectiveness outcomes. Intervention 6: Intervention group 6: placebo, in this group, only physiological serum will be injected into patients. These patients will also be examined at intervals of 1, 3, 7, 14, 28 days in terms of safety and effectiveness outcomes. Intervention 7: Control group: They do not receive any treatment other than common medications.","Intervention name : tocilizumab&lt;br&gt;INN of the intervention : tocilizumab&lt;br&gt;Dosage And administration of the intervention : Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg. Up to 1 additional dose may be given.&lt;br&gt;Control intervention name : -&lt;br&gt;INN of the control intervention : -&lt;br&gt;Dosage And administration of the control intervention : -","Ciclesonide is inhaled three times a day at a dose of 400 microgram once a day for seven consecutive days.","Immediate favipiravir arm: Favipiravir administered orally between Day 1 and Day 10, 1800 mg twice a day on Day 1 followed by 800 mg twice a day from Day 2&lt;br&gt;Delayed favipiravir arm: Favipiravir administered orally between Day 6 and Day 15, 1800 mg twice a day on Day 6 followed by 800 mg twice a day from Day 7","Intervention 1: Intervention group: They will receive 400 mg of hydroxychloroquine (Tehran Darou, Iran) a week for eight weeks and also this group will receive routine care for Corona's new disease. Intervention 2: Control group: They will receive routine care for Corona's new disease.","Reading a message that encourage to stay at home&lt;br&gt;Reading a message that encourage to stay at home&lt;br&gt;Reading a message that encourage to stay at home&lt;br&gt;Reading a message that encourage to stay at home&lt;br&gt;Reading a message that encourage to stay at home","Intervention 1: Intervention group: PO Hydroxychloroquine 200 mg and PO tenofovir 300 mg once a day for 7 days. Intervention 2: Control group: PO Hydroxychloroquine 200 mg once a day for 7 days.","Intervention 1: Intervention group: one colchicine 1mg tablet daily for two weeks. Intervention 2: Control group: placebo with same appearance of colchicine tablet one daily for 2 weeks.","Intervention 1: Intervention group: Patients in intervention group in addition to the standard antiviral treatment of the two-drug regimen, NBS powder will be prescribe is below: Dosage of NBS is 500 mg capsules daily in four capsules (two grams) given in divided doses of one gram in the morning and one gram in the evening for 4 weeks. Intervention 2: Control group: standard antiviral treatment of the two-drug regimen including: Hydroxychloroquine - Caltra (Lupinavir + Ritonavir).","Intervention 1: Intervention group: Two curcumin-piperine capsules (500 mg of curcumin + 5 mg of piperine) will be given daily for 2 weeks after lunch and dinner. Intervention 2: Control group: 2 placebos (500 mg of maltodextrin) daily after lunch and dinner for 2 weeks.","Intervention 1: Intervention group: Hydroxychloroquine nasal spray (500g/dose) 1 puff in each nostril every 12 hours, for 7 days (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: Routine treatment according to the latest national guideline for the treatment of new corona-virus.","Diagnosis with rapid antibody kit","Intervention 1: Intervention group 1: hospitalized patients received convalescent plasma with 2-5 cc/kg transfused on 1, 3, 5 days after treatment that treated with the standard national guideline. Intervention 2: Intervention group 2: hospitalized patients received convalescent plasma with 8-10 cc/kg transfused on 1 day after treatment that treated with the standard national guideline. Intervention 3: Control group: hospitalized patients treated with the standard national guideline.","Intervention 1: Intervention group: In addition to the treatment protocol, patients receive 7 cc of jujube twice a day, 7 cc each. Intervention 2: Control group: The treatment is done according to the protocol and is only for comparison with the intervention group.","Intervention group: Low dose RT.","Wearable biological monitoring device","Intervention 1: Intervention group 1: Routine care plus intravenous hydrocortisone 50 mg every 6 hours for 5 days. Intervention 2: Intervention group 2: Routine care plus intravenous methylprednisolone 40 mg every 12 hours for 5 days. Intervention 3: Intervention group 3: Routine care plus intravenous dexamethasone 20 mg daily for 5 days.",";Placebo;Measles Mumps and Rubella vaccine",";Chloroquine phosphate;Hydroxychloroquine sulphate;Placebo","Intervention 1: Intervention group: Interferon Beta 1a  nasal spray  1 puff in each nostril every 6 hours, for 14 days (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: Routine treatment according to the latest national guideline for the treatment of new corona-virus.",";IHP Detox tea;Placebo","Drug;Hydroxychloroquine;Group 1 - Hydroxychloroquine, 400 mg 12/12h, oral, on the first day followed by Hydroxychloroquine, 400 mg once daily, oral for  6 days, totaling 7 days of treatment - 650 patients &lt;br&gt;&lt;br&gt;Grupo 2 - Control - 650 patients",";normal practice neither trial drug;Hydroxychloroquine plus Lopinavir Ritonavir;Lopinavir Ritonavir;Hydroxychloroquine",";Already established protocols for prevevntion and treatment;Folic acid oral tablet.","Local standard of care alone, &lt;br&gt;OR local standard of care plus one of:&lt;br&gt;Remdesivir &lt;br&gt;Chloroquine or hydroxychloroquine &lt;br&gt;Lopinavir with Ritonavir &lt;br&gt;Lopinavir with Ritonavir &lt;br&gt;;as per the hospital standards; Daily infusion for 10 days;Two oral loading doses, then orally twice daily for 10 days;Orally twice daily for 14 days;Interferon: daily injection for 6 days;standard care;Remdesivir;Chloroquine or hydroxychloroquine ;Lopinavir with Ritonavir ;Lopinavir with Ritonavir plus Interferon","1. Control group - 210 participants&lt;br&gt;Control group will recieve proper COVID19 treatment but will not recieve hydroxychloroquine, chloroquine, azythromicyn or other macrolide.&lt;br&gt;&lt;br&gt;2. HCQA - 210 participants&lt;br&gt;HCQA group will recieve proper COVID19 treatment and hydroxychloroquine 400mg + azythromicyn 500mg once a day, oral, enteral or intravenous, for 7 days&lt;br&gt;&lt;br&gt;3. HCQ - 210 participants&lt;br&gt;HCQ group will recieve proper COVID19 treatment, and hydroxychloroquine 400mg once a day, oral, enteral or intravenous, for 7 days;Drug;Hydroxychloroquine;Azithromycin","Drug;Azithromycin;Hydroxychloroquine;Chloroquine;Initial sample size 90 people, which was divided into four groups&lt;br&gt;Group 1: Asymptomatic patients, no drug intervention was performed&lt;br&gt;Group 2: Patients with mild symptoms did not undergo any specific drug intervention&lt;br&gt;Group 3: Patients with moderate symptoms were prescribed hydroxychloroquine associated with azithromycin&lt;br&gt;Group 4: Serious patients referred to hospital treatment","Dosing and Administration&lt;br&gt;Subjects will be randomized 1:1 to receive either active product or placebo. Initially, the trial will have 2 arms: &lt;br&gt;-Remdesivir will be administered as a 200 mg IV loading dose on Day 1, followed by a 100 mg once-daily IV maintenance dose for the duration of the hospitalization up to a 10 day total course. If a subject is no longer hospitalized, then infusions will no longer be given. &lt;br&gt;-A matching placebo will be given at an equal volume at the same schedule. &lt;br&gt;&lt;br&gt;Any dose that is delayed, but still the same study day, may be given. Any dose that is missed (not given that calendar day) is not made up.","Hyperimmune plasma anti-SARS-CoV-2&lt;br&gt;20 patients will be included and will be compared with historical controls, that were admitted before the start of the current study;Biological/vaccine;Immunization, Passive","Drug;Anticoagulants;Patients will be randomized in a 1: 1: 1 ratio among three groups through a digital application.&lt;br&gt;Group 1) Full heparinization with enoxaparin: Full heparinization will be performed with enoxaparin adjusted for creatinine clerance according to the scheme below): 10 patients&lt;br&gt;&lt;br&gt;Creatinine clearance &lt;75 years&gt; 75 years&lt;br&gt;&gt; 50 ml / min 1 mg / Kg SC BID 0.75 mg / Kg SC BID&lt;br&gt;30-50 ml / min 0.75 mg / Kg BID 1 mg / Kg SC 1x&lt;br&gt;10-30 ml / min 1 mg / kg SC1x 0.75 mg / kg 1x&lt;br&gt;&lt;10 ml / h Will not be included Will not be included&lt;br&gt;&lt;br&gt;As renal function can change during the study, we consider daily creatinine dosage necessary and the adjustment of the dose of enoxaparin should be performed daily according to the evolution of renal function. Duration of heparinization: 96 hours. Enoxaparin may be extended up to 7-10 days at the discretion of the medical team for those patients who show significant clinical improvement. Enoxaparin may be suspended at any time if any major or minor bleeding is observed according to the safety criteria included in this study or platelet count below 30,000 mm3.&lt;br&gt;&lt;br&gt;Group 2) Full heparinization with unfractionated heparin: 10 patients&lt;br&gt;Initial bolus: 60UI / Kg (maximum: 4000 IU)&lt;br&gt;Initial infusion: 12 IU / Kg / hour (maximum: 1000U / h)&lt;br&gt;Therapeutic goal: maintain APTT between 50-70 seconds (ratio between 1.5 and 2.0)&lt;br&gt;Standard solution: 25,000 IU of heparin in 250 ml of SF0.9% (100 IU / ml)&lt;br&gt;APTT (seconds) Bolus Suspension Change in infusion rate Repeat APTT&lt;br&gt;&lt;36 Repeat bolus 0 min + 1ml / h 6 hours&lt;br&gt;36-49 0 0 min + 1ml / h 6 hours&lt;br&gt;50-70 0 0 min 0 12 hours&lt;br&gt;71-89 0 0 min - 2ml / h 12 hours&lt;br&gt;81-100 0 30 min - 4ml / h 6 hours&lt;br&gt;101-130 0 60 min - 6ml / h 6 hours&lt;br&gt;&gt; 130 0 60 min -12 ml / h 6 hours&lt;br&gt;Example: patient","COVID-19 patients are randomly assigned to the group which adds Favipiravir and Nafamostat Mesilate to standard treatment or the group which add Favipiravir to standard treatment","Supportive care + favipiravir 1800 mg ? 2 times/day ? 1 day + 800 mg ? 2 times/day ? 4 (minimum) -13 days (Maximum), Supportive care (symptomatic therapy) ? 14 days (Maximum)","- Control Group: Conventional treatment Basic (conventional) treatment planned in the hospital for the management of contacts and suspects of SARS-CoV-2 infection.   - Experimental Group: Conventional treatment + CIGB 2020 vaccine Basic (conventional) treatment planned in the hospital for the management of contacts and suspects of SARS-CoV-2 infection. In addition, patients will receive treatment with the CIGB 2020 vaccine nasal (scheme 0-7-14 days) and sublingually (one daily dose for 14 days).","TREATMENT SCHEME  o\tAn intravenous dose of 200 mg (8 vials of itolizumab) will be administered once the inclusion criteria are met. o\tA second dose, after 72 hours, will be administered if the patient still has signs of respiratory failure or macrophage activation syndrome.  The treatment will be administered concomitant with the protocol tretaments approved by Ministry of Public Health","Group CIGB-258 peptide: 1 mg intravenously every 12 hours until extubation, followed by the same dose every 24 hours for three days (in patients with mechanical ventilation, where the dose can be increased to 2 mg if at 72 hours, there is no clinical, blood gas, and radiological improvement) or 1 mg intravenously every 24 hours in patients without mechanical ventilation, until their condition reverts.","Drug;Clinical Trial;Medical Examination;A total of 140 (one hundred and forty) patients diagnosed with severe acute respiratory syndrome will be invited to participate in the study, and, after signing the informed consent form, they will be randomized into two groups, which will be treated according to the protocol : Control Group (70 patients): will receive intravenous infusion in peripheral venous access of Placebo (Glucose 5% 100mL) in 20h (single dose). Intervention Group (70 patients): will receive intravenous infusion in peripheral venous access of N acetylcysteine in a total dose of 300 mg / kg, with the first dose being 200 mg / kg in 4 hours and the second dose 100 mg / kg in 16 hours ( Single dose). Serum tests (30mL of blood from peripheral venous access) and arterial blood gases will be collected from all patients. Patients will be monitored daily by reviewing medical records and clinical data will be recorded on a RedCap form.","Chloroquine 10 mg base/kg once a day on Day 1 and Day 8, Vitamin C 1000 mg once a day from Day 1 to Day 14","Group A: HeberFERON (Recombinant Interferon Alpha Gamma, 3.5 MUI), subcutaneously, twice a week for three consecutive weeks. Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b, 3.0 MUI), subcutaneously, three times per week for three consecutive weeks. All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra, chloroquine, azithromycin or rocefin, depending on the magnitude of respiratory symptoms.","We reduce the dose of each herb to 1/30 to explore the feasibility of prophylactic use. The QFPDT decoction is prepared by boiling the mixed herbs in 600 ml of water for 1 h and divided into six aliquots. The subjects are instructed to take the aliquot of the decoction orally 40 min after each breakfast and dinner for 3 days.","Group I: Recombinant human interferon (IFN) alpha-2b, 1 drop (0.05 mL) in each nostril (0.5 MIU IFN alpha 2b), every 12 hours (2.0 MIU daily) for 5 consecutive days. Group II: Recombinant human interferon (IFN) alpha-2b, 3 drops (0.15 mL) sublingually (1.5 MIU IFN alpha 2b), every 12 hours (3.0 MIU daily) for 5 consecutive days. Group III: Recombinant human interferon (IFN) alpha-2b, 1 drop (0.05 mL) in each nostril (0.5 MIU IFN alpha 2b), every 6 hours (4.0 MIU daily) for 5 consecutive days. Group IV: Recombinant human interferon (IFN) alpha-2b, 5 drops (0.25 mL) sublingually (2.5 MIU IFN alpha 2b), every 12 hours (5.0 MIU daily) for 5 consecutive days. Group V: Recombinant human interferon (IFN) alpha-2b, 2 drops (0.1 mL) in each nostril (1.0 MIU IFN alpha 2b), every 8 hours (6.0 MIU daily) for 5 consecutive days. Group VI: Recombinant human interferon (IFN) alpha-2b, 12 drops (0.6 mL) diluted in 2 mL of water for injection, aerosolized (6.0 MIU IFN alpha 2b), every 12 hours (12.0 MIU daily) for 5 consecutive days.","Group name:Standard of care Type of group;2 N of participants:200 Intervention(s) description:Standard of care that all patients with COVID recieve at the hospital. &lt;br&gt;Group name:Standard of care plus lopinavir with ritonavir plus interferon beta 1a Type of group;1 N of participants:200 Intervention(s) description:Standard care that is given to all COVID patients who come to this hospital / clinic plus Lopinavir with Ritonavir (orally twice a day for 14 days) plus interferon beta 1a (daily injection for 6 days). Lopinavir / Ritonavir is available from multiple manufacturers as fixed-dose thermostable tablets for oral administration: Lopinavir 200mg with Ritonavir 50mg per tablet. The oral solution for patients who cannot swallow is a light yellow to orange liquid containing 400 mg Lopinavir and 100 mg Ritonavir per 5 ml (80 mg Lopinavir and 20 mg Ritonavir per ml). Interferon beta 1a is supplied as a sterile solution that does not contain any preservative available in a pre-filled syringe. It is provided as a single dose pre-filled graduated syringe available in two strengths; either 44 micrograms per 0.5 ml or 22 micrograms per 0.5 ml (allowing a convenient supply of 44 ug doses for subcutaneous use). The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe. Contains the following inactive ingredients: Albumin (Human), Mannitol, Sodium Acetate, Water for Injection.&lt;br&gt;","Patients treated at home: Group I (experimental 1): Nebulization with Homeostec (5 ml) + Paracetamol (500 mg). The patient will receive a bottle with 5 ml of Homeostec (electrolysed solution with neutral pH), which will be placed in the nebulizer container. The patient will receive sprays for 15 min, three times a day for 7 days. In addition, you can take Paracetamol 500 mg (orally) every 6 hours.Other medications may be added at the discretion of the treating physician as deemed necessary for the patient. Group II (experimental 2): Nebulization with Homeostec (5 ml) + Paracetamol (500 mg) + Homeostec (15 ml). The patient will receive a bottle with 5 ml of Homeostec (neutral pH electrolyzed solution), which will be placed in the nebulizer container. The patient will receive sprays for 15 min, three times a day for 7 days. Additionally, 15 ml of Homeostec will be administered intravenously loaded in a 20 ml syringe. The solution will be applied to an arm vein using a butterfly-type IV application catheter connected to the syringe, in a period of 1 to 2 min, once every 24 hours for 7 days, by research personnel who will visit the patient in his home. In addition, you can take Paracetamol 500 mg (orally) every 6 hours. Other medications may be added at the discretion of the treating physician as deemed necessary for the patient. Group III (control 1): Paracetamol (500 mg). The patient will receive Paracetamol 500 mg (orally) every 6 hours. Other medications may be added at the discretion of the treating physician as deemed necessary for the patient.  Hospitalized patients (Includes patients on a regular floor or intensive care unit, with or without mechanical ventilation): Group IV (experimental 3): Homeostec (15 ml) + Paracetamol (500 mg). The patient will receive 15 ml o","Duration: 1 hour&lt;br&gt;Dose: JHQG Granule 5 g&lt;br&gt;Number of doses: 1","Intervention1: Topical Lignocaine: Topical lignocaine lozenges to be used before collecting nasal and throat swabs for Covid-19&lt;br&gt;",";COVID19 vaccine;Rabies vaccine","Group 1: Respiratory Exercise Program (REP) (n=33)&lt;br&gt;\tThe REP will consist of 10 exercises based on the recommendations made by the official Physiotherapy organizations at the institutional level (College of Physiotherapists of the Community of Madrid, Spain), with scientific evidence, consisting of exhalation and inspiration exercises, diaphragmatic reeducation and rib cage mobility. The REP will be taught to patients telematically in the first session, and it will be carried out once a day, for 21 days, at the patient's home, between 11 a.m. The REP will be reinforced by a physical therapist daily, through telematic control by videoconference with each patient.&lt;br&gt;&lt;br&gt;Group 2: Non-specific Toning Exercise Program (NTEP) (n=33)&lt;br&gt;\tThe NTEP will consist of 10 exercises based on the recommendations about toning exercises, general and functional muscle work of the lower and upper limb and trunk muscles, made by the official Physiotherapy organizations at the institutional level (College of Physiotherapists of the Community of Madrid, Spain), with scientific evidence. The NTEP will be taught to patients in the first session, and it will be carried out once a day, for 21 days, at the patient's home, between 11 a.m. and 12 a.m. The NTEP will be reinforced by a physical therapist daily, through telematic control by videoconference with each patient.&lt;br&gt;&lt;br&gt;Group 3: Sham Program (SP) (n=33)&lt;br&gt;\tThe Sham Program consists of 10 sedentary exercises based on sophrology and meditation, with mental exercises of visualization, concentration and mental activity. The SP will be taught to patients in the first session telematically, and it will be carried out once a day, for 21 days, at the patient's home, between 11 a.m. and 12 a.m. The SP will be reinforced by a physical therapis;Other;Exercise Therapy;Placebo Effect","Subjects 18+ years-old, healthcare professionals directly involved in patients assistance during pandemia COVID-19, temporarily removed from their duties, because of the onset of respiratory symptoms or fever, with suspected or confirmed infection by the SARS-CoV-2, will be randomized in the proportion of 4:1 to the intervention groups (experimental and control) for the proceedings described below. High-risk groups for severe forms of COVID-19 (age &gt; 60 years and chronic diseases), as well as those with compromised general health at initial assessment, with indicated emergency evaluation or hospital admission will be excluded.&lt;br&gt;&lt;br&gt;Group 1 (experimental), N=200 participants:&lt;br&gt;&lt;br&gt;-Immediate removal from workplace, initially for 6 days&lt;br&gt;&lt;br&gt;-RT-PCR testing in the 1st day of workplace removal (D0)&lt;br&gt;&lt;br&gt;-Return for new RT-PCR testing in the 7th day (D7)&lt;br&gt;&lt;br&gt;-Return to work in the 8th day, if both RT-PCR tests (D0 and D7) resulted negative.&lt;br&gt;&lt;br&gt;-If any of the RT-PCR tests (D0 or D7) resulted positive, the professional will be kept away from work, and will do another RT-PCR test in the 10th day (D10).&lt;br&gt;&lt;br&gt;-If the RT-PCR (D10) results negative, the return to work will occur in the 11th day.&lt;br&gt;&lt;br&gt;-If the RT-PCR (D10) results positive, the return to work will take place in the 15th day.&lt;br&gt;&lt;br&gt;-Serology for SARS-CoV-2 will be tested between the 15th and 21st day after symptoms onset or the removal from the workplace.&lt;br&gt;&lt;br&gt;-Suspected cases of COVID-19 not eligible to this protocol will remain absent from workplace for 14 days with subsequent return to work, if assymptomatic for at least 72h, ou otherwise will follow the regular proceedings of their Institution to removal from and return to work of healthcare professionals suspected of SARS-Cov-2 infections.&lt;;Other;Laboratory Test","This will be a placebo-controlled, randomized, clinical trial. &lt;br&gt;&lt;br&gt;The study will be carried out among all eligible persons meeting the inclusion/exclusion criteria directed to be quarantined in quarantine centers (QCs) of the Sri Lanka Navy, Ministry of Defense  &lt;br&gt;&lt;br&gt;Informed consent will be obtained, and a patient information leaflet will be provided. Those willing to undergo the trial will be randomized and monitored for development of symptoms or rRT-PCR positivity for SARS-CoV-2 virus. All eligible participants who test negative for the virus on rRT-PCR at baseline, will be randomly assigned to the following study arms within 48 hours of admission.&lt;br&gt;&lt;br&gt;Participants will be allocated to the study arms using simple randomization where each personnel will be considered as a unit. A list of the Navy personnel in the Quarantine centers (QCs) along with their names and national identity card numbers will be obtained. Each personnel will be given a unique number starting from 1 up to the total number of personnel undergoing quarantine in all the QCs. This will be used as a sampling frame for selecting study participants.&lt;br&gt;&lt;br&gt;Microsoft Excel will be used to generate 400 random numbers without replacement from an integer vector starting from 1 to total number of persons in the QCs and the resulted numbers will be recorded in the exact order which they are generated. The personnel belong to the first 200 random identification numbers in the list will be selected to the intervention group (i.e. receive the envelops numbered from 1 to 200) and the second 200 will be selected to the control group (i.e. receive the envelops numbered from 201 to 400).  &lt;br&gt;&lt;br&gt;Allocation concealment will be maintained by packing the interventional product and the placebo in similar e","1. Control group - 15 participants&lt;br&gt;The Control group will receive proper COVID19 treatment but will not receive hydroxychloroquine, chloroquine, azithromycin, or another macrolide.&lt;br&gt;PT-BR&lt;br&gt;EN&lt;br&gt;2. G1 - 15 participants&lt;br&gt;This group will receive proper COVID19 treatment and hydroxychloroquine 400mg + azithromycin 500mg bid D0, orally, or enterally, and the following days, hydroxychloroquine 400mg + azithromycin 500mg once each, orally, or enterally, for 10 days or negative PCR, what comes first. &lt;br&gt;3. G2 - 15 participants&lt;br&gt;This group will receive proper COVID19 treatment and hydroxychloroquine 200mg + azithromycin 500mg bid D0, orally, or enterally, and the following days, hydroxychloroquine 200mg + azithromycin 500mg once each, orally, or enterally, for 10 days or negative PCR, what comes first.;Drug;Hydroxychloroquine;Azithromycin","Intervention1: Samshamani Vati (500 mg twice daily after food with warm water for 15 days), Sudarshan Ghana Vati (250 mg thrice daily after food with warm water for 15 days), Khadiradi Vati (250 mg twice daily for chewing for 15 days), Murrchhita Tila Taila (for Nasya (nasal instillation) 2 drops in each nostril in morning and evening for 15 days), Aesenic Album 30 (4 tablets before lunch for 3 days): For 15 days&lt;br&gt;Intervention2: Sudarshan Ghana Vati: 250 mg thrice daily after food with warm water for 15 days&lt;br&gt;Intervention3: Khadiradi Vati: 250 mg twice daily for chewing for 15 days&lt;br&gt;Intervention4: Murrchhita Tila Taila: for Nasya (nasal instillation) 2 drops in each nostril in morning and evening for 15 days&lt;br&gt;Intervention5: Aesenic Album 30: 4 tablets before lunch for 3 days&lt;br&gt;Control Intervention1: Not Applicable: Not Applicable&lt;br&gt;","Intervention1: Shanshamani Vati or&lt;br&gt;Sudarshana Ghanavati or Ashwagandha: 1.Sanshamani Vati 500mg Two times Before meal with water for 1 month&lt;br&gt;2.Sudarshna Ghanavati 500mg two times before meal with water for 1 month&lt;br&gt;3. Ashwagandha 500 mg two times before meal with water for 1 month&lt;br&gt;Total duration of therapy is 1 month&lt;br&gt;Control Intervention1: Not Applicable: Not Applicable&lt;br&gt;","Procedure/surgery;Dialysis;When renal acute support is indicated, patients will be submitted to a block randomization process through the Randomization.com website and allocated into 2 groups: Early Indication Group: indication of RAS regardless of acute kidney injury (AKI) stage; Standard indication Group: RAS indication when the presence of demand and renal capacity imbalance is identified. Within each group a second randomization will be performed: Prolonged Intermittent Hemodialysis: characterized by blood and dialysate flows of 200 mL / min and 300 mL / min, respectively, and duration of 6 hours; Continuous venovenous hemodialysis (HDC): defined as a 24-hour continuous treatment that uses blood and dialysate flows between 100-150 mL / min and 1000-1500 mL / hour, respectively. Regional anticoagulation will be performed with 4% trisodium citrate and M100 hemofilter will be used.","Intervention1: Ivermectin: The doses are as follows (based on body weight)&lt;br&gt;15 - 24 kg: 3 mg PO once&lt;br&gt;25 - 35 kg: 6 mg PO once&lt;br&gt;36 - 50 kg: 9 mg PO once&lt;br&gt;51 - 65 kg: 12 mg PO once&lt;br&gt;66 - 79 kg: 15 mg PO once&lt;br&gt;80 kg and  15 kg: 200 ug/kg PO once&lt;br&gt;Control Intervention1: patients will receive the standard protocol for management of COVID 19 infection.: patients will receive the standard protocol for management of COVID 19 infection.&lt;br&gt;","Intervention1: Lowest driving pressure guided PEEP: Initial PEEP would be kept at 5 cmH2O and driving pressure would be noted. PEEP would be stepped up in increments of 1 and the corresponding ?P would be checked after 1 minute. The PEEP levels at which ?P is the least would be chosen. In case the driving pressure achieved is same for more than one consecutive value of PEEP, then the lowest level of PEEP would be chosen.&lt;br&gt;After 12 hours, driving pressures would be checked again and the same protocol would be followed to find the lowest ?P. If it is noted at any point that ?P increases with increase in PEEP, then PEEP would be reduced in decrements of 1 until the lowest ?P is achieved. The rest of the ventilator settings would be as per ARDSnet protocol.&lt;br&gt;Control Intervention1: Conventional lung protective ventilation strategy( ARDSnet protocol): Ventilator settings used would be as per the PEEP/FiO2 combinations used in ARDSnet protocol.&lt;br&gt;","HA330 hemoperfusion&lt;br&gt;- HA330 hemoperfusion will be performed on a daily basis with a 6-hour duration per session until 1) 7 days, 2) IL-6 &lt;400 pg/mL, 3) clinically improved (defined by 3.1) PF ratio &gt;300 for at least 48 hours or 3.2) spontaneous respiration), whichever comes first.&lt;br&gt;, Usual care will be provided including antivirals, IV fluids, vasopressors, oxygenation and ventilatory support, steroid, antibiotics, IVIG","Intervention1: SSV Formulation Tablets: Each tablet of 500 mg to be consumed orally twice a day immediately after meals for 15 days.&lt;br&gt;Control Intervention1: Not Applicable: Not Applicable&lt;br&gt;","Intervention1: Remdesivir: local standard of care plus Remdesivir (daily infusion for 10 days) &lt;br&gt;&lt;br&gt;Intervention2: chloroquine or hydroxychloroquine: local standard of care plus chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)&lt;br&gt;Intervention3: Lopinavir with Ritonavir (orally twice daily for 14 days): Local standard of Care plus Lopinavir with Ritonavir (orally twice daily for 14 days)&lt;br&gt;Intervention4: Lopinavir with Ritonavir (ditto) plus Interferon: Local standard of care plus Lopinavir with Ritonavir ((orally twice daily for 14 days) plus Interferon (daily injection for 6 days).&lt;br&gt;Control Intervention1: Local standard of care: Local standard of care&lt;br&gt;","Intervention1: Favipiravir 200mg Tablets: Dosage Form: Tablets. &lt;br&gt;Dosage Frequency: 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days.&lt;br&gt;Mode of Administration: Oral&lt;br&gt;&lt;br&gt;Control Intervention1: Standard Supportive Care: These patients will be managed by standard supportive care.&lt;br&gt;","Intervention1: Imatinib - Oral Drug: Imatinib- 600mg per oral once daily&lt;br&gt;(D1-D14)&lt;br&gt;Control Intervention1: supportive care: supportive care&lt;br&gt;","Intervention1: Chest X-Ray  Artificial Intelligence Module: Chest X-Ray in 3 arms :-&lt;br&gt;1. COVID - 19 + ve patients&lt;br&gt;2. Pneumonia patients&lt;br&gt;3. X- Rays of no respiratory illness patients&lt;br&gt;Intervention2: CT - Scan of THORAX Artificial Intelligence  Module: CT - Scan Thorax in 3 Arms -&lt;br&gt;1. COVID-19 +ve patients &lt;br&gt;2. Pneumonia patients &lt;br&gt;3. Normal willing population&lt;br&gt;Intervention3: Voice Sampling Artificial Intelligence Module: Voice Sampling through Android App and storage through Cloud in 3 arms -&lt;br&gt;1. COVID-19 patients&lt;br&gt;2. Pneumonia patients&lt;br&gt;3. Normal willing population&lt;br&gt;Control Intervention1: Normal subjects Chest X-Ray , CT-Scan Thorax and Voice sampling: Normal and willing subjects Chest X-Ray, CT-Scan and Voice sampling through android app and storage in cloud&lt;br&gt;","Intervention1: Alternate Nostril Breathing &lt;br&gt;&amp; &lt;br&gt;Guided Meditation: (1) Nadi Shodhan Pranayama ?? Alternate nostril breathing will be taught where the participant is seated comfortably with spine erect, head straight and eyes closed gently. The left hand will be placed in chin mudra with the thumb and index fingers opposing each other and in a gentle touch. The rest of three fingers are kept straight. The right hand is used to perform the alternate nostril breathing such that the thumb is on the right nostril, index and middle fingers between the eyebrows and ring and little fingers. The participants are then taught the procedure to breath through alternate nostrils for about 5 mins. (2) Panchakosha Meditation ?? The participants will be asked to sit with eyes closed and listen to the instructions given. The Panchakosha meditation is a guided meditation that takes about 15 to 18 minutes. After which participants are again asked to do the Nadi Shodhan Pranayama for about 5 minutes.&lt;br&gt;The participants will then be given the instructions for daily practice of this pranayama and meditation technique by giving them the YouTube links for the other guided meditation techniques.&lt;br&gt;These interventions will be delivered by the Principal Investigator who has been trained as a teacher by the Art of Living Foundation in the teaching of these techniques. The session will be conducted remotely using Zoom video calling app.&lt;br&gt;At the end of two weeks period, the participants will be asked to again respond to an online questionnaire which will assess their psychological parameters, sleep quality and coping abilities. At this point, the Intervention Arm participants will be asked to return a sheet that marks their adherence to the protocol.&lt;br&gt;Control Intervention1: Waitlisted Control: The control","Intervention1: Kashaya(Decoction): 90-100 ml of kashaya of Tinospora cordifolia stem added with 2gms of finelly powdered dried Piperlongum fruit,once in the morning before breakfast and once in the evening before dinner as add on therapy in addition to standard of care medicines&lt;br&gt;Control Intervention1: Standard of Care: Patients on Standard care medicines who do not agree to take the ayurvedic medicine.&lt;br&gt;","Intervention1: Ashwagandha tablet: Ashwagandha tablet (250mg ) two tablet twice daily for one month&lt;br&gt;Control Intervention1: nil: nil&lt;br&gt;","Intervention1: HCQS -MIMS Regimen: 300 mg daily x 1 wk followed by 300 mg weekly&lt;br&gt;Intervention2: Hydroxychloroquine: 300 mg daily x 7 days followed by 300 mg weekly x 7 weeks&lt;br&gt;Control Intervention1: Hydro Chloroquine(HCQ)-ICMR regimen: Group 2 : &lt;br&gt;400 mg bd for one day followed by 400 mg weekly for 7 weeks to be taken with meals (or until the epidemic stops) (ICMR Regimen)&lt;br&gt;Both groups will be advised to follow strict measures of self hygiene, social distancing and other routine protocols issued by IMA and Government bodies to prevent transmission. &lt;br&gt;&lt;br&gt;&lt;br&gt;","Intervention1: group-A: 1.\tTabSamshamani Vati  250 mg 2 bid after food with water for 60 days&lt;br&gt;2.\tHerbal tea ?? 150 ml in the morning once daily for 60 days( Preparation of Herbal tea: Boil 150 ml (1 glass) of water, at the time of boiling add 1 small tsf (3gms) of powder boil for 1-2 minutes. Switch off the stove and keep the lid for 1-2 mins till it settles and this herbal tea is ready to drink warm after filtering)&lt;br&gt;3.\tApplication of Anu taila  This oil is to be applied locally inside both the nostrils. This is to be applied in the morning before b and before leaving home and before retiring to bed.&lt;br&gt;4.\tHaridra khanda , 3gms bid with milk before food. (if sore throat, cold, cough seen)&lt;br&gt;Control Intervention1: group-B: conventional medicine preventive guidelines&lt;br&gt;","Intervention1: Topical Nasal 0.03% chloroquine eye drops: To receive 0.03% Chloroquine drops 1ml ?? 6 times daily X 10 days. &lt;br&gt;\t\t+ all treatments &amp; observations recommended by the treatment team&lt;br&gt;&lt;br&gt;Control Intervention1: Standard Treatment: Control Arm - all treatments &amp; observations recommended by the treatment team&lt;br&gt;                           No nasal drops&lt;br&gt;&lt;br&gt;","Intervention1: To teach ventilatory management in COVID19 patients: &lt;br&gt;&lt;br&gt;&lt;br&gt;classes will be conducted using HPS (human patient simualator ) and 3classes one on arterial blood gases ,one on basics of mechanical ventilation ,and finally mechanical ventilation in covid patients.A debriefing session will be carried out after every scenario, which will start with the trainee describing what happened during the scenario. This will be followed by analytical phase in which the trainee will be asked the successful aspects of the scenario and the factors that could have been improved. In the last phase of debriefing session, participants will be asked to reflect upon their training.&lt;br&gt;A pre &amp; post evaluation (Total 20 questions each carries 1 mark) will be conducted to assess the effectiveness of the in teaching module. The scores will be compared by wilcoxon sign rank test. &lt;br&gt;Skill based assessment will be conducted by DOPS method. &lt;br&gt;Feedback will be taken from the participants in a five point likert??s scale at the end of the teaching learning session.&lt;br&gt;&lt;br&gt;","Intervention1: ZingiVir H: It is a poly herbomineral drug.Therapeutic dose:  &lt;br&gt;ONE tablet (500 mg) each consumed once in 3 hours 1 hour between 6 AM and 9 PM in a given day (6AM, 9AM, 12Noon, 3PM, 6PM, 9PM) for a minimum duration of 10 days to Maximum 15 days as per the clinical conditions and disease outcome.&lt;br&gt;Control Intervention1: not applicable: not applicable&lt;br&gt;","Intervention1: Chloroquine phosphate: Chloroquine phosphate tablets will be given in the dose of 500 mg twice daily for 10 days to the patients who meets the inclusion criteria&lt;br&gt;Control Intervention1: No drug: Chloroquine will not be given to control group. These patients will be managed as per standard protocol.&lt;br&gt;","Intervention1: Hydroxychloroquine: 400 mg bid Day1 followed by 200 mg bid on Days 2 to 7&lt;br&gt;Intervention2: Ciclesonide: 200 mcg bid for 7 days&lt;br&gt;Intervention3: Ivermectin: 12 mg OD for 7 days&lt;br&gt;Control Intervention1: Standard of Care: Supportive management as per national guidelines&lt;br&gt;","Intervention1: recombinant BCG vaccine, VPM1002: Dose : 0.1 ml, single dose of the reconstituted vaccine to be administered as an intradermal injection&lt;br&gt;Control Intervention1: Placebo, 0.9% sodium chloride: Dose : 0.1 ml, single dose to be administered as an intradermal injection&lt;br&gt;","Intervention1: Convalescent plasma: Convalescent plasma, 2 doses of 200 mL each, from recovered COVID-19 patient.&lt;br&gt;Control Intervention1: Usual care for COVID-19 disease: Usual care for COVID-19 disease&lt;br&gt;","Intervention1: convalescent plasma: COVID-19 patients will be treated with convalescent plasma obtained from previously infected and recovered COVID-19 patients. 500-800 mL of Convalescent Plasma in two-three divided doses by slow intravenous injection&lt;br&gt;Control Intervention1: NA: NA&lt;br&gt;","Intervention1: Arm A Best supportive care with Itolizumab: Start at 1.6 mg/kg dose iv infusion, if well tolerated and improvement in patient observed, investigator has the discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen.&lt;br&gt;Control Intervention1: Arm B Best supportive care: By best supportive care?? which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy, will be administered. The best supportive care will be as per institution standard&lt;br&gt;","Intervention1: Homeopathy Medicines - Ars Alb, Camphora, Bryonia Alba, Helleborus niger, Justicia Adhatoda.: Oral Route&lt;br&gt;In 30c, 1M and 3x potency.&lt;br&gt;Twice a day till relief from symptoms or tests are negative.&lt;br&gt;Control Intervention1: NOT APPLICABLE: NOT APPLICABLE&lt;br&gt;","Intervention1: BCG-Denmark (Green Signal): BCG-Denmark (Green Signal), 0.1 ml, intradermal injection in left deltoid area&lt;br&gt;Control Intervention1: Placebo: Normal saline, 0.1 ml administered intradermally in the deltoid area of left arm&lt;br&gt;","Intervention1: Suspension of heat killed (autoclaved)Mycobacterium w: 0.3 ml (0.1 ml x 3 Inj.) of Mw intra-dermal for 3 consecutive days with Standard therapy of COVID-19&lt;br&gt;Control Intervention1: Placebo: 0.3 ml (0.1 ml x 3 Inj.) of Placebo intra-dermal for 3 consecutive days with Standard therapy of COVID-19&lt;br&gt;","Other: Placebo;Drug: Losartan","Drug: Placebo oral tablet;Drug: Placebo oral tablet;Drug: Hydroxychloroquine;Drug: Azithromycin","Intervention1: Ivermectin: Cases of COVID 19 shall be&lt;br&gt;treated with Ivermectin 200 to 400mcg per kg body weight on day 1 and day 2 along with&lt;br&gt;standard treatment of the hospital protocol&lt;br&gt;Control Intervention1: Standard treatment as per hospital protocol for COVID 19: Cases of&lt;br&gt;COVID 19 shall be treated with standard treatment as per hospital protocol for COVID 19 until the recovery.&lt;br&gt;","Intervention1: Hydroxychloroquine sulfate (HCQs): HCQ 400mg BD on D1 and 400 mg OD on D2 - 5&lt;br&gt;&lt;br&gt;Intervention2: Hydroxychloroquine sulphate high dose HCQh): HCQ 600 mg BD on D1 and 600 mg OD on D2 - 5&lt;br&gt;&lt;br&gt;Intervention3: HCQ high dose (HCQh): HCQ 600mg BD D1&lt;br&gt;HCQ 300mg BD D2 - D5&lt;br&gt;Control Intervention1: HCQ AZT: HCQ 400mg BD AZT 500mg OD D1&lt;br&gt;HCQ 400mg OD AZT 250 mg OD D2 - D5&lt;br&gt;","Intervention1: Povidone Iodine: 2% Povidone Iodine gargle diluted to 1% (w/v) is used as oropharyngeal gargle and intranasal application given 4 times to 48 laboratory tested COVID-19 patients and followed up for 12 weeks&lt;br&gt;Control Intervention1: normal saline: 48 patients  laboratory tested COVID-19 positive  selected and tested on  7th and 21st day for comparison and followed for 12 weeks to check for any relapse&lt;br&gt;","Intervention1: Convalescent Plasma: 200 ml of ABO compatible plasma  transfusion will be done to the subject randomized for the therapy&lt;br&gt;Control Intervention1: Standard care of treatment: control group will be treated as per Standard care of treatment. The Ministry of Health and Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity. For the management of ARDS or sepsis, the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented.&lt;br&gt;","Other: Standard of care;Drug: Tocilizumab;Drug: Nivolumab;Drug: Chloroquine analog (GNS651)","Drug: Hydroxychloroquine;Drug: Azithromycin;Dietary Supplement: Vitamin C;Dietary Supplement: Vitamin D;Dietary Supplement: Zinc","Intervention1: Dabur Chyawanprash: Dosage and Treatment Duration: &lt;br&gt;Adults (13 -70 years): One teaspoonful (approx. 12 gm of Chyawanprash) twice daily followed by milk&lt;br&gt;Children (5-12 years): Half teaspoonful (approx. 6 gm of Chyawanprash)  twice daily followed by milk&lt;br&gt;&lt;br&gt;Control Intervention1: Milk with Turmeric powder: 200 ml milk with turmeric powder twice daily&lt;br&gt;Control Intervention2: Milk: One cup of milk (approx 200 ml) twice daily&lt;br&gt;","Intervention1: Niclosamide: 500 mg bid for 7-14 days&lt;br&gt;Control Intervention1: Standard of care: As per MoHFW, GoI guidelines&lt;br&gt;","Intervention1: cadamba drug therapy: 1st 3 days 6 doses in every 2 hours &lt;br&gt;QID 3 days &lt;br&gt;then TDS for weeks &lt;br&gt;potency 200&lt;br&gt;&lt;br&gt;","Intervention1: BCG  (Brand Name Tubervac, Serum Institute of India)&lt;br&gt;Tamiflu&lt;br&gt;Hydroxychloroquine&lt;br&gt;Azithromycin: DOSAGE: 0.1 ml BCG should be administered once during the entire period of the trial&lt;br&gt; &lt;br&gt;ROUTE OF ADMINISTRATION: Intradermal Injection &lt;br&gt;&lt;br&gt;COMPOSITION : Live, attenuated BCG Vaccine (Bacillus Calmette-Guerin Strain) Each 1 ml contains between 2 x 106 and 8 x 106 Colony Forming Units (C.F.U.) Diluent: Sodium Chloride Injection I.P.&lt;br&gt;Intervention2: BCG plus STANDARD of CARE as suggested by DCGI: DOSE 0.1 ml&lt;br&gt;ROUTE OF ADMINISTRATION Intradermal&lt;br&gt;FREQUENCY Only once during the entire trial&lt;br&gt;DURATION 1-2 min time required to inject subject. It is not continuous therapy.&lt;br&gt;&lt;br&gt;Control Intervention1: Tamiflu&lt;br&gt;Hydroxychloroquine&lt;br&gt;Azithromycin: None&lt;br&gt;Control Intervention2: SALINE plus STANDARD of CARE as suggested by DCGI: DOSE 0.1 ml&lt;br&gt;ROUTE OF ADMINISTRATION Intradermal&lt;br&gt;FREQUENCY Only once during the entire trial&lt;br&gt;DURATION 1-2 min time required to inject subject. It is not continuous therapy.&lt;br&gt;","Intervention1: Homoeopathic Medicine: Homoeopathic medicine Arsenic album 30c will be given to population residing in hot spots of Red zones of Covid-19 out break. The medicine will be given as medicated globules. 2-4 medicated globules will be given twice daily for 7 days.&lt;br&gt;","Intervention1: MyVir tablets: Dosage Form: Tablet &lt;br&gt;Duration : Day 1 to Day 21 &lt;br&gt;Route : Orally twice daily after meal&lt;br&gt;Control Intervention1: Standard treatment as per hospital protocol for COVID 19: Cases of COVID 19 shall be treated with standard treatment as per hospital protocol for COVID 19 until the recovery&lt;br&gt;&lt;br&gt;Day 1 to Day 21 Route : Orally twice daily after meal As per the Hospital guidelines.&lt;br&gt;Route : Orally&lt;br&gt;Dose: As per standard Hospital policy&lt;br&gt;","Intervention1: Homoeopathic medicine: Homoeopathic medicines will be given to this group patients as an add-on to standard treatmet. Following Individualization medicines will be selected keeping in view pathological aspect of disease. Dose and potency will be according to the frequency, intensity and duration of signs and symptoms. Repetitions will vary from cae to case basis cosidering disease state and vitality of patient. Range of potency from 30, 200, 1M etc will be used.&lt;br&gt;Control Intervention1: Placebo: Placebo group patients will receive identical placebo (globules moistened with dispensing alcohol) as an add on to standard protocol treatment. Dose repetition will be a in similar pattern to medicine group.&lt;br&gt;","Intervention1: hydroxychloroquine along with Standard care Personal protective equipment: 800 mg of hydroxychloroquine on the day of enrollment and 400mg once a week after that for a total of 12 weeks&lt;br&gt;along with standard care Personal protective equipment&lt;br&gt;Control Intervention1: Standard care Personal protective equipment: standard care Personal protective equipment&lt;br&gt;","Intervention1: Guduchi tablet: Tab Guduchi 500mg twice daily for one month&lt;br&gt;Control Intervention1: nil: nil&lt;br&gt;","Intervention1: Yashtimadhu tablet: YASHTIMADHU TABLET -250 mg X 2 tablets b.d.&lt;br&gt;for one month&lt;br&gt;&lt;br&gt;Control Intervention1: nil: nil&lt;br&gt;","Intervention1: Tab Hydroxycholoroquine on day 1 followed by 400 mg OD for 5 days: the efficacy of HCQ as treatment for mild COVID-19 with high risk will be elucidated.&lt;br&gt;the safety of HCQ as treatment for mild COVID-19 with high risk characteristics will be addressed .&lt;br&gt;Intervention2: Tab Hydroxychloroquine (HCQ)400 mg BD on day 1 followed by 400 mg OD for total 5 days&lt;br&gt;: Hydroxychloroquine (HCQ), sold under the brand name Plaquenil among others, is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquineommon side effects include vomiting, headache, changes in vision, and muscle weakness&lt;br&gt;Intervention3: HYDROOXYCHLOROQUINE: HCQ 400 MG BD ON DAY 1 FOLLOWED BY 400 MG OD FOR TOTAL 5 DAYS&lt;br&gt;Control Intervention1: SYMPTOMATIC TREATMENT: CONTROL GROUP WILL RECEIVE SYMPTOMATIC TREATMENT which includes paracetamol and other drugs according to symptoms.&lt;br&gt;","Intervention1: Herbal formulation - Aayudh Advance: Herbal formulation - Aayudh Advanced is a health supplement that helps boost immunity. This product is made from all-natural farm grown extracts. Each essential oil added into this concoction has been specially chosen for its individual immunomodulatory and protective characteristics. When mixed, these oils yield synergistic effect to protect the body from bacteria, viruses and fungi. Their potency is further increased when the mixture is converted into colloids. These colloids provide exponential efficacy that makes the product highly desirable health supplement, immunity booster, bactericide and virucide. &lt;br&gt;&lt;br&gt;Dose is 10 ml three times a day orally before meal. &lt;br&gt;&lt;br&gt;The study shall be from Patients initiation of treatment till complete recovery and discharge from the hospital.&lt;br&gt;Control Intervention1: As Standard treatment suggested by WHO: As standard treatment suggested by WHO For Covid-19 Patients.&lt;br&gt;&lt;br&gt;&lt;br&gt;The study shall be from Patients initiation of treatment till complete recovery and discharge from the hospital.&lt;br&gt;","Intervention1: ARSENIC ALBUM 30: HOMOEOPATHIC MEDICINE ARSENIC ALBUM IN POTNTISED FORM OF 30 CENTICIMAL POTENCY OD DAILY FOR 3 DAYS&lt;br&gt;Control Intervention1: NOT APPLICABLE: NOT APPLICABLE&lt;br&gt;","Intervention1: Thymoquinone 50 mg tablet as an add on to best supportive as per guidelines of clinical management of COVID-19 as issued by MOHFW.: Dose : 50 mg once daily for 14 days&lt;br&gt;Control Intervention1: best supportive care: Best supportive care will be as defined in Guidelines on Clinical Management of COVID-19 issued by MOHFW.&lt;br&gt;","Intervention1: group A -Tab Samshamani Vati &lt;br&gt;2.Anu taila&lt;br&gt;3.rock salt and turmeric duration&lt;br&gt;4.Ayush preventive guidelines: 1.Tab Samshamani Vati 250 mg 2 bid after food with water &lt;br&gt;2.Application of Anu taila 2 drops each  nostrils once a day after bath in the morning&lt;br&gt;3.Gargle with warm water mixed with rock salt and turmeric&lt;br&gt;4.Ayush preventive guidelines for COVID 19 with Yoga and Pranayama- for 8 week&lt;br&gt;&lt;br&gt;Control Intervention1: Group B: Conventional preventive medicine guidelines&lt;br&gt;","Drug: NORS (Nitric Oxide Releasing Solution);Drug: NORS (Nitric Oxide Releasing Solution)","Drug: Baricitinib Oral Tablet;Drug: Imatinib tablets;Drug: Lopinavir/ritonavir;Drug: Hidroxicloroquine","Intervention1: Group I: Ayurveda intervention AYUSH-64 as add-on to standard treament: AYUSH 64: 2 Tablets (500mg each) thrice daily with water after meal for 1 month&lt;br&gt;Control Intervention1: Group II: Standard treatment for COVID-19 infection: Standard treatments for COVID-19 infection as per Maharashtra guidelines&lt;br&gt;","Drug: Acalabrutinib","Other: standard western medicine treatment;Other: Chinese medicine treatment;Drug: YinHu QingWen Decoction(low dose);Drug: YinHu QingWen Decoction","Drug: Hydroxychloroquine;Dietary Supplement: Vitamin C;Dietary Supplement: Vitamin D;Dietary Supplement: Zinc","Drug: Ringer's Acetate","Drug: Methylprednisolone","Drug: Yinhu Qingwen Granula;Drug: Yin Hu Qing Wen Granula(low does);Other: standard medical treatment","Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic","Drug: Hydroxychloroquine;Drug: Clevudine","Drug: Hydroxychloroquine;Drug: Placebo","Drug: Placebos;Drug: Leronlimab (700mg)","Other: Plasma Donation","Drug: Suspension of heat killed (autoclaved) Mycobacterium w;Drug: Standard therapy of COVID-19","Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients","Drug: Heparin","Other: Moxibustion plus Cupping","Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Placebo oral tablet","Drug: Placebos;Drug: Leronlimab (700mg)","Drug: DAS181;Drug: Placebo","Other: Placebo;Drug: Ketamine;Drug: Naltrexone","Procedure: Robot Assisted Percutaneous Cardiovascular Intervention","Drug: Hydroxychloroquine;Other: Placebo","Device: Oxygen supply;Drug: Low molecular weight heparin;Drug: Corticosteroid;Drug: Azithromycin;Drug: Tocilizumab Injection [Actemra];Drug: Ritonavir/lopinavir;Drug: Hydroxychloroquine Sulfate;Radiation: Low-dose radiotherapy","Drug: Etoposide","Biological: Mesenchymal cells;Drug: Standard of care","Behavioral: Brief educational video","Drug: Melphalan;Other: Standard of care","Drug: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)","Biological: Blood samples collection;Other: Saliva collection","Biological: Blood sample;Biological: Low or upper respiratory tract sample;Biological: Stool collection or fecal swab;Genetic: Blood sample for whole genome sequencing;Other: phone call","Drug: IMU-838;Other: Placebo","Drug: Acalabrutinib","Other: Exercise Group","Drug: Zanubrutinib;Drug: Supportive Care;Drug: Placebo","Drug: Hydroxychloroquine","Behavioral: Internet-based self-help;Behavioral: Internet-based self-help after 3 weeks","Drug: Lopinavir-Ritonavir;Drug: Corticosteroid;Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Tocilizumab","Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells;Other: Standard treatment according to the Clinical protocols","Biological: Convalescent plasma;Drug: Standard of care","Device: Emergency Ventilator Splitter","Drug: Clazakizumab;Other: Placebo","Drug: Zilucoplan;Drug: Placebo","Drug: azoximer bromide;Other: Placebo","Device: Helmet Continuous Positive Airway Pressure (CPAP);Device: High Flow Nasal Oxygen (HFNO)","Drug: Azithromycin;Drug: Chloroquine;Drug: Ivermectin;Drug: Nitazoxanide","Drug: Azithromycin Capsule","Diagnostic Test: FilmArray Pneumonia","Other: Pulmonary and Motor Rehabilitation","Drug: Ciclesonide Inhalation Aerosol","Drug: NP-120 (Ifenprodil)","Drug: Plasma from COVID-19 convalescent patient;Drug: Human immunoglobulin","Dietary Supplement: Acacia Senegal;Dietary Supplement: Pectin","Other: Deep Breathing training;Other: Compassion focused intervention","Drug: MAS825;Drug: Matching placebo","Biological: BCG GROUP;Other: PLACEBO GROUP","Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]","Other: NaCl Solution","Biological: Convalescent Plasma from COVID-19 donors","Other: Neuromuscular Electrical Stimulation;Other: Physical Therapy Exercise","Device: Intubation Box;Device: Aerosol Box","Biological: anti-SARS-CoV-2 convalescent plasma","Combination Product: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid","Drug: Nitric Oxide","Dietary Supplement: Ascorbic Acid;Dietary Supplement: Zinc Gluconate;Dietary Supplement: Ascorbic Acid and Zinc Gluconate;Other: Standard of Care","Drug: Standard of Care;Drug: Remdesivir","Drug: Placebo;Drug: PUL-042 Inhalation Solution","Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28;Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28;Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28;Other: Two doses of placebo at the schedule of day 0,28","Other: Serologic testing","Other: Self-prone position recommendation;Other: Usual care","Other: Saline with Baby Shampoo Nasal Irrigation;Other: Saline Nasal Irrigation","Other: Standard of care treatment;Drug: Favipiravir","Drug: Honey;Drug: Nigella Sativa / Black Cumin;Drug: Placebos","Drug: Hydroxychloroquine Sulfate;Drug: Ascorbic Acid","Other: Matched Placebo Hydroxychloroquine;Drug: Hydroxychloroquine - Weekly Dosing;Drug: Hydroxychloroquine - Daily dosing","Diagnostic Test: VitalConnect Vital Sign Patch","Drug: Peginterferon Lambda-1A;Other: placebo","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Device: Biosensors","Drug: Hydroxychloroquine Sulfate;Drug: Bromhexine 8 MG","Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment;Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment;Drug: Standard treatment","Drug: Hydrocortisone;Drug: Sodium Chloride 9mg/mL","Biological: anti-SARS-CoV-2 convalescent plasma","Other: convalescent plasma","Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma","Drug: Hydroxychloroquine","Biological: SARILUMAB","Drug: Almitrine;Drug: Placebo","Drug: Therapeutic Anticoagulation","Drug: Povidone-Iodine Nasal Spray and Gargle;Drug: Povidone-Iodine Nasal Spray and Gargle","Drug: Anakinra plus oSOC;Drug: oSOC","Drug: Sitagliptin","Drug: Enoxaparin;Drug: Enoxaparin","Device: Calm Meditation App","Device: Hydrogen Oxygen Generator with Nebulizer;Other: Standard-of-care","Behavioral: Mindfulness training (MT) Connect","Biological: Blood collection on their first consultation and 10 to 14 days later;Biological: Blood collection on admission and longitudinally","Biological: BNT162a1;Biological: BNT162b1;Biological: BNT162b2;Biological: BNT162c2;Other: Placebo","Other: PSG","Biological: Anti- SARS-CoV-2 Plasma;Biological: SARS-CoV-2 non-immune Plasma","Procedure: Auricular neuromodulation;Procedure: Control","Drug: Sirukumab;Drug: Placebo;Other: Standard of Care (SOC)","Other: Convalescent SARS COVID-19 plasma;Other: Placebo","Drug: LEAF-4L6715;Drug: LEAF-4L7520","Drug: Interleukin-7;Drug: Placebos","Biological: Convalescent Plasma","Drug: Convalescent Plasma Transfusion;Other: Supportive Care;Drug: Random Donor Plasma","Biological: N-803;Other: Saline","Other: blood samples","Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2;Other: Routine care for COVID-19 patients","Drug: Interferon beta 1a;Drug: Placebo","Drug: Hydroxychloroquine;Other: Placebo;Radiation: Radiation therapy","Drug: Lopinavir-Ritonavir;Drug: Hydroxychloroquine","Biological: AV-COVID-19","Biological: Convalescent plasma","Biological: Biological test","Drug: poractant alfa","Other: COVID-19 patients","Drug: Sarilumab Prefilled Syringe","Drug: Prazosin;Other: Standard of care","Biological: MultiStem;Biological: Placebo","Other: plasma hyperimmune;Drug: standard therapy","Device: V/Q Vest","Drug: HCQ + Intravenous Famotidine;Drug: HCQ + Placebo","Drug: Hydroxychloroquine;Drug: Favipiravir;Other: Routine care for COVID-19 patients","Drug: Hydroxychloroquine;Drug: Mannitol","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber);Device: vv-ECMO only (no cytokine adsorption)","Device: gammaCore Sapphire (non-invasive vagus nerve stimulator);Other: Standard of care therapies","Drug: Oral 25-Hydroxyvitamin D3","Drug: Lucinactant","Diagnostic Test: Biological Sample Collection","Biological: convalescent plasma","Device: Continuous Positive Airway Pressure","Procedure: Prone position ventilation","Diagnostic Test: SARS-CoV2 serum antibody testing","Behavioral: Therapy Intervention","Biological: SARS-CoV-2 convalescent plasma","Patients with confirmed severe SARS-CoV-2 infection will be screened and those that meet eligibility criteria, and who consented (or whose next of kin or guardian consent will be enrolled in the study. Patients will be randomized 2:1 on  Day 1 to receive a single dose of 400 mg TCZ (Actemra, Roche Products Pty Limited) administered intravenously over 1 h (in addition to standard of care), or standard of care alone.&lt;br&gt; Standard of care will be determined by the treating clinician for each individual patient and will be in accordance with the evolving treatment guidelines for critically ill patients with COVID-19. Treatments may include antiviral agents (e.g. LPV/r, HCQ), or antibiotics (use adjunctive therapies such as steroids is discouraged but will be allowed if deemed necessary). Adherance to the intervention will be recorded in product accountability log and source data verification.&lt;br&gt;Clinical data collection (ICU interventions including drug treatments, vital signs, adverse events) and safety blood sampling will be performed daily until day 29, ICU discharge, or death, whichever is earlier. If the participant is discharged from ICU but remains hospitalised, data will be collected daily until day 8 and also on Days 15 and Day 29. If the patient is discharged prior to Day 15 or Day 29, then a phone call will be made to ascertain clinical status. Blood sampling for immunological analyses, and chest imaging, will be performed at baseline and select timepoints during the study.&lt;br&gt;We hypothesise that TCZ treatment in conjunction with standard of care will lead to a reduction in the number of days patients admitted to the ICU with severe SARS-CoV-2 infection require ventilatory support, compared with standard of care alone.&lt;br&gt;A total of 150 patients are planned to b","Dietary Supplement: Ergocalciferol;Dietary Supplement: Vitamin D3","Drug: XCEL-UMC-BETA;Other: Placebo","Other: Public space exposure","Intervention 1&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Lopinavir/ritonavir&lt;br&gt;Intervention Description: Lopinavir (400mg)/ritonavir (100mg) twice daily for 10 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;Intervention 2&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Hydroxychloroquine&lt;br&gt;Intervention Description: 800mg twice a day (4x200mg administered 12 hours apart) on Day 1, followed by 400mg twice a day for 6 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;Intervention 3&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Lopinavir / ritonavir plus hydroxychloroquine&lt;br&gt;Intervention Description: Lopinavir (400mg)/ritonavir (100mg) twice daily for 10 days plus hydroxychloroquine 800mg twice a day (4x200mg administered 12 hours apart) on Day 1, followed by 400mg twice a day for 6 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;","The aim of this project is to conduct a preliminary (uncontrolled) quasi-experimental before and after study of a novel smartphone application designed to support the mental health and wellbeing of Junior Medical Officers across New South Wales. In response to the latest developments with regards to the coronavirus outbreak, the app will contain a dedicated session providing guidance for junior doctors who have pandemic-related anxieties and concerns. &lt;br&gt;&lt;br&gt;The Shift app's conceptual design was modelled after HeadGear, an evidence-informed app delivered by the Black Dog Institute that has been shown to alleviate mental health concerns in working populations (Deady et al., 2018). The prototype and the current version of the Shift app have been adjusted in close collaboration with medical doctors, NSW Health, external digital project designers, and in-house IT developers, user experience, digital learning, and marketing and communication experts within the Black Dog Institute. Initial pilot testing of the Shift app prototype [approved by the South Eastern Sydney Local Health District HREC protocol number 2019/ETH00318, N = 22] resulted in design, content, and user experience updates of the app. &lt;br&gt;&lt;br&gt;Shift is a smartphone application compatible with Apple and Android operating systems. Shift delivers its contents through text, audio, and video addressing topics such as depression, anxiety, traumatic stress, burnout, alcohol and drug use, sleep health, shift work, exams and interviews, work/life balance, diet, exercise, rural and regional placements, bullying, grief, calling for a consult, feeling inadequate, and anxieties related to the coronavirus pandemic. Shift incorporates general therapeutic elements from cognitive behavioural therapy such as thought evaluation","Combination Product: Favipiravir and Hydroxychloroquine","&lt;br&gt;                The study aims to examine the effect of an online parent training in reducing parental stress during Covid-19 pandemic and to determine the optimal design of the program by means of engagement in, satisfaction with, and efficacy of the program.&lt;br&gt;&lt;br&gt;                The training program consists of two modules, one focusing on parents stress, and the second focusing on childrens stress and parenting practices that are appropriate during the pandemic time. Each module consists of 5 topics with short psychoeducative videos and written materials, while quizzes, worksheets, and feedback forms are included for increasing engagement. Parents can flexibly go through the topics during two weeks, requiring a 15-30-minutes daily online activity.&lt;br&gt;&lt;br&gt;                To explore the optimal structure of the training, participants will be randomized into three conditions.&lt;br&gt;                In group 1., parents complete the online training program without having any contact with other participants or the clinician who follows their completion. The clinician contacts a parent only in case of emergency.&lt;br&gt;                In group 2., an online forum will be added to the structure of the training, where participants can share their experiences and contact each other, and ask the clinician. The clinician will be involved in the forum and answer the questions.&lt;br&gt;                In group 3., in addition to this, the clinician will give personal feedback to assignments submitted by the participants.&lt;br&gt;&lt;br&gt;                Block randomization with randomly selected block sizes of 6, 12 is used. The randomization scheme is generated by using the Web site Randomization.com (http://www.randomization.com&lt;br&gt;","This is a two- stage study.&lt;br&gt; Stage 1:  Patients will receive STC3141 60 mg/hr as an initial infusion rate which was based on phase Ia study in health volunteer and 60mg/hr is the dosage in long term infusion in phase Ia without aPTT increase, followed by a dose increase of 10 mg/hr every 6 hours  until the max infusion rate is 100 mg/hr or the aPTT reaches 1.5 x ULN which ever comes first, then the infusion rate will be fixed in the rest of time. The infusion will continue at this rate for 72 hr. &lt;br&gt;Stage 2: Arm 1 will receive STC3141 with the initial infusion rate decided from Stage 1 by DSMB, the dosage will be adjusted every 6 hours according to subjects aPTT as same as stage 1. The target aPTT and Maximum dosage will be based on DSMB recommendation based on data from stage 1. The infusion last up to 120 hours, unless the patients is well enough to be discharged from ICU, or pass away or experienced intolerable adverse event etc.","Drug: Resiniferatoxin;Drug: Placebo","Treatment: Other- Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001)&lt;br&gt;&lt;br&gt;Intervention group: Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 1 and Day 3) PLUS standard of care in ICU&lt;br&gt;&lt;br&gt;Control group: standard of care in ICU&lt;br&gt;&lt;br&gt;The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus platform technology. Cymerus refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.&lt;br&gt;The PI or authorised designee will ensure that the study treatment at site is safely handled and administered in compliance with requirements. The infusion of the treatment itself will last no longer than 40 minutes, at a rate of 1mL/min, administered via ICU staff.","&lt;br&gt;                Patients will be randomised to receive either 1:1 oral Hydroxychloroquine (HCQ) or standard care (no HCQ). Randomisation will be carried out using a validated bespoke automated randomisation system. Randomisation will be stratified by PROTECT sub-group, age and centre.&lt;br&gt;&lt;br&gt;                Haemodialysis subgroup&lt;br&gt;                Dosing: 600mg per week given as 200mg three times per week after each haemodialysis session for 6 months&lt;br&gt;&lt;br&gt;                Vasculitis and transplant subgroups&lt;br&gt;                Dosing: 800mg for first 2 days followed by 400mg once a week for 6 months&lt;br&gt;&lt;br&gt;                Duration of follow up (all subgroups):&lt;br&gt;                Until the end of the trial, on average 6 months&lt;br&gt;","Procedure: Ophthalmologic exam","&lt;br&gt;                The study will be conducted on 25 participants in a hospital setting. Each study participant will give a sample of saliva then use a spray or mouthwash/gargle of PVP-I for one minute followed by PVP-I atomised into each nostril using a simple device, not dissimilar to using a commercial nasal spray. Over the next 2 hours they will provide 5 further saliva samples for analysis.&lt;br&gt;&lt;br&gt;                5 of the 25 patients will undergo the same process, but using water as a control.&lt;br&gt;","&lt;br&gt;                Patients who meet the inclusion and exclusion criteria will be allocated into the study by simple randomization generated by random numbers with the SPSS software to one of the two treatment groups:&lt;br&gt;                1. Group 1 (G1) will receive standard therapy for COVID-19 (SARS-CoV-2 infection) and immune plasma from convalescent patients (PC)&lt;br&gt;                2. Group 2 (G2) will receive standard therapy against COVID-19 (SARS-CoV-2 infection) and non-immune plasma&lt;br&gt;&lt;br&gt;                Patients will receive 5mL of plasma/Kg of body weight intravenous (IV) for one occasion.&lt;br&gt;&lt;br&gt;                Patients will be followed up daily for 21 days or until the day of hospital discharge before the 21 days. If patients require a longer hospital stay, data from the patients will be collected at the time of discharge too. The clinical status of the patient will be assessed before the start of therapy (baseline) and on days 1, 3, 7, 14, and 21. SOFA, thoracic X-ray and/or tomography if possible will also be documented at discharge.&lt;br&gt;","Biological: COVID-19 Convalescent Plasma","&lt;br&gt;                Allocation to either rapid local sequencing (c. 24-48 h) or lack of rapid local sequencing (i.e. via Wellcome Sanger Institute at &gt;96 h) will be dependent on the time of the study (see below). All sites will perform both rapid and standard sequencing in sequentially.&lt;br&gt;&lt;br&gt;                Proposed study duration: 12 months; comprising 6 months of set-up, baseline data collection, interventional data collection) and up to 6 months of data cleaning, data analysis and reporting.&lt;br&gt;&lt;br&gt;                Study intervention: Genomic-sequence informed IPC measures: Use of virus (COVID-19) genome sequence report to inform infection prevention control procedures. Rapid or standard (time to return to sites) receipt of virus (COVID-19) genomic sequencing reports.&lt;br&gt;&lt;br&gt;                1. Baseline/control phase 1&lt;br&gt;                Sample collection and genomic sequencing from COVID-19 positive participants suspected of acquiring infection in hospital (suspected nosocomial COVID-19 infection where tested positive &gt;48 h after hospital admission) where sequencing reports are not received by Infection Prevention Control (IPC) site teams.&lt;br&gt;&lt;br&gt;                2. Site intervention phase&lt;br&gt;                Sample collection and genomic sequencing from COVID-19 positive participants suspected of acquiring infection in hospital where sequencing reports generated both rapid or standard and received by site IPC teams for interpretation and action.&lt;br&gt;&lt;br&gt;                3. Control phase 2&lt;br&gt;                Sample collection and genomic sequencing from COVID-19 positive participants suspected of acquiring infection in hospital where sequencing reports not interpreted/actioned by IPC site teams - where deemed ethical and approved by oversight committee.&lt;br&gt;&lt;br&gt;                Cohort follow baseline (no report receipt","&lt;br&gt;                The trial will initially be two-arm, comparing usual care to usual care with hydroxychloroquine treatment.&lt;br&gt;&lt;br&gt;                The trial will be implemented in the first instance in practices that are already part of the RCGP RSC Network. Currently, over 500 practices are part of this network, with 100 already offering a sentinel viral swabbing service which is being scaled up and due to the pandemic, all practices in the UK have been asked to join the RCGP RSC Network.&lt;br&gt;&lt;br&gt;                A platform trial, in contrast to say a  traditional two-arm design, allows multiple arms to be considered simultaneously, and interventions can be dropped and replaced as evidence emerges for effectiveness or lack of it. The intent is to establish an on-going trial infrastructure within a master protocol that uses all the data already accumulated for the assessment of current and subsequently introduced interventions. New interventions will only be added after submission to the appropriate approval bodies.&lt;br&gt;&lt;br&gt;                The PRINCIPLE trial will begin as a 1:1 randomised trial of usual care plus study-specific medication (in the first instance hydroxychloroquine) versus usual care alone but the study design has the capability to add additional interventions over time. The evaluation of any new interventions will be governed by the master protocol, including adaptive and decision criteria. In addition, the inclusion of any new interventions will require supplementary appendices to the protocol and SAP.&lt;br&gt;&lt;br&gt;                The initial drug is hydroxychloroquine sulphate 200 mg tablets. The tablets are for oral administration. One tablet (200 mg) hydroxychloroquine to be taken twice daily for 7 days by mouth (14 tablets in total). This is the standard therapeutic dose for its n","&lt;br&gt;                Randomisation will be performed according to a 1:1 ratio (Usual Care/Control Arm vs. Research Arms). Patients will be randomised using an online randomisation system, using stratification (variable of care status, either on ward or ICU) via minimisation, where relevant to the research arms.&lt;br&gt;&lt;br&gt;                Initial approval was received for a single centre trial, but an amendment is underway to make this a multi-centre trial.&lt;br&gt;&lt;br&gt;                Patients will be randomised into either a control group, or to receive an interventional treatment.&lt;br&gt;                Arm 1: Usual Care (Control)&lt;br&gt;                Arm 2: Usual Care + Gemtuzumab Ozogamicin&lt;br&gt;&lt;br&gt;                Gemtuzumab Ozogamicin will be given intravenously into the arm on up to three separate occasions: on Day 1, Day 5 and Day 10 of the trial. The patient may not receive all three doses if they have recovered or they develop side effects and their trial doctor decides that they should not have any more. Participants will be actively followed up for 28 days from the first dose.&lt;br&gt;&lt;br&gt;                Please Note: Additional intervention arms will be added during the trial via substantial amendment to the protocol&lt;br&gt;","Drug: Hydroxychloroquine Sulfate 200 MG","Drug: Drug: Isotretinoin plus Tamoxifen;Drug: Aerosolized Isotretinoin plus Tamoxifen","Group A:self-service pulmonary rehabilitation;Group B:Internet-assisted pulmonary rehabilitation;","Case series:Convalescent Plasma of COVID-19 patients;","Drug: Dociparastat sodium;Drug: Placebo","Interventions group: &lt;br&gt;Simulation General Anaesthesia: GENERAL ANAESTHESIA (GA) for emergency caesarean delivery category 1 (Cat -1) in a patient with confirmed COVID  19.&lt;br&gt;Simulation Spinal A: SPINAL ANAESTHESIA (SA) for emergency caesarean delivery category 1 (Cat -1) in a patient with confirmed COVID  19.&lt;br&gt;&lt;br&gt;The second intervention will occur immediately after the first intervention once the simulation setting is ready to start. &lt;br&gt;&lt;br&gt;&lt;br&gt;Simulators&lt;br&gt;1.\tGeneral Anaesthesia - SiMoM (Laerdal Medical, Stavanger, Norway). The intubation will be a Cormack &amp; Lehane grade-1 laryngoscopic view, allowing intubation on the first attempt. There will be an intravenous line connected to fluids in the simulator where medications can be injected. &lt;br&gt;2.\tSpinal Anaesthesia - Spinal injection simulator (Lifeform Spinal Injection Simulator / NASCO, Fort Atkinson). For this simulation, an actor will simulate a pregnant patient to be seated in position for the procedure. There will be a line connected to fluids to simulate an intravenous line. Once the actor is in adequate position, the spinal simulator will be put on his side. The SA will be performed in the simulator.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;For both interventions&lt;br&gt;&lt;br&gt;To maintain a realistic simulation, the flowchart used for the simulation is the same used in our institution for management of suspected or confirmed COVID  19 patients. Consultants will have to follow the Mackay Hospital and Health Service Perioperative Workflow for Suspected or Confirmed COVID-19 Cases. All teams involved in the simulation will follow their roles based on the flowchart. This flowchart based on recommendations on the Perioperative management of suspected/ confirmed cases of COVID-19.1&lt;br&gt;It briefly, it consists of:&lt;br&gt;Preoperative considera","The administration of inhaled isoflurane for sedation, compared to intravenous sedation. In this pilot study, patients will intermittent receive inhaled or intravenous sedation, according to the randomisation scheme.","&lt;br&gt;                The researchers aim to conduct a pilot prospective design of 6 to 12 months duration regarding the use of therapeutic plasma exchange (TPE) in serious COVID-19. The study will be multicenter. Adult ICU patients with serious/life-threatening COVID-19 receiving standard empiric therapies as per institutional and international protocols such as available antiviral treatments, hydroxychloroquine, mechanical (ARDS-net and prone position) ventilation,  fluid resuscitation, vasoactive substances, antibiotics amongst other usual ICU supportive therapies will be randomised to control or TPE groups. Those in the control group will receive usual care. Those in the TPE group will receive usual care plus TPE therapy.&lt;br&gt;&lt;br&gt;                Randomization of the aforementioned groups will be done as follows. Eligible consented patients will be randomized after their stratification by ICU center and two PaO2/FIO2 ratio categories (&gt;150 and &lt;=150). Randomization will occur in variable block sizes of 4 to 8 patients. The researchers will utilize a web-based randomization service (randomize.net) to allocate patients to their respective strata prior to the intervention or control therapy. Given the nature of the TPE technology, the intervention will be unblinded (open label); hence, no enrollment concealment will be expedited. However, the lack of allocation concealment will be mitigated as much as possible by the following measures.                                                                       First, the primary outcome of mortality will not be disputable. Second, the researchers have standardized co-interventions that impact on mortality as much as possible. These interventions include:&lt;br&gt;                1. Concomitant drug therapies for COVID-19&lt;br&gt;                2. Algor","All participants will receive at the different time intervals through our custom-made Digital Cardiac Counselling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes. Additional to above participants, the intervention group will receive through the Digital Cardiac Counselling platform different modules with E-counselling for risk factors evaluated in the questionnaires. Additional to known risk factors a Covid-19 module will be used as well.&lt;br&gt;Digital counselling&lt;br&gt;&lt;br&gt;The digital counselling modules for intervention group are described below:&lt;br&gt; &lt;br&gt;-Screening for reduced physical fitness. If there are signs for a decreased physical condition we will refer the patient, after consultation, for a digital intake with our physiotherapist. The patients then get access to a digital module with information and videos of physical exercise training. The patient gets a trainings schedule and we will contact the patient after about 1 and 3 weeks to check their progression and to give additional advice when needed. &lt;br&gt; &lt;br&gt;-Screening for smoking. If the patient smokes and is motivated to quit smoking, we will refer, after consultation, for a digital intake with one of our stop smoking nurses. Then, a digital and telephone supported counselling will start after an informed and shared decision making with the nurse. When needed, supportive medication can be prescribed. &lt;br&gt; &lt;br&gt;-Screening for malnutrition and obesity. If there are signs of malnutrition (MUST-score) or obesity (BMI &gt;30) we will refer the patient, after consultation, for a digital intake with a dietician. The patients then get access to a digital module with information about a healthy diet. We will contact the patient ever 2 weeks in case of malnutrition and","Three conditions are tested (each lasting 30 min, the measurement period): &lt;br&gt;1. Oxygen delivery via a nonrebreathing mask (current standard of care) with sufficient inflow of O2 (which does not create PEEP).  &lt;br&gt;2. Oxygen delivery via the face mask with zero PEEP in order to test the effect of the mask alone. &lt;br&gt;3. Oxygen delivery via the face mask with PEEP of 7.5 cmH2O in order to test effect of moderate PEEP.","All COVID-19 patients with an indication for admittance to the ICU department will be included and will (after informed consent) be rondomised to receive a bolus of alkaline phosphatase of 1000iU, followed by 9000 iU the same day. For the 3 consecutive days 10.000iU/day on top of regular care.","&lt;br&gt;                Current interventions as of 22/05/2020:&lt;br&gt;&lt;br&gt;                Volunteers will initially be required to complete an online screening. This is an initial confirmation of eligibility. Volunteers will initially be invited for a screening visit. Prior to attending they will have received written information about the study and had time to consider it. At the screening visit, a doctor will explain about the study and answer any questions they may have. If the volunteer decides to take part, they will be asked to sign a consent form. The doctor will then check whether the volunteer is eligible to take part. This will involve taking a medical history, performing a physical examination, taking blood tests, urine tests, and measuring blood pressure and temperature.&lt;br&gt;&lt;br&gt;                The doctor will then write to the volunteer's own GP to enquire about their medical health. If all the inclusion criteria are met and none of the exclusion criteria are present then the volunteer is invited to return for vaccination. Due to the need for rapid delivery of this study, there will be minimal flexibility around appointment dates.&lt;br&gt;&lt;br&gt;                Before vaccination, volunteers will be asked about their recent health to ensure that they are still medically fit. They will have blood tests taken and participants will be randomised (Group 1: 3:1, Group 2: 5:1, Groups 3-5: 1:1) to receive either ChAdOx1 nCoV-19 or MenACWY.&lt;br&gt;&lt;br&gt;                Group 1&lt;br&gt;                80 participants aged 56-&lt;70 years will receive either single dose ChAdOx1 nCoV-19 5 x 10(10) virus particles (vp) or MenACWY at day 0, or two dose ChAdOx1 nCoV-19 5 x 10(10) vp or MenACWY at day 0 and day 28, then followed up at days 3, 7, 14, 28, 56, 182 and 364. Two dose subgroups will have additional visits at days 31, 3","&lt;br&gt;                ARM 1-schools: Will remain closed for 5-10 level pupils.&lt;br&gt;                ARM-2-schools: Will open for 5-10 level pupils.&lt;br&gt;                The study period will last 4 weeks. The primary outcome measure will include data from 2 weeks after the commencement of the trial, and until 4 weeks after the trial period. We plan to randomise through a simple transparent process, e.g. a televised draw. We will do this by stratified randomisation, with separate draws of schools for each municipality. Hence, half of the schools in each municipality will be allocated to opening for all grades (110), and the other half to remaining closed for 510 grade (partial closure).&lt;br&gt;&lt;br&gt;","Prevent a supine position during sleep by the use of a Sleep Position Trainer, a small wearable device that trains patients to not sleep on their back by using gentle vibrations (1:1 randomization). In both groups sleep position will be continuously registered.","BCG-vaccine","1.\tPlacebo treatment&lt;br&gt;2.\tBCG vaccination&lt;br&gt;3.\tBCG vaccination + oral bisphosphonate supplementation (alendronic acid)&lt;br&gt;4.\tBCG vaccination + MMR vaccine&lt;br&gt;5.\tMMR vaccine alone&lt;br&gt;","Experimental group:standard treatment + shuanghuanglian treatment;Control group:standard treatment;","Case series:Taking artemisinin-pipequine tablets;","&lt;br&gt;Trade Name: Alveofact&lt;br&gt;Product Name: Alveofact&lt;br&gt;Pharmaceutical Form: Powder for nebuliser suspension&lt;br&gt;INN or Proposed INN: SF-RI 1&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 45-&lt;br&gt;&lt;br&gt;","control group:basic western medical therapies;experimental group:Reduning injection combined with basic western medical therapies;","Patients in this study are treated with intravenous tociluzumab: 8 mg/kg (maximum dose 800 mg), which can be repeated at the same dose after 8 hours if the hypoxia has not improved. This is the approved dose for cytokine release syndrome.","&lt;br&gt;Product Name: otilimab&lt;br&gt;Product Code: GSK3196165&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: OTILIMAB&lt;br&gt;CAS Number: 1638332-55-4&lt;br&gt;Current Sponsor code: GSK3196165&lt;br&gt;Other descriptive name: Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: IMU-838&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Vidofludimus calcium&lt;br&gt;CAS Number: 1354012-90-0&lt;br&gt;Current Sponsor code: VIDO-06, IM90838, SC90838&lt;br&gt;Other descriptive name: Vidofludimus calcium anhydrous&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 22.5-&lt;br&gt;&lt;br&gt;Trade Name: Tamiflu 75 mg Hard Capsules&lt;br&gt;Product Name: Tamiflu 75 mg Hard Capsules&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Oseltamivir&lt;br&gt;CAS Number: 196618-13-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;Trade Name: Tamiflu 6 mg/ml powder for oral suspension&lt;br&gt;Product Name: Tamiflu 6 mg/ml powder for oral suspension&lt;br&gt;Pharmaceutical Form: Oral suspension&lt;br&gt;INN or Proposed INN: Oseltamivir&lt;br&gt;CAS Number: 196618-13-0&lt;br&gt;Concentration unit: ml millilitre(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: azithromycine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 117772-70-0&lt;br&gt;&lt;br&gt;Trade Name: azithromycine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 117772-70-0&lt;br&gt;&lt;br&gt;Trade Name: azithromycine&lt;br&gt;Pharmaceutical Form: Syrup&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 117772-70-0&lt;br&gt;&lt;br&gt;","Infotainment intervention with (social) media and influencers.","&lt;br&gt;Trade Name: Roactemra&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Selinexor&lt;br&gt;Product Code: KPT-330, XPOVIO&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Selinexor&lt;br&gt;CAS Number: 1393477-72-9&lt;br&gt;Current Sponsor code: KPT-330&lt;br&gt;Other descriptive name: SELINEXOR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","All treatment arms contain standard supportive care during hospital and:&lt;br&gt;1.\tChloroquine arm: loading dose 600mg as chloroquine base followed by 300mg 12 hours later followed by 300mg twice a day; total treatment duration 5 days (same dose as LCI guideline) &lt;br&gt;2.\tHydroxychloroquine arm: loading dose 400mg bid followed by 200mg twice a day; total treatment duration 5 days (same dose as LCI guideline)&lt;br&gt;3.\tNo antiviral treatment arm","&lt;br&gt;Trade Name: Videsil 100.000 UI&lt;br&gt;Pharmaceutical Form: Oral solution in sachet&lt;br&gt;INN or Proposed INN: COLECALCIFEROL&lt;br&gt;CAS Number: 67-97-0&lt;br&gt;Other descriptive name: VITAMIN D3&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 100.000-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: BIO101&lt;br&gt;Product Code: BIO101&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: NA&lt;br&gt;CAS Number: 5289-74-7&lt;br&gt;Current Sponsor code: BIO101&lt;br&gt;Other descriptive name: 20-hydroxyecdysone&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 175-&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Drug: Standard of care;Drug: TAK-981","&lt;br&gt;Trade Name: Hidroxicloroquina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;Current Sponsor code: REMDESIVIR&lt;br&gt;Other descriptive name: REMDESIVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Chloroquine&lt;br&gt;CAS Number: 54-05-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Kaletra&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Rebif&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;CAS Number: 220581-49-7&lt;br&gt;Current Sponsor code: Interferon beta-1a&lt;br&gt;Other descriptive name: Interferon beta-1a&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 152-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: TD-0903&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;INN or Proposed INN: TD-0903&lt;br&gt;Current Sponsor code: TD-0903&lt;br&gt;Other descriptive name: TD-0903&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-10&lt;br&gt;Pharmaceutical form of the placebo: Inhalation solution&lt;br&gt;Route of administration of the placebo: Inhalation use&lt;br&gt;&lt;br&gt;","Drug: Remdesivir;Drug: Standard of Care","Drug: Aviptadil by intravenous infusion + maximal intensive care;Drug: Normal Saline Infusion + Maximal intensive care","&lt;br&gt;Trade Name: BCG Vaccine 'AJ Vaccines'&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Bacillus Calmette-Guerin&lt;br&gt;Other descriptive name: BACILLUS CALMETTE-GUERIN VACCINE&lt;br&gt;Concentration unit: CFU/ml colony forming unit(s)/millilitre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 2 x 10_5-8 x 10_5&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intradermal use&lt;br&gt;&lt;br&gt;","Drug: Hydroxychloroquine + azithromycin;Drug: Hydroxychloroquine Oral Product","Drug: Colchicine","Drug: Chloroquine or Hydroxychloroquine;Drug: Placebo","Drug: CD24Fc;Drug: Placebo","Imatinib or placebo","Drug: 0.9%NaCl;Drug: BCG Vaccine","Drug: Sarilumab SAR153191;Drug: Placebo","Drug: Hydroxychloroquine + azithromycin;Drug: Hydroxychloroquine","Drug: Chloroquine phosphate;Other: Telemedicine","Drug: Azithromycin;Drug: Placebos","Drug: Nitric Oxide","Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate","Drug: Hyperbaric oxygen","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","&lt;br&gt;Product Name: Brensocatib&lt;br&gt;Product Code: INS1007&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Brensocatib&lt;br&gt;CAS Number: 1802148-05-5&lt;br&gt;Current Sponsor code: INS1007&lt;br&gt;Other descriptive name: AZD7986&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Drug: Tocilizumab;Biological: Pembrolizumab (MK-3475)","Procedure: Human biological samples","Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate;Drug: Baricitinib (janus kinase inhibitor)","Drug: Hydroxychloroquine;Drug: Placebo","Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin;Other: Usual antibiotic treatment","Drug: Valsartan (Diovan);Drug: Placebo oral tablet","Drug: Hydroxychloroquine;Drug: Placebo","&lt;br&gt;Trade Name: ROACTEMRA&lt;br&gt;Product Name: tocilizumab&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Current Sponsor code: TOCILIZUMAB&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","Drug: BLD-2660","Drug: Linagliptin;Drug: Insulin regimen","Drug: Nitric Oxide Gas;Other: Inhaled Supplemental Oxygen","&lt;br&gt;Product Name: LEVOFLOXACIN&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: LEVOFLOXACIN &lt;br&gt;CAS Number: CAS 138199-7&lt;br&gt;&lt;br&gt;Product Name: HYDROCORTISONE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: HYDROCORTISONE&lt;br&gt;CAS Number: 50-23-7&lt;br&gt;&lt;br&gt;Product Name: CEFTRIAXONE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CEFTRIAXONE&lt;br&gt;CAS Number: 73384-59-5&lt;br&gt;&lt;br&gt;Product Name: AZITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: AZITHROMYCIN&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;&lt;br&gt;Product Name: CLARITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CLARITHROMYCIN&lt;br&gt;CAS Number: 81103-11-9&lt;br&gt;Other descriptive name: CLARITHROMYCIN LACTOBIONATE&lt;br&gt;&lt;br&gt;Product Name: ERYTHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: ERYTHROMYCIN &lt;br&gt;CAS Number: 3847-29-8&lt;br&gt;&lt;br&gt;Product Name: AMOXICILLINE-CLAVULANTE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: AMOXICILLIN &lt;br&gt;CAS Number: 34642-77-8&lt;br&gt;INN or Proposed INN: POTASSIUM CLAVULANATE&lt;br&gt;CAS Number: 61177-45-5&lt;br&gt;&lt;br&gt;Product Name: AZITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: AZITHROMYCIN MONOHYDRATE&lt;br&gt;CAS Number: 121470-24-4&lt;br&gt;&lt;br&gt;Product Name: CLARITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CLARITHROMYCIN&lt;br&gt;CAS Number: 81103-11-9&lt;br&gt;&lt;br&gt;Product Name: PIPERACILLIN-TAZOBACTAM&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: PIPERACILLIN&lt;br&gt;CAS Number: 66258-76-2&lt;br&gt;INN or Proposed INN: TAZOBACTAM &lt;br&gt;CAS Number: CAS 89785-84&lt;br&gt;&lt;br&gt;Product Name: ROXITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: ROXITHROMYCIN&lt;br&gt;CAS Number: 80214-83-1&lt;br&gt;Other descriptive name: ROXITHROMYCIN&lt;br&gt;&lt;br&gt;Product Name: CEFTAROLINE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CEFTAROLINE FOSAMIL&lt;br&gt;CAS Number: 229016-73-3&lt;br&gt;Other descriptive name: CEFTAROLINE FOSAMIL&lt;br&gt;&lt;br&gt;Product Name: MOXIFLOXACIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: MOXIFLOXACIN &lt;br&gt;CAS Number: 186826-86-8&lt;br&gt;Other descriptive name: MOXIFLOXACIN HYDROCHLORIDE&lt;br&gt;&lt;br&gt;Trade Name: Oseltamivi","Drug: Peginterferon lambda alfa-1a subcutaneous injection;Other: Saline","Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector);Other: Placebo","Biological: Convalescent plasma","Drug: Stem Cell Product","Drug: Sirolimus;Drug: Placebo","Drug: Placebo;Drug: TD-0903","Biological: Placebo Vaccine;Biological: BCG Vaccine","Other: Convalescent plasma","Drug: Transfusion of COVID-19 convalescent plasma","Drug: Gimsilumab;Drug: Placebo","Drug: Ruxolitinib;Procedure: Peripheral blood draw","Other: convalescent plasma from recovered COVID 19 donor","Drug: Colchicine Tablets;Other: Current care per UCLA treating physicians","Biological: serology test;Diagnostic Test: NG Biotech;Biological: nasopharyngeal swab;Biological: rectal swab;Biological: saliva sample","&lt;br&gt;Product Name: ChAdOx1 nCoV-19&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Powder and solvent for solution for injection&lt;br&gt;Route of administration of the placebo: Intramuscular use&lt;br&gt;&lt;br&gt;Trade Name: Nimenrix&lt;br&gt;Product Name: Nimenrix&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Menveo&lt;br&gt;Product Name: Menveo&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;&lt;br&gt;","Drug: Povidone-Iodine 2%;Drug: Povidone-Iodine 0.5%;Drug: Isotonic saline 0.9%","Biological: Lenzilumab;Drug: Standard of Care","Biological: Convalescent COVID 19 Plasma","Drug: Nitric Oxide Gas","Drug: HCQ;Drug: HCQ+AZT;Drug: Placebo","Procedure: alveolar recruitment","Drug: Hydroxychloroquine;Other: Placebo","Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia Apheresis System (Optia SPD Protocol)","Drug: Placebo;Drug: HB-adMSC","Drug: Hydroxychloroquine;Other: Placebo","Drug: Leflunomide","Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP);Biological: Standard Plasma (FFP)","Drug: Ascorbic Acid;Drug: Hydroxychloroquine Sulfate;Drug: Azithromycin;Drug: Folic Acid","Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.","Biological: blood samples","Drug: Budesonide Nasal;Other: Physiological serum","Drug: Clazakizumab;Drug: Placebo","Diagnostic Test: conjunctival swab","Drug: Hydroxychloroquine","Drug: Hydroxychloroquine SAR321068;Drug: Placebo","Drug: Alteplase 50 MG [Activase];Drug: Alteplase 100 MG [Activase]","Drug: Hydroxychloroquine (HCQ);Drug: Azithromycin (Azithro);Drug: Placebo for Hydroxychloroquine;Drug: Placebo for Azithromycin","Drug: Tranexamic acid tablets;Drug: Placebo oral tablet","Biological: Plasma;Other: Best Available Therapy","Other: Cash transfer","Drug: TJ003234;Drug: Placebo","Biological: Bactek-R","Drug: AVM0703;Drug: Placebo;Drug: hydrocortisone","Drug: Enoxaparin","Behavioral: Usual care positioning with no instructions;Behavioral: Intermittent prone positioning instructions","Drug: Fluvoxamine;Drug: Placebo","Drug: Ruxolitinib;Drug: Placebo","Drug: Dietary Supplement containing resistant starch;Dietary Supplement: Placebo Starch","Drug: LY3127804;Drug: Placebo","Drug: FT516","Drug: RBT-9 (90 mg);Drug: 0.9% sodium chloride (normal saline)","Drug: Anakinra alone (stages 2b/3);Drug: Anakinra and Ruxolitinib (overcome stage 3);Other: Standard of care","Biological: Hyperimmune plasma;Drug: Hidroxicloroquina + Azitromicina o Lopinavir/ritonavir + Interferon -1b + Hidroxicloroquina","Drug: SnPP Protoporphyrin plus Sunlight exposure;Drug: SnPP Protoporphyrin plus Sunlight exposure;Drug: SnPP Protoporphyrin plus Sunlight exposure;Drug: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.;Other: placebo","Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.;Drug: Transfusion of standard Plasma.","Radiation: Low Dose Radiation Therapy","Device: Telerehabilitation","Biological: SARS-CoV-2 rS;Other: Matrix-M Adjuvant;Other: NSS Saline Placebo","Drug: Doxycycline;Drug: Placebo","Drug: Vazegepant (BHV-3500);Drug: Placebo","Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.;Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection;Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation;Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation","Device: current IPAC-UHN PPE;Device: modified IPAC-UHN PPE","Biological: SARS-CoV-2 convalescent plasma;Biological: Plasma from a volunteer donor","Drug: Hydroxychloroquine","Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Zinc Sulfate;Drug: Doxycycline","Drug: Hydroxychloroquine;Dietary Supplement: Vitamin D","Drug: Hydroxychloroquine;Drug: Lopinavir/ritonavir 400 mg/100 mg;Other: Placebo","Drug: Baricitinib;Drug: Hydroxychloroquine;Drug: Placebo Administration","Drug: Sodium Bicarbonate","Drug: N-acetylcysteine","Behavioral: Computer task questionnaires","Drug: Camostat Mesilate;Other: Placebo","Drug: Prednisone;Drug: Hydrocortisone","Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma","Drug: Hydroxychloroquine Sulfate 200 MG;Other: Placebo","Drug: Canakinumab;Drug: Placebo","Dietary Supplement: Quercetin Prophylaxis;Dietary Supplement: Quercetin Treatment","Diagnostic Test: RT-PCR Covid-19","Biological: Otilimab;Biological: Placebo;Drug: Standard of care","Behavioral: Nudge","Diagnostic Test: Low-dose Chest CT","Drug: Atorvastatin","Biological: V-SARS","Biological: CYNK-001","Drug: Canakinumab Injection 600mg;Drug: Canakinumab Injection 300mg;Drug: Placebos","Drug: Support treatment;Drug: Inactivated convalescent plasma","Drug: Plitidepsin 1.5 mg/day;Drug: Plitidepsin 2.0 mg/day;Drug: Plitidepsin 2.5 mg/day","Drug: Inhaled Hypertonic ibuprofen","Drug: Enoxaparin Prophylactic Dose;Drug: Heparin Infusion;Drug: Heparin SC;Drug: Enoxaparin/Lovenox Intermediate Dose","Biological: Tocilizumab","Behavioral: Anxiety Reduction Training;Behavioral: Kundalini Yoga and Anxiety Reduction Training;Behavioral: Meditation and Anxiety Reduction Training","Drug: Oxytocin;Drug: Standard of Care","Biological: Remestemcel-L;Drug: Placebo","Behavioral: Messaging","Other: Prone positioning","Biological: SARS-CoV-2 convalescent plasma","Biological: Organicell Flow;Other: Placebo","Drug: Peginterferon Lambda-1A","Drug: Veru-111","Drug: Artemisinin / Artesunate;Other: placebo","Drug: Nitric Oxide","Device: non-contact magnetically-controlled capsule endoscopy","Biological: PLX-PAD;Biological: Placebo","Drug: Desferal 500 MG Injection","Drug: Tofacitinib;Drug: Hydroxychloroquine","Drug: Convalescent Plasma","Drug: Wharton's jelly derived Mesenchymal stem cells.;Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)","Drug: Ivermectin;Drug: Placebo","Other: Standard of care;Drug: Baricitinib;Drug: Ravulizumab","Device: COViage","Drug: LB1148;Drug: Placebo","Radiation: Low Dose Radiotherapy","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma);Biological: Control (albumin 5%)","Drug: Ciclesonide;Drug: Placebo","Drug: IVERMECTIN (IVER P) arm will receive IVM 600 g / kg once daily plus standard care. CONTROL arm will receive standard care.","Dietary Supplement: Probiotic","Other: Prone position","Drug: ArtemiC;Drug: Placebo","Drug: DFV890;Drug: Standard of Care (SoC)","Drug: Dipyridamole 100 Milligram(mg);Drug: Placebo oral tablet","Drug: Convalescent plasma","Device: MLS Laser;Other: Regular Inpatient Medical Care","Drug: MSTT1041A;Drug: MSTT1041A-matched Placebo;Drug: UTTR1147A;Drug: UTTR1147A-matched Placebo","Drug: Hydroxychloroquine;Drug: Ivermectin;Drug: Placebo","Biological: IC14;Other: Placebo","Device: Active PBMT/sMF;Device: Placebo PBMT/sMF","Diagnostic Test: Ejaculated semen sample","Drug: Standard Treatment;Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions","Behavioral: Mindfulness","Biological: COVID-19 Specific T Cell derived exosomes (CSTC-Exo)","Drug: Montelukast 10mg","Diagnostic Test: COVID-19 PCR and Serology","Drug: Cyclosporine;Drug: Standard treatment","Drug: EIDD-2801;Drug: Placebo","Drug: Convalescent Plasma","Other: convalescent plasma application to SARS-CoV-2 infected patients","Drug: Hydroxychloroquine;Drug: Hydroxychloroquine + Azithromycin","Drug: Ulinastatin;Drug: Placebo","Drug: Baricitinib Oral Tablet","Drug: EDP1815;Drug: Dapagliflozin;Drug: Ambrisentan;Other: Standard of care","Combination Product: stem cells","Radiation: Lung Irradiation","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil];Drug: Azithromycin 250 MG Oral Capsule;Drug: Placebo oral tablet;Drug: Placebo oral capsule","Behavioral: The CRAFT program (adapted due to COVID-19);Behavioral: The MBSR program (adapted due to COVID-19)","Drug: Povidone-Iodine;Drug: Normal saline","Drug: ABX464;Drug: Placebo","Biological: COVID-19 convalescent hyperimmune plasma;Biological: Non-convalescent fresh frozen plasma (Standard plasma)","Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :","Behavioral: Mindfulness intervention;Behavioral: Non-Mindfulness intervention","Drug: Silymarin;Drug: Placebo","Behavioral: Intervention program","Device: Robotic therapy","Drug: Ivermectin 6 MG Oral Tablet (2 tablets)","Drug: Hydroxychloroquine","Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed;Drug: Group 2: control group with enoxaparin 40mg/d","Biological: MSC Treatment;Biological: Saline Control","Drug: Angiotensin Receptor Blockers","Other: Digital cardiac Counseling","Biological: CONVALESCENT PLASMA","Behavioral: Internet-based guided self-help based on CBT principles","Procedure: Awake Prone Positioning;Procedure: Standard care","Behavioral: Intervention App","Device: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette","Radiation: Ultra-Low-dose radiotherapy;Device: ventilatory support with oxygen therapy;Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Piperacillin/tazobactam;Drug: Low molecular weight heparin;Drug: Corticosteroid injection;Drug: Tocilizumab","Biological: COVID-19 convalescent plasma;Biological: Anti-COVID-19 human immunoglobulin;Drug: Standard (specific) therapy for COVID-19","Drug: Imatinib;Drug: Placebo oral tablet","Device: SCD","Drug: AMY-101;Other: WFI 5% glucose","Behavioral: Brief cognitive behavioural therapy;Behavioral: Crisis intervention therapy","Radiation: Low dose radiation therapy","Biological: ResCure","Drug: Hydroxychloroquine;Drug: Placebo","Drug: Aerosolized 13 cis retinoic acid;Drug: Aerosolized All trans retinoic acid;Other: Placebo","Drug: Dexamethasone","Drug: AT-527;Other: Placebo","Behavioral: Basic Body Awareness Therapy;Behavioral: Psychological treatment","Drug: Levilimab;Drug: Placebo","Drug: Clarithromycin","Device: Helmet CPAP;Device: HFNC","Dietary Supplement: Vitamin C;Drug: Hydroxychloroquine;Drug: Azithromycin;Dietary Supplement: Zinc Citrate;Dietary Supplement: Vitamin D3;Dietary Supplement: Vitamin B12","Biological: ACT-20-MSC;Biological: ACT-20-CM;Biological: Placebo","Other: Ayurveda","Biological: anti-SARS-CoV-2 convalescent plasma","Diagnostic Test: conjunctival RT PCR","Biological: COVID-19 Convalescent Plasma","Drug: Mavrilimumab;Drug: Placebo","Drug: Heparin;Drug: 0.9% Sodium-chloride","Drug: Inhaled nitric oxide (iNO);Drug: Nitrogen gas;Drug: Oxygen gas","Biological: Mesenchymal Stromal Cells","Biological: Octagam 10%;Other: Placebo","Device: Nitric Oxide delivered via LungFit system","Device: Patient Status Engine","Biological: BM-Allo.MSC;Biological: Placebo","Behavioral: Yoga group;Behavioral: High Intensity Interval Training group;Behavioral: Combination","Drug: Degarelix;Other: Saline","Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml","Drug: Resveratrol;Dietary Supplement: Vitamin D3","Drug: Sargramostim;Other: Normal Saline 0.9%","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);Biological: Placebo","Behavioral: Daily Coping Toolkit","Other: Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later","Other: after-each-case room disinfection;Other: daily room disinfection","Dietary Supplement: Lactobaciltus rhamnosus GG;Dietary Supplement: Lactobaciltus rhamnosus GG Placebo","Drug: Vitamin C;Drug: Control","Device: TCC-COVID mHealth solution","Device: Flow controlled ventilation (Evone-ventilator)","Drug: Niclosamide;Drug: Placebo;Other: Telehealth monitoring","Drug: Ivermectin;Drug: Azithromycin;Drug: Cholecalciferol","Device: Bedside lung ultrasound","Biological: human cord tissue mesenchymal stromal cells","Biological: SOC plus 15mg/kg EB05 IV;Other: SOC plus Placebo IV","Drug: Baricitinib","Behavioral: Chat-based support;Behavioral: AWARD plus COVID-specific advice;Behavioral: AWARD advice;Behavioral: COVID-19 related health warning leaflet;Behavioral: Health warning leaflet;Behavioral: SMS-based support;Behavioral: Referral card;Behavioral: COSH Self-help smoking cessation booklet","Drug: Mavrilimumab;Drug: Placebos","Behavioral: Digital Health Online Platform","Dietary Supplement: Nigella sativa","Drug: TD-0903;Drug: Placebo","Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients );Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)","Other: Placebo;Drug: Remdesivir;Drug: Baricitinib","Biological: ChAdOx1 nCoV-19;Biological: MenACWY vaccine;Biological: ChAdOx1 nCoV-19 + boost;Biological: MenACWY vaccine + boost;Biological: ChAdox1 n-CoV vaccine low dose","Drug: LSALT peptide;Drug: Placebo","Other: Physiotherapy","Drug: Favipiravir;Drug: Only Standard Treatment","Biological: Partially HLA-matched Virus Specific T cells (VSTs)","Drug: TXA127;Drug: Placebo","Procedure: Prone Positioning (PP)","Drug: Enoxaparin;Drug: Prophylactic/Intermediate Dose Enoxaparin","Drug: Sodium Nitrite;Drug: Normal Saline","Diagnostic Test: Novel laser inferometry test for CORONA virus","Drug: APL-9;Other: Vehicle Control","Diagnostic Test: biological samples day of delivery","Procedure: Stellate Ganglion Block","Drug: Pulmozyme;Drug: Placebo","Drug: Ivermectin;Drug: Doxycycline;Drug: Chloroquine","Drug: Hydroxychloroquine Sulfate Tablets;Drug: Lopinavir/ Ritonavir Oral Tablet;Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets;Drug: Placebo","Dietary Supplement: ARBOX;Other: PLACEBO","Dietary Supplement: Aa palm berry extract - natural product;Other: Placebo","Drug: PH94B","Drug: Colchicine;Drug: Ruxolitinib 5 MG;Drug: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX];Other: standard therapy","Dietary Supplement: L-citrulline;Other: Placebo","Biological: Convalescent Plasma;Biological: Lactated Ringer's Solution or Sterile Saline","Drug: IgIV","Biological: Convalescent plasma","Drug: Tocilizumab","Diagnostic Test: PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)","Drug: Pacritinib;Drug: Placebo"],["N/A","Phase 4","Phase 2/Phase 3","0","Phase 4","Phase 4","N/A","0","N/A","N/A","0","0","N/A","4","0","0","4","0","0","4","0","4","0","N/A","0","4","N/A","0","0","4","N/A","0","0","N/A","0","4","4","4","0","N/A","0","0","0","0","0","0","0","0","0","4","0","N/A","0","0","0","0","0","0","4","4","0","Phase 2","New Treatment Measure Clinical Study","0","4","N/A","N/A","0","N/A","N/A","0","0","0","0","0","0","0","0","0","4","0","N/A","0","0","N/A","4","0","0","0","N/A","4","Phase 2","N/A","N/A","3","0","New Treatment Measure Clinical Study","2","4","N/A","0","2","N/A","0","0","4","3","0","0","4","0","0","0","0","N/A","N/A","4","N/A","4","4","1-2","N/A","0","Phase 2","Phase 2","0","4","4","4","4","4","Phase 1/Phase 2","Phase 2","0","N/A","4","N/A","0","1","Phase 2","0","N/A","N/A","0","0","0","0","N/A","N/A","0","0","N/A","4","New Treatment Measure Clinical Study","0","0","0","4","N/A","2","4","0","4","4","0","4","4","N/A","4","4","4","4","N/A","Phase 1","4","Phase 4","N/A","Phase 3","0","0","0","0","0","N/A","4","0","0","N/A","0","N/A","N/A","N/A","N/A","4","N/A","N/A","N/A","0","0","N/A","4","0","4","0","0","0","0","N/A","1","0","N/A","0","N/A","1","0","4","N/A","0","N/A","0","0","0","\n                Human pharmacology (Phase I): no\n                Therapeutic exploratory (Phase II): no\n                Therapeutic confirmatory - (Phase III): yes\n                Therapeutic use (Phase IV): no\n","4","0","Early Phase 1","4","1-2","N/A","4","0","4","4","N/A","New Treatment Measure Clinical Study","0","0","Retrospective study","Phase 2","0","4","N/A","4","0","0","0","0","N/A","N/A","4","0","0","0","0","0","0","0","N/A","0","1","0","4","Phase 1","0","N/A","Early Phase 1","N/A","0","N/A","0","N/A","0","0","4","N/A","0","2-3","Phase 4","1","N/A","0","N/A","N/A","Phase 4","N/A","4","4","4","Phase 1","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","N/A","Phase 4","N/A","Phase 4","Phase 3","Phase 1/Phase 2","Phase 2/Phase 3","N/A","N/A","2","0","N/A","0","N/A","N/A","4","N/A","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","4","0","Retrospective study","N/A","N/A","Phase 2","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","0","Phase 2/Phase 3","N/A","Phase 2/Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 2/Phase 3","Early Phase 1","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","1","N/A","N/A","1","Not Applicable","Phase 1/Phase 2","N/A","N/A","4","0","0","2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 2","Phase 2","Phase 2/Phase 3","Phase 2/Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 3","Phase 2","Phase 4","N/A","Early Phase 1","N/A","Phase 3","N/A","N/A","Phase 3","N/A","Phase 1/Phase 2","N/A","Phase 1","Phase 2","Phase 2/Phase 3","Phase 4","Not Applicable","Phase 2","Not Applicable","Phase 2","Not Applicable","0","Phase 1 / Phase 2","N/A","0","N/A","2","0","4","1-2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): \nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): \nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 3","Phase 3","Phase 4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 2","Phase 3","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 2/Phase 3","Phase 3","N/A","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 2/Phase 3","Phase 2/Phase 3","Phase 3","N/A","Phase 3","Phase 2","Phase 4","Phase 2","Phase 2","N/A","Phase 4","N/A","N/A","N/A","N/A","Phase 1/Phase 2","Phase 2","Phase 2","N/A","N/A","N/A","Phase 3","Phase 3","Phase 4","N/A","Phase 2","Phase 3","Phase 1/Phase 2","Phase 3","Phase 3","Not Applicable","Phase 2","Phase 3","N/A","1","N/A","Not Applicable","Not Applicable","0","N/A","Phase 0","0","0","0","Phase 2","Not Applicable","Not Applicable","N/A","4","4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): yes\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","2-3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","2-3","3","4","2-3","2-3","2","2-3","3","2-3","3","N/A","N/A","3","3","3","2","1-2","3","3","2","3","3","N/A","3","3","3","2","3","2-3","3","2","3","3","N/A","1","2-3","3","2-3","Phase 2/Phase 3","Phase 3","Phase 2","3","Phase 1","N/A","Phase 1","N/A","2","Phase 3","Phase 3","Phase 3","N/A","Phase 2/Phase 3","N/A","Phase 1","Phase 3","2","Phase 3","Phase 2/Phase 3","Phase 3","Phase 2","Phase 2","Phase 1","Phase 4","Phase 3","Phase 4","Phase 3","Phase 2/Phase 3","Phase 3","N/A","N/A","Phase 1/Phase 2","N/A","N/A","Phase 2","N/A","N/A","N/A","Phase 3","N/A","N/A","Phase 2","N/A","Phase 2","Phase 2","Phase 3","Phase 1/Phase 2","Phase 2","Phase 2","Phase 1/Phase 2","N/A","N/A","Phase 3","Phase 3","Phase 1/Phase 2","Phase 2/Phase 3","Phase 4","Phase 2","N/A","Phase 3","Phase 2","N/A","N/A","Phase 3","N/A","N/A","Phase 2","Phase 2","Phase 2","Phase 2","Phase 3","Phase 2/Phase 3","N/A","Phase 2","Phase 2","Phase 3","Phase 2","Phase 4","Phase 3","Phase 4","Phase 2","Phase 2","Phase 2","Phase 2/Phase 3","Phase 3","N/A","N/A","N/A","Phase 2/Phase 3","Phase 2/Phase 3","Phase 4","Phase 3","Phase 2/Phase 3","Phase 2","Phase 2","Phase 3","Phase 3","Phase 2/Phase 3","N/A","Phase 1/Phase 2","Phase 1/Phase 2","N/A","Phase 2","Phase 2","Phase 4","Phase 1","Phase 2/Phase 3","N/A","Phase 2","Phase 2","Phase 4","N/A","Phase 3","Phase 2","Phase 3","N/A","Phase 2","Phase 3","Phase 2","Phase 1","N/A","Not Applicable","N/A","Phase 2/Phase 3","N/A","Phase 2","N/A","Phase III","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Not Applicable","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Not Applicable","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2 / Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Not Applicable","New Treatment Measure Clinical Study","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 3","N/A","Early Phase 1","N/A","0","Phase 2","Phase 2/Phase 3","Phase 3","Phase 2","N/A","Phase 1","Phase 1","Phase 3","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","0","0","N/A","N/A","Phase 2","N/A","Phase 1","Phase 2/Phase 3","Phase 2","Phase 2/Phase 3","Phase 2","N/A","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 2/Phase 3","Phase 3","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 2/Phase 3","Phase 4","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 1","Phase 1/Phase 2","Phase 3","Early Phase 1","Early Phase 1","Phase 3","Phase 2","Phase 2","Phase 3","N/A","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 1","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 2/Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","Phase 4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 2","N/A","Phase 2","Phase 2/Phase 3","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 1/Phase 2","Phase 2","Phase 4","Phase 4","Phase 3","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","N/A","Phase 2/Phase 3","Phase 3","Phase 2","N/A","Phase 2/Phase 3","Phase 2","Phase 3","Phase 2/Phase 3","N/A","N/A","Phase 4","Phase 2","N/A","Phase 3","Phase 2","N/A","Early Phase 1","Phase 3","N/A","N/A","N/A","N/A","N/A","Phase 3","Phase 3","Phase 3","N/A","Phase 4","N/A","Phase 3","Phase 2","N/A","Phase 2","N/A","Phase 2","N/A","N/A","N/A","Phase 2","Phase 2","N/A","Phase 4","Phase 2","Phase 2/Phase 3","Phase 3","Phase 2","N/A","N/A","Phase 3","N/A","Phase 1","Phase 3","Phase 2","Phase 3","Phase 2","Not Applicable","Phase 2","N/A","Phase II","Not Applicable","Not Applicable","Phase III","0","N/A","4","N/A","N/A","0","1-2","4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): yes\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): yes\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","Phase 1/Phase 2","Phase 3","Phase 2","Phase 3","Phase 2","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 2","Phase 4","Phase 1/Phase 2","Phase 1/Phase 2","Phase 3","N/A","Phase 3","Phase 1/Phase 2","Phase 2","N/A","Phase 4","Phase 2","N/A","Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2/Phase 3","Phase 3","Phase 2","N/A","Phase 2/Phase 3","Phase 3","Phase 2","Phase 2","Phase 1/Phase 2","Phase 3","Phase 2/Phase 3","Phase 3","Phase 3","N/A","Phase 4","Phase 2","Phase 1/Phase 2","N/A","N/A","N/A","Phase 3","Phase 2/Phase 3","N/A","Phase 2","N/A","N/A","Phase 2","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","Early Phase 1","N/A","N/A","Phase 2","N/A","Phase 3","Phase 2","Phase 4","N/A","Not Applicable","N/A","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","N/A","N/A","Phase 3","Retrospective study","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","Phase 2","Phase 3","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 3","N/A","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 3","Phase 1","N/A","Phase 2","Early Phase 1","Phase 1","Phase 1/Phase 2","N/A","N/A","N/A","Phase 4","Phase 2","Phase 2","N/A","Phase 3","N/A","Phase 2","Phase 3","N/A","Phase 3","Phase 2","N/A","Phase 2","Phase 3","Phase 3","N/A","Phase 2","N/A","Phase 3","Phase 4","Phase 3","N/A","Phase 1","Phase 2/Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","Phase 3","N/A","N/A","N/A","Phase 3","Phase 2/Phase 3","Phase 2","Phase 2","Phase 3","Phase 2","N/A","N/A","N/A","Phase 3","Phase 2","Phase 1","Phase 3","Phase 4","Phase 2","Phase 3","Phase 2","N/A","Phase 4","N/A","Phase 2/Phase 3","N/A","N/A","Phase 2","Phase 2/Phase 3","Phase 2","Phase 2","N/A","Phase 2","Phase 2/Phase 3","N/A","N/A","Phase 2","Early Phase 1","Phase 2","N/A","Phase 2","Phase 4","Phase 3","Phase 2","Phase 2","Phase 2","Phase 1","Phase 4","Phase 2","N/A","Phase 2","Phase 2","Phase 1/Phase 2","N/A","Phase 3","Phase 1","Phase 1/Phase 2","N/A","N/A","Phase 3","Phase 3","Phase 2","N/A","Phase 3","N/A","Phase 1","N/A","N/A","Phase II/III","Phase 2","Phase 1/Phase 2","Phase 2/Phase 3","0","4","4","0","I","4","IIb","Phase 3","Not Applicable","Not Applicable","N/A","N/A","I","N/A","N/A","N/A","N/A","II-III","N/A","2-3","3","N/A","3","N/A","II","3","N/A","3","3","2","3","3","4","2","2","3","2-3","3","3","2-3","1-2","1-2","3","3","2-3","2","3","2-3","3","1-2","2-3","3","1-2","3","3","3","2-3","3","3","2-3","2-3","2","2","3","3","N/A","N/A","3","3","2","3","N/A","2-3","3","4","3","2","3","3","2-3","3","N/A","1-2","3","2-3","3","3","2-3","3","3","2","2","N/A","3","N/A","3","3","3","3","N/A","1-2","2-3","0 (exploratory trials)","2-3","3","N/A","2-3","2-3","N/A","2","2","2-3","3","2-3","2-3","3","3","3","2-3","3","3","N/A","3","3","1-2","2-3","3","3","3","2-3","2-3","2","3","3","Phase2","2-3","3","2-3","3","2","1-2","3","2","2","3","Not selected","3","3","3","N/A","3","Not selected","2-3","3","1-2","Not selected","2","Not Applicable","Phase-3","3","Not Applicable","3","Phase-3","Phase-2","3","3","N/A","3","N/A","2","3","Phase 2/Phase 3","1-2","N/A","N/A","N/A","Phase 4","2","Not selected","1","0","1-2","Not selected","N/A","Phase-1","N/A","N/A","Phase 4","2","Phase 3","Phase 3/ Phase 4","N/A","Phase 3","Phase 3","N/A","Phase 3","Phase 3","Phase 3","Phase 2","N/A","N/A","Phase 3","Phase 2/ Phase 3","Phase 3","Phase 2","Phase 2","N/A","Phase 4","N/A","Phase 2","Phase 3","Phase 2","Phase 1/ Phase 2","Phase 2","Phase 1/ Phase 2","N/A","N/A","Phase 2","Phase 2","N/A","Phase 3","N/A","Phase 2","Phase 2","Phase 2","N/A","Phase 2","Phase 3","Phase 2","N/A","Post Marketing Surveillance","Phase 2/ Phase 3","N/A","Phase 1/ Phase 2","Phase 2/ Phase 3","Phase 2","Phase 2","Phase 2/ Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","Phase 3/ Phase 4","Phase 2","Phase 2/Phase 3","Phase 2","N/A","N/A","Phase 2/Phase 3","N/A","Phase 2","Phase 3","Phase 2","N/A","N/A","N/A","N/A","N/A","Phase 3","Phase 2","Phase 2/Phase 3","Phase 2","N/A","Phase 2","N/A","Phase 2","Phase 2","N/A","Phase 2","Phase 1","N/A","N/A","Phase 2/Phase 3","Phase 2","N/A","Phase 2","Phase 4","N/A","Phase 2/Phase 3","Phase 1/Phase 2","Phase 2/Phase 3","N/A","Phase 2","Phase 2","Phase 2/Phase 3","N/A","Phase 3","Phase 3","N/A","N/A","Phase 2","Phase 2/Phase 3","Phase 3","Phase 2/Phase 3","N/A","Phase 2","Phase 3","N/A","Phase 4","N/A","Phase 2/Phase 3","N/A","N/A","Early Phase 1","Phase 1","Phase 1","N/A","Phase 3","Phase 2","Phase 1/Phase 2","N/A","N/A","N/A","Phase 2","Phase 3","Phase 2/Phase 3","Phase 3","N/A","Phase 2","Phase 3","N/A","Early Phase 1","Phase 2/Phase 3","Phase 3","Phase 2","N/A","Early Phase 1","N/A","Phase 2","Phase 3","Phase 3","Phase 2","Phase 3","Phase 3","Phase 4","N/A","N/A","N/A","N/A","Phase 1/Phase 2","N/A","Phase 2","N/A","Phase 2","N/A","Phase 1/Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","N/A","N/A","Phase 2","Phase 2","Phase 3","Phase 1/Phase 2","Phase 2","N/A","Phase 2","N/A","Early Phase 1","Phase 2","Phase 2/Phase 3","Phase 2/Phase 3","N/A","Phase 3","Phase 2/Phase 3","Phase 2/Phase 3","N/A","N/A","Phase 2/Phase 3","Phase 1/Phase 2","N/A","Phase 2/Phase 3","N/A","N/A","N/A","N/A","Phase 1/Phase 2","Phase 1 / Phase 2","Phase 3","Phase 1/Phase 2","N/A","Phase 3","Phase 1","N/A","Not Applicable","Phase 2","Phase 3","Phase 1 / Phase 2","Phase II/III","N/A","Not Applicable","Phase II/III","Phase 1","Not Applicable","Phase III","Phase II","Phase 2/Phase 3","Phase 2","N/A","0","Phase 2/Phase 3","Not Applicable",null,"Not Applicable",null,null,null,"Phase II/III","Not Applicable",null,null,null,"N/A","4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","0",null,"Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n",null,"Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n",null,"Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 1","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 3","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","Phase 2","N/A","Phase 3",null,"Phase 3","Phase 3","Phase 3","Phase 4","Phase 3","Phase 2","Phase 2","Phase 2/Phase 3","Phase 1","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 2","N/A","Phase 2","Phase 3","N/A","Phase 4","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 4","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 2","Phase 2","Phase 2/Phase 3","Phase 1/Phase 2","Phase 2","Phase 1","Phase 4","Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 1/Phase 2","Phase 3","Early Phase 1","Phase 2","Phase 3","N/A","Phase 2/Phase 3","N/A","Phase 2","Phase 3","Phase 1","Phase 3","Phase 2/Phase 3","Phase 2","N/A","Phase 3","Phase 2","N/A","Phase 3","Phase 1","Phase 2","Phase 2","Phase 2","Phase 2","N/A","Phase 1/Phase 2","Phase 3","Phase 1/Phase 2","Phase 3","N/A","Phase 2","Phase 3","Phase 3","Phase 2","Phase 1","Phase 2","Phase 2","Phase 1/Phase 2","Phase 1","Phase 3","Phase 1/Phase 2","N/A","Phase 1","Phase 3","Phase 2/Phase 3","Phase 3","N/A","Phase 2","Phase 2","Phase 4","Phase 3","Phase 2","Phase 2","Early Phase 1","Phase 2","N/A","Phase 2","Phase 3","N/A","Phase 2","Phase 3","N/A","N/A","Phase 2","N/A","N/A","Phase 2","Phase 1/Phase 2","Phase 1/Phase 2","Phase 2","Phase 2","Phase 1","N/A","Phase 4","Phase 2","N/A","Phase 2","Phase 3","N/A","N/A","Phase 1/Phase 2","Phase 1/Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","N/A","Phase 2","Phase 4","Phase 2","Phase 2","Phase 1/Phase 2","Phase 2","Phase 4","N/A","Phase 2","Phase 1/Phase 2","Phase 2","Phase 3","Phase 2","N/A","N/A","Phase 2","Phase 2","Phase 2","Phase 3","Phase 2","Phase 2","Phase 3","Phase 2","N/A","N/A","Phase 1/Phase 2","N/A","Phase 1","Phase 2/Phase 3","N/A","Phase 4","Phase 1","Phase 2","N/A","Phase 3","Phase 1/Phase 2","Phase 2","Phase 2/Phase 3","N/A","N/A","Phase 2","N/A","Phase 1","Phase 2/Phase 3","Phase 2","Phase 3","N/A","Phase 3","N/A","N/A","N/A","Phase 2","Phase 4","Phase 1/Phase 2","Phase 4","N/A","Phase 2","N/A","N/A","Phase 3","N/A","N/A","Phase 2/Phase 3","Phase 3","N/A","Phase 2","N/A","N/A","Phase 1","Phase 3","Phase 2","Phase 3","Phase 2","N/A","Phase 3","Phase 2","N/A","Phase 2","Phase 1/Phase 2","N/A","N/A","N/A","Phase 1","Phase 2","Phase 4","Phase 2","Phase 1","Phase 3","N/A","Phase 1","Phase 1","N/A","Phase 2","Phase 3","Phase 2","Phase 2","Phase 1/Phase 2","N/A","N/A","N/A","N/A","Phase 3","N/A","N/A","Phase 2","N/A","N/A","Phase 1/Phase 2","Phase 2","Phase 2","N/A","Phase 2","N/A","Phase 2","Phase 2","N/A","Phase 3","Phase 2/Phase 3","Phase 2","N/A","Phase 2/Phase 3","Phase 1","Phase 2","N/A","Phase 3","Phase 2","N/A","Phase 1/Phase 2","N/A","N/A","Phase 2","Phase 2/Phase 3","Phase 3","N/A","Phase 2","Phase 2","Phase 2","N/A","Phase 2","Phase 2","Phase 2","Phase 3","N/A","Phase 3"],[0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,null,0,null,null,null,0,0,null,null,null,0,0,0,1,null,0,0,0,null,0,0,null,0,0,0,0,0,0,0,0,0,0,0,0,0,null,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,null,0,null,null,null,0,0,null,null,null,0,0,0,0,null,0,0,0,null,0,0,null,0,0,1,0,0,0,0,0,0,0,0,0,0,null,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,1,1,1,0,1,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,1,0,1,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,null,0,null,null,null,0,0,null,null,null,0,0,1,0,null,1,1,1,null,1,1,null,0,1,0,0,0,1,0,1,0,0,1,0,0,null,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,1,1,1,0,0,0],[0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,null,0,null,null,null,0,0,null,null,null,0,0,0,0,null,0,0,0,null,0,0,null,0,0,0,0,0,0,1,0,1,1,0,0,1,null,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1],[0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,null,0,null,null,null,0,0,null,null,null,0,1,0,0,null,0,0,0,null,0,0,null,1,0,0,1,1,0,0,0,0,0,0,0,0,null,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,0,1,0,0,1,null,1,null,null,null,1,1,null,null,null,1,0,0,0,null,0,0,0,null,0,0,null,0,0,0,0,0,0,0,0,0,0,0,1,0,null,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0],[null,4,3,0,4,4,null,0,null,null,0,0,null,4,0,0,4,0,0,4,0,4,0,null,0,4,null,0,0,4,null,0,0,null,0,4,4,4,0,null,0,0,0,0,0,0,0,0,0,4,0,null,0,0,0,0,0,0,4,4,0,2,null,0,4,null,null,0,null,null,0,0,0,0,0,0,0,0,0,4,0,null,0,0,null,4,0,0,0,null,4,2,null,null,3,0,null,2,4,null,0,2,null,0,0,4,3,0,0,4,0,0,0,0,null,null,4,null,4,4,2,null,0,2,2,0,4,4,4,4,4,2,2,0,null,4,null,0,1,2,0,null,null,0,0,0,0,null,null,0,0,null,4,null,0,0,0,4,null,2,4,0,4,4,0,4,4,null,4,4,4,4,null,1,4,4,null,3,0,0,0,0,0,null,4,0,0,null,0,null,null,null,null,4,null,null,null,0,0,null,4,0,4,0,0,0,0,null,1,0,null,0,null,1,0,4,null,0,null,0,0,0,3,4,0,1,4,2,null,4,0,4,4,null,null,0,0,null,2,0,4,null,4,0,0,0,0,null,null,4,0,0,0,0,0,0,0,null,0,1,0,4,1,0,null,1,null,0,null,0,null,0,0,4,null,0,3,4,1,null,0,null,null,4,null,4,4,4,1,3,3,null,4,null,4,3,2,3,null,null,2,0,null,0,null,null,4,null,0,3,4,0,null,null,null,2,3,2,0,3,null,3,4,3,1,0,2,1,null,null,1,null,2,null,null,4,0,0,2,3,2,3,2,4,2,2,3,3,4,3,2,4,null,1,null,3,null,null,3,null,2,null,1,2,3,4,null,2,null,2,null,0,2,null,0,null,2,0,4,2,2,3,3,3,3,4,3,2,4,3,3,3,2,3,3,2,3,2,3,3,4,2,2,2,3,2,3,3,3,null,2,3,3,3,3,null,3,2,4,2,2,null,4,null,null,null,null,2,2,2,null,null,null,3,3,4,null,2,3,2,3,3,null,2,3,null,1,null,null,null,0,null,0,0,0,0,2,null,null,null,4,4,4,3,2,3,3,2,3,3,2,3,4,2,4,null,2,2,3,3,2,4,4,null,2,4,2,2,4,2,3,2,2,3,3,3,3,4,3,3,2,3,3,3,3,null,null,3,3,3,2,2,3,3,2,3,3,null,3,3,3,2,3,3,3,2,3,3,null,1,3,3,3,3,3,2,3,1,null,1,null,2,3,3,3,null,3,null,1,3,2,3,3,3,2,2,1,4,3,4,3,3,3,null,null,2,null,null,2,null,null,null,3,null,null,2,null,2,2,3,2,2,2,2,null,null,3,3,2,3,4,2,null,3,2,null,null,3,null,null,2,2,2,2,3,3,null,2,2,3,2,4,3,4,2,2,2,3,3,null,null,null,3,3,4,3,3,2,2,3,3,3,null,2,2,null,2,2,4,1,3,null,2,2,4,null,3,2,3,null,2,3,2,1,null,null,null,3,null,2,null,null,2,4,3,null,4,null,3,2,2,3,2,2,3,null,null,null,3,4,3,null,1,null,0,2,3,3,2,null,1,1,3,0,2,0,0,null,null,2,null,1,3,2,3,2,null,null,4,3,3,3,4,3,4,2,3,1,2,3,1,1,3,2,2,3,null,null,2,1,2,2,3,3,3,4,2,2,2,null,2,3,2,2,2,2,4,4,3,null,3,3,null,3,3,2,null,3,2,3,3,null,null,4,2,null,3,2,null,1,3,null,null,null,null,null,3,3,3,null,4,null,3,2,null,2,null,2,null,null,null,2,2,null,4,2,3,3,2,null,null,3,null,1,3,2,3,2,null,2,null,null,null,null,null,0,null,4,null,null,0,2,4,2,2,3,2,4,3,3,2,2,2,2,2,2,2,2,2,2,3,3,2,3,2,3,2,3,3,2,2,4,2,2,3,null,3,2,2,null,4,2,null,3,2,2,2,2,3,3,2,null,3,3,2,2,2,3,3,3,3,null,4,2,2,null,null,null,3,3,null,2,null,null,2,null,null,null,null,null,null,null,null,1,null,null,2,null,3,2,4,null,null,null,null,2,null,2,3,3,null,null,3,null,2,2,3,null,3,0,2,4,2,0,2,2,3,3,2,2,2,4,2,3,2,2,3,3,3,3,4,2,2,4,2,2,2,3,3,2,3,3,null,2,3,null,2,3,null,2,2,2,2,3,null,null,4,4,3,1,null,2,1,1,2,null,null,null,4,2,2,null,3,null,2,3,null,3,2,null,2,3,3,null,2,null,3,4,3,null,1,3,2,2,2,2,3,null,null,null,3,3,2,2,3,2,null,null,null,3,2,1,3,4,2,3,2,null,4,null,3,null,null,2,3,2,2,null,2,3,null,null,2,1,2,null,2,4,3,2,2,2,1,4,2,null,2,2,2,null,3,1,2,null,null,3,3,2,null,3,null,1,null,null,null,2,2,3,0,4,4,0,null,4,null,3,null,null,null,null,null,null,null,null,null,null,null,3,3,null,3,null,null,3,null,3,3,2,3,3,4,2,2,3,3,3,3,3,2,2,3,3,3,2,3,3,3,2,3,3,2,3,3,3,3,3,3,3,3,2,2,3,3,null,null,3,3,2,3,null,3,3,4,3,2,3,3,3,3,null,2,3,3,3,3,3,3,3,2,2,null,3,null,3,3,3,3,null,2,3,0,3,3,null,3,3,null,2,2,3,3,3,3,3,3,3,3,3,3,null,3,3,2,3,3,3,3,3,3,2,3,3,2,3,3,3,3,2,2,3,2,2,3,null,3,3,3,null,3,null,3,3,2,null,2,null,3,3,null,3,3,2,3,3,null,3,null,2,3,3,2,null,null,null,4,2,null,1,0,2,null,null,1,null,null,4,2,3,4,null,3,3,null,3,3,3,2,null,null,3,3,3,2,2,null,4,null,2,3,2,2,2,2,null,null,2,2,null,3,null,2,2,2,null,2,3,2,null,null,3,null,2,3,2,2,3,2,2,2,2,4,2,3,2,null,null,3,null,2,3,2,null,null,null,null,null,3,2,3,2,null,2,null,2,2,null,2,1,null,null,3,2,null,2,4,null,3,2,3,null,2,2,3,null,3,3,null,null,2,3,3,3,null,2,3,null,4,null,3,null,null,1,1,1,null,3,2,2,null,null,null,2,3,3,3,null,2,3,null,1,3,3,2,null,1,null,2,3,3,2,3,3,4,null,null,null,null,2,null,2,null,2,null,2,2,2,2,1,null,null,2,2,3,2,2,null,2,null,1,2,3,3,null,3,3,3,null,null,3,2,null,3,null,null,null,null,2,2,3,2,null,3,1,null,null,2,3,2,null,null,null,null,1,null,null,null,3,2,null,0,3,null,null,null,null,null,null,null,null,null,null,null,null,4,2,0,null,2,2,2,null,2,2,null,4,2,1,4,4,2,3,2,3,3,2,null,3,null,3,3,3,4,3,2,2,3,1,3,2,null,2,3,null,4,3,2,2,4,2,4,2,2,3,2,2,1,4,3,2,2,2,2,2,null,2,2,3,1,2,3,null,3,null,2,3,1,3,3,2,null,3,2,null,3,1,2,2,2,2,null,2,3,2,3,null,2,3,3,2,1,2,2,2,1,3,2,null,1,3,3,3,null,2,2,4,3,2,2,1,2,null,2,3,null,2,3,null,null,2,null,null,2,2,2,2,2,1,null,4,2,null,2,3,null,null,2,2,2,2,2,2,null,2,4,2,2,2,2,4,null,2,2,2,3,2,null,null,2,2,2,3,2,2,3,2,null,null,2,null,1,3,null,4,1,2,null,3,2,2,3,null,null,2,null,1,3,2,3,null,3,null,null,null,2,4,2,4,null,2,null,null,3,null,null,3,3,null,2,null,null,1,3,2,3,2,null,3,2,null,2,2,null,null,null,1,2,4,2,1,3,null,1,1,null,2,3,2,2,2,null,null,null,null,3,null,null,2,null,null,2,2,2,null,2,null,2,2,null,3,3,2,null,3,1,2,null,3,2,null,2,null,null,2,3,3,null,2,2,2,null,2,2,2,3,null,3],[0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,null,0,null,null,null,0,0,null,null,null,0,0,0,0,null,0,0,0,null,0,0,null,0,0,0,0,0,0,0,0,0,0,0,0,0,null,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0],[1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,0,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,1,1,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,0,1,1,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,1,0,1,1,1,0,1,1,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,1],[0,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,1,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0],[1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0],[0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0],[0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0],[0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1],[0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,1,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0],[0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1],[0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,1,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,1,0,1,0,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,1,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,1,0,1,1,0,1,1,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0],[0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>TrialID<\/th>\n      <th>Scientific title<\/th>\n      <th>Countries<\/th>\n      <th>Intervention<\/th>\n      <th>Phase<\/th>\n      <th>fase0<\/th>\n      <th>fase1<\/th>\n      <th>fase2<\/th>\n      <th>fase3<\/th>\n      <th>fase4<\/th>\n      <th>faseNULL<\/th>\n      <th>fase_maxima<\/th>\n      <th>multiplas_fases<\/th>\n      <th>grupo_drogas<\/th>\n      <th>grupo_outros_tratamentos<\/th>\n      <th>grupo_no_identificado<\/th>\n      <th>grupo_preveno<\/th>\n      <th>categoria_antimalrico<\/th>\n      <th>categoria_antivirais<\/th>\n      <th>categoria_plasma_de pessoas curadas<\/th>\n      <th>categoria_outras_drogas<\/th>\n      <th>categoria_medicina_tradicional chinesa<\/th>\n      <th>categoria_no_identificado<\/th>\n      <th>categoria_testes<\/th>\n      <th>categoria_corticides<\/th>\n      <th>categoria_clulas-tronco<\/th>\n      <th>categoria_ventilao_pulmonar<\/th>\n      <th>categoria_anticorpos_monoclonais<\/th>\n      <th>categoria_anti-inflamatrio<\/th>\n      <th>categoria_comportamental_ou atividade fsica<\/th>\n      <th>categoria_inibidores_de enzimas do tipo quinases<\/th>\n      <th>categoria_nk_cells<\/th>\n      <th>categoria_vacinas<\/th>\n      <th>categoria_antibiticos<\/th>\n      <th>categoria_imunomoduladores<\/th>\n      <th>substancia_cloroquina_ou hidroxicloroquina<\/th>\n      <th>substancia_arbidol_(umifenovir)<\/th>\n      <th>substancia_outras_drogas<\/th>\n      <th>substancia_no_identificado<\/th>\n      <th>substancia_lopinavir/ritonavir<\/th>\n      <th>substancia_outros_antivirais<\/th>\n      <th>substancia_corticides<\/th>\n      <th>substancia_azvudine<\/th>\n      <th>substancia_tocilizumab_ou sarilumab<\/th>\n      <th>substancia_anti-inflamatrio<\/th>\n      <th>substancia_interferon<\/th>\n      <th>substancia_favipiravir<\/th>\n      <th>substancia_outros_anticorpos monoclonais<\/th>\n      <th>substancia_inibidores_de enzimas do tipo quinases<\/th>\n      <th>substancia_remdesivir<\/th>\n      <th>substancia_azithromycin<\/th>\n      <th>substancia_anakinra<\/th>\n      <th>substancia_imunomoduladores<\/th>\n      <th>substancia_outros_antibiticos<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"Bfrtip","buttons":["csv","excel"],"columnDefs":[{"className":"dt-right","targets":[6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="critrios-de-classificao" class="section level3">
<h3>Critrios de classificao</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-21b30f6c297188b8d63a" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-21b30f6c297188b8d63a">{"x":{"filter":"none","caption":"<caption>**regex** = regular expression (padres textuais); **variavel** = onde o padro  buscado: Intervention ou Scientific title+Intervention (\"concat\")<\/caption>","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27"],["Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Outros tratamentos","Outros tratamentos","Outros tratamentos","Outros tratamentos","Outros tratamentos","Outros tratamentos","Preveno","Preveno","Preveno"],["Anticorpos monoclonais","Anticorpos monoclonais","Antimalrico","Antivirais","Antivirais","Antivirais","Antivirais","Antivirais","Antivirais","Anti-inflamatrio","Corticides","Antibiticos","Antibiticos","Inibidores de enzimas do tipo quinases","Imunomoduladores","Outras drogas","Outras drogas","Outras drogas","Clulas-Tronco","Medicina Tradicional Chinesa","Plasma de pessoas curadas","Ventilao Pulmonar","NK cells","Comportamental ou atividade fsica","Vacinas","Testes","Outras formas de preveno"],["tocilizumab ou sarilumab","outros anticorpos monoclonais","cloroquina ou hidroxicloroquina","favipiravir","lopinavir/ritonavir","remdesivir","azvudine","arbidol (Umifenovir)","outros antivirais","Anti-inflamatrio","corticides","azithromycin","outros antibiticos","Inibidores de enzimas do tipo quinases","Imunomoduladores","Interferon","Anakinra","Outras drogas",null,null,null,null,null,null,null,null,null],["concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","Intervention","concat","concat","concat","concat","concat","Intervention","concat","concat","concat"],["(tocilizu|sarilu)mab","(bevacizu|Eculizu|Leronli|Siltuxi|Clazakizu|Mavrilimu|Meplazu|Nivolu)mab","(h[iy]drox[iy])?c(h)?loroquin[ea]","Favipiravir","lopinavir|ritonavir","(remdezi|remdesi)vir","Azvudine","A(r)?bidol|Umifenovir","(Oseltami|daruna|danopre|tenofo|Galidesi)vir|antiviral|ASC(-)?09|TMC[ -]?310911|cobicistat|emtricitabine|Ganovo|Ribavirin","(Naprox|Ibuprof|Aspir)[ei]n|Colchicine|Xiyanping|Jakotinib|Glycyrrhizinate","(cortic|ster)oid(s)?|(Methylprednisol|Dexamethas)one","Azithromycin","(Amoxicill|Moxifloxac|Levofloxac)in","((Barici|Ruxoli|Acalabru|Ima|Tofaci)ti|Nintenda)nib","Immunomodul","Interferon","Anakinra","Drug:","(stem|mononuclear) cell","TCM|traditional chinese|traditional medicine|herb(s|al)?|Tanreqing|ba(-)?bao(-)?dan|reduning|RDN|Qing-Wen|Bai-Du-Yin|Shuang-Huang-Lian|Huo-Shen|Xue-Bi-Jing","plasma|immunoglobulin","ventilat|intubat|oxid|Inhalation|nitric oxide|chlorine dioxide|oxygen|NORS","NK cell","behavior|mindful|exercise","vaccin(e)?","test|diagnos|detect","prevent"]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>grupo<\/th>\n      <th>categoria<\/th>\n      <th>substancia<\/th>\n      <th>variavel<\/th>\n      <th>regex<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"tip","order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}]}},"evals":[],"jsHooks":[]}</script>
<!-- ### Drogas EUA  -->
<!-- ```{r} -->
<!-- DT::datatable(drugs_grupos_count,   -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ```    -->
<!-- ### Nomes de substncias UE -->
<!-- ```{r} -->
<!-- DT::datatable(eu_substance_count,   -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ``` -->
<!-- ### Dados EUA -->
<!-- ```{r} -->
<!-- DT::datatable(eua, filter = "top",   -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ```    -->
<!-- ### Dados China -->
<!-- ```{r} -->
<!-- DT::datatable(china, filter = "top", -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ``` -->
<!-- ### Dados UE -->
<!-- ```{r} -->
<!-- DT::datatable(eu_data, filter = "top",   -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ```    -->
<!-- ### Dados OMS -->
<!-- ```{r} -->
<!-- DT::datatable(select(oms, -`Inclusion Criteria`, -`Exclusion Criteria`),  -->
<!--               filter = "top",   -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ``` -->
</div>
</div>

</div>

<script>

$(document).ready(function () {

  // add bootstrap table styles to pandoc tables
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');

  // initialize mathjax
  var script = document.createElement("script");
  script.type = "text/javascript";
  script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
  document.getElementsByTagName("head")[0].appendChild(script);

});
</script>

<script type="text/javascript">
$(document).ready(function () {
  FlexDashboard.init({
    theme: "cosmo",
    fillPage: true,
    orientation: "columns",
    storyboard: false,
    defaultFigWidth: 576,
    defaultFigHeight: 460,
    defaultFigWidthMobile: 360,
    defaultFigHeightMobile: 460
  });
});
</script>

</body>
</html>
